{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Pipeline for Question Answering -  ESG Assessment Projects BNP"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### PARTIE CODE -------------------------------------------------------------------------------------------------"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Loading all our nlp models ! (property of BNP Paribas Risk Air Team)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Once deleted, variables cannot be recovered. Proceed (y/[n])? y\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "ERROR:root:Invalid alias: The name clear can't be aliased because it is another magic command.\n",
      "ERROR:root:Invalid alias: The name more can't be aliased because it is another magic command.\n",
      "ERROR:root:Invalid alias: The name less can't be aliased because it is another magic command.\n",
      "ERROR:root:Invalid alias: The name man can't be aliased because it is another magic command.\n"
     ]
    }
   ],
   "source": [
    "%reset"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "TODO remaining: \n",
    "    - Traiter les espaces en trop du aux caracteres hexadécimaux dans les questions: Done\n",
    "    - Traiter les espaces après dans les questions?: Done\n",
    "    - Tester les modules et leur dépendences : Done\n",
    "    - Ajouter token spécial pour chiffres: Done"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "%run pdf_reader/reader.ipynb\n",
    "%run utils/generate_squad_examples.ipynb\n",
    "%run nlp_models_retrievers/Bert.ipynb\n",
    "%run nlp_models_retrievers/Infersent.ipynb\n",
    "%run nlp_models_retrievers/Tf_Idf.ipynb\n",
    "%run nlp_models_retrievers/Tf_Idf_Farahat_Bert.ipynb"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/williamlambert/anaconda3/lib/python3.7/site-packages/sklearn/externals/joblib/__init__.py:15: DeprecationWarning: sklearn.externals.joblib is deprecated in 0.21 and will be removed in 0.23. Please import this functionality directly from joblib, which can be installed with: pip install joblib. If this warning is raised when loading pickled models, you may need to re-serialize those models with scikit-learn 0.21+.\n",
      "  warnings.warn(msg, category=DeprecationWarning)\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "import os\n",
    "import re\n",
    "import sys\n",
    "import uuid\n",
    "import prettytable\n",
    "import time\n",
    "import cProfile\n",
    "import re\n",
    "\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import tinyarray\n",
    "import nltk\n",
    "import torch\n",
    "\n",
    "\"\"\" If you never installed punkt and wordnet:\n",
    "nltk.download('punkt') \n",
    "nltk.download('wordnet')\n",
    "!python -m textblob.download_corpora\n",
    "\"\"\"\n",
    "from tqdm import tqdm\n",
    "from tika import parser\n",
    "from nltk import tokenize as tkn\n",
    "from string import digits\n",
    "from nltk import pos_tag, word_tokenize\n",
    "\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "import sklearn.feature_extraction.text as skf\n",
    "from sklearn.base import BaseEstimator\n",
    "from nltk.stem.porter import PorterStemmer\n",
    "from nltk.stem.wordnet import WordNetLemmatizer\n",
    "\n",
    "from textblob import TextBlob\n",
    "from models import InferSent\n",
    "import enchant\n",
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "from sklearn import decomposition\n",
    "from sklearn import datasets\n",
    "import matplotlib.pyplot as plt\n",
    "from mpl_toolkits.mplot3d import Axes3D\n",
    "import numpy as np\n",
    "\n",
    "import spherecluster\n",
    "from sklearn import decomposition\n",
    "from sklearn import datasets\n",
    "pd.set_option('display.max_colwidth', 200)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "import torch.nn as nn\n",
    "\n",
    "\n",
    "class InferSent_(InferSent):\n",
    "\n",
    "    def __init__(self, config):\n",
    "        super(InferSent, self).__init__()\n",
    "        self.bsize = config['bsize']\n",
    "        self.word_emb_dim = config['word_emb_dim']\n",
    "        self.enc_lstm_dim = config['enc_lstm_dim']\n",
    "        self.pool_type = config['pool_type']\n",
    "        self.dpout_model = config['dpout_model']\n",
    "        self.version = 1 if 'version' not in config else config['version']\n",
    "\n",
    "        self.enc_lstm = nn.LSTM(self.word_emb_dim, self.enc_lstm_dim, 1,\n",
    "                                bidirectional=True, dropout=self.dpout_model)\n",
    "\n",
    "        assert self.version in [1, 2]\n",
    "        if self.version == 1:\n",
    "            self.bos = '<s>'\n",
    "            self.eos = '</s>'\n",
    "            self.max_pad = True\n",
    "            self.moses_tok = False\n",
    "        elif self.version == 2:\n",
    "            self.bos = '<p>'\n",
    "            self.eos = '</p>'\n",
    "            self.max_pad = False\n",
    "            self.moses_tok = True\n",
    "\n",
    "    def is_cuda(self):\n",
    "        # either all weights are on cpu or they are on gpu\n",
    "        return self.enc_lstm.bias_hh_l0.data.is_cuda\n",
    "\n",
    "    def forward(self, sent_tuple):\n",
    "        # sent_len: [max_len, ..., min_len] (bsize)\n",
    "        # sent: (seqlen x bsize x worddim)\n",
    "        sent, sent_len = sent_tuple\n",
    "\n",
    "        # Sort by length (keep idx)\n",
    "        sent_len_sorted, idx_sort = np.sort(sent_len)[::-1], np.argsort(-sent_len)\n",
    "        sent_len_sorted = sent_len_sorted.copy()\n",
    "        idx_unsort = np.argsort(idx_sort)\n",
    "\n",
    "        idx_sort = torch.from_numpy(idx_sort).cuda() if self.is_cuda() \\\n",
    "            else torch.from_numpy(idx_sort)\n",
    "        sent = sent.index_select(1, idx_sort)\n",
    "\n",
    "        # Handling padding in Recurrent Networks\n",
    "        sent_packed = nn.utils.rnn.pack_padded_sequence(sent, sent_len_sorted)\n",
    "        sent_output = self.enc_lstm(sent_packed)[0]  # seqlen x batch x 2*nhid\n",
    "        sent_output = nn.utils.rnn.pad_packed_sequence(sent_output)[0]\n",
    "\n",
    "        # Un-sort by length\n",
    "        idx_unsort = torch.from_numpy(idx_unsort).cuda() if self.is_cuda() \\\n",
    "            else torch.from_numpy(idx_unsort)\n",
    "        sent_output = sent_output.index_select(1, idx_unsort)\n",
    "\n",
    "        # Pooling\n",
    "        if self.pool_type == \"mean\":\n",
    "            sent_len = torch.FloatTensor(sent_len.copy()).unsqueeze(1).cuda()\n",
    "            emb = torch.sum(sent_output, 0).squeeze(0)\n",
    "            emb = emb / sent_len.expand_as(emb)\n",
    "        elif self.pool_type == \"max\":\n",
    "            if not self.max_pad:\n",
    "                sent_output[sent_output == 0] = -1e9\n",
    "            emb = torch.max(sent_output, 0)[0]\n",
    "            if emb.ndimension() == 3:\n",
    "                emb = emb.squeeze(0)\n",
    "                assert emb.ndimension() == 2\n",
    "\n",
    "        return emb\n",
    "\n",
    "    def set_w2v_path(self, w2v_path):\n",
    "        self.w2v_path = w2v_path\n",
    "\n",
    "    def get_word_dict(self, sentences, tokenize=True):\n",
    "        # create vocab of words\n",
    "        word_dict = {}\n",
    "        sentences = [s.split() if not tokenize else self.tokenize(s) for s in sentences]\n",
    "        for sent in sentences:\n",
    "            for word in sent:\n",
    "                if word not in word_dict:\n",
    "                    word_dict[word] = ''\n",
    "        word_dict[self.bos] = ''\n",
    "        word_dict[self.eos] = ''\n",
    "        return word_dict\n",
    "\n",
    "    def get_w2v(self, word_dict):\n",
    "        assert hasattr(self, 'w2v_path'), 'w2v path not set'\n",
    "        # create word_vec with w2v vectors\n",
    "        word_vec = {}\n",
    "        with open(self.w2v_path) as f:\n",
    "            for line in f:\n",
    "                word, vec = line.split(' ', 1)\n",
    "                if word in word_dict:\n",
    "                    word_vec[word] = np.fromstring(vec, sep=' ')\n",
    "        print('Found %s(/%s) words with w2v vectors' % (len(word_vec), len(word_dict)))\n",
    "        return word_vec\n",
    "\n",
    "    def get_w2v_k(self, K):\n",
    "        assert hasattr(self, 'w2v_path'), 'w2v path not set'\n",
    "        # create word_vec with k first w2v vectors\n",
    "        k = 0\n",
    "        word_vec = {}\n",
    "        with open(self.w2v_path) as f:\n",
    "            for line in f:\n",
    "                word, vec = line.split(' ', 1)\n",
    "                if k <= K:\n",
    "                    word_vec[word] = np.fromstring(vec, sep=' ')\n",
    "                    k += 1\n",
    "                if k > K:\n",
    "                    if word in [self.bos, self.eos]:\n",
    "                        word_vec[word] = np.fromstring(vec, sep=' ')\n",
    "\n",
    "                if k > K and all([w in word_vec for w in [self.bos, self.eos]]):\n",
    "                    break\n",
    "        return word_vec\n",
    "\n",
    "    def build_vocab(self, sentences, tokenize=True):\n",
    "        assert hasattr(self, 'w2v_path'), 'w2v path not set'\n",
    "        word_dict = self.get_word_dict(sentences, tokenize)\n",
    "        self.word_vec = self.get_w2v(word_dict)\n",
    "        print('Vocab size : %s' % (len(self.word_vec)))\n",
    "\n",
    "    # build w2v vocab with k most frequent words\n",
    "    def build_vocab_k_words(self, K):\n",
    "        assert hasattr(self, 'w2v_path'), 'w2v path not set'\n",
    "        self.word_vec = self.get_w2v_k(K)\n",
    "        print('Vocab size : %s' % (K))\n",
    "\n",
    "    def update_vocab(self, sentences, tokenize=True):\n",
    "        assert hasattr(self, 'w2v_path'), 'warning : w2v path not set'\n",
    "        assert hasattr(self, 'word_vec'), 'build_vocab before updating it'\n",
    "        word_dict = self.get_word_dict(sentences, tokenize)\n",
    "\n",
    "        # keep only new words\n",
    "        for word in self.word_vec:\n",
    "            if word in word_dict:\n",
    "                del word_dict[word]\n",
    "\n",
    "        # udpate vocabulary\n",
    "        if word_dict:\n",
    "            new_word_vec = self.get_w2v(word_dict)\n",
    "            self.word_vec.update(new_word_vec)\n",
    "        else:\n",
    "            new_word_vec = []\n",
    "        print('New vocab size : %s (added %s words)'% (len(self.word_vec), len(new_word_vec)))\n",
    "\n",
    "    def get_batch(self, batch):\n",
    "        # sent in batch in decreasing order of lengths\n",
    "        # batch: (bsize, max_len, word_dim)\n",
    "        embed = np.zeros((len(batch[0]), len(batch), self.word_emb_dim))\n",
    "\n",
    "        for i in range(len(batch)):\n",
    "            for j in range(len(batch[i])):\n",
    "                embed[j, i, :] = self.word_vec[batch[i][j]]\n",
    "\n",
    "        return torch.FloatTensor(embed)\n",
    "\n",
    "    def tokenize(self, s):\n",
    "        from nltk.tokenize import word_tokenize\n",
    "        if self.moses_tok:\n",
    "            s = ' '.join(word_tokenize(s))\n",
    "            s = s.replace(\" n't \", \"n 't \")  # HACK to get ~MOSES tokenization\n",
    "            return s.split()\n",
    "        else:\n",
    "            return word_tokenize(s)\n",
    "\n",
    "    def prepare_samples(self, sentences, bsize, tokenize, verbose):\n",
    "        sentences = [[self.bos] + s.split() + [self.eos] if not tokenize else\n",
    "                     [self.bos] + self.tokenize(s) + [self.eos] for s in sentences]\n",
    "        n_w = np.sum([len(x) for x in sentences])\n",
    "\n",
    "        # filters words without w2v vectors\n",
    "        for i in range(len(sentences)):\n",
    "            s_f = [word for word in sentences[i] if word in self.word_vec]\n",
    "            if not s_f:\n",
    "                import warnings\n",
    "                warnings.warn('No words in \"%s\" (idx=%s) have w2v vectors. \\\n",
    "                               Replacing by \"</s>\"..' % (sentences[i], i))\n",
    "                s_f = [self.eos]\n",
    "            sentences[i] = s_f\n",
    "\n",
    "        lengths = np.array([len(s) for s in sentences])\n",
    "        n_wk = np.sum(lengths)\n",
    "        if verbose:\n",
    "            print('Nb words kept : %s/%s (%.1f%s)' % (\n",
    "                        n_wk, n_w, 100.0 * n_wk / n_w, '%'))\n",
    "\n",
    "        # sort by decreasing length\n",
    "        lengths, idx_sort = np.sort(lengths)[::-1], np.argsort(-lengths)\n",
    "        sentences = np.array(sentences)[idx_sort]\n",
    "\n",
    "        return sentences, lengths, idx_sort\n",
    "\n",
    "    def encode(self, sentences, bsize=64, tokenize=True, verbose=False):\n",
    "        tic = time.time()\n",
    "        sentences, lengths, idx_sort = self.prepare_samples(\n",
    "                        sentences, bsize, tokenize, verbose)\n",
    "\n",
    "        embeddings = []\n",
    "        for stidx in range(0, len(sentences), bsize):\n",
    "            batch = self.get_batch(sentences[stidx:stidx + bsize])\n",
    "            if self.is_cuda():\n",
    "                batch = batch.cuda()\n",
    "            with torch.no_grad():\n",
    "                batch = self.forward((batch, lengths[stidx:stidx + bsize])).data.cpu().numpy()\n",
    "            embeddings.append(batch)\n",
    "        embeddings = np.vstack(embeddings)\n",
    "\n",
    "        # unsort\n",
    "        idx_unsort = np.argsort(idx_sort)\n",
    "        embeddings = embeddings[idx_unsort]\n",
    "\n",
    "        if verbose:\n",
    "            print('Speed : %.1f sentences/s (%s mode, bsize=%s)' % (\n",
    "                    len(embeddings)/(time.time()-tic),\n",
    "                    'gpu' if self.is_cuda() else 'cpu', bsize))\n",
    "        return embeddings\n",
    "\n",
    "    def visualize(self, sent, tokenize=True,display=False):\n",
    "\n",
    "        sent = sent.split() if not tokenize else self.tokenize(sent)\n",
    "        sent = [[self.bos] + [word for word in sent if word in self.word_vec] + [self.eos]]\n",
    "\n",
    "        if ' '.join(sent[0]) == '%s %s' % (self.bos, self.eos):\n",
    "            import warnings\n",
    "            warnings.warn('No words in \"%s\" have w2v vectors. Replacing \\\n",
    "                           by \"%s %s\"..' % (sent, self.bos, self.eos))\n",
    "        batch = self.get_batch(sent)\n",
    "\n",
    "        if self.is_cuda():\n",
    "            batch = batch.cuda()\n",
    "        output = self.enc_lstm(batch)[0]\n",
    "        output, idxs = torch.max(output, 0)\n",
    "        # output, idxs = output.squeeze(), idxs.squeeze()\n",
    "        idxs = idxs.data.cpu().numpy()\n",
    "        argmaxs = [np.sum((idxs == k)) for k in range(len(sent[0]))]\n",
    "\n",
    "        # visualize model\n",
    "        \n",
    "        \n",
    "        x = range(len(sent[0]))\n",
    "        y = [100.0 * n / np.sum(argmaxs) for n in argmaxs]\n",
    "        if display:\n",
    "            plt.xticks(x, sent[0], rotation=45)\n",
    "            plt.bar(x, y)\n",
    "            plt.ylabel('%')\n",
    "            plt.title('Visualisation of words importance')\n",
    "            plt.show()\n",
    "\n",
    "        return output, idxs,y,sent[0]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 1)  Pdf Retriever (using Tika & Enchant / np.vectorize for faster performance)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "class pdfconverter():\n",
    "    \n",
    "    def __init__(self,directory_path='../question_answering/pdf_files/'):\n",
    "        self.english_voc=enchant.Dict(\"en_US\")\n",
    "        self.text_processor_pdf=np.vectorize(self.text_preprocessing_pdf,otypes=[str])\n",
    "        self.df = pd.DataFrame(columns=['pdf','directory','directory_index','raw paragraphs','paragraphs'])\n",
    "        self.parser=[]\n",
    "        self.parser_raw=[]\n",
    "        self.directory_path=directory_path\n",
    "\n",
    "        self.list_folder=[]\n",
    "        self.paths={}\n",
    "        for r,d,f in os.walk(self.directory_path):\n",
    "            \n",
    "            for folder in d:\n",
    "                self.list_folder.append(folder)\n",
    "\n",
    "        for folder in self.list_folder:\n",
    "            for i,pdf in enumerate(os.listdir(os.path.join(self.directory_path,folder))):\n",
    "                if pdf!= '.DS_Store':\n",
    "                    self.paths[folder]=self.paths.get(folder,[])+[(i,pdf)]\n",
    "        \n",
    "    def transform(self):\n",
    "        \"\"\"Pdf-files reader with Apache Tika\"\"\"\n",
    "        count=1\n",
    "        for i,folder in enumerate(self.list_folder):\n",
    "            path=os.path.join(self.directory_path,folder)\n",
    "            for j,pdf in enumerate(os.listdir(path)):\n",
    "                if pdf!= '.DS_Store':\n",
    "                    self.df.loc[count] = [pdf,folder, i+1,None,None]\n",
    "                    \n",
    "                    \"\"\" 0- Read Pdf file \"\"\"\n",
    "                    raw = parser.from_file(os.path.join(path,pdf))\n",
    "                    s = raw['content']\n",
    "                    \n",
    "                    \"\"\" 1- Handle linebreaks to optimize TextBlob.sentences results\"\"\"\n",
    "                    s=self.treat_new_line(s)\n",
    "                    \n",
    "                    \"\"\" 2- Divide text by sentences using TextBlob\"\"\"\n",
    "                    blob=TextBlob(s)\n",
    "                    paragraphs = np.array([str(s) for s in blob.sentences],dtype=str)\n",
    "                    self.parser = []\n",
    "                    self.parser_raw=[]\n",
    "                    p=self.text_processor_pdf(paragraphs)\n",
    "                    \n",
    "                    \"\"\"\n",
    "                    3- Get rid of bad text data:\n",
    "                    Discard sentences with too long word (16 is the 99% quantile in english)\n",
    "                    Discard sentences with too much upper words (CREDENTIALS, Link, TITLE ..)\n",
    "                    \"\"\"\n",
    "                    index_=[i for i,c in enumerate(self.parser) if (True in [len(w)>=16 for w in c.split()] )]\n",
    "                    index_raw=[i for i,c in enumerate(self.parser_raw) if np.sum([w==w.upper() for w in c.split()])>=4]\n",
    "                    index=list(set(index_ + index_raw))\n",
    "                    self.df.loc[count,'paragraphs']=np.delete(np.array(self.parser),index)\n",
    "                    self.df.loc[count,'raw paragraphs']=np.delete(np.array(self.parser_raw),index)\n",
    "                    count+=1\n",
    "                            \n",
    "                    print(\"{} succesfully converted \".format(pdf))\n",
    "                \n",
    "        \"\"\"\n",
    "        for i, pdf in enumerate(self.list_pdf):\n",
    "            if pdf!= '.DS_Store':\n",
    "                #try:\n",
    "                self.df.loc[i] = [pdf, {None}]\n",
    "                raw = parser.from_file(os.path.join(self.directory_path,pdf))\n",
    "                s = raw['content']\n",
    "                paragraphs = np.array(re.split(u'\\n(?=\\u2028|[A-Z-0-9])', s),dtype=str)\n",
    "                self.parser = []\n",
    "                p=self.text_processor_pdf(paragraphs)\n",
    "\n",
    "                self.df.loc[i,'paragraphs']=self.parser\n",
    "                        #df.loc[i, 'paragraphs'] = list_par\n",
    "                print(\"{} succesfully converted \".format(pdf))\n",
    "                #except:\n",
    "                    #print(\"{} Error converting\".format(pdf))\n",
    "        \"\"\"\n",
    "        return self.df\n",
    "    \n",
    "    def remove_non_alpha(self,text):\n",
    "        \n",
    "        \"\"\" Remove non alpha-decimal caracters that are not dot or linebreaker \"\"\"\n",
    "        \n",
    "        removelist=\"-\\.\\/\"\n",
    "        re_alpha_numeric1=r\"[^0-9a-zA-Z\"+removelist+\" ]\"\n",
    "        clean_text=re.sub(re_alpha_numeric1,'',text)\n",
    "        clean_text=clean_text.replace('/',' ')\n",
    "        clean_text=re.sub(' +', ' ', clean_text)\n",
    "        return clean_text\n",
    "    \n",
    "    def treat_new_line(self,text):\n",
    "        \"\"\" \n",
    "        This function is aimed to deal with all types of linebreaks we met during our tests \n",
    "        There is linebreaks dure to cut-sentences, cut-words, bullet-list, title, new paragraphs, or sentences breaks\n",
    "        \"\"\"\n",
    "        text=text.replace('.\\n','. ')\n",
    "        text=re.sub(r'(\\n\\s*)+\\n+', '\\n\\n',text )\n",
    "        \n",
    "        lw=text.split('\\n\\n')\n",
    "        lw=[c for c in lw if c.replace(' ','')!='']\n",
    "            \n",
    "        for i in range(1,len(lw)):\n",
    "            try:\n",
    "\n",
    "                el=lw[i]\n",
    "                if len(el)>=1:\n",
    "                    try:\n",
    "                        first_w=el.split()[0]\n",
    "                    except:\n",
    "                        first_w=el\n",
    "                    first_l=first_w[0]\n",
    "                    if first_l.isupper() :\n",
    "                        if len(lw[i-1])>0 and lw[i-1].replace(' ','') !='':\n",
    "                            if lw[i-1].replace(' ','')[-1] not in [\":\",'.',\"-\",'/',\"'\",\";\"]:\n",
    "                                prec=lw[i-1].split(\".\")[-1]\n",
    "                                merge=(prec+' '+lw[i]).split()\n",
    "                                dic=dict(nltk.tag.pos_tag(merge))\n",
    "                                proper_noun=dic[first_w]=='NNP'\n",
    "                                if not proper_noun:\n",
    "                                    if not \".\" in lw[i-1]:\n",
    "                                        lw[i-1]=lw[i-1]+\".\\n\\n \"\n",
    "                                    else:\n",
    "                                        lw[i-1]=lw[i-1][:-1]+\".\\n\\n \"\n",
    "                                else:\n",
    "                                    lw[i-1]+=' '\n",
    "\n",
    "\n",
    "                    elif first_l.islower():\n",
    "                        if len(lw[i-1])>0 and lw[i-1][-1].replace(' ','')!='':\n",
    "\n",
    "                            if lw[i-1][-1].replace(' ','')[-1]!='-':\n",
    "                                lw[i-1]+=\"\"\n",
    "                            else:\n",
    "\n",
    "                                ltemp_prev=lw[i-1].split(' ')\n",
    "                                ltemp_next=lw[i].split(' ')\n",
    "                                motprev=ltemp_prev[-1][:-1]\n",
    "                                motnext=lw[i].split(' ')[0]\n",
    "                                if len((motprev+' '+motnext).split())==2:\n",
    "\n",
    "                                    if self.english_voc.check(motprev) and self.english_voc.check(motnext) and not self.english_voc.check(\"\".join([motprev,motnext])) :\n",
    "                                        newmot=\" \".join([motprev,motnext])\n",
    "                                    else:\n",
    "                                        newmot=\"\".join([motprev,motnext])\n",
    "                                    ltemp_prev[-1]=newmot\n",
    "                                    ltemp_next[0]=\"\"\n",
    "                                    lw[i-1]=\" \".join(ltemp_prev)\n",
    "                                    lw[i]=\" \".join(ltemp_next)\n",
    "                    else:\n",
    "                        lw[i-1]+=\"\\n\\n\"\n",
    "            \n",
    "            except:\n",
    "                print('Error occurs, the reader may not be suitable for your pdf files')\n",
    "            \n",
    "            \n",
    "        text=\"\".join(lw)\n",
    "        \n",
    "        lw=text.split('\\n')\n",
    "        lw=[c for c in lw if c.replace(' ','')!='']\n",
    "        for i in range(1,len(lw)):\n",
    "            try:\n",
    "                el=lw[i]\n",
    "                if len(el)>=1:\n",
    "                    try:\n",
    "                        first_w=el.split()[0]\n",
    "                    except:\n",
    "                        first_w=el\n",
    "                    first_l=first_w[0]\n",
    "                    if first_l.isupper() :\n",
    "                        if len(lw[i-1])>0 and lw[i-1].replace(' ','')!='':\n",
    "                            if lw[i-1].replace(' ','')[-1] not in [\":\",'.',\"-\",'/',\"'\",\";\"]:\n",
    "                                prec=lw[i-1].split(\".\")[-1]\n",
    "                                merge=(prec+' '+lw[i]).split()\n",
    "                                dic=dict(nltk.tag.pos_tag(merge))\n",
    "                                proper_noun=dic[first_w]=='NNP'\n",
    "                                if not proper_noun:\n",
    "                                    if not \".\" in lw[i-1]:\n",
    "                                        lw[i-1]=lw[i-1]+\".\\n\\n \"\n",
    "                                    else:\n",
    "                                        lw[i-1]=lw[i-1][:-1]+\".\\n\\n \"\n",
    "                                else:\n",
    "                                    lw[i-1]+=' '\n",
    "                    elif first_l.islower():\n",
    "                        if len(lw[i-1])>0 and lw[i-1].replace(' ','')!='':\n",
    "                            if lw[i-1].replace(' ','')[-1]==\"-\":\n",
    "                                ltemp_prev=lw[i-1].split(' ')\n",
    "                                ltemp_next=lw[i].split(' ')\n",
    "                                motprev=ltemp_prev[-1][:-1]\n",
    "                                motnext=lw[i].split(' ')[0]\n",
    "                                if len((motprev+' '+motnext).split())==2:\n",
    "                                    if self.english_voc.check(motprev) and self.english_voc.check(motnext) and not self.english_voc.check(\"\".join([motprev,motnext])) :\n",
    "                                        newmot=\" \".join([motprev,motnext])\n",
    "                                    else:\n",
    "                                        newmot=\"\".join([motprev,motnext])\n",
    "                                    ltemp_prev[-1]=newmot\n",
    "                                    ltemp_next[0]=\"\"\n",
    "                                    lw[i-1]=\" \".join(ltemp_prev)\n",
    "                                    lw[i]=\" \".join(ltemp_next)\n",
    "\n",
    "\n",
    "\n",
    "                            else:\n",
    "                                lw[i-1]+=\" \"\n",
    "                    else:\n",
    "                        lw[i-1]+=\" \"\n",
    "        \n",
    "            except:\n",
    "                print('Error occurs, the reader may not be suitable for your pdf files')\n",
    "        \n",
    "        text=\"\".join(lw)\n",
    "        return text\n",
    "    \n",
    "    \"\"\"\n",
    "    def remove_end_paragraphs(self,p):\n",
    "        if '-\\n' in p:\n",
    "            paraph=[]\n",
    "            ltemp=p.split(' ')\n",
    "            for mot in ltemp:\n",
    "                if '-\\n' in mot:\n",
    "                    if len(mot.replace('-\\n',' ').split())==2:\n",
    "                        mot1,mot2=mot.replace('-\\n',' ').split()\n",
    "                        if self.english_voc.check(mot1) and self.english_voc.check(mot2) and not self.english_voc.check(\"\".join([mot1,mot2])) :\n",
    "                            newmot=\" \".join([mot1,mot2])\n",
    "                        else:\n",
    "                            newmot=\"\".join([mot1,mot2])\n",
    "                        paraph.append(newmot)\n",
    "                else:\n",
    "                    paraph.append(mot)\n",
    "            p=\" \".join(paraph)\n",
    "        return p.replace('\\n',' ')\n",
    "    \"\"\"\n",
    "    \n",
    "    def cut_text(self,p):\n",
    "        \"\"\" Cut text into sentences \"\"\"\n",
    "        if len(p)>=100:\n",
    "            phrases=self.remove_non_alpha(p)    \n",
    "            phrases=phrases.replace('.',' ')\n",
    "            phrases=phrases.replace('-',' ')\n",
    "            phrases=re.sub(' +', ' ', phrases)\n",
    "            phrases=re.sub(r'([0-9]+(?=[a-z])|(?<=[a-z])[0-9]+)',\"\",phrases)\n",
    "            phrases=phrases.lower()\n",
    "            self.parser.append(re.sub(' +', ' ', phrases))\n",
    "            \n",
    "        return None \n",
    "    \n",
    "    def cut_text_raw(self,p):\n",
    "        \"\"\"Cut raw/untreated text into sentences \"\"\"\n",
    "        \n",
    "        if len(self.remove_non_alpha(p))>=100:\n",
    "            self.parser_raw.append(re.sub(' +', ' ', p))\n",
    "            \n",
    "        return None\n",
    "    \n",
    "    def text_preprocessing_pdf(self,p):\n",
    "        \"\"\" Pipeline of sentences-preprocessing using np.vectorize for faster results \"\"\"\n",
    "        #remover_end_paragraphs=np.vectorize(self.remove_end_paragraphs,otypes=[str])\n",
    "        cleaner=np.vectorize(self.remove_non_alpha,otypes=[str])\n",
    "        cut_text=np.vectorize(self.cut_text,otypes=[str])\n",
    "        cut_text_raw=np.vectorize(self.cut_text_raw,otypes=[str])\n",
    "        cut_text_raw(p)\n",
    "        p=cleaner(p)\n",
    "        cut_text(p)\n",
    "        return p\n",
    "\n",
    "\n",
    "    \n",
    "    \n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2) Tf Idf search ranking retriever with Porter-Stemming, Cosine Similarity and n-grams"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.set_option('display.max_colwidth', 20000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "class TfidfRetriever(BaseEstimator):\n",
    "    \"\"\"\n",
    "    A scikit-learn wrapper for TfidfRetriever. Trains a tf-idf matrix from a corpus\n",
    "    of documents then finds the most N similar documents of a given input document by\n",
    "    taking the dot product of the vectorized input document and the trained tf-idf matrix.\n",
    "    \n",
    "    Parameters\n",
    "    ----------\n",
    "    ngram_range : bool, optional\n",
    "        [shape of ngram used to build vocab] (the default is False)\n",
    "    max_df : bool, optional\n",
    "        [while building vocab delete words that have a frequency>max_df] (the default is False)\n",
    "    stop_words : str, optional\n",
    "        ['english is the only value accepted'] (the default is False)\n",
    "    paragraphs : iterable\n",
    "        an iterable which yields either str, unicode or file objects\n",
    "    top_n : int\n",
    "        maximum number of top articles to retrieve\n",
    "        header should be of format: title, paragraphs.\n",
    "    verbose : bool, optional\n",
    "        If true, all of the warnings related to data processing will be printed.\n",
    "    Attributes\n",
    "    ----------\n",
    "    vectorizer : TfidfVectorizer\n",
    "        See https://scikit-learn.org/stable/modules/generated/sklearn.feature_extraction.text.TfidfVectorizer.html\n",
    "    tfidf_matrix : sparse matrix, [n_samples, n_features]\n",
    "        Tf-idf-weighted document-term matrix.\n",
    "        \n",
    "    Examples\n",
    "    --------\n",
    "    >>> retriever = TfidfRetriever(ngram_range=(1, 2), max_df=0.85, stop_words='english')\n",
    "    >>> retriever.fit(X=df['content'])\n",
    "    \n",
    "    >>> doc_index=int(input('Which document do you want to use for your question?'))\n",
    "    >>> retriever.transform(X=df.loc[doc_index,'content'])\n",
    "    \n",
    "    >>> Q=str(input('Enter your question'))\n",
    "    >>> Q=retriever.vectorizer.transform([Q])\n",
    "    >>> closest_docs,scores = self.retriever.predict(newQst,df.loc[doc_index,'content'])\n",
    "    \"\"\"\n",
    "\n",
    "    def __init__(self,\n",
    "                 ngram_range=(1, 2),\n",
    "                 max_df=0.85,\n",
    "                 stop_words='english',\n",
    "                 paragraphs=None,\n",
    "                 verbose=False, top_n=5,\n",
    "                lemmatize=True,\n",
    "                transform_text=True):\n",
    "\n",
    "        self.ngram_range = (1,1)\n",
    "        self.max_df = max_df\n",
    "        self.stop_words = stop_words\n",
    "        self.paragraphs = paragraphs\n",
    "        self.top_n = top_n\n",
    "        self.verbose = verbose\n",
    "        self.transform_text=transform_text\n",
    "        self.lemmatize=lemmatize and self.transform_text\n",
    "        self.stem=not lemmatize and self.transform_text\n",
    "        if self.stem: self.stemmer=PorterStemmer()\n",
    "        else: self.lemmatizer=WordNetLemmatizer() \n",
    "        self.stop_words_list=[self.tokenize(word)[0] for word in list(skf._check_stop_list('english'))]\n",
    "\n",
    "    def stem_tokens(self,tokens, stemmer):\n",
    "        stemmed = []\n",
    "        for item in tokens:\n",
    "            stemmed.append(stemmer.stem(item))\n",
    "        return stemmed\n",
    "    \n",
    "    def lemmatize_tokens(self,tokens,lemmatizer):\n",
    "        lemmas=[]\n",
    "        for item in tokens:\n",
    "            for word, tag in pos_tag(word_tokenize(item)):\n",
    "                wntag = tag[0].lower()\n",
    "                wntag = wntag if wntag in ['a', 'r', 'n', 'v'] else None\n",
    "                if not wntag:\n",
    "                    lemma = word\n",
    "                else:\n",
    "                    lemma = lemmatizer.lemmatize(word, wntag)\n",
    "            \n",
    "            lemmas.append(lemma)\n",
    "        return lemmas\n",
    "\n",
    "        \"\"\"\n",
    "        for item in tokens:\n",
    "            lemmas.append(lemmatizer.lemmatize(item))\n",
    "        return lemmas\n",
    "        \"\"\"\n",
    "\n",
    "    def tokenize(self,text):\n",
    "        tokens = nltk.word_tokenize(text)\n",
    "        if self.lemmatize:\n",
    "        #stems = self.stem_tokens(tokens, self.stemmer)\n",
    "            lemmas=self.lemmatize_tokens(tokens,self.lemmatizer)\n",
    "            return lemmas\n",
    "        elif self.stem:\n",
    "            stems = self.stem_tokens(tokens, self.stemmer)\n",
    "            return stems\n",
    "        else:\n",
    "            return tokens\n",
    "        \n",
    "        \n",
    "    def fit(self, X, y=None): #generate features and return tfidf scores matrix \n",
    "\n",
    "        self.vectorizer = TfidfVectorizer(ngram_range=self.ngram_range,\n",
    "                                          max_df=self.max_df,\n",
    "                                   stop_words=self.stop_words_list,tokenizer=self.tokenize)\n",
    "        self.vectorizer.fit(X)\n",
    "        return self\n",
    "    \n",
    "    def transform(self,X,y=None):\n",
    "        self.tfidf_matrix=self.vectorizer.transform(X)\n",
    "        return self\n",
    "    \n",
    "    def predict(self, X, metadata):\n",
    "        tfidf_matrix=self.tfidf_matrix[metadata[0]:metadata[1],:]\n",
    "        #cherche les querries les plus proches de chaque sentence\n",
    "        t0 = time.time()\n",
    "        question_vector = self.vectorizer.transform([X])\n",
    "        scores = pd.DataFrame(tfidf_matrix.dot(question_vector.T).toarray())\n",
    "        closest_docs_indices = scores.sort_values(by=0, ascending=False).index[:self.top_n].values\n",
    "\n",
    "        # inspired from https://github.com/facebookresearch/DrQA/blob/50d0e49bb77fe0c6e881efb4b6fe2e61d3f92509/scripts/reader/interactive.py#L63\n",
    "        if self.verbose:\n",
    "            rank = 1\n",
    "            table = prettytable.PrettyTable(['rank', 'index', 'title'])\n",
    "            for i in range(len(closest_docs_indices)):\n",
    "                index = closest_docs_indices[i]\n",
    "                if self.paragraphs:\n",
    "                    article_index = self.paragraphs[int(index)]['index']\n",
    "                    title = metadata.iloc[int(article_index)]['title']\n",
    "                else:\n",
    "                    title = metadata.iloc[int(index)]['title']\n",
    "                table.add_row([rank, index, title])\n",
    "                rank+=1\n",
    "            print(table)\n",
    "            print('Time: {} seconds'.format(round(time.time() - t0, 5)))\n",
    "\n",
    "        return closest_docs_indices,scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "I\n",
      "love\n",
      "potatoe\n",
      "cabbage\n",
      "holistic\n",
      "engineering\n",
      "and\n",
      "that\n",
      "be\n",
      "my\n",
      "life\n",
      "when\n",
      "I\n",
      "be\n",
      "pay\n",
      "attention\n"
     ]
    }
   ],
   "source": [
    "from nltk.stem import WordNetLemmatizer\n",
    "from nltk import pos_tag, word_tokenize\n",
    "wnl = WordNetLemmatizer()\n",
    "sent = 'I love potatoe cabbage holistic engineering and that is my life when I am paying attention'\n",
    "for word, tag in pos_tag(word_tokenize(sent)):\n",
    "    wntag = tag[0].lower()\n",
    "    wntag = wntag if wntag in ['a', 'r', 'n', 'v'] else None\n",
    "    if not wntag:\n",
    "        lemma = word\n",
    "    else:\n",
    "        lemma = wnl.lemmatize(word, wntag)\n",
    "    print(lemma)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Infersent search ranking retriever (used Tokenizing and Finetuning for our dataset + PCA to speed-up a bit )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "class InfersentRetriever(BaseEstimator):\n",
    "    \"\"\"\n",
    "    A scikit-learn estimator for TfidfRetriever. Trains a tf-idf matrix from a corpus\n",
    "    of documents then finds the most N similar documents of a given input document by\n",
    "    taking the dot product of the vectorized input document and the trained tf-idf matrix.\n",
    "    \n",
    "    Parameters\n",
    "    ----------\n",
    "    Ktop_words: int\n",
    "        number of words used for sentence embeddings (the K most frequent english words - \n",
    "        for more information see Infersent repository.)\n",
    "    paragraphs : iterable\n",
    "        an iterable which yields either str, unicode or file objects\n",
    "    top_n : int\n",
    "        maximum number of top articles to retrieve\n",
    "        header should be of format: title, paragraphs.\n",
    "    verbose : bool, optional\n",
    "        If true, all of the warnings related to data processing will be printed.\n",
    "    Attributes\n",
    "    \"\"\" \n",
    "    def __init__(self,\n",
    "                 top_n=3,\n",
    "                Ktop_words=500000,\n",
    "                sentences=None,\n",
    "                verbose=False,\n",
    "                model_path=None, \n",
    "                w2v_path=None):\n",
    "        self.top_n = top_n\n",
    "        self.verbose = verbose\n",
    "        self.Ktop_words=Ktop_words\n",
    "        self.w2v_path=w2v_path\n",
    "        self.model_path=model_path\n",
    "        self.kwargs_Infersent = {'bsize': 64, 'word_emb_dim': 300, 'enc_lstm_dim': 2048,\n",
    "                        'pool_type': 'max', 'dpout_model': 0.0, 'version': 2}\n",
    "        \n",
    "        self.infersent = InferSent_(self.kwargs_Infersent)\n",
    "        self.infersent.load_state_dict(torch.load(self.model_path))\n",
    "        self.infersent.set_w2v_path(self.w2v_path)\n",
    "        self.infersent.build_vocab_k_words(K=self.Ktop_words)\n",
    "        \n",
    "    def fit(self,X,y=None):\n",
    "        \"\"\" X: any iterable which contains words to finetune vocabulary \"\"\"\n",
    "        self.infersent.update_vocab(list([s for s in X ]))\n",
    "        return self\n",
    "    \n",
    "    def transform(self,X,y=None):\n",
    "        \"\"\" X: any iterable which contains sentences to embed \"\"\"\n",
    "        \n",
    "        self.embeddings = self.infersent.encode(list([s for s in X ]),tokenize=True)\n",
    "        self.embeddings=np.apply_along_axis(lambda v: self.normalize(v), 1,self.embeddings)\n",
    "        self.pca = decomposition.PCA(n_components=900)\n",
    "        self.pca.fit(self.embeddings)\n",
    "        self.embeddings=self.pca.transform(self.embeddings)\n",
    "        self.reduced_embeddings = np.apply_along_axis(lambda v: self.normalize(v), 1,self.embeddings)\n",
    "        return self\n",
    "\n",
    "    def normalize(self,array):\n",
    "        return array/np.linalg.norm(array)\n",
    "    \n",
    "    def predict(self,X,metadata):\n",
    "\n",
    "        reduced_embeddings=self.reduced_embeddings[metadata[0]:metadata[1],:]\n",
    "        question=self.infersent.encode([X])\n",
    "        encoded_question=self.normalize(question)\n",
    "        transformed_question=self.pca.transform(encoded_question)\n",
    "        self.reduced_question=self.normalize(transformed_question)\n",
    "        \n",
    "        self.data=reduced_embeddings.dot(self.reduced_question.T)\n",
    "        self.scores_inf=pd.DataFrame(self.data,index=range(len(self.data)))\n",
    "        self.closest_docs_indices = self.scores_inf.sort_values(by=0, ascending=False).index[:self.top_n].values\n",
    "        \n",
    "        return self.closest_docs_indices,self.scores_inf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "class BertRetriever(BaseEstimator):\n",
    "    def __init__(self,top_n=5):\n",
    "        self.top_n = top_n\n",
    "        self.bert=SentenceTransformer('bert-large-nli-stsb-mean-tokens')\n",
    "    def fit(self,X,y=None):\n",
    "        \"\"\" X: any iterable which contains words to finetune vocabulary \"\"\"\n",
    "        return self\n",
    "    \n",
    "    def transform(self,X,y=None):\n",
    "        \"\"\" X: any iterable which contains sentences to embed \"\"\"\n",
    "        self.embeddings = self.bert.encode(list([s for s in X ]))\n",
    "        self.reduced_embeddings = np.apply_along_axis(lambda v: self.normalize(v), 1,self.embeddings)\n",
    "        return self\n",
    "    \n",
    "    def normalize(self,array):\n",
    "        return array/np.linalg.norm(array)\n",
    "    \n",
    "    def predict(self,X,metadata):\n",
    "        \n",
    "        question=self.bert.encode([X])\n",
    "        encoded_question=self.normalize(question)\n",
    "        self.reduced_question=self.normalize(question)\n",
    "        \n",
    "        reduced_embeddings=self.reduced_embeddings[metadata[0]:metadata[1],:]\n",
    "        \n",
    "        data=reduced_embeddings.dot(self.reduced_question.T)\n",
    "        self.scores_inf=pd.DataFrame(data,index=range(len(data)))\n",
    "        closest_docs_indices = self.scores_inf.sort_values(by=0, ascending=False).index[:self.top_n].values\n",
    "        return closest_docs_indices,self.scores_inf\n",
    "\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "class DistiLBertRetriever(BertRetriever):\n",
    "    def __init__(self,top_n=3):\n",
    "        super(BertRetriever, self).__init__()\n",
    "        self.bert=SentenceTransformer('distilbert-base-uncased')\n",
    "    def fit(self,X,y=None):\n",
    "        \"\"\" X: any iterable which contains words to finetune vocabulary \"\"\"\n",
    "        return self\n",
    "    \n",
    "    def transform(self,X,y=None):\n",
    "        \"\"\" X: any iterable which contains sentences to embed \"\"\"\n",
    "        self.embeddings = self.bert.encode(list([s for s in X ]))\n",
    "        self.reduced_embeddings = np.apply_along_axis(lambda v: self.normalize(v), 1,self.embeddings)\n",
    "        return self\n",
    "    \n",
    "    def normalize(self,array):\n",
    "        return array/np.linalg.norm(array)\n",
    "    \n",
    "    def predict(self,X,metadata):\n",
    "\n",
    "        question=self.bert.encode([X])\n",
    "        encoded_question=self.normalize(question)\n",
    "        self.reduced_question=self.normalize(question)\n",
    "        \n",
    "        reduced_embeddings=self.reduced_embeddings[metadata[0]:metadata[1],:]\n",
    "        \n",
    "        data=reduced_embeddings.dot(self.reduced_question.T)\n",
    "        self.scores_inf=pd.DataFrame(data,index=range(len(data)))\n",
    "        closest_docs_indices = self.scores_inf.sort_values(by=0, ascending=False).index[:self.top_n].values\n",
    "        return closest_docs_indices,self.scores_inf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "class Tfidf_FarahatCluster_Bert(BaseEstimator):\n",
    "    \"\"\"\n",
    "    A scikit-learn estimator for TfidfRetriever. Trains a tf-idf matrix from a corpus\n",
    "    of documents then finds the most N similar documents of a given input document by\n",
    "    taking the dot product of the vectorized input document and the trained tf-idf matrix.\n",
    "    \n",
    "    Parameters\n",
    "    ----------\n",
    "    ngram_range : bool, optional\n",
    "        [shape of ngram used to build vocab] (the default is False)\n",
    "    max_df : bool, optional\n",
    "        [while building vocab delete words that have a frequency>max_df] (the default is False)\n",
    "    stop_words : str, optional\n",
    "        ['english is the only value accepted'] (the default is False)\n",
    "    paragraphs : iterable\n",
    "        an iterable which yields either str, unicode or file objects\n",
    "    top_n : int\n",
    "        maximum number of top articles to retrieve\n",
    "        header should be of format: title, paragraphs.\n",
    "    verbose : bool, optional\n",
    "        If true, all of the warnings related to data processing will be printed.\n",
    "    Attributes\n",
    "    ----------\n",
    "    vectorizer : TfidfVectorizer\n",
    "        See https://scikit-learn.org/stable/modules/generated/sklearn.feature_extraction.text.TfidfVectorizer.html\n",
    "    tfidf_matrix : sparse matrix, [n_samples, n_features]\n",
    "        Tf-idf-weighted document-term matrix.\n",
    "        \n",
    "    Examples\n",
    "    --------\n",
    "    >>> retriever = TfidfRetriever(ngram_range=(1, 2), max_df=0.85, stop_words='english')\n",
    "    >>> retriever.fit(X=df['content'])\n",
    "    \n",
    "    >>> doc_index=int(input('Which document do you want to use for your question?'))\n",
    "    >>> retriever.transform(X=df.loc[doc_index,'content'])\n",
    "    \n",
    "    >>> Q=str(input('Enter your question'))\n",
    "    >>> Q=retriever.vectorizer.transform([Q])\n",
    "    >>> closest_docs,scores = self.retriever.predict(newQst,df.loc[doc_index,'content'])\n",
    "    \"\"\"\n",
    "\n",
    "    def __init__(self, TF_emb, q_emb, content, content_doc,stemmed_content, vocab, l_querries,l_querries_raw, by_querries=True, top_n=5,threshold_w=0.002, portion_w=1.0,rank=500,verbose=False):\n",
    "\n",
    "        self.top_n = top_n\n",
    "        self.verbose = verbose\n",
    "        self.TF_emb=TF_emb\n",
    "        self.threshold_importance=threshold_w\n",
    "        self.prop_w=portion_w\n",
    "        self.rk=rank\n",
    "        self.by_querries=by_querries\n",
    "        self.querries=l_querries.copy() #(dataframe querries with word importance)\n",
    "        self.querries_raw=l_querries_raw.copy()\n",
    "        self.content=content\n",
    "        self.content_doc=content_doc\n",
    "        self.stemmed_content=stemmed_content\n",
    "        self.vocab=vocab\n",
    "        self.dic_emb={}\n",
    "        self.q_emb=q_emb\n",
    "    \n",
    "    def select_term_Naystrom(self,T):\n",
    "\n",
    "        #T is the Tf-Idf Matrix \n",
    "        #s is the fraction of important words that we want to retrieve (s=1.0 generally)\n",
    "        print('begin of term selection')\n",
    "        #Retrieve all the stems of tf-idf vocabulary\n",
    "        terms=self.vocab\n",
    "        \n",
    "        #First we remove digits of the terms candidate\n",
    "        n=int(self.prop_w*len(terms))\n",
    "        idx_words=[]\n",
    "        for i,term in enumerate(terms):\n",
    "            try: float(term)\n",
    "            except: idx_words.append(i)\n",
    "\n",
    "        #Secondly we set a threshold to select words that appear at least each p documents\n",
    "\n",
    "        #Set threshold to select words that appear at least each p documents \n",
    "        self.freq_term=np.zeros((len(self.content),len(terms)))\n",
    "        \n",
    "        for j,stem in enumerate(self.stemmed_content):\n",
    "            for i,c in enumerate(terms):\n",
    "                if c in stem:\n",
    "                    self.freq_term[j,i]+=1\n",
    "                    \n",
    "        self.freq_term_by_doc=np.apply_along_axis(lambda x: np.mean(x),0,self.freq_term)\n",
    "        ids=np.where(self.freq_term_by_doc>self.threshold_importance )[0]\n",
    "        idx_words=[ i for i in ids if i in idx_words]\n",
    "\n",
    "\n",
    "        #Init selection of terms with most correlation \n",
    "        if self.prop_w!=1.0:\n",
    "            prob=np.sum(np.abs(T)>0,axis=0)\n",
    "            prob=prob/np.sum(prob)\n",
    "            prob=np.squeeze(prob)\n",
    "            idx=[]\n",
    "            m=len(idx_words)\n",
    "\n",
    "            for i in range(n):\n",
    "\n",
    "                p=int(np.random.choice(m,1,prob[0]))\n",
    "                idx.append(int(idx_words[p]))\n",
    "                prob[idx_words[p]]=0\n",
    "                prob=prob/np.sum(prob)\n",
    "\n",
    "            return idx,np.squeeze(T[:,idx])\n",
    "        \n",
    "        else:\n",
    "            idx=idx_words\n",
    "            self.idx=idx\n",
    "            return idx,np.squeeze(T[:,idx])\n",
    "        print('end of term selection')\n",
    "    \n",
    "    \n",
    "\n",
    "    def fit(self, X, y=None): \n",
    "\n",
    "        return self\n",
    "\n",
    "    def transform(self): #generate new enhanced tf-idf-farahat features ( co-occurence weight frequency matrix) \n",
    "        \n",
    "        idx,A=self.select_term_Naystrom(self.TF_emb.toarray())   \n",
    "        \n",
    "        #Full rank approximation\n",
    "        if self.rk==-1:\n",
    "            self.rk=len(idx)\n",
    "                \n",
    "        qemb=self.q_emb\n",
    "        print('begin of creation kernel')\n",
    "        \n",
    "        X=self.TF_emb.toarray().transpose()\n",
    "        X=np.c_[X,qemb]\n",
    "\n",
    "        L=np.eye(X.shape[0])*np.sqrt(X.shape[0])\n",
    "        L_inv=np.linalg.inv(L)\n",
    "        G=L_inv@X@X.transpose()@L_inv\n",
    "        Gs=G[idx,:]\n",
    "        Gs=Gs[:,idx]\n",
    "        S,V,D=np.linalg.svd(Gs, full_matrices=True)\n",
    "        Ssub,Vsub=S[:,:self.rk], np.diag(V)[:self.rk,:self.rk]\n",
    "        #Ssub,Vsub=S,np.diag(V)\n",
    "        #G=Ssub@Vsub$Ssub.transpose() but this operation is not necessary, we just need the decomposition of G\n",
    "\n",
    "        D_sub_inv=np.diag(np.apply_along_axis(lambda x: 1/np.sqrt(x) , 0, V[:self.rk]))\n",
    "        #D_sub_inv=np.diag(np.apply_along_axis(lambda x: 1/np.sqrt(x) , 0, V))\n",
    "        W=(((D_sub_inv@Ssub.transpose())@X[idx,:])@(X.transpose()))@X\n",
    "        self.TF_FARAHAT_emb=np.apply_along_axis(lambda x: x/np.sqrt(np.sum(x**2)), 1,W.transpose())\n",
    "        print('end of creation kernel')\n",
    "        return self\n",
    "\n",
    "    \n",
    "    \n",
    "\n",
    "    \n",
    "\n",
    "    def predict(self,metadata,repo):\n",
    "        print('begin Tf_farahat_predict')\n",
    "        self.content_repo=self.content_doc[repo]\n",
    "        questions=self.querries['query'].tolist()\n",
    "        W_=self.TF_FARAHAT_emb\n",
    "        print('begin scores compute and ranking')\n",
    "        scores=W_[-len(questions):]@(W_[metadata[0]:metadata[1]].transpose())\n",
    "        print('end scores compute')\n",
    "        rank=np.apply_along_axis(lambda x:np.argsort(-x),1,scores)\n",
    "        raw_or_treated=1 #raw text\n",
    "        print('end scores ranking, scores.shape=',scores.shape)\n",
    "        \n",
    "        all_answers=[]\n",
    "        all_scores=[]\n",
    "        all_indices=[]\n",
    "        all_models=[]\n",
    "        all_ranks=[]\n",
    "        all_querries=[]\n",
    "        \n",
    "        for question in range(len(questions)):\n",
    "            cluster_ids=[]\n",
    "            answers=[]\n",
    "            answers_raw=[]\n",
    "            dic_answers={}\n",
    "            count_answers=1\n",
    "            #print('*****  Question {} : {} {}'.format(question,questions[question],'********'))\n",
    "            rk=0\n",
    "            count=0\n",
    "            #print('\\n----------------\\n')\n",
    "            w_important=[w for w in questions[question].split(\" \") if w==w.upper() ]\n",
    "            #Display best candidates according to clustering\n",
    "            \n",
    "            ### Special words retrieval (Tf-Idf search) ###\n",
    "            if w_important !=[]:\n",
    "          \n",
    "                for w in w_important:\n",
    "                    ll=QAmodel.retriever.tokenize(w)\n",
    "                    #print(\"w,ll=\",w,ll)\n",
    "                    if ll!=[]:\n",
    "                        w=ll[0]\n",
    "                        best_id=[i for i in range(rank.shape[1]) if w in self.content_repo[0][rank[question,i]].split(' ')]\n",
    "                        if best_id!=[]:\n",
    "                            id_match=best_id[0]\n",
    "                            result=self.content_repo[raw_or_treated][rank[question,id_match]]\n",
    "                            #print('Special Anserw : {}'.format(self.content_repo[raw_or_treated][rank[question,id_match]]))\n",
    "                            #print('\\n----------------\\n')\n",
    "\n",
    "\n",
    "                            all_indices.extend([rank[question,id_match]])\n",
    "                            all_scores.extend([scores[question,rank[question,id_match]]])\n",
    "                            all_answers.extend([result])\n",
    "                            all_ranks.append(rk+1)\n",
    "                            all_models.append(\"Tf-Idf- Semantic Kernel- Bert\")\n",
    "                            all_querries.append(self.querries_raw[question])\n",
    "                            rk+=1\n",
    "                            count_answers+=1\n",
    "            \n",
    "            ###Normal Loop Spherical Kmeans Clustering and Applying Bert encoder###\n",
    "            #1 Get clusters\n",
    "            print('begin loop cluster retriever')\n",
    "            for answ in range(30):\n",
    "                while True:\n",
    "                    answer_raw=self.content_repo[raw_or_treated][rank[question,count]]\n",
    "                    answer=self.content_repo[1-raw_or_treated][rank[question,count]]\n",
    "                    dic_answers[answer]=dic_answers.get(answer,0)+1\n",
    "                    if dic_answers[answer]==1:\n",
    "                        break\n",
    "                    cluster_ids.append(metadata[0]+rank[question,count])\n",
    "                    count+=1\n",
    "                \n",
    "                answers.append(answer)\n",
    "                answers_raw.append(answer_raw)\n",
    "\n",
    "                #print('Anserw n°{} : {}'.format(count_answers,answer))\n",
    "                #print('\\n----------------\\n')\n",
    "                \n",
    "            print('end loop cluster retriever')\n",
    "\n",
    "            #2) Use Bert encoder inside clusters + cosine similarity retrieval\n",
    "            Qst=questions[question].lower()\n",
    "            newQst=pdfconverter().remove_non_alpha(Qst)\n",
    "            newQst=newQst.replace('.','')\n",
    "\n",
    "            print('initiate bert cluster retriever')\n",
    "            bert=BertRetriever(top_n=5)\n",
    "            \n",
    "            #embeddings = bert.transform(list([s for s in answers ]))\n",
    "            try:\n",
    "                bert.embeddings = [QAmodel.bert.embeddings[i] for i in cluster_ids]\n",
    "                bert.reduced_embeddings = np.apply_along_axis(lambda v: bert.normalize(v), 1,bert.embeddings)\n",
    "            except:\n",
    "                indices_saved=[i for (i,c) in enumerate(answers) if c in self.dic_emb.keys()]\n",
    "                print('just saved {} bert encodings'.format(len(indices_saved)))\n",
    "                indices_new=[i for i in range(len(answers)) if i not in indices_saved ]\n",
    "                indices_sort=indices_saved+indices_new\n",
    "                indices_unsort=np.argsort(indices_sort)\n",
    "                saved_embeddings=np.array([self.dic_emb[answers[i]] for i in indices_saved])\n",
    "                new_item=[answers[i] for i in indices_new]\n",
    "                if indices_new!=[]:\n",
    "                    bert.transform(list(new_item))\n",
    "                    new_embeddings=bert.reduced_embeddings\n",
    "                \n",
    "                for (i,s) in enumerate(new_item):\n",
    "                    print('shape1=',new_embeddings[i].shape)\n",
    "                    self.dic_emb[s]=new_embeddings[i]\n",
    "                    \n",
    "                print('shape2=',saved_embeddings.shape,new_embeddings.shape)\n",
    "                if indices_saved!=[]:\n",
    "                    if indices_new==[]:\n",
    "                        bert.reduced_embeddings=saved_embeddings\n",
    "                    else:\n",
    "                        bert.reduced_embeddings=np.r_[saved_embeddings,new_embeddings][indices_unsort]\n",
    "                \n",
    "                \n",
    "                \n",
    "            print('begin reranking prediction with bert class')\n",
    "            indices,scores_bert=bert.predict(newQst,[0,len(answers)])\n",
    "            scores_bert=scores_bert.loc[indices].values[:,0]\n",
    "            text=[ answers_raw[i] for i in indices]\n",
    "            print('end reranking prediction with bert class')\n",
    "            for i,c in enumerate(text):\n",
    "                \n",
    "                #print('Anserws n° {} : {}'.format(i+1,c))\n",
    "                #print('\\n----------------\\n')\n",
    "                all_ranks.append(rk+1)\n",
    "                all_models.append(\"Tf-Idf- Semantic Kernel- Bert\")\n",
    "                all_querries.append(self.querries_raw[question])\n",
    "                rk+=1\n",
    "               \n",
    "            all_answers.extend(text)\n",
    "            all_scores.extend(scores_bert)\n",
    "            all_indices.extend(rank[question,:30][indices])\n",
    "            #all_indices.extend(np.array(range(len(self.content_repo[0])))[rank[question,:self.top_n]])\n",
    "            \n",
    "        return pd.DataFrame(np.c_[all_querries,all_models,all_ranks,all_indices,all_answers, all_scores],columns=['Question','Model','Rank','Doc_index','Answer','Score'])\n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3) Unsupervised Question answering Pipeline (text ranking-retriever for a given querry)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "class QApipeline():\n",
    "    \"\"\"\n",
    "    ## kwargs :\n",
    "    path_to_directory (str) : Directory to train language model tfidf\n",
    "    ngram_range=(1,3) (tuple) : ngram range for tfidf words\n",
    "    max_df=0.85 (float) : When building the vocabulary ignore terms that have a document frequency strictly \n",
    "                        ## higher than the given threshold (corpus-specific stop words). \n",
    "                        ## If float, the parameter represents a proportion of documents, integer absolute counts. \n",
    "                        ## This parameter is ignored if vocabulary is not None\n",
    "    stop_words (str) : Language for tfidf (default 'english')\n",
    "    paragraphs=None\n",
    "    top=3 (int) : How many paragraphs to retrieve for querry matching (can be modified by threshold)\n",
    "    verbose=False : print time of execution to build tfidf matrix and print errors\n",
    "    MODEL_PATH = 'dataset/encoder/infersent2.pkl' \n",
    "    W2V_PATH = 'dataset/fastText/crawl-300d-2M.vec'  \n",
    "    \"\"\"\n",
    "    \n",
    "    def __init__(self,**kwargs):\n",
    "        \n",
    "        \n",
    "        #new kwargs: 'threshold' (float between 0.5 and 1.0)\n",
    "        \n",
    "        self.kwargs_Tf_Idf = {key: value for key, value in kwargs.items()\n",
    "                         if key in TfidfRetriever.__init__.__code__.co_varnames}\n",
    "\n",
    "        self.kwargs_converter = {key: value for key, value in kwargs.items()\n",
    "                            if key in pdfconverter.__init__.__code__.co_varnames}\n",
    "        \n",
    "        self.kwargs_Infersent={key: value for key, value in kwargs.items()\n",
    "                         if key in InfersentRetriever.__init__.__code__.co_varnames}\n",
    "        self.kwargs_Bert={key: value for key, value in kwargs.items()\n",
    "                         if key in BertRetriever.__init__.__code__.co_varnames}\n",
    "        self.kwargs_others={key: value for key, value in kwargs.items()\n",
    "                            if ((key not in pdfconverter.__init__.__code__.co_varnames) and (key not in TfidfRetriever.__init__.__code__.co_varnames))}\n",
    "        \n",
    "        \n",
    "        \n",
    "        self.multisearch=kwargs['multisearch']\n",
    "        self.TF_Idf_enhanced=kwargs['TfIdf_enhanced']\n",
    "        self.threshold=kwargs['threshold']\n",
    "        self.df=pdfconverter(**self.kwargs_converter).transform()\n",
    "        self.l_questions=kwargs['l_questions']\n",
    "        self.Qst_raw=self.l_questions.copy()\n",
    "        self.sentences_chunk=kwargs['sentences_chunk']\n",
    "        \n",
    "        #Build vocabulary\n",
    "        self.content =[] \n",
    "        self.voc=[]\n",
    "        np.vectorize(lambda x: self.voc.extend(self.string_retriever(x.split())),otypes=[object])(np.array(self.content))\n",
    "        self.voc=set(self.voc)\n",
    "        \n",
    "        #Extract all contents of repositories and index it \n",
    "        self.content=[]\n",
    "        self.content_raw=[]\n",
    "        self.contents_doc=[]\n",
    "        self.borders=[0]\n",
    "        for j,repo in enumerate(sorted(list(set(self.df.directory_index)))):\n",
    "            dic_s=[{},{}]\n",
    "            remove_idx=[[],[]]\n",
    "            content_doc=[]\n",
    "            content_doc_raw=[]\n",
    "            title=self.df[self.df.directory_index==repo].directory.tolist()[0]\n",
    "            self.df[self.df.directory_index==repo]['raw paragraphs'].apply(lambda x: self.update_dic(x,dic_s,0,remove_idx))\n",
    "            self.df[self.df.directory_index==repo]['paragraphs'].apply(lambda x: self.update_dic(x,dic_s,1,remove_idx))\n",
    "            self.df[self.df.directory_index==repo]['raw paragraphs'].apply(lambda x: content_doc_raw.extend(x))\n",
    "            self.df[self.df.directory_index==repo]['paragraphs'].apply(lambda x: content_doc.extend(x))\n",
    "            \n",
    "            #Use treated text length to cap text size and raw_text size\n",
    "            remove_idx=list(set(remove_idx[0]+remove_idx[1]))\n",
    "            content_doc=np.delete(np.array(content_doc),remove_idx)\n",
    "            content_doc_raw=np.delete(np.array(content_doc_raw),remove_idx)\n",
    "            \n",
    "            content=[content_doc[i] for i in range(len(content_doc)) if (len(content_doc[i])>=50 )]\n",
    "            content_raw=[content_doc_raw[i] for i in range(len(content_doc)) if (len(content_doc[i])>=50)]\n",
    "            self.borders.append(len(content))\n",
    "            print(\"repo: {} , size={}\".format(repo,len(content)))\n",
    "            self.content.extend(list(content))\n",
    "            self.content_raw.extend(list(content_raw))\n",
    "            self.contents_doc.append([content,content_raw])\n",
    "            \n",
    "        self.borders=list(np.cumsum(self.borders))\n",
    "        if self.sentences_chunk>1:\n",
    "\n",
    "            self.content=[ ' '.join(x) for x in zip(self.content[0::2], self.content[1::2]) ]\n",
    "            self.content_raw=[ ' '.join(x) for x in zip(self.content_raw[0::2], self.content_raw[1::2]) ]\n",
    "            for i,(L1,L2) in enumerate(self.contents_doc):\n",
    "                self.contents_doc[i][0]=[ ' '.join(x) for x in zip(L1[0::2], L1[1::2]) ]\n",
    "                self.contents_doc[i][1]=[ ' '.join(x) for x in zip(L2[0::2], L2[1::2]) ]\n",
    "            self.borders=[int(i/2) for i in self.borders]\n",
    "\n",
    "        for i,c in enumerate(self.borders[:-1]):\n",
    "            a=self.borders[i]\n",
    "            content=self.contents_doc[i][0]\n",
    "            content_raw=self.contents_doc[i][1]\n",
    "\n",
    "            for z,s in enumerate(content):\n",
    "\n",
    "                l=s.split(\" \")\n",
    "                for j,w in enumerate(l):\n",
    "                    try:\n",
    "                        float(w)\n",
    "                        l[j]=\"XXX\"\n",
    "                    except:\n",
    "                        l[j]=w\n",
    "                try:\n",
    "                    self.content[a+z]=\" \".join(l)\n",
    "                except:\n",
    "                    print(\"error! \",a,z,self.borders,len(self.content))\n",
    "                self.contents_doc[i][0][z]=\" \".join(l)\n",
    "                \n",
    "\n",
    "            for z,s in enumerate(content_raw):\n",
    "                l=s.split(\" \")\n",
    "                for j,w in enumerate(l):\n",
    "                    try:\n",
    "                        float(w)\n",
    "                        l[j]=\"XXX\"\n",
    "                    except:\n",
    "                        l[j]=w\n",
    "                try:\n",
    "                    self.content_raw[a+z]=\" \".join(l)\n",
    "                except:\n",
    "                    print(\"error! \",a,z,self.borders,len(self.content))\n",
    "\n",
    "                self.contents_doc[i][1][z]=\" \".join(l)\n",
    "\n",
    "                            \n",
    "                        \n",
    "                \n",
    "                \n",
    "                \n",
    "            \n",
    "        \n",
    "        \n",
    "    def update_dic(self,l,d,pos,r_index):\n",
    "        for i,c in enumerate(l):\n",
    "            \n",
    "            d=d[pos].copy()\n",
    "            d[c]=d.get(c,0)+1\n",
    "            d[pos]=d\n",
    "            if d[pos][c]>1:\n",
    "                r_index[pos].append(i)\n",
    "        return None\n",
    "    \n",
    "    def fit(self):\n",
    "        \n",
    "            #Fit Infersent-Glove\n",
    "    \n",
    "        #We need to init Infersent at least for the querry builder\n",
    "        self.inferst = InfersentRetriever(**self.kwargs_Infersent)\n",
    "            \n",
    "        if self.multisearch:\n",
    "            #Fit Infersent\n",
    "            self.inferst.fit(self.content)\n",
    "            self.inferst.transform(self.content)\n",
    "            \n",
    "            \n",
    "            #Fit Bert pretrained\n",
    "            self.bert=BertRetriever(**self.kwargs_Bert)\n",
    "            self.bert.fit(self.content)#no finetuning for Bert\n",
    "            self.bert.transform(self.content)\n",
    "        \n",
    "        #Fit Tf-Idf\n",
    "        self.retriever = TfidfRetriever(**self.kwargs_Tf_Idf)\n",
    "        self.retriever.fit(self.content)\n",
    "        self.retriever.transform(self.content)\n",
    "        \n",
    "    \n",
    "        #Initiate Tf-Idf enhanced\n",
    "        if self.TF_Idf_enhanced:\n",
    "            print(\"beginning of Tf_idf_farahat fit\")\n",
    "            TF=self.retriever.tfidf_matrix\n",
    "            dataQu=self.generate_querries(self.l_questions)\n",
    "            querries=dataQu['words_sort'].tolist()\n",
    "            for i,q in enumerate(querries):\n",
    "                q=' '.join(list(q))\n",
    "                q=q.lower()\n",
    "                q=pdfconverter().remove_non_alpha(q)\n",
    "                q=q.replace('.','')\n",
    "                querries[i]=q\n",
    "\n",
    "            q_emb=self.retriever.vectorizer.transform(querries).toarray().transpose()\n",
    "            content=self.content\n",
    "            stemmed_content=[self.retriever.tokenize(s) for s in self.content]\n",
    "            voc=self.retriever.vectorizer.get_feature_names()\n",
    "            self.tf_idf_farahat=Tfidf_FarahatCluster_Bert(TF,q_emb,content,self.contents_doc.copy(),stemmed_content,voc,dataQu,self.Qst_raw)\n",
    "            self.tf_idf_farahat.transform()\n",
    "            print(\"end of Tf_idf_farahat fit\")\n",
    "        return self\n",
    "    \n",
    "    \n",
    "        #Initialisation of Tf-Idf-Farahat\n",
    "    \n",
    "    def predict(self,Qst,VE_type='DP',VE_cdt='',range_chunks=(5,20)):\n",
    "        \"\"\"\n",
    "        kwargs:\n",
    "        ##VE_type: 'DP' for Detect Presence of 'VE' for Value extraction\n",
    "        ##Qst: Querry\n",
    "        ##VE_cdt : null\n",
    "        ##range_chunks: (tuple object) lower and upper bounds for text length\n",
    "        \"\"\"\n",
    "    \n",
    "        #Ask for the repository to question\n",
    "        df_show=self.df[['directory']].drop_duplicates(subset=['directory']).reset_index(drop=True)\n",
    "        repo=int(input(('\\n\\n Choose a repository \\n\\n'+ '{}'+'\\n\\n').format(df_show.to_string())))\n",
    "        \n",
    "        min_,max_=range_chunks\n",
    "        \n",
    "        #Apply corpus transformations to querry for parcimony\n",
    "        Qst=[q.lower() for q in self.Qst_raw]\n",
    "        newQst=[ pdfconverter().remove_non_alpha(q) for q in Qst]\n",
    "        newQst=[q.replace('.','') for q in newQst]\n",
    "        \n",
    "        self.Q_emb=self.retriever.vectorizer.transform(newQst)\n",
    "        \n",
    "        #Infersent and Bert Loop Retriever ------ (look for most similar sentence using Infersent / Bert embeddings )\n",
    "        self.dataframe_infersent=[]\n",
    "        self.dataframe_bert=[]\n",
    "        self.dataframe_tf_farahat=[]\n",
    "        try :\n",
    "            self.multisearch==True\n",
    "            print(\"deep neural networks in action..\")\n",
    "        except:\n",
    "            print(\"fail\")\n",
    "        if self.multisearch :\n",
    "            \n",
    "            #Infersent ranking\n",
    "            print(\"beginning of Infersent..\")\n",
    "            all_scores=[]\n",
    "            all_models=[]\n",
    "            all_querries=[]\n",
    "            all_ranks=[]\n",
    "            all_indices=[]\n",
    "            all_answers=[]\n",
    "            for i,qu in enumerate(newQst):\n",
    "                \n",
    "                indices,scores=self.inferst.predict(qu,[self.borders[repo],self.borders[repo+1]])\n",
    "                p=len(indices)\n",
    "                try :\n",
    "                    bbb=indices[1]\n",
    "                except:\n",
    "                    print('Fail')\n",
    "                all_scores.extend(scores.loc[indices].values[:,0])\n",
    "                all_answers.extend([ self.contents_doc[repo][1][i] for i in indices])\n",
    "                all_models.extend(['Infersent Bi-Lstm']*p)\n",
    "                all_ranks.extend(list(range(1,p+1)))\n",
    "                all_querries.extend([self.Qst_raw[i]]*p)\n",
    "                all_indices.extend(indices)\n",
    "            \n",
    "            self.dataframe_infersent=pd.DataFrame(np.c_[all_querries,all_models,all_ranks,all_indices,all_answers,all_scores],columns=['Question','Model','Rank','Doc_index','Answer','Score'])\n",
    "            try :\n",
    "                series=self.dataframe_infersent.iloc[0]\n",
    "            except:\n",
    "                print(\"PROBLEM DATA INFERSENT:\",all_scores,all_answers,all_models,all_ranks,all_querries,all_indices)\n",
    "            print(\"Infersent ranking finished!\")\n",
    "                \n",
    "        \n",
    "            #Bert ranking\n",
    "            print(\"beginning of bert..\")\n",
    "            all_scores=[]\n",
    "            all_models=[]\n",
    "            all_querries=[]\n",
    "            all_ranks=[]\n",
    "            all_indices=[]\n",
    "            all_answers=[]\n",
    "            for i,qu in enumerate(newQst):\n",
    "                indices,scores=self.bert.predict(qu,[self.borders[repo],self.borders[repo+1]])\n",
    "                p=len(indices)\n",
    "                all_scores.extend(scores.loc[indices].values[:,0])\n",
    "                all_answers.extend([ self.contents_doc[repo][1][i] for i in indices])\n",
    "                all_models.extend(['Bert - transformer']*p)\n",
    "                all_ranks.extend(list(range(1,p+1)))\n",
    "                all_querries.extend([self.Qst_raw[i]]*p)\n",
    "                all_indices.extend(indices)\n",
    "            self.dataframe_bert=pd.DataFrame(np.c_[all_querries,all_models,all_ranks,all_indices,all_answers,all_scores],columns=['Question','Model','Rank','Doc_index','Answer','Score'])\n",
    "            print(\"bert ranking finished !\")\n",
    "    \n",
    "            \n",
    "        #Tf-Idf Farahat Ranking\n",
    "        \n",
    "        if self.TF_Idf_enhanced :\n",
    "            print('begin of Tf-idf Farahat ranking predict')\n",
    "            self.dataframe_tf_farahat=self.tf_idf_farahat.predict([self.borders[repo],self.borders[repo+1]],repo)\n",
    "            print(\"Tf-idf Farahat ranking finished!\")\n",
    "            \n",
    "        \n",
    "        #Tf-Idf Loop Retriever (look for a variable sized textchunk which match the querry using Tf-Idf)  ------\n",
    "        print(\"beginning of Tf_idf_lemmatize..\")\n",
    "        all_scores=[]\n",
    "        all_models=[]\n",
    "        all_querries=[]\n",
    "        all_ranks=[]\n",
    "        all_indices=[]\n",
    "        all_answers=[]\n",
    "        \n",
    "        dataQu=self.generate_querries(self.l_questions)\n",
    "        querries=dataQu['words_sort'].tolist()\n",
    "        for i,q in enumerate(querries):\n",
    "            q=' '.join(list(q))\n",
    "            q=q.lower()\n",
    "            q=pdfconverter().remove_non_alpha(q)\n",
    "            q=q.replace('.','')\n",
    "            querries[i]=q\n",
    "\n",
    "        for iq,qu in enumerate(newQst):\n",
    "          \n",
    "            closest_docs_indices,scores = self.retriever.predict(querries[iq],[self.borders[repo],self.borders[repo+1]])\n",
    "            self.test=[self.contents_doc[repo][1][u] for u in closest_docs_indices]\n",
    "            self.test2=[self.contents_doc[repo][0][u] for u in closest_docs_indices]\n",
    "            selected_extract=[self.contents_doc[repo][0][u] for u in closest_docs_indices]\n",
    "            selection=pd.DataFrame(selected_extract,index=closest_docs_indices,columns=['extract'])\n",
    "\n",
    "            extract_chunks=[]\n",
    "            scores_chunks=[]\n",
    "            contexts=[]\n",
    "\n",
    "            #Searching for optimal textchunk size that match the querry \n",
    "            for ind in selection.index:\n",
    "                extract=selection.loc[ind,'extract']\n",
    "                temp_scores=[]\n",
    "                temp=[]\n",
    "\n",
    "                for chunksize in range(min_,max_+1):\n",
    "                    array=extract.split(' ')\n",
    "                    if len(array)<chunksize and len(array)>min_:\n",
    "                        temp.append(extract)\n",
    "                        embed=self.retriever.vectorizer.transform([extract])\n",
    "                        temp_scores.append(embed.dot(self.Q_emb[iq].T).toarray()[0,0])\n",
    "                    else:\n",
    "                        for j in range(len(array)):\n",
    "                            if j+chunksize<=len(array)-1:\n",
    "                                smallchunk=' '.join(array[j:j+chunksize]).lower()\n",
    "                                embed=self.retriever.vectorizer.transform([smallchunk])\n",
    "                                temp_scores.append(embed.dot(self.Q_emb[iq].T).toarray()[0,0])\n",
    "                                temp.append(smallchunk)\n",
    "\n",
    "                if temp_scores!=[]:\n",
    "                    #print(\"temp_score=\",temp_scores)\n",
    "                    temp_scores=np.array(temp_scores)\n",
    "                    pos,score=np.argmax(temp_scores),np.max(temp_scores)\n",
    "                    scores_chunks.append(score)\n",
    "                    extract_chunks.append(temp[pos])\n",
    "                    contexts.append(ind)\n",
    "            #print(\"scores_chunks=\",scores_chunks)\n",
    "            scores_chunks=np.array(scores_chunks)\n",
    "            pos=(scores_chunks>self.threshold)\n",
    "            scores_chunks=scores_chunks[pos]\n",
    "            selected_indices=np.array(contexts)[pos]\n",
    "            selected_extracts=np.array(extract_chunks)[pos]\n",
    "            #selected_contexts=np.array(selection[selection.index==selected_indices][\"extract\"])\n",
    "            selected_contexts=np.array(self.contents_doc[repo][1])[selected_indices]\n",
    "            p=len(scores_chunks)\n",
    "            \n",
    "            all_models.extend(['Tf-Idf + Lemmatizer']*p)\n",
    "            all_scores.extend(scores_chunks)\n",
    "            all_querries.extend([self.Qst_raw[iq]]*p)\n",
    "            idx_sort=np.argsort(-scores_chunks)\n",
    "            all_ranks.extend((np.ones(p)+np.arange(p))[np.argsort(idx_sort)])\n",
    "            all_indices.extend(selected_indices)\n",
    "            all_answers.extend(selected_contexts)\n",
    "            #print(\"mod,scores,querr,idx,rks,answ\",len(all_models),len(all_scores),len(all_querries),len(all_indices),len(all_ranks),len(all_answers))\n",
    "            \n",
    "        #dataframe=pd.DataFrame(np.c_[selected_extracts,selected_contexts,selected_indices,scores_chunks],columns=['chunk','context','doc index','scores']).sort_values(by='scores',ascending=False)\n",
    "        #['Question','Model','Rank','Doc_index','Answer','Score']\n",
    "        self.dataframe=pd.DataFrame(np.c_[all_querries,all_models,all_ranks,all_indices,all_answers,all_scores],columns=['Question','Model','Rank','Doc_index','Answer','Score']).sort_values(by=['Question','Score'],ascending=False)\n",
    "        print(\"Tf_idf_lemmatize ranking finished !\")\n",
    "        \n",
    "        if VE_type=='DP':\n",
    "            #return closest_passages_chunks[pos],scores_chunks[pos]\n",
    "            return self.dataframe,self.dataframe_infersent,self.dataframe_bert,self.dataframe_tf_farahat\n",
    "        \n",
    "        if VE_type=='VE':\n",
    "            JSON=generate_squad_examples(Qst,selected_indices,self.df_doc)\n",
    "            return JSON\n",
    "\n",
    "    def string_retriever(self,sentence_list):\n",
    "        return [w  for w in sentence_list if not w.isdigit()]\n",
    "    \n",
    "    def generate_querries(self,querries):\n",
    "        querries=[pdfconverter().remove_non_alpha(q) for q in querries]    \n",
    "        sentences=[s[0].lower()+s[1:].replace('?','')  for s in querries]\n",
    "        i=0\n",
    "        important_words=[]\n",
    "        unsorted_words=[]\n",
    "\n",
    "        for qu in sentences:\n",
    "\n",
    "            #Get scores from infersent visualization function (max-pooling et each layer)\n",
    "            tensor,vector,scores,words=self.inferst.infersent.visualize(qu)\n",
    "            scores=np.array(scores[1:len(scores)-1])\n",
    "            words=np.array(words[1:len(words)-1])\n",
    "\n",
    "            #Remove stopwords from querries and attributed scores\n",
    "            pos=[i for i,c in enumerate(list(words)) if c not in self.retriever.stop_words_list]\n",
    "            words=words[pos]\n",
    "            scores=np.array(scores)[pos]\n",
    "            scores=scores/np.sum(scores)\n",
    "\n",
    "            #Sort query words by word importance keeping idx in memory to unsort it back\n",
    "            data=pd.DataFrame(np.c_[words,scores],columns=['word','score'])\n",
    "            idx=np.argsort(-np.array(data.score.values,dtype='float64'))\n",
    "            idx_unsort=np.argsort(idx)\n",
    "            data=data.sort_values(by=['score'],ascending=False)\n",
    "            new_words=data.word.values\n",
    "            new_scores=np.array(data.score.values,dtype=float)\n",
    "\n",
    "            #Keeping a set of words that satisfy 70% of cumulative importance\n",
    "            score_cum=np.cumsum(new_scores)\n",
    "            pos=score_cum<0.75\n",
    "            lw=new_words[pos]\n",
    "            ls=new_scores[pos]\n",
    "            lw_unsort=words[pos[idx]]\n",
    "\n",
    "            important_words.append(lw)\n",
    "            unsorted_words.append(lw_unsort)\n",
    "            i+=1\n",
    "\n",
    "        return pd.DataFrame(np.c_[querries, important_words,unsorted_words],columns=['query','words_sort','words_unsort'])\n",
    "\n",
    "        \n",
    "            \n",
    "        \n",
    "\n",
    "        "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Tests of retrievers and Comparison between Tf-Idf and Infersent GloVe and Bert"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Tf-Idf/ FastText or Glove / Bert"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "questions=['Does the company operate in countries out of the European Union?',\n",
    "'Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries',\n",
    "'Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?',\n",
    "'Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?',\n",
    "'Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?',\n",
    "           'Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?',\n",
    "'Has the company formalized  a strategy to reduce its greenhouse gas  emissions?',\n",
    "'Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?',\n",
    "'Does the company monitor performance indicators to assess its progress compared to its climate related commitments?',\n",
    "'Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?',\n",
    "'Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?',\n",
    "'Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)',\n",
    "'Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?',\n",
    "'Is there a crisis management scheme to cope with an identified issue on product safety?']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "args_Tf_Idf={'directory_path':'../question_answering/pdf_files/','w2v_path': 'dataset/GloVe/glove.840B.300d.txt', 'model_path': 'dataset/encoder/infersent2.pkl' ,'top_n':5,'threshold':0.00,'multisearch':False,'TfIdf_enhanced':False,'ngram_range':(1, 2),'lemmatize':False,'transform_text':True,'l_questions':questions,'sentences_chunk':1}\n",
    "args_Infersent={'directory_path':'../question_answering/pdf_files/','w2v_path': 'dataset/fastText/crawl-300d-2M.vec', 'model_path': 'dataset/encoder/infersent2.pkl' ,'top_n':5,'threshold':0.00,'multisearch':True,'TfIdf_enhanced':True,'ngram_range':(1, 1),'lemmatize':True,'transform_text':True,'l_questions':questions,'sentences_chunk':1}\n",
    "args_Tf_Idf_Farahat={'directory_path':'../question_answering/pdf_files/','w2v_path': 'dataset/fastText/crawl-300d-2M.vec', 'model_path': 'dataset/encoder/infersent2.pkl' ,'top_n':5,'threshold':0.00,'multisearch':False,'TfIdf_enhanced':True,'lemmatize':False,'ngram_range':(1, 1),'transform_text':True,'l_questions':questions,'sentences_chunk':1}\n",
    "args_All_transforms={'directory_path':'../question_answering/pdf_files/','w2v_path': 'dataset/fastText/crawl-300d-2M.vec', 'model_path': 'dataset/encoder/infersent2.pkl' ,'top_n':5,'threshold':0.00,'multisearch':True,'TfIdf_enhanced':True,'lemmatize':False,'ngram_range':(1, 1),'transform_text':True,'l_questions':questions,'sentences_chunk':1}\n",
    "args_FinalModel={'directory_path':'../question_answering/pdf_files/','w2v_path': 'dataset/fastText/crawl-300d-2M.vec', 'model_path': 'dataset/encoder/infersent2.pkl' ,'top_n':5,'threshold':0.00,'multisearch':False,'TfIdf_enhanced':True,'lemmatize':False,'ngram_range':(1, 1),'transform_text':True,'l_questions':questions,'sentences_chunk':1}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "cdp-2018-climate-change-information-request-response.pdf succesfully converted \n",
      "q.pdf succesfully converted \n",
      "cdp-2018-water-information-request-response.pdf succesfully converted \n",
      "novartis-annual-report-2018-en.pdf succesfully converted \n",
      "repo: 1 , size=4869\n",
      "Vocab size : 500000\n",
      "Found 232(/683) words with w2v vectors\n",
      "New vocab size : 500234 (added 232 words)\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/williamlambert/anaconda3/lib/python3.7/site-packages/sklearn/feature_extraction/text.py:300: UserWarning: Your stop_words may be inconsistent with your preprocessing. Tokenizing the stop words generated tokens ['anywh', 'becau', 'el', 'elsewh', 'everywh', 'ind', 'otherwi', 'plea', 'somewh'] not in stop_words.\n",
      "  'stop_words.' % sorted(inconsistent))\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "beginning of Tf_idf_farahat fit\n",
      "begin of term selection\n",
      "begin of creation kernel\n",
      "end of creation kernel\n",
      "end of Tf_idf_farahat fit\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<__main__.QApipeline at 0x1a4e7ac278>"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "QAmodel=QApipeline(**args_All_transforms)\n",
    "QAmodel.fit()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Roche:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0  Novartis\n",
      "\n",
      "0\n",
      "deep neural networks in action..\n",
      "beginning of Infersent..\n",
      "Infersent ranking finished!\n",
      "beginning of bert..\n",
      "bert ranking finished !\n",
      "begin of Tf-idf Farahat ranking predict\n",
      "begin Tf_farahat_predict\n",
      "begin scores compute and ranking\n",
      "end scores compute\n",
      "end scores ranking, scores.shape= (14, 4869)\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "begin loop cluster retriever\n",
      "end loop cluster retriever\n",
      "initiate bert cluster retriever\n",
      "begin reranking prediction with bert class\n",
      "end reranking prediction with bert class\n",
      "Tf-idf Farahat ranking finished!\n",
      "beginning of Tf_idf_lemmatize..\n",
      "Tf_idf_lemmatize ranking finished !\n"
     ]
    }
   ],
   "source": [
    "data1,data2,data3,data4=QAmodel.predict(questions, VE_type='DP',range_chunks=(8,35))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Model</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Doc_index</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1001</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>0.236880133650043</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1008</td>\n",
       "      <td>On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.</td>\n",
       "      <td>0.20524048022241717</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>1390</td>\n",
       "      <td>We are all encouraged to identify areas for improvements and continuously work towards a better environment.</td>\n",
       "      <td>0.15551753454349201</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1331</td>\n",
       "      <td>Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.</td>\n",
       "      <td>0.15210973009495576</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>710</td>\n",
       "      <td>We identified human rights which are potentially susceptible to violations, as well as their associated risks.</td>\n",
       "      <td>0.10852181013467649</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1460</td>\n",
       "      <td>misleading and suggestive statements may trigger an investigation against Roche as a company as well as against the employee involved.</td>\n",
       "      <td>0.22415137867296625</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>398</td>\n",
       "      <td>By the end of 2018, XXX pharmaceutical companies and associations were involved in this programme, in which partners such as the World Bank Group and the Union for International Cancer Control (UICC) participate.</td>\n",
       "      <td>0.18608275289688142</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>530</td>\n",
       "      <td>Apprentices can gain valuable experience in XXX professions, including informatics, biology, chemistry, automation and electronics.</td>\n",
       "      <td>0.1647406882130872</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>980</td>\n",
       "      <td>In addition, businesses are expected to become pro-active and make an active contribution to improve the situation, before the implementation of legal frameworks and beyond their legal boundaries.</td>\n",
       "      <td>0.14135675343842524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>771</td>\n",
       "      <td>Capital structure Business activities are carried out through Group subsidiaries and associated companies.</td>\n",
       "      <td>0.10965299618531675</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>376</td>\n",
       "      <td>During the operation, the surgeons realised that the cancer had spread and this had not been detected earlier.</td>\n",
       "      <td>0.26288882124175217</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>689</td>\n",
       "      <td>We investigate counter­ feits detected at different locations around the world to find out if they originated from the same source.</td>\n",
       "      <td>0.23458010644549057</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>286</td>\n",
       "      <td>Detecting progression of the disease earlier and in a quantifiable manner will be a significant innovation for the MS community.</td>\n",
       "      <td>0.21658518844310068</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1571</td>\n",
       "      <td>The CMS focuses on prevention, detection and responding to non-compliance behaviour by comprehensively involving people, principles, policies and processes.</td>\n",
       "      <td>0.2106377916861496</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>406</td>\n",
       "      <td>Capabilities to run infusion facilities and having sufficient numbers of trained nurses and doctors are difficult to find in some countries.</td>\n",
       "      <td>0.1699191509390749</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>561</td>\n",
       "      <td>Since 2010, Genentech has reduced greenhouse gas emissions from energy used at its SSF campus by over 30%, thanks in part to its green building programme.</td>\n",
       "      <td>0.7435059359644431</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>968</td>\n",
       "      <td>Proactively seeking new technologies \\tDecreasing energy consumption \\tReducing greenhouse gas emissions.</td>\n",
       "      <td>0.5774563434102837</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>941</td>\n",
       "      <td>We planned and performed our procedures in accordance with the International Standard on Assurance Engagements (ISAE 3000) (revised) ‘Assurance engagements other than audits or reviews of historical financial information’, and, in respect of greenhouse gas emissions, with the International Standard on Assurance .</td>\n",
       "      <td>0.47222375810607753</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>942</td>\n",
       "      <td>Engagements (ISAE 3410) ‘Assurance Engagements on Greenhouse Gas Statements’, issued by the International Auditing and Assurance Standards Board.</td>\n",
       "      <td>0.36414900462001387</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>572</td>\n",
       "      <td>We were able to reduce our scope XXX GHG emissions by 1.9% by implementing energy­saving measures that reduced the amount of fuel we use to heat, cool and operate our sites.</td>\n",
       "      <td>0.32155993400457095</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>570</td>\n",
       "      <td>Our emissions strategy prescribes a continuous improvement at our manufacturing sites, while our aim is to avoid, reduce, and control air pollutants in line with our eco­balance goals.</td>\n",
       "      <td>0.6747827811482299</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>818</td>\n",
       "      <td>The company has a formal policy governing the engagement of the statutory auditor for non­audit services.</td>\n",
       "      <td>0.4594362592269168</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>1497</td>\n",
       "      <td>In addition, we participate in more formal and structured engagement, such as meetings, forums and other events, and carry out consultations and surveys.</td>\n",
       "      <td>0.2883580337566423</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>18</td>\n",
       "      <td>Our Pharmaceuticals and Diagnostics Divisions and global functions conduct a formal risk assessment process at least once a year and must develop risk plans for their most material risks.</td>\n",
       "      <td>0.27176447864675596</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>786</td>\n",
       "      <td>The Pharmaceuticals and Diagnostics Divisions and global functions conduct a formal risk assessment process at least once a year and must develop risk plans for their most material risks.</td>\n",
       "      <td>0.27176447864675596</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Has the company formalized  a strategy to reduce its greenhouse gas  emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>561</td>\n",
       "      <td>Since 2010, Genentech has reduced greenhouse gas emissions from energy used at its SSF campus by over 30%, thanks in part to its green building programme.</td>\n",
       "      <td>0.7136269954498731</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Has the company formalized  a strategy to reduce its greenhouse gas  emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>941</td>\n",
       "      <td>We planned and performed our procedures in accordance with the International Standard on Assurance Engagements (ISAE 3000) (revised) ‘Assurance engagements other than audits or reviews of historical financial information’, and, in respect of greenhouse gas emissions, with the International Standard on Assurance .</td>\n",
       "      <td>0.6723469907592654</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Has the company formalized  a strategy to reduce its greenhouse gas  emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>968</td>\n",
       "      <td>Proactively seeking new technologies \\tDecreasing energy consumption \\tReducing greenhouse gas emissions.</td>\n",
       "      <td>0.5892024351667124</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Has the company formalized  a strategy to reduce its greenhouse gas  emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>951</td>\n",
       "      <td>Roche accident rate, energy consumption, greenhouse gas emissions related to energy consumption, water, waste, contributions to public policy stakeholders, representation of women in key leadership roles) concerning completeness, accuracy, adequacy and consistency; • Review of documentation and analysis of relevant policies and principles .</td>\n",
       "      <td>0.5379591697166606</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Has the company formalized  a strategy to reduce its greenhouse gas  emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>942</td>\n",
       "      <td>Engagements (ISAE 3410) ‘Assurance Engagements on Greenhouse Gas Statements’, issued by the International Auditing and Assurance Standards Board.</td>\n",
       "      <td>0.5184713459276016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>941</td>\n",
       "      <td>We planned and performed our procedures in accordance with the International Standard on Assurance Engagements (ISAE 3000) (revised) ‘Assurance engagements other than audits or reviews of historical financial information’, and, in respect of greenhouse gas emissions, with the International Standard on Assurance .</td>\n",
       "      <td>0.5691246419921216</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>561</td>\n",
       "      <td>Since 2010, Genentech has reduced greenhouse gas emissions from energy used at its SSF campus by over 30%, thanks in part to its green building programme.</td>\n",
       "      <td>0.538760472442861</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>951</td>\n",
       "      <td>Roche accident rate, energy consumption, greenhouse gas emissions related to energy consumption, water, waste, contributions to public policy stakeholders, representation of women in key leadership roles) concerning completeness, accuracy, adequacy and consistency; • Review of documentation and analysis of relevant policies and principles .</td>\n",
       "      <td>0.45536876654363795</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>942</td>\n",
       "      <td>Engagements (ISAE 3410) ‘Assurance Engagements on Greenhouse Gas Statements’, issued by the International Auditing and Assurance Standards Board.</td>\n",
       "      <td>0.4388728189308897</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>968</td>\n",
       "      <td>Proactively seeking new technologies \\tDecreasing energy consumption \\tReducing greenhouse gas emissions.</td>\n",
       "      <td>0.41462106589967984</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>951</td>\n",
       "      <td>Roche accident rate, energy consumption, greenhouse gas emissions related to energy consumption, water, waste, contributions to public policy stakeholders, representation of women in key leadership roles) concerning completeness, accuracy, adequacy and consistency; • Review of documentation and analysis of relevant policies and principles .</td>\n",
       "      <td>0.3668570524001521</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>556</td>\n",
       "      <td>Secondly, we endeavour to reduce usage of fossil fuels, cut energy consumption, and increase the proportion of sustainable energy.</td>\n",
       "      <td>0.3375888106534711</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>554</td>\n",
       "      <td>Improvements in terms of decreasing energy consumption, air emissions, water consumption, and the weight of chemical waste, has led to a further improvement of 3.3% compared to XXX</td>\n",
       "      <td>0.2982669320591099</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>968</td>\n",
       "      <td>Proactively seeking new technologies \\tDecreasing energy consumption \\tReducing greenhouse gas emissions.</td>\n",
       "      <td>0.2393790608438896</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>558</td>\n",
       "      <td>Our success in reducing energy consumption and carbon dioxide emissions can be credited to initiatives like the renovation of the chimney on the Basel site.</td>\n",
       "      <td>0.22309245863638655</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress compared to its climate related commitments?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>550</td>\n",
       "      <td>We are committed to continuously monitoring key performance indicators (eg, the five­ year goals on page 81), and our aim is to cover at least 95% of each key performance indicator.</td>\n",
       "      <td>0.513939959376975</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress compared to its climate related commitments?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>992</td>\n",
       "      <td>We review and monitor progress internally and report externally, such as on our website and in our Annual Report.</td>\n",
       "      <td>0.3353529725353087</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress compared to its climate related commitments?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>1479</td>\n",
       "      <td>Our commitment to long-term thinking is further emphasised through our “Five-Year Corporate Goals” which serve as a bonus-relevant yardstick and against which progress is monitored annually.</td>\n",
       "      <td>0.2723925346419676</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress compared to its climate related commitments?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1539</td>\n",
       "      <td>Roche is committed to high standards of performance and sustainability in all its activities, including in its dealings with business partners.</td>\n",
       "      <td>0.2544647272540468</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress compared to its climate related commitments?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>28</td>\n",
       "      <td>Information about Roche is committed to transparent reporting and we endeavour to drive our economic, social and environmental performance with the same diligence as our financial performance.</td>\n",
       "      <td>0.1873654610694597</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>673</td>\n",
       "      <td>As our accident rate is so low, a single accident, resulting in a longer absence, can lead to fluctuations in the accident rate key figure.</td>\n",
       "      <td>0.3431017382006426</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>671</td>\n",
       "      <td>Over the years, we have implemented a variety of initiatives to improve our already excellent track record in the areas of accidents and health.</td>\n",
       "      <td>0.2897115781222824</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>1547</td>\n",
       "      <td>If a business partner does not comply with applicable laws, regulations, industry codes, contractual terms or with generally accepted sustainability standards, Roche requests appropriate remedial measures and will, if necessary, terminate the cooperation.</td>\n",
       "      <td>0.22618718099440643</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1549</td>\n",
       "      <td>– Request appropriate remedial measures if we become aware of a compliance issue with a business partner.</td>\n",
       "      <td>0.21185449189310548</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>668</td>\n",
       "      <td>Compliance Occupational accidents Drug efficacy, safety and counterfeiting Data transparency on clinical trials.</td>\n",
       "      <td>0.2056707996620998</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>673</td>\n",
       "      <td>As our accident rate is so low, a single accident, resulting in a longer absence, can lead to fluctuations in the accident rate key figure.</td>\n",
       "      <td>0.32448326409384565</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>671</td>\n",
       "      <td>Over the years, we have implemented a variety of initiatives to improve our already excellent track record in the areas of accidents and health.</td>\n",
       "      <td>0.27399033012162477</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>1547</td>\n",
       "      <td>If a business partner does not comply with applicable laws, regulations, industry codes, contractual terms or with generally accepted sustainability standards, Roche requests appropriate remedial measures and will, if necessary, terminate the cooperation.</td>\n",
       "      <td>0.2290184794787049</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1549</td>\n",
       "      <td>– Request appropriate remedial measures if we become aware of a compliance issue with a business partner.</td>\n",
       "      <td>0.20240583200119183</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>668</td>\n",
       "      <td>Compliance Occupational accidents Drug efficacy, safety and counterfeiting Data transparency on clinical trials.</td>\n",
       "      <td>0.1945100387807495</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>990</td>\n",
       "      <td>This commitment is reflected in our Roche Group Code of Conduct, Supplier Code of Conduct, the Roche Employment Policy and the Roche Policy on Safety, Security, Health and Environmental Protection, all being embedded throughout the Roche Group.</td>\n",
       "      <td>0.4110420092380608</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>818</td>\n",
       "      <td>The company has a formal policy governing the engagement of the statutory auditor for non­audit services.</td>\n",
       "      <td>0.3761107077041517</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>547</td>\n",
       "      <td>Our Corporate Principles and the Safety, Security, Health and Environmental Protection (SHE) Policy ensure that we commit to the highest standards of environmental protection.</td>\n",
       "      <td>0.33013798795212834</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1171</td>\n",
       "      <td>We must carefully consider the potential conflict of interest prior to the acceptance of secondary employment.</td>\n",
       "      <td>0.218251943367355</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>441</td>\n",
       "      <td>In August, we formally launched our partnership with the Kenya Medical Research Institute by installing a cobas XXX for HIV assays.</td>\n",
       "      <td>0.19511106342647616</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>70 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                        Question  \\\n",
       "67                                                                                                                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "65                                                                                                                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "66                                                                                                                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "68                                                                                                                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "69                                                                                                                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "11                                                                                                 Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?   \n",
       "14                                                                                                 Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?   \n",
       "10                                                                                                 Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?   \n",
       "13                                                                                                 Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?   \n",
       "12                                                                                                 Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?   \n",
       "5                                                                                                     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "6                                                                                                     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "8                                                                                                     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "9                                                                                                     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "7                                                                                                     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "36                                                                                      Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?   \n",
       "35                                                                                      Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?   \n",
       "39                                                                                      Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?   \n",
       "37                                                                                      Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?   \n",
       "38                                                                                      Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?   \n",
       "17                                                                                                                              Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "15                                                                                                                              Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "16                                                                                                                              Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "18                                                                                                                              Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "19                                                                                                                              Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "31                                                                                                                                                               Has the company formalized  a strategy to reduce its greenhouse gas  emissions?   \n",
       "33                                                                                                                                                               Has the company formalized  a strategy to reduce its greenhouse gas  emissions?   \n",
       "30                                                                                                                                                               Has the company formalized  a strategy to reduce its greenhouse gas  emissions?   \n",
       "34                                                                                                                                                               Has the company formalized  a strategy to reduce its greenhouse gas  emissions?   \n",
       "32                                                                                                                                                               Has the company formalized  a strategy to reduce its greenhouse gas  emissions?   \n",
       "..                                                                                                                                                                                                                                           ...   \n",
       "52                                                                                                                               Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?   \n",
       "51                                                                                                                               Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?   \n",
       "54                                                                                                                               Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?   \n",
       "53                                                                                                                               Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?   \n",
       "50                                                                                                                               Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?   \n",
       "46                                                                                                                  Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?   \n",
       "47                                                                                                                  Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?   \n",
       "45                                                                                                                  Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?   \n",
       "48                                                                                                                  Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?   \n",
       "49                                                                                                                  Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?   \n",
       "41                                                                                                                           Does the company monitor performance indicators to assess its progress compared to its climate related commitments?   \n",
       "40                                                                                                                           Does the company monitor performance indicators to assess its progress compared to its climate related commitments?   \n",
       "42                                                                                                                           Does the company monitor performance indicators to assess its progress compared to its climate related commitments?   \n",
       "44                                                                                                                           Does the company monitor performance indicators to assess its progress compared to its climate related commitments?   \n",
       "43                                                                                                                           Does the company monitor performance indicators to assess its progress compared to its climate related commitments?   \n",
       "25                                                                                                                         Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?   \n",
       "26                                                                                                                         Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?   \n",
       "28                                                                                                                         Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?   \n",
       "29                                                                                                                         Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?   \n",
       "27                                                                                                                         Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?   \n",
       "20                                                                                       Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "21                                                                                       Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "24                                                                                       Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "22                                                                                       Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "23                                                                                       Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "58  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)   \n",
       "55  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)   \n",
       "59  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)   \n",
       "56  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)   \n",
       "57  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)   \n",
       "\n",
       "                  Model Rank Doc_index  \\\n",
       "67  Tf-Idf + Lemmatizer  1.0      1001   \n",
       "65  Tf-Idf + Lemmatizer  2.0      1008   \n",
       "66  Tf-Idf + Lemmatizer  3.0      1390   \n",
       "68  Tf-Idf + Lemmatizer  4.0      1331   \n",
       "69  Tf-Idf + Lemmatizer  5.0       710   \n",
       "11  Tf-Idf + Lemmatizer  1.0      1460   \n",
       "14  Tf-Idf + Lemmatizer  2.0       398   \n",
       "10  Tf-Idf + Lemmatizer  3.0       530   \n",
       "13  Tf-Idf + Lemmatizer  4.0       980   \n",
       "12  Tf-Idf + Lemmatizer  5.0       771   \n",
       "5   Tf-Idf + Lemmatizer  1.0       376   \n",
       "6   Tf-Idf + Lemmatizer  2.0       689   \n",
       "8   Tf-Idf + Lemmatizer  3.0       286   \n",
       "9   Tf-Idf + Lemmatizer  4.0      1571   \n",
       "7   Tf-Idf + Lemmatizer  5.0       406   \n",
       "36  Tf-Idf + Lemmatizer  1.0       561   \n",
       "35  Tf-Idf + Lemmatizer  2.0       968   \n",
       "39  Tf-Idf + Lemmatizer  3.0       941   \n",
       "37  Tf-Idf + Lemmatizer  4.0       942   \n",
       "38  Tf-Idf + Lemmatizer  5.0       572   \n",
       "17  Tf-Idf + Lemmatizer  1.0       570   \n",
       "15  Tf-Idf + Lemmatizer  2.0       818   \n",
       "16  Tf-Idf + Lemmatizer  3.0      1497   \n",
       "18  Tf-Idf + Lemmatizer  4.0        18   \n",
       "19  Tf-Idf + Lemmatizer  5.0       786   \n",
       "31  Tf-Idf + Lemmatizer  1.0       561   \n",
       "33  Tf-Idf + Lemmatizer  2.0       941   \n",
       "30  Tf-Idf + Lemmatizer  3.0       968   \n",
       "34  Tf-Idf + Lemmatizer  4.0       951   \n",
       "32  Tf-Idf + Lemmatizer  5.0       942   \n",
       "..                  ...  ...       ...   \n",
       "52  Tf-Idf + Lemmatizer  1.0       941   \n",
       "51  Tf-Idf + Lemmatizer  2.0       561   \n",
       "54  Tf-Idf + Lemmatizer  3.0       951   \n",
       "53  Tf-Idf + Lemmatizer  4.0       942   \n",
       "50  Tf-Idf + Lemmatizer  5.0       968   \n",
       "46  Tf-Idf + Lemmatizer  1.0       951   \n",
       "47  Tf-Idf + Lemmatizer  2.0       556   \n",
       "45  Tf-Idf + Lemmatizer  3.0       554   \n",
       "48  Tf-Idf + Lemmatizer  4.0       968   \n",
       "49  Tf-Idf + Lemmatizer  5.0       558   \n",
       "41  Tf-Idf + Lemmatizer  1.0       550   \n",
       "40  Tf-Idf + Lemmatizer  2.0       992   \n",
       "42  Tf-Idf + Lemmatizer  3.0      1479   \n",
       "44  Tf-Idf + Lemmatizer  4.0      1539   \n",
       "43  Tf-Idf + Lemmatizer  5.0        28   \n",
       "25  Tf-Idf + Lemmatizer  1.0       673   \n",
       "26  Tf-Idf + Lemmatizer  2.0       671   \n",
       "28  Tf-Idf + Lemmatizer  3.0      1547   \n",
       "29  Tf-Idf + Lemmatizer  4.0      1549   \n",
       "27  Tf-Idf + Lemmatizer  5.0       668   \n",
       "20  Tf-Idf + Lemmatizer  1.0       673   \n",
       "21  Tf-Idf + Lemmatizer  2.0       671   \n",
       "24  Tf-Idf + Lemmatizer  3.0      1547   \n",
       "22  Tf-Idf + Lemmatizer  4.0      1549   \n",
       "23  Tf-Idf + Lemmatizer  5.0       668   \n",
       "58  Tf-Idf + Lemmatizer  1.0       990   \n",
       "55  Tf-Idf + Lemmatizer  2.0       818   \n",
       "59  Tf-Idf + Lemmatizer  3.0       547   \n",
       "56  Tf-Idf + Lemmatizer  4.0      1171   \n",
       "57  Tf-Idf + Lemmatizer  5.0       441   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                    Answer  \\\n",
       "67                                                                                                                                                                                                       As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "65                                                                                                                                                                                                 On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.   \n",
       "66                                                                                                                                                                                                                                            We are all encouraged to identify areas for improvements and continuously work towards a better environment.   \n",
       "68                                                                                                                                                                                                                           Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.   \n",
       "69                                                                                                                                                                                                                                          We identified human rights which are potentially susceptible to violations, as well as their associated risks.   \n",
       "11                                                                                                                                                                                                                  misleading and suggestive statements may trigger an investigation against Roche as a company as well as against the employee involved.   \n",
       "14                                                                                                                                    By the end of 2018, XXX pharmaceutical companies and associations were involved in this programme, in which partners such as the World Bank Group and the Union for International Cancer Control (UICC) participate.   \n",
       "10                                                                                                                                                                                                                     Apprentices can gain valuable experience in XXX professions, including informatics, biology, chemistry, automation and electronics.   \n",
       "13                                                                                                                                                    In addition, businesses are expected to become pro-active and make an active contribution to improve the situation, before the implementation of legal frameworks and beyond their legal boundaries.   \n",
       "12                                                                                                                                                                                                                                              Capital structure Business activities are carried out through Group subsidiaries and associated companies.   \n",
       "5                                                                                                                                                                                                                                           During the operation, the surgeons realised that the cancer had spread and this had not been detected earlier.   \n",
       "6                                                                                                                                                                                                                      We investigate counter­ feits detected at different locations around the world to find out if they originated from the same source.   \n",
       "8                                                                                                                                                                                                                         Detecting progression of the disease earlier and in a quantifiable manner will be a significant innovation for the MS community.   \n",
       "9                                                                                                                                                                                             The CMS focuses on prevention, detection and responding to non-compliance behaviour by comprehensively involving people, principles, policies and processes.   \n",
       "7                                                                                                                                                                                                             Capabilities to run infusion facilities and having sufficient numbers of trained nurses and doctors are difficult to find in some countries.   \n",
       "36                                                                                                                                                                                              Since 2010, Genentech has reduced greenhouse gas emissions from energy used at its SSF campus by over 30%, thanks in part to its green building programme.   \n",
       "35                                                                                                                                                                                                                                               Proactively seeking new technologies \\tDecreasing energy consumption \\tReducing greenhouse gas emissions.   \n",
       "39                              We planned and performed our procedures in accordance with the International Standard on Assurance Engagements (ISAE 3000) (revised) ‘Assurance engagements other than audits or reviews of historical financial information’, and, in respect of greenhouse gas emissions, with the International Standard on Assurance .   \n",
       "37                                                                                                                                                                                                       Engagements (ISAE 3410) ‘Assurance Engagements on Greenhouse Gas Statements’, issued by the International Auditing and Assurance Standards Board.   \n",
       "38                                                                                                                                                                           We were able to reduce our scope XXX GHG emissions by 1.9% by implementing energy­saving measures that reduced the amount of fuel we use to heat, cool and operate our sites.   \n",
       "17                                                                                                                                                                Our emissions strategy prescribes a continuous improvement at our manufacturing sites, while our aim is to avoid, reduce, and control air pollutants in line with our eco­balance goals.   \n",
       "15                                                                                                                                                                                                                                               The company has a formal policy governing the engagement of the statutory auditor for non­audit services.   \n",
       "16                                                                                                                                                                                               In addition, we participate in more formal and structured engagement, such as meetings, forums and other events, and carry out consultations and surveys.   \n",
       "18                                                                                                                                                             Our Pharmaceuticals and Diagnostics Divisions and global functions conduct a formal risk assessment process at least once a year and must develop risk plans for their most material risks.   \n",
       "19                                                                                                                                                             The Pharmaceuticals and Diagnostics Divisions and global functions conduct a formal risk assessment process at least once a year and must develop risk plans for their most material risks.   \n",
       "31                                                                                                                                                                                              Since 2010, Genentech has reduced greenhouse gas emissions from energy used at its SSF campus by over 30%, thanks in part to its green building programme.   \n",
       "33                              We planned and performed our procedures in accordance with the International Standard on Assurance Engagements (ISAE 3000) (revised) ‘Assurance engagements other than audits or reviews of historical financial information’, and, in respect of greenhouse gas emissions, with the International Standard on Assurance .   \n",
       "30                                                                                                                                                                                                                                               Proactively seeking new technologies \\tDecreasing energy consumption \\tReducing greenhouse gas emissions.   \n",
       "34  Roche accident rate, energy consumption, greenhouse gas emissions related to energy consumption, water, waste, contributions to public policy stakeholders, representation of women in key leadership roles) concerning completeness, accuracy, adequacy and consistency; • Review of documentation and analysis of relevant policies and principles .   \n",
       "32                                                                                                                                                                                                       Engagements (ISAE 3410) ‘Assurance Engagements on Greenhouse Gas Statements’, issued by the International Auditing and Assurance Standards Board.   \n",
       "..                                                                                                                                                                                                                                                                                                                                                     ...   \n",
       "52                              We planned and performed our procedures in accordance with the International Standard on Assurance Engagements (ISAE 3000) (revised) ‘Assurance engagements other than audits or reviews of historical financial information’, and, in respect of greenhouse gas emissions, with the International Standard on Assurance .   \n",
       "51                                                                                                                                                                                              Since 2010, Genentech has reduced greenhouse gas emissions from energy used at its SSF campus by over 30%, thanks in part to its green building programme.   \n",
       "54  Roche accident rate, energy consumption, greenhouse gas emissions related to energy consumption, water, waste, contributions to public policy stakeholders, representation of women in key leadership roles) concerning completeness, accuracy, adequacy and consistency; • Review of documentation and analysis of relevant policies and principles .   \n",
       "53                                                                                                                                                                                                       Engagements (ISAE 3410) ‘Assurance Engagements on Greenhouse Gas Statements’, issued by the International Auditing and Assurance Standards Board.   \n",
       "50                                                                                                                                                                                                                                               Proactively seeking new technologies \\tDecreasing energy consumption \\tReducing greenhouse gas emissions.   \n",
       "46  Roche accident rate, energy consumption, greenhouse gas emissions related to energy consumption, water, waste, contributions to public policy stakeholders, representation of women in key leadership roles) concerning completeness, accuracy, adequacy and consistency; • Review of documentation and analysis of relevant policies and principles .   \n",
       "47                                                                                                                                                                                                                      Secondly, we endeavour to reduce usage of fossil fuels, cut energy consumption, and increase the proportion of sustainable energy.   \n",
       "45                                                                                                                                                                    Improvements in terms of decreasing energy consumption, air emissions, water consumption, and the weight of chemical waste, has led to a further improvement of 3.3% compared to XXX   \n",
       "48                                                                                                                                                                                                                                               Proactively seeking new technologies \\tDecreasing energy consumption \\tReducing greenhouse gas emissions.   \n",
       "49                                                                                                                                                                                            Our success in reducing energy consumption and carbon dioxide emissions can be credited to initiatives like the renovation of the chimney on the Basel site.   \n",
       "41                                                                                                                                                                   We are committed to continuously monitoring key performance indicators (eg, the five­ year goals on page 81), and our aim is to cover at least 95% of each key performance indicator.   \n",
       "40                                                                                                                                                                                                                                       We review and monitor progress internally and report externally, such as on our website and in our Annual Report.   \n",
       "42                                                                                                                                                          Our commitment to long-term thinking is further emphasised through our “Five-Year Corporate Goals” which serve as a bonus-relevant yardstick and against which progress is monitored annually.   \n",
       "44                                                                                                                                                                                                         Roche is committed to high standards of performance and sustainability in all its activities, including in its dealings with business partners.   \n",
       "43                                                                                                                                                        Information about Roche is committed to transparent reporting and we endeavour to drive our economic, social and environmental performance with the same diligence as our financial performance.   \n",
       "25                                                                                                                                                                                                             As our accident rate is so low, a single accident, resulting in a longer absence, can lead to fluctuations in the accident rate key figure.   \n",
       "26                                                                                                                                                                                                        Over the years, we have implemented a variety of initiatives to improve our already excellent track record in the areas of accidents and health.   \n",
       "28                                                                                         If a business partner does not comply with applicable laws, regulations, industry codes, contractual terms or with generally accepted sustainability standards, Roche requests appropriate remedial measures and will, if necessary, terminate the cooperation.   \n",
       "29                                                                                                                                                                                                                                               – Request appropriate remedial measures if we become aware of a compliance issue with a business partner.   \n",
       "27                                                                                                                                                                                                                                        Compliance Occupational accidents Drug efficacy, safety and counterfeiting Data transparency on clinical trials.   \n",
       "20                                                                                                                                                                                                             As our accident rate is so low, a single accident, resulting in a longer absence, can lead to fluctuations in the accident rate key figure.   \n",
       "21                                                                                                                                                                                                        Over the years, we have implemented a variety of initiatives to improve our already excellent track record in the areas of accidents and health.   \n",
       "24                                                                                         If a business partner does not comply with applicable laws, regulations, industry codes, contractual terms or with generally accepted sustainability standards, Roche requests appropriate remedial measures and will, if necessary, terminate the cooperation.   \n",
       "22                                                                                                                                                                                                                                               – Request appropriate remedial measures if we become aware of a compliance issue with a business partner.   \n",
       "23                                                                                                                                                                                                                                        Compliance Occupational accidents Drug efficacy, safety and counterfeiting Data transparency on clinical trials.   \n",
       "58                                                                                                    This commitment is reflected in our Roche Group Code of Conduct, Supplier Code of Conduct, the Roche Employment Policy and the Roche Policy on Safety, Security, Health and Environmental Protection, all being embedded throughout the Roche Group.   \n",
       "55                                                                                                                                                                                                                                               The company has a formal policy governing the engagement of the statutory auditor for non­audit services.   \n",
       "59                                                                                                                                                                         Our Corporate Principles and the Safety, Security, Health and Environmental Protection (SHE) Policy ensure that we commit to the highest standards of environmental protection.   \n",
       "56                                                                                                                                                                                                                                          We must carefully consider the potential conflict of interest prior to the acceptance of secondary employment.   \n",
       "57                                                                                                                                                                                                                     In August, we formally launched our partnership with the Kenya Medical Research Institute by installing a cobas XXX for HIV assays.   \n",
       "\n",
       "                  Score  \n",
       "67    0.236880133650043  \n",
       "65  0.20524048022241717  \n",
       "66  0.15551753454349201  \n",
       "68  0.15210973009495576  \n",
       "69  0.10852181013467649  \n",
       "11  0.22415137867296625  \n",
       "14  0.18608275289688142  \n",
       "10   0.1647406882130872  \n",
       "13  0.14135675343842524  \n",
       "12  0.10965299618531675  \n",
       "5   0.26288882124175217  \n",
       "6   0.23458010644549057  \n",
       "8   0.21658518844310068  \n",
       "9    0.2106377916861496  \n",
       "7    0.1699191509390749  \n",
       "36   0.7435059359644431  \n",
       "35   0.5774563434102837  \n",
       "39  0.47222375810607753  \n",
       "37  0.36414900462001387  \n",
       "38  0.32155993400457095  \n",
       "17   0.6747827811482299  \n",
       "15   0.4594362592269168  \n",
       "16   0.2883580337566423  \n",
       "18  0.27176447864675596  \n",
       "19  0.27176447864675596  \n",
       "31   0.7136269954498731  \n",
       "33   0.6723469907592654  \n",
       "30   0.5892024351667124  \n",
       "34   0.5379591697166606  \n",
       "32   0.5184713459276016  \n",
       "..                  ...  \n",
       "52   0.5691246419921216  \n",
       "51    0.538760472442861  \n",
       "54  0.45536876654363795  \n",
       "53   0.4388728189308897  \n",
       "50  0.41462106589967984  \n",
       "46   0.3668570524001521  \n",
       "47   0.3375888106534711  \n",
       "45   0.2982669320591099  \n",
       "48   0.2393790608438896  \n",
       "49  0.22309245863638655  \n",
       "41    0.513939959376975  \n",
       "40   0.3353529725353087  \n",
       "42   0.2723925346419676  \n",
       "44   0.2544647272540468  \n",
       "43   0.1873654610694597  \n",
       "25   0.3431017382006426  \n",
       "26   0.2897115781222824  \n",
       "28  0.22618718099440643  \n",
       "29  0.21185449189310548  \n",
       "27   0.2056707996620998  \n",
       "20  0.32448326409384565  \n",
       "21  0.27399033012162477  \n",
       "24   0.2290184794787049  \n",
       "22  0.20240583200119183  \n",
       "23   0.1945100387807495  \n",
       "58   0.4110420092380608  \n",
       "55   0.3761107077041517  \n",
       "59  0.33013798795212834  \n",
       "56    0.218251943367355  \n",
       "57  0.19511106342647616  \n",
       "\n",
       "[70 rows x 6 columns]"
      ]
     },
     "execution_count": 107,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "list_questions_results=data2.Question.unique().tolist()\n",
    "dic_questions={}\n",
    "for i,s in enumerate(list_questions_results):\n",
    "    dic_questions[s]=i+1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [],
   "source": [
    "frames_Novartis=[data1,data2,data3,data4]\n",
    "result_Novartis = pd.concat(frames_Novartis)\n",
    "result_Novartis['Rank']=result_Novartis['Rank'].map(lambda x: x[0])\n",
    "result_Novartis['Q_id']=result_Novartis.apply(lambda x: dic_questions[x.Question],axis=1)\n",
    "result_Novartis['Company']=['Novartis']*len(result_Novartis)\n",
    "results_Novartis=result_Novartis.sort_values(by=['Q_id','Company','Model','Rank']).reset_index(drop=True)[['Question','Q_id','Company','Model','Answer','Rank','Score','Doc_index']]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Q_id</th>\n",
       "      <th>Company</th>\n",
       "      <th>Model</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Score</th>\n",
       "      <th>Doc_index</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.57026166</td>\n",
       "      <td>2499</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.5109576</td>\n",
       "      <td>2459</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.48538196</td>\n",
       "      <td>2637</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.48038045</td>\n",
       "      <td>226</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.480069</td>\n",
       "      <td>1928</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4667485</td>\n",
       "      <td>2227</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.4663378</td>\n",
       "      <td>2130</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.4505594</td>\n",
       "      <td>2683</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.42783558</td>\n",
       "      <td>1920</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.42783558</td>\n",
       "      <td>3103</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6198342429415247</td>\n",
       "      <td>2416</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.5869482063619555</td>\n",
       "      <td>2130</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>In addition, it does not sell short assets it does not have, or does not know it will have, in the future.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.39312472620836497</td>\n",
       "      <td>4628</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3019442945156682</td>\n",
       "      <td>882</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2949217573271527</td>\n",
       "      <td>4655</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.30886894</td>\n",
       "      <td>2485</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.29680955</td>\n",
       "      <td>1920</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.29680955</td>\n",
       "      <td>3103</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28595233</td>\n",
       "      <td>3104</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX</td>\n",
       "      <td>5</td>\n",
       "      <td>0.28595233</td>\n",
       "      <td>1921</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>At the same time, other companies with specialized expertise or business models are entering the Item XXX</td>\n",
       "      <td>1</td>\n",
       "      <td>0.54087555</td>\n",
       "      <td>1835</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.51713026</td>\n",
       "      <td>2747</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.51357496</td>\n",
       "      <td>4514</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.49095944</td>\n",
       "      <td>2393</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.48801655</td>\n",
       "      <td>2499</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.32053015</td>\n",
       "      <td>2227</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.31352153</td>\n",
       "      <td>843</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.30220336</td>\n",
       "      <td>2785</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.30220336</td>\n",
       "      <td>2094</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2962501</td>\n",
       "      <td>1981</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>250</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.30741232834573573</td>\n",
       "      <td>873</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>251</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.2629575541037144</td>\n",
       "      <td>2573</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>252</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>In addition, it does not sell short assets it does not have, or does not know it will have, in the future.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.2512910648903934</td>\n",
       "      <td>4628</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>253</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.2087611172195355</td>\n",
       "      <td>3832</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>254</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.19363820084091854</td>\n",
       "      <td>4669</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>255</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6607314</td>\n",
       "      <td>2429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>256</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.45916152</td>\n",
       "      <td>873</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>257</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.45632774</td>\n",
       "      <td>2393</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>258</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Defining the Global Health &amp; Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.44425339</td>\n",
       "      <td>652</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.4298969</td>\n",
       "      <td>425</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>260</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.7060776</td>\n",
       "      <td>1163</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.62601626</td>\n",
       "      <td>1064</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>262</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6205468</td>\n",
       "      <td>170</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>263</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.61974794</td>\n",
       "      <td>65</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>264</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.61974794</td>\n",
       "      <td>1392</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>265</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.33742234</td>\n",
       "      <td>1604</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>266</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.33742234</td>\n",
       "      <td>1602</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>267</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Remediation plans to address information security, data privacy and business continuity risks are on track.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.31877115</td>\n",
       "      <td>3637</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>268</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3186491</td>\n",
       "      <td>185</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>269</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).</td>\n",
       "      <td>5</td>\n",
       "      <td>0.31634763</td>\n",
       "      <td>1163</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>270</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.362225367191791</td>\n",
       "      <td>477</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>271</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.340272807114573</td>\n",
       "      <td>123</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>272</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.33558396034435095</td>\n",
       "      <td>1880</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>273</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.2577721065766643</td>\n",
       "      <td>659</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.23025861380513102</td>\n",
       "      <td>117</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>275</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.55075574</td>\n",
       "      <td>1512</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>276</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.511887</td>\n",
       "      <td>1592</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>277</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.5090189</td>\n",
       "      <td>34</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>278</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization).</td>\n",
       "      <td>4</td>\n",
       "      <td>0.5047898</td>\n",
       "      <td>1033</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>279</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.48939437</td>\n",
       "      <td>1501</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>280 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                         Question  \\\n",
       "0                                                                                Does the company operate in countries out of the European Union?   \n",
       "1                                                                                Does the company operate in countries out of the European Union?   \n",
       "2                                                                                Does the company operate in countries out of the European Union?   \n",
       "3                                                                                Does the company operate in countries out of the European Union?   \n",
       "4                                                                                Does the company operate in countries out of the European Union?   \n",
       "5                                                                                Does the company operate in countries out of the European Union?   \n",
       "6                                                                                Does the company operate in countries out of the European Union?   \n",
       "7                                                                                Does the company operate in countries out of the European Union?   \n",
       "8                                                                                Does the company operate in countries out of the European Union?   \n",
       "9                                                                                Does the company operate in countries out of the European Union?   \n",
       "10                                                                               Does the company operate in countries out of the European Union?   \n",
       "11                                                                               Does the company operate in countries out of the European Union?   \n",
       "12                                                                               Does the company operate in countries out of the European Union?   \n",
       "13                                                                               Does the company operate in countries out of the European Union?   \n",
       "14                                                                               Does the company operate in countries out of the European Union?   \n",
       "15                                                                               Does the company operate in countries out of the European Union?   \n",
       "16                                                                               Does the company operate in countries out of the European Union?   \n",
       "17                                                                               Does the company operate in countries out of the European Union?   \n",
       "18                                                                               Does the company operate in countries out of the European Union?   \n",
       "19                                                                               Does the company operate in countries out of the European Union?   \n",
       "20     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "21     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "22     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "23     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "24     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "25     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "26     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "27     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "28     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "29     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "..                                                                                                                                            ...   \n",
       "250  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "251  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "252  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "253  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "254  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "255  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "256  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "257  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "258  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "259  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "260                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "261                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "262                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "263                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "264                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "265                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "266                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "267                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "268                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "269                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "270                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "271                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "272                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "273                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "274                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "275                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "276                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "277                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "278                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "279                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "\n",
       "     Q_id   Company                          Model  \\\n",
       "0       1  Novartis             Bert - transformer   \n",
       "1       1  Novartis             Bert - transformer   \n",
       "2       1  Novartis             Bert - transformer   \n",
       "3       1  Novartis             Bert - transformer   \n",
       "4       1  Novartis             Bert - transformer   \n",
       "5       1  Novartis              Infersent Bi-Lstm   \n",
       "6       1  Novartis              Infersent Bi-Lstm   \n",
       "7       1  Novartis              Infersent Bi-Lstm   \n",
       "8       1  Novartis              Infersent Bi-Lstm   \n",
       "9       1  Novartis              Infersent Bi-Lstm   \n",
       "10      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "11      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "12      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "13      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "14      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "15      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "16      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "17      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "18      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "19      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "20      2  Novartis             Bert - transformer   \n",
       "21      2  Novartis             Bert - transformer   \n",
       "22      2  Novartis             Bert - transformer   \n",
       "23      2  Novartis             Bert - transformer   \n",
       "24      2  Novartis             Bert - transformer   \n",
       "25      2  Novartis              Infersent Bi-Lstm   \n",
       "26      2  Novartis              Infersent Bi-Lstm   \n",
       "27      2  Novartis              Infersent Bi-Lstm   \n",
       "28      2  Novartis              Infersent Bi-Lstm   \n",
       "29      2  Novartis              Infersent Bi-Lstm   \n",
       "..    ...       ...                            ...   \n",
       "250    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "251    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "252    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "253    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "254    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "255    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "256    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "257    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "258    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "259    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "260    14  Novartis             Bert - transformer   \n",
       "261    14  Novartis             Bert - transformer   \n",
       "262    14  Novartis             Bert - transformer   \n",
       "263    14  Novartis             Bert - transformer   \n",
       "264    14  Novartis             Bert - transformer   \n",
       "265    14  Novartis              Infersent Bi-Lstm   \n",
       "266    14  Novartis              Infersent Bi-Lstm   \n",
       "267    14  Novartis              Infersent Bi-Lstm   \n",
       "268    14  Novartis              Infersent Bi-Lstm   \n",
       "269    14  Novartis              Infersent Bi-Lstm   \n",
       "270    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "271    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "272    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "273    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "274    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "275    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "276    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "277    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "278    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "279    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Answer  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                        Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.   \n",
       "1                                                                                                                                                                                                                                                                                                                In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing.   \n",
       "2                                                                                                                                                                                                              In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                    These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets.   \n",
       "4                                                                                                                                                                     In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies.   \n",
       "5                                                                                                                                                                                                                                                                                                                                                            Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.   \n",
       "6                                                                                                                                                                                                                                                                                                                                                                     For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                          The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe.   \n",
       "8                                                                                                                                                                                                                                                                                                                                                                 Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                 Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "10                                                                                                                                                                                                                                                                                                                                   Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states).   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                    For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.   \n",
       "12                                                                                                                                                                                                                                                                                                                                                                         In addition, it does not sell short assets it does not have, or does not know it will have, in the future.   \n",
       "13                                                                                                                                                                                                                                                                                                                                              For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.   \n",
       "14                                                                                                                                                                                                                                                                                                     The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.   \n",
       "15                                                                                                                                                                                                                                                                                    In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries.   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "17                                                                                                                                                                                                                                                                                                                                              For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.   \n",
       "18                                                                                                                                                                                                                                                                                                                                                            We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions.   \n",
       "19                                                                                                                                                                                     The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX   \n",
       "20                                                                                                                                                                                                                                                                                                                                                                          At the same time, other companies with specialized expertise or business models are entering the Item XXX   \n",
       "21                                                                                                                                                                                                                                                                                                                            Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.   \n",
       "22                                                                                                                                                                                                                                                                                                                                             Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans.   \n",
       "23                                                                                                                                                                                                                                                                                                                                       Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.   \n",
       "24                                                                                                                                                                                                                                                                                                                                                       Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.   \n",
       "25                                                                                                                                                                                                                                                                                                                                                           Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.   \n",
       "26                                                                                                                                                                                                                                                                                                                                 There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector.   \n",
       "27                                                                                                                                                                                                                                                                                                                    The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.   \n",
       "28                                                                                                                                                                                                                                                                                                                    The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.   \n",
       "29                                                                                                                                                                                                                           In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland.   \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
       "250                                                                                                                                                                                                                                                                                                                                                  Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.   \n",
       "251                                                                                                                                                                                                                                                                                                                           Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose.   \n",
       "252                                                                                                                                                                                                                                                                                                                                                                        In addition, it does not sell short assets it does not have, or does not know it will have, in the future.   \n",
       "253                                                                                                                                                                                                                                                                                                                                                 Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information.   \n",
       "254                                                                                                                                                                                                                                                                                          The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates.   \n",
       "255                                                                                                                                                                                                                                                           After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP).   \n",
       "256                                                                                                                                                                                                                                                                                                                                                  Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.   \n",
       "257                                                                                                                                                                                                                                                                                                                                      Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.   \n",
       "258                                                                                                                                                                                                                                                                                                                           Defining the Global Health & Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company.   \n",
       "259                                                                                                                                                                                                                                                                                                          Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company.   \n",
       "260                                                                                                                                                                                                                                                                                                                                                This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).   \n",
       "261                                                                                                                                   Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review.   \n",
       "262                                                                                                                                                                                                                                                                                                                                                             To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary.   \n",
       "263                                                                                                                                                                                                                                                                                              Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.   \n",
       "264                                                                                                                                                                                                                                                                                              Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.   \n",
       "265                                                                                                                                                                                                                                                                                                                                        Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.   \n",
       "266                                                                                                                                                                                                                                                                                                                                        Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.   \n",
       "267                                                                                                                                                                                                                                                                                                                                                                       Remediation plans to address information security, data privacy and business continuity risks are on track.   \n",
       "268                                                                                                                                                                                                                                                                                                                                                    This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management.   \n",
       "269                                                                                                                                                                                                                                                                                                                                                This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).   \n",
       "270                                                                                                                                                                                                                                                                                                                                        That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change.   \n",
       "271                                                                                                                                                                                                                                                                                            While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts.   \n",
       "272                                                                                                                                                                                                                                    Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs.   \n",
       "273                                                                                                                                                                                                                                                                                                                              The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices.   \n",
       "274                                                                                                                                                                                                                                                                                                                                                                        Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes.   \n",
       "275                                                                                                                                                                                                           A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action.   \n",
       "276                                                                                                                                                                                                                                                                                                              Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience.   \n",
       "277                                                                                                                                                                                                                                                                                                                    Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business.   \n",
       "278  We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization).   \n",
       "279                                                                                                                                                                                                                                                                                                              This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed.   \n",
       "\n",
       "    Rank                Score Doc_index  \n",
       "0      1           0.57026166      2499  \n",
       "1      2            0.5109576      2459  \n",
       "2      3           0.48538196      2637  \n",
       "3      4           0.48038045       226  \n",
       "4      5             0.480069      1928  \n",
       "5      1            0.4667485      2227  \n",
       "6      2            0.4663378      2130  \n",
       "7      3            0.4505594      2683  \n",
       "8      4           0.42783558      1920  \n",
       "9      5           0.42783558      3103  \n",
       "10     1   0.6198342429415247      2416  \n",
       "11     2   0.5869482063619555      2130  \n",
       "12     3  0.39312472620836497      4628  \n",
       "13     4   0.3019442945156682       882  \n",
       "14     5   0.2949217573271527      4655  \n",
       "15     1           0.30886894      2485  \n",
       "16     2           0.29680955      1920  \n",
       "17     3           0.29680955      3103  \n",
       "18     4           0.28595233      3104  \n",
       "19     5           0.28595233      1921  \n",
       "20     1           0.54087555      1835  \n",
       "21     2           0.51713026      2747  \n",
       "22     3           0.51357496      4514  \n",
       "23     4           0.49095944      2393  \n",
       "24     5           0.48801655      2499  \n",
       "25     1           0.32053015      2227  \n",
       "26     2           0.31352153       843  \n",
       "27     3           0.30220336      2785  \n",
       "28     4           0.30220336      2094  \n",
       "29     5            0.2962501      1981  \n",
       "..   ...                  ...       ...  \n",
       "250    1  0.30741232834573573       873  \n",
       "251    2   0.2629575541037144      2573  \n",
       "252    3   0.2512910648903934      4628  \n",
       "253    4   0.2087611172195355      3832  \n",
       "254    5  0.19363820084091854      4669  \n",
       "255    1            0.6607314      2429  \n",
       "256    2           0.45916152       873  \n",
       "257    3           0.45632774      2393  \n",
       "258    4           0.44425339       652  \n",
       "259    5            0.4298969       425  \n",
       "260    1            0.7060776      1163  \n",
       "261    2           0.62601626      1064  \n",
       "262    3            0.6205468       170  \n",
       "263    4           0.61974794        65  \n",
       "264    5           0.61974794      1392  \n",
       "265    1           0.33742234      1604  \n",
       "266    2           0.33742234      1602  \n",
       "267    3           0.31877115      3637  \n",
       "268    4            0.3186491       185  \n",
       "269    5           0.31634763      1163  \n",
       "270    1    0.362225367191791       477  \n",
       "271    2    0.340272807114573       123  \n",
       "272    3  0.33558396034435095      1880  \n",
       "273    4   0.2577721065766643       659  \n",
       "274    5  0.23025861380513102       117  \n",
       "275    1           0.55075574      1512  \n",
       "276    2             0.511887      1592  \n",
       "277    3            0.5090189        34  \n",
       "278    4            0.5047898      1033  \n",
       "279    5           0.48939437      1501  \n",
       "\n",
       "[280 rows x 8 columns]"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results_Novartis"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Pfizer:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0     Roche\n",
      "1   Johnson\n",
      "2    Pfizer\n",
      "\n",
      "1\n",
      "deep neural networks in action..\n",
      "beginning of Infersent..\n",
      "Infersent ranking finished!\n",
      "beginning of bert..\n",
      "bert ranking finished !\n",
      "begin of Tf-idf Farahat ranking predict\n",
      "Tf-idf Farahat ranking finished!\n",
      "beginning of Tf_idf_lemmatize..\n",
      "Tf_idf_lemmatize ranking finished !\n"
     ]
    }
   ],
   "source": [
    "data1,data2,data3,data4=QAmodel.predict(questions, VE_type='DP',range_chunks=(8,35))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [],
   "source": [
    "list_questions_results=data2.Question.unique().tolist()\n",
    "dic_questions={}\n",
    "for i,s in enumerate(list_questions_results):\n",
    "    dic_questions[s]=i+1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "frames_Johnson=[data1,data2,data3,data4]\n",
    "result_Johnson= pd.concat(frames_Johnson)\n",
    "result_Johnson['Rank']=result_Johnson['Rank'].map(lambda x: x[0])\n",
    "result_Johnson['Q_id']=result_Johnson.apply(lambda x: dic_questions[x.Question],axis=1)\n",
    "result_Johnson['Company']=['Johnson']*len(result_Johnson)\n",
    "results_Johnson=result_Johnson.sort_values(by=['Q_id','Company','Model','Rank']).reset_index(drop=True)[['Question','Q_id','Company','Model','Answer','Rank','Score','Doc_index']]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Johnson"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0     Roche\n",
      "1   Johnson\n",
      "2    Pfizer\n",
      "\n",
      "2\n",
      "deep neural networks in action..\n",
      "beginning of Infersent..\n",
      "Infersent ranking finished!\n",
      "beginning of bert..\n",
      "bert ranking finished !\n",
      "begin of Tf-idf Farahat ranking predict\n",
      "Tf-idf Farahat ranking finished!\n",
      "beginning of Tf_idf_lemmatize..\n",
      "Tf_idf_lemmatize ranking finished !\n"
     ]
    }
   ],
   "source": [
    "data1,data2,data3,data4=QAmodel.predict(questions, VE_type='DP',range_chunks=(8,35))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "frames_Pfizer=[data1,data2,data3,data4]\n",
    "result_Pfizer= pd.concat(frames_Pfizer)\n",
    "result_Pfizer['Rank']=result_Pfizer['Rank'].map(lambda x: x[0])\n",
    "result_Pfizer['Q_id']=result_Pfizer.apply(lambda x: dic_questions[x.Question],axis=1)\n",
    "result_Pfizer['Company']=['Pfizer']*len(result_Pfizer)\n",
    "results_Pfizer=result_Pfizer.sort_values(by=['Q_id','Company','Model','Rank']).reset_index(drop=True)[['Question','Q_id','Company','Model','Answer','Rank','Score','Doc_index']]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Pfizer"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "All"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "results_Novartis=results_PfizerRocheJohnson.sort_values(by=['Q_id','Company','Model','Rank']).reset_index(drop=True)[['Question','Q_id','Company','Model','Answer','Rank','Score','Doc_index']]\n",
    "results_Novartis.to_csv('Results_PfizerRocheJohnson.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Q_id</th>\n",
       "      <th>Company</th>\n",
       "      <th>Model</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Score</th>\n",
       "      <th>Doc_index</th>\n",
       "      <th>Context_Answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.46158153</td>\n",
       "      <td>2329</td>\n",
       "      <td>During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences. During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. Legal Proceedings Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.39178875</td>\n",
       "      <td>993</td>\n",
       "      <td>We also reviewed and updated our governance structure for managing human rights across our value chain. The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work. Quarterly EGC meetings provide a forum for updates on human rights topics, with an established process for elevating issues to the Johnson &amp; Johnson Executive Committee, our Board of Directors and Board Committees if warranted.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.38455927</td>\n",
       "      <td>954</td>\n",
       "      <td>• Clinical Data Transparency: We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries; publication of results in peer-reviewed journals; and sharing of clinical study reports and participant-level data from clinical trials. Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe. • Political Engagement: As a global healthcare company, we work with many stakeholders in the markets where we operate, and we take a stance on and support certain public policies in the United States and in different parts of the world as they relate to our core business of advancing health.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.38348675</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.37289336</td>\n",
       "      <td>1536</td>\n",
       "      <td>These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.40787455</td>\n",
       "      <td>1040</td>\n",
       "      <td>The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.39962035</td>\n",
       "      <td>1536</td>\n",
       "      <td>These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.39595923</td>\n",
       "      <td>1051</td>\n",
       "      <td>The Commonsense Principles XXX aspire to promote a constructive dialogue on good corporate governance to benefit the millions of . Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets. They are an updated version of the Commonsense Principles successfully launched in XXX to build momentum around the corporate governance conversation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA).</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3935492</td>\n",
       "      <td>903</td>\n",
       "      <td>Our compliance guidelines and policies meet or exceed legal and regulatory requirements in every jurisdiction where we operate. This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, Johnson &amp; Johnson actively participates in the work of industry associations, and helps develop industry codes for ethical and compliant marketing and selling of products.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.38491276</td>\n",
       "      <td>1377</td>\n",
       "      <td>Throughout Johnson &amp; Johnson’s history, we have maintained a strong, consistent andwe have maintained a strong, consistent andwe have maintained a strong, consistent and sustainable business. The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base. We are structured to meet the current and future needs of patients meet the current and future needs of patients meet the current and future needs of patients and consumers globally, and to address the and consumers globally, and to address the and consumers globally, and to address the challenges and opportunities that the worldchallenges and opportunities that the worldchallenges and opportunities that the world of healthcare presents.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4036158531671312</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.3691630723837139</td>\n",
       "      <td>1040</td>\n",
       "      <td>The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.3506139660462462</td>\n",
       "      <td>935</td>\n",
       "      <td>It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.33417458782649534</td>\n",
       "      <td>1932</td>\n",
       "      <td>Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>• Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2932092398258069</td>\n",
       "      <td>1041</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations. • Resources: The GPT assists operating companies with designating privacy resources, considering their local requirements and the risk environments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.38348675</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.34441066</td>\n",
       "      <td>1560</td>\n",
       "      <td>The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.33205885</td>\n",
       "      <td>935</td>\n",
       "      <td>It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28211266</td>\n",
       "      <td>1524</td>\n",
       "      <td>This Committee oversees and coordinates the activities of the Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Johnson &amp; Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.27888668</td>\n",
       "      <td>1521</td>\n",
       "      <td>The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. Johnson &amp; Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world. The Executive Committee of Johnson &amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "      <td>1</td>\n",
       "      <td>0.47936144</td>\n",
       "      <td>1525</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "      <td>2</td>\n",
       "      <td>0.47936144</td>\n",
       "      <td>1514</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.47532654</td>\n",
       "      <td>1521</td>\n",
       "      <td>Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3949507</td>\n",
       "      <td>1618</td>\n",
       "      <td>He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain. He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX Biosimilars have the potential to expand patient access to treatment and to create a more sustainable health care system.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.38917118</td>\n",
       "      <td>1586</td>\n",
       "      <td>She has held roles of increasing global responsibility throughout her career including site leadership, global strategic planning, contractor management, supply chain management and product portfolio leadership. Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States. She has been a member of the PGS Leadership Team since XXX and has represented PGS on several of Pfizer’s Business Leadership Teams.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Member of the American Society for Clinical Investigation and the Association of American Physicians.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.47606385</td>\n",
       "      <td>1495</td>\n",
       "      <td>Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.4706573</td>\n",
       "      <td>1521</td>\n",
       "      <td>Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.36455357</td>\n",
       "      <td>1553</td>\n",
       "      <td>Prior to joining Pfizer in 2009, Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.34432322</td>\n",
       "      <td>1513</td>\n",
       "      <td>He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.34432322</td>\n",
       "      <td>1524</td>\n",
       "      <td>He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>810</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4069019011783869</td>\n",
       "      <td>1684</td>\n",
       "      <td>We take a scientific approach to providing the educational, emotional and psychosocial resources that can help make a real difference in outcomes for cancer patients by leveraging insights and data to inform our content. We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers. To help patients better manage their lives with cancer, this year we launched Pfizer Oncology Together™, a first-of-its-kind program for patient access solutions and personalized support for those using Pfizer Oncology medicines in the U.S. As part of the program, patients will have access to a team of representatives with social work experience ‘Care Champions’ who provide support beyond traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>811</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.3302193053380653</td>\n",
       "      <td>1415</td>\n",
       "      <td>In addition, we implemented disaster relief protocols for our patient assistance programs, allowing existing patients who get their medicines through a Pfizer patient assistance program to request early refills or new shipping addresses, and temporarily waiving financial documentation requirements for eligible new patients who may have lost their paperwork in these crises or their aftermath. When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations. We provided colleagues who work at our Puerto Rico manufacturing and commercial sites with personal care kits, generators and other items to help them through the devastating situation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>812</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.24796468911997185</td>\n",
       "      <td>1820</td>\n",
       "      <td>Access our policy paper on our antibiotic stewardship, and read more about Pfizer’s leadership in the fight against AMR. Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers. While we experienced an increase in our injury rates in 2017, mainly as a result of increased slips, trips and falls and ergonomic injuries, overall our rates are low and comparable to industry benchmarks.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>813</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.19808354546703097</td>\n",
       "      <td>1034</td>\n",
       "      <td>It is only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all XXX states and the District of Columbia and administers all product donation programs for Pfizer. By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis. Available at: http://www.worldbank.org/en/news/pressrelease/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>814</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.17020474685648126</td>\n",
       "      <td>115</td>\n",
       "      <td>Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee. Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals. Pfizer supports the development and adoption of novel, non animal test methods for assessing the safety of new products that can reduce, replace or refine the use of animal testing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>815</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.75440013</td>\n",
       "      <td>146</td>\n",
       "      <td>http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential. That’s why we all share responsibility for reporting safety, quality or performance issues concerning Pfizer products.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>816</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.7390721</td>\n",
       "      <td>145</td>\n",
       "      <td>Competitively sensitive information may not be discussed with friends or former colleagues employed by competitor companies whether in a business or a social setting. http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>817</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6721467</td>\n",
       "      <td>345</td>\n",
       "      <td>Our Commitment…12 \\tHealthcare Laws and Regulatory Requirements…12 \\tAnti-Bribery and Anti-Corruption…13 \\tResearch and Development…15 \\tManufacturing and Supply Quality…17 \\tInteractions with Patients and Patient Organizations…18. The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20. Our Commitment…22 \\tPatents, Trademarks and Copyrights…22 \\tBooks and Record Keeping…22 \\tConfidential and Proprietary Information…23 \\tPrivacy of Personal Data…25 \\tRecords and Information Management…26 \\tAcceptable Use of Information Systems…27 \\tConflicts of Interest…28 \\tSocial Media…30 \\tInside Information…31 \\tCompetitive Intelligence…32 \\tGlobal Trade Control Laws…33.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>818</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.5399316</td>\n",
       "      <td>1226</td>\n",
       "      <td>With XXX manufacturing sites around the world under Pfizer Global Supply (PGS), we harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines. Leveraging Science to Create Supply Chain Solutions Pfizer’s goal is for patients to receive uninterrupted access to our medicines and vaccines.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>819</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.5385889</td>\n",
       "      <td>113</td>\n",
       "      <td>We are committed to the development of publications that report the results of Company-sponsored clinical research studies accurately and objectively and to the disclosure of funding and editorial support. Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted. Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>820</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6585443</td>\n",
       "      <td>1114</td>\n",
       "      <td>What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments. I interact regularly at work calls me and mentions that a patient of hers on Roche drug X was recently hospitalised with pneumonia and died.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>821</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.6315596</td>\n",
       "      <td>1001</td>\n",
       "      <td>The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>822</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6132648</td>\n",
       "      <td>1113</td>\n",
       "      <td>– Immediately report customer complaints relating to Roche medical devices to the local regulatory and quality function. What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>823</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Help &amp; advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.60540605</td>\n",
       "      <td>1118</td>\n",
       "      <td>A In case of an adverse event you should report at least the following four elements: Patient, Reporter, Event and Product (PREP). Help &amp; advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g. Speak up: If you believe in good faith that in connection with business where Roche is involved someone has done, is doing, or may be about to do something that violates quality standards and good practices, speak up by using the available speak up channels.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>824</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.6024178</td>\n",
       "      <td>588</td>\n",
       "      <td>Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>825</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.37645185</td>\n",
       "      <td>994</td>\n",
       "      <td>A cross-divisional working group has established a checklist on Due Diligence for External Business Partners, mainly focusing on agents and distributors. It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework. We maintain and improve operational-level grievance mechanisms, which we understand to encompass also a preventive function.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>826</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>– Contact the related expert department in a timely manner in case of questions or to address an error.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.31262755</td>\n",
       "      <td>1319</td>\n",
       "      <td>– Check for compliance with national and international customs, trade and export control regulations when developing and adapting processes. – Contact the related expert department in a timely manner in case of questions or to address an error. A Every employee asking for the shipment of goods is accountable for providing complete and truthful information for export or import processing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>827</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.29044554</td>\n",
       "      <td>1553</td>\n",
       "      <td>If the remuneration is not commensurate with the services provided, you should not accept the consultant’s request. Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution. Roche protects human rights and does not tolerate behaviour by its business partners which is not in line with applicable laws and generally accepted sustainability standards.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>828</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>It contains the annual financial statements, consolidated financial statements and non­financial performance indicators.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28880537</td>\n",
       "      <td>22</td>\n",
       "      <td>Our financial and non­financial reporting consists of the Annual Report, the Finance Report and the online report. It contains the annual financial statements, consolidated financial statements and non­financial performance indicators. The financial reporting scope is defined and outlined in our Finance Report, and there have been no significant changes in scope in XXX compared to XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>829</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.286755</td>\n",
       "      <td>1324</td>\n",
       "      <td>You should seek guidance from your local logistics department and your local Export Control Officer before processing any shipment. A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation. A Roche does not tolerate any violation of the regulations and will take appropriate corrective measures and sanctions.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>830</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.20979829278490708</td>\n",
       "      <td>1008</td>\n",
       "      <td>Our challenge is to focus our efforts where we see the biggest risks and the biggest levers for remediation and improvement. On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses. We maintain a system of consistent global standards, which we also apply to our business partners, for example, in areas like R&amp;D, clinical trials, manufacturing and distribution.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>831</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.17727548268874965</td>\n",
       "      <td>1337</td>\n",
       "      <td>Corporate Integrity Q I work in a clinical research unit and have access to identifiable health information which I would like to share with a colleague. A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence. As a Roche employee you have a strict obligation to treat such information as confidential and to share it only with colleagues who need to know in order to do their work, in accordance with the purpose the data was obtained for and only if and as allowed under applicable law.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>832</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.1638004762981347</td>\n",
       "      <td>1331</td>\n",
       "      <td>Roche is committed to respecting data privacy and has developed principles that must be consistently applied when processing personal data within the Roche Group and by its business partners. Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed. Roche takes due care to prevent any misuse of or unauthorised access to such identifiable health information within its control.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>833</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We are all encouraged to identify areas for improvements and continuously work towards a better environment.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.16292468426596937</td>\n",
       "      <td>1390</td>\n",
       "      <td>Every employee is personally responsible for safety, security, health and environmental protection at the workplace to the full extent required by his/her duties to the best of his/her knowledge, ability and experience. We are all encouraged to identify areas for improvements and continuously work towards a better environment. As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>834</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We identified human rights which are potentially susceptible to violations, as well as their associated risks.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.1151118637289961</td>\n",
       "      <td>710</td>\n",
       "      <td>We do this by assessing the risks of potential violations, promoting awareness, fostering due diligence, strengthening the legal framework and collaborating on collective actions, and transparent communication. We identified human rights which are potentially susceptible to violations, as well as their associated risks. To enhance awareness, we created a video that explained human rights and Roche’s endeavours with a simple message to our employees: ‘Within your sphere of influence, ensure human rights are respected.’.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>835</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6315596</td>\n",
       "      <td>1001</td>\n",
       "      <td>The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>836</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.6024178</td>\n",
       "      <td>588</td>\n",
       "      <td>Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>837</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.5972139</td>\n",
       "      <td>1385</td>\n",
       "      <td>As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment. Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices. We take all reasonable and practical steps to ensure that we provide a safe, secure, healthy and clean working environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>838</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.58856523</td>\n",
       "      <td>1394</td>\n",
       "      <td>If a meeting in person is needed, reduce the number of participants – send a competent representative instead of a whole team. We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience. In addition, the book “Lifesavers for millions” has been published by Editiones Roche, Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding intellectual property rights, speak up by using the available speak up channels.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>839</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.5406029</td>\n",
       "      <td>717</td>\n",
       "      <td>These include excessive overtime, improper pay for overtime, insufficient number of rest days, and inadequate payment of social benefits. For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment. The RocheAbility network, for instance, fosters the inclusion of Basel and Kaiseraugst employees with disabilities and focuses on the strengths and abilities of each individual.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>840 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                    Question  \\\n",
       "0                           Does the company operate in countries out of the European Union?   \n",
       "1                           Does the company operate in countries out of the European Union?   \n",
       "2                           Does the company operate in countries out of the European Union?   \n",
       "3                           Does the company operate in countries out of the European Union?   \n",
       "4                           Does the company operate in countries out of the European Union?   \n",
       "5                           Does the company operate in countries out of the European Union?   \n",
       "6                           Does the company operate in countries out of the European Union?   \n",
       "7                           Does the company operate in countries out of the European Union?   \n",
       "8                           Does the company operate in countries out of the European Union?   \n",
       "9                           Does the company operate in countries out of the European Union?   \n",
       "10                          Does the company operate in countries out of the European Union?   \n",
       "11                          Does the company operate in countries out of the European Union?   \n",
       "12                          Does the company operate in countries out of the European Union?   \n",
       "13                          Does the company operate in countries out of the European Union?   \n",
       "14                          Does the company operate in countries out of the European Union?   \n",
       "15                          Does the company operate in countries out of the European Union?   \n",
       "16                          Does the company operate in countries out of the European Union?   \n",
       "17                          Does the company operate in countries out of the European Union?   \n",
       "18                          Does the company operate in countries out of the European Union?   \n",
       "19                          Does the company operate in countries out of the European Union?   \n",
       "20                          Does the company operate in countries out of the European Union?   \n",
       "21                          Does the company operate in countries out of the European Union?   \n",
       "22                          Does the company operate in countries out of the European Union?   \n",
       "23                          Does the company operate in countries out of the European Union?   \n",
       "24                          Does the company operate in countries out of the European Union?   \n",
       "25                          Does the company operate in countries out of the European Union?   \n",
       "26                          Does the company operate in countries out of the European Union?   \n",
       "27                          Does the company operate in countries out of the European Union?   \n",
       "28                          Does the company operate in countries out of the European Union?   \n",
       "29                          Does the company operate in countries out of the European Union?   \n",
       "..                                                                                       ...   \n",
       "810  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "811  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "812  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "813  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "814  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "815  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "816  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "817  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "818  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "819  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "820  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "821  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "822  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "823  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "824  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "825  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "826  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "827  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "828  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "829  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "830  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "831  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "832  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "833  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "834  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "835  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "836  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "837  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "838  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "839  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "\n",
       "     Q_id  Company                          Model  \\\n",
       "0       1  Johnson             Bert - transformer   \n",
       "1       1  Johnson             Bert - transformer   \n",
       "2       1  Johnson             Bert - transformer   \n",
       "3       1  Johnson             Bert - transformer   \n",
       "4       1  Johnson             Bert - transformer   \n",
       "5       1  Johnson              Infersent Bi-Lstm   \n",
       "6       1  Johnson              Infersent Bi-Lstm   \n",
       "7       1  Johnson              Infersent Bi-Lstm   \n",
       "8       1  Johnson              Infersent Bi-Lstm   \n",
       "9       1  Johnson              Infersent Bi-Lstm   \n",
       "10      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "11      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "12      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "13      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "14      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "15      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "16      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "17      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "18      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "19      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "20      1   Pfizer             Bert - transformer   \n",
       "21      1   Pfizer             Bert - transformer   \n",
       "22      1   Pfizer             Bert - transformer   \n",
       "23      1   Pfizer             Bert - transformer   \n",
       "24      1   Pfizer             Bert - transformer   \n",
       "25      1   Pfizer              Infersent Bi-Lstm   \n",
       "26      1   Pfizer              Infersent Bi-Lstm   \n",
       "27      1   Pfizer              Infersent Bi-Lstm   \n",
       "28      1   Pfizer              Infersent Bi-Lstm   \n",
       "29      1   Pfizer              Infersent Bi-Lstm   \n",
       "..    ...      ...                            ...   \n",
       "810    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "811    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "812    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "813    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "814    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "815    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "816    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "817    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "818    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "819    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "820    14    Roche             Bert - transformer   \n",
       "821    14    Roche             Bert - transformer   \n",
       "822    14    Roche             Bert - transformer   \n",
       "823    14    Roche             Bert - transformer   \n",
       "824    14    Roche             Bert - transformer   \n",
       "825    14    Roche              Infersent Bi-Lstm   \n",
       "826    14    Roche              Infersent Bi-Lstm   \n",
       "827    14    Roche              Infersent Bi-Lstm   \n",
       "828    14    Roche              Infersent Bi-Lstm   \n",
       "829    14    Roche              Infersent Bi-Lstm   \n",
       "830    14    Roche            Tf-Idf + Lemmatizer   \n",
       "831    14    Roche            Tf-Idf + Lemmatizer   \n",
       "832    14    Roche            Tf-Idf + Lemmatizer   \n",
       "833    14    Roche            Tf-Idf + Lemmatizer   \n",
       "834    14    Roche            Tf-Idf + Lemmatizer   \n",
       "835    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "836    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "837    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "838    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "839    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                        Answer  \\\n",
       "0                                                                                                 During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands.   \n",
       "1                                                                                                                                                         The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work.   \n",
       "2                Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe.   \n",
       "3                                                                                                                                                                                                          The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "4                                                                                                                                                                                                                  The products sold in international business include those developed in the U.S. and by subsidiaries abroad.   \n",
       "5                                                                                                                                                                                                                     Policies in accordance with new requirements or changes in the law of the countries in which we operate.   \n",
       "6                                                                                                                                                                                                                  The products sold in international business include those developed in the U.S. and by subsidiaries abroad.   \n",
       "7                                                                                                                                                                       Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets.   \n",
       "8    This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA).   \n",
       "9                                                                                                                                                                                                   The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base.   \n",
       "10                                                                                                                                                                                                         The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "11                                                                                                                                                                                                                    Policies in accordance with new requirements or changes in the law of the countries in which we operate.   \n",
       "12                                                                                                                                                                                               They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.   \n",
       "13                                                                                                                                     However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.   \n",
       "14                                                                                                                   • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.   \n",
       "15                                                                                                                                                                                                         The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "16                                                                                                                   The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.   \n",
       "17                                                                                                                                                                                               They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.   \n",
       "18                                                                                      Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.   \n",
       "19                                                                                                                                                                            Johnson & Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world.   \n",
       "20                                                                                                                                                     He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX   \n",
       "21                                                                                                                                                     He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX   \n",
       "22                                                                                                                                                          Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.   \n",
       "23                                                                                                                                                  He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX   \n",
       "24                                                                                                                                                Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States.   \n",
       "25                                                                                                                                                                                                                       Member of the American Society for Clinical Investigation and the Association of American Physicians.   \n",
       "26                                                                                                                                                          Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.   \n",
       "27                                                                                                                                           Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors.   \n",
       "28                                                                                                                                                                                      In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.   \n",
       "29                                                                                                                                                                                      In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.   \n",
       "..                                                                                                                                                                                                                                                                                                                         ...   \n",
       "810                                                                                                                                                We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers.   \n",
       "811                                     When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations.   \n",
       "812                                                                                                                                                                               Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers.   \n",
       "813                                                                                                                                                                                                                    By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis.   \n",
       "814                                                                                                                                         Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals.   \n",
       "815                                                                                                                                                                                                            Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.   \n",
       "816                                                                                                                                                                                                            http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products.   \n",
       "817                                                                                                                                    The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20.   \n",
       "818                                                                                                                                                                          In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines.   \n",
       "819                                                                                                        Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted.   \n",
       "820                                                                                                     If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.   \n",
       "821                                                                                                                                                                          As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "822                                                                                                                                                                                                         What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?.   \n",
       "823                                                                                                   Help & advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g.   \n",
       "824                                                                                                                                                                                                           At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.   \n",
       "825                                                                                                                                                                                                        It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework.   \n",
       "826                                                                                                                                                                                                                    – Contact the related expert department in a timely manner in case of questions or to address an error.   \n",
       "827                                                                                                                                                                                                                  Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution.   \n",
       "828                                                                                                                                                                                                   It contains the annual financial statements, consolidated financial statements and non­financial performance indicators.   \n",
       "829                                                                                                                                                       A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation.   \n",
       "830                                                                                                                                                                    On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.   \n",
       "831                                                                                                                                                                            A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence.   \n",
       "832                                                                                                                                                                                              Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.   \n",
       "833                                                                                                                                                                                                               We are all encouraged to identify areas for improvements and continuously work towards a better environment.   \n",
       "834                                                                                                                                                                                                             We identified human rights which are potentially susceptible to violations, as well as their associated risks.   \n",
       "835                                                                                                                                                                          As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "836                                                                                                                                                                                                           At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.   \n",
       "837                                                                                                                                                      Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices.   \n",
       "838                                                                                                                                                        We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience.   \n",
       "839                                                                                   For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment.   \n",
       "\n",
       "    Rank                Score Doc_index  \\\n",
       "0      1           0.46158153      2329   \n",
       "1      2           0.39178875       993   \n",
       "2      3           0.38455927       954   \n",
       "3      4           0.38348675      1925   \n",
       "4      5           0.37289336      1536   \n",
       "5      1           0.40787455      1040   \n",
       "6      2           0.39962035      1536   \n",
       "7      3           0.39595923      1051   \n",
       "8      4            0.3935492       903   \n",
       "9      5           0.38491276      1377   \n",
       "10     1   0.4036158531671312      1925   \n",
       "11     2   0.3691630723837139      1040   \n",
       "12     3   0.3506139660462462       935   \n",
       "13     4  0.33417458782649534      1932   \n",
       "14     5   0.2932092398258069      1041   \n",
       "15     1           0.38348675      1925   \n",
       "16     2           0.34441066      1560   \n",
       "17     3           0.33205885       935   \n",
       "18     4           0.28211266      1524   \n",
       "19     5           0.27888668      1521   \n",
       "20     1           0.47936144      1525   \n",
       "21     2           0.47936144      1514   \n",
       "22     3           0.47532654      1521   \n",
       "23     4            0.3949507      1618   \n",
       "24     5           0.38917118      1586   \n",
       "25     1           0.47606385      1495   \n",
       "26     2            0.4706573      1521   \n",
       "27     3           0.36455357      1553   \n",
       "28     4           0.34432322      1513   \n",
       "29     5           0.34432322      1524   \n",
       "..   ...                  ...       ...   \n",
       "810    1   0.4069019011783869      1684   \n",
       "811    2   0.3302193053380653      1415   \n",
       "812    3  0.24796468911997185      1820   \n",
       "813    4  0.19808354546703097      1034   \n",
       "814    5  0.17020474685648126       115   \n",
       "815    1           0.75440013       146   \n",
       "816    2            0.7390721       145   \n",
       "817    3            0.6721467       345   \n",
       "818    4            0.5399316      1226   \n",
       "819    5            0.5385889       113   \n",
       "820    1            0.6585443      1114   \n",
       "821    2            0.6315596      1001   \n",
       "822    3            0.6132648      1113   \n",
       "823    4           0.60540605      1118   \n",
       "824    5            0.6024178       588   \n",
       "825    1           0.37645185       994   \n",
       "826    2           0.31262755      1319   \n",
       "827    3           0.29044554      1553   \n",
       "828    4           0.28880537        22   \n",
       "829    5             0.286755      1324   \n",
       "830    1  0.20979829278490708      1008   \n",
       "831    2  0.17727548268874965      1337   \n",
       "832    3   0.1638004762981347      1331   \n",
       "833    4  0.16292468426596937      1390   \n",
       "834    5   0.1151118637289961       710   \n",
       "835    1            0.6315596      1001   \n",
       "836    2            0.6024178       588   \n",
       "837    3            0.5972139      1385   \n",
       "838    4           0.58856523      1394   \n",
       "839    5            0.5406029       717   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Context_Answer  \n",
       "0                                                                                                                                                                                                                                                        During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences. During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.  \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                     We also reviewed and updated our governance structure for managing human rights across our value chain. The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work. Quarterly EGC meetings provide a forum for updates on human rights topics, with an established process for elevating issues to the Johnson & Johnson Executive Committee, our Board of Directors and Board Committees if warranted.  \n",
       "2    • Clinical Data Transparency: We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries; publication of results in peer-reviewed journals; and sharing of clinical study reports and participant-level data from clinical trials. Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe. • Political Engagement: As a global healthcare company, we work with many stakeholders in the markets where we operate, and we take a stance on and support certain public policies in the United States and in different parts of the world as they relate to our core business of advancing health.  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "4                                                                                                                                                                                                                                                                                                                                 These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.  \n",
       "5                                                                                                                                                                                                                                                                                                                                                                       The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.  \n",
       "6                                                                                                                                                                                                                                                                                                                                 These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     The Commonsense Principles XXX aspire to promote a constructive dialogue on good corporate governance to benefit the millions of . Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets. They are an updated version of the Commonsense Principles successfully launched in XXX to build momentum around the corporate governance conversation.  \n",
       "8                                                                                                                                                                                                                                                                                                                   Our compliance guidelines and policies meet or exceed legal and regulatory requirements in every jurisdiction where we operate. This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, Johnson & Johnson actively participates in the work of industry associations, and helps develop industry codes for ethical and compliant marketing and selling of products.  \n",
       "9                                                                                                                                                                                 Throughout Johnson & Johnson’s history, we have maintained a strong, consistent andwe have maintained a strong, consistent andwe have maintained a strong, consistent and sustainable business. The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base. We are structured to meet the current and future needs of patients meet the current and future needs of patients meet the current and future needs of patients and consumers globally, and to address the and consumers globally, and to address the and consumers globally, and to address the challenges and opportunities that the worldchallenges and opportunities that the worldchallenges and opportunities that the world of healthcare presents.  \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "11                                                                                                                                                                                                                                                                                                                                                                      The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.  \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.  \n",
       "13                                                                                                                                                                                                                                                                                                                                                                           Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.  \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations. • Resources: The GPT assists operating companies with designating privacy resources, considering their local requirements and the risk environments.  \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "16                                                                                                                                                                                                                                          The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.  \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                  This Committee oversees and coordinates the activities of the Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.  \n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                                                               The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. Johnson & Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world. The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.  \n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.  \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.  \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                               Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.  \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                               He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain. He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX Biosimilars have the potential to expand patient access to treatment and to create a more sustainable health care system.  \n",
       "24                                                                                                                                                                                                                                                                                                                                                                                                                               She has held roles of increasing global responsibility throughout her career including site leadership, global strategic planning, contractor management, supply chain management and product portfolio leadership. Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States. She has been a member of the PGS Leadership Team since XXX and has represented PGS on several of Pfizer’s Business Leadership Teams.  \n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association.  \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                               Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.  \n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Prior to joining Pfizer in 2009, Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council.  \n",
       "28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX  \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX  \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ...  \n",
       "810        We take a scientific approach to providing the educational, emotional and psychosocial resources that can help make a real difference in outcomes for cancer patients by leveraging insights and data to inform our content. We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers. To help patients better manage their lives with cancer, this year we launched Pfizer Oncology Together™, a first-of-its-kind program for patient access solutions and personalized support for those using Pfizer Oncology medicines in the U.S. As part of the program, patients will have access to a team of representatives with social work experience ‘Care Champions’ who provide support beyond traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs.  \n",
       "811                                                                        In addition, we implemented disaster relief protocols for our patient assistance programs, allowing existing patients who get their medicines through a Pfizer patient assistance program to request early refills or new shipping addresses, and temporarily waiving financial documentation requirements for eligible new patients who may have lost their paperwork in these crises or their aftermath. When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations. We provided colleagues who work at our Puerto Rico manufacturing and commercial sites with personal care kits, generators and other items to help them through the devastating situation.  \n",
       "812                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Access our policy paper on our antibiotic stewardship, and read more about Pfizer’s leadership in the fight against AMR. Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers. While we experienced an increase in our injury rates in 2017, mainly as a result of increased slips, trips and falls and ergonomic injuries, overall our rates are low and comparable to industry benchmarks.  \n",
       "813                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   It is only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all XXX states and the District of Columbia and administers all product donation programs for Pfizer. By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis. Available at: http://www.worldbank.org/en/news/pressrelease/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis XXX  \n",
       "814                                                                                                                                                                                                                                                                                                                                                                                      Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee. Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals. Pfizer supports the development and adoption of novel, non animal test methods for assessing the safety of new products that can reduce, replace or refine the use of animal testing.  \n",
       "815                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential. That’s why we all share responsibility for reporting safety, quality or performance issues concerning Pfizer products.  \n",
       "816                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Competitively sensitive information may not be discussed with friends or former colleagues employed by competitor companies whether in a business or a social setting. http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.  \n",
       "817                                                                                                                                          Our Commitment…12 \\tHealthcare Laws and Regulatory Requirements…12 \\tAnti-Bribery and Anti-Corruption…13 \\tResearch and Development…15 \\tManufacturing and Supply Quality…17 \\tInteractions with Patients and Patient Organizations…18. The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20. Our Commitment…22 \\tPatents, Trademarks and Copyrights…22 \\tBooks and Record Keeping…22 \\tConfidential and Proprietary Information…23 \\tPrivacy of Personal Data…25 \\tRecords and Information Management…26 \\tAcceptable Use of Information Systems…27 \\tConflicts of Interest…28 \\tSocial Media…30 \\tInside Information…31 \\tCompetitive Intelligence…32 \\tGlobal Trade Control Laws…33.  \n",
       "818                                                                                                                                                                                                                                                                                                                                                                                    With XXX manufacturing sites around the world under Pfizer Global Supply (PGS), we harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines. Leveraging Science to Create Supply Chain Solutions Pfizer’s goal is for patients to receive uninterrupted access to our medicines and vaccines.  \n",
       "819                                                                                                                                                                                                                                                                                                                             We are committed to the development of publications that report the results of Company-sponsored clinical research studies accurately and objectively and to the disclosure of funding and editorial support. Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted. Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee.  \n",
       "820                                                                                                                                                                                                                                                                                                                                                                                                                                                                             What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments. I interact regularly at work calls me and mentions that a patient of hers on Roche drug X was recently hospitalised with pneumonia and died.  \n",
       "821                                                                                                                                                                                                                                                 The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.  \n",
       "822                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 – Immediately report customer complaints relating to Roche medical devices to the local regulatory and quality function. What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.  \n",
       "823                                                                                                                                                                                                                                                                                                                                     A In case of an adverse event you should report at least the following four elements: Patient, Reporter, Event and Product (PREP). Help & advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g. Speak up: If you believe in good faith that in connection with business where Roche is involved someone has done, is doing, or may be about to do something that violates quality standards and good practices, speak up by using the available speak up channels.  \n",
       "824                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.  \n",
       "825                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         A cross-divisional working group has established a checklist on Due Diligence for External Business Partners, mainly focusing on agents and distributors. It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework. We maintain and improve operational-level grievance mechanisms, which we understand to encompass also a preventive function.  \n",
       "826                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             – Check for compliance with national and international customs, trade and export control regulations when developing and adapting processes. – Contact the related expert department in a timely manner in case of questions or to address an error. A Every employee asking for the shipment of goods is accountable for providing complete and truthful information for export or import processing.  \n",
       "827                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      If the remuneration is not commensurate with the services provided, you should not accept the consultant’s request. Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution. Roche protects human rights and does not tolerate behaviour by its business partners which is not in line with applicable laws and generally accepted sustainability standards.  \n",
       "828                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Our financial and non­financial reporting consists of the Annual Report, the Finance Report and the online report. It contains the annual financial statements, consolidated financial statements and non­financial performance indicators. The financial reporting scope is defined and outlined in our Finance Report, and there have been no significant changes in scope in XXX compared to XXX  \n",
       "829                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   You should seek guidance from your local logistics department and your local Export Control Officer before processing any shipment. A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation. A Roche does not tolerate any violation of the regulations and will take appropriate corrective measures and sanctions.  \n",
       "830                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Our challenge is to focus our efforts where we see the biggest risks and the biggest levers for remediation and improvement. On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses. We maintain a system of consistent global standards, which we also apply to our business partners, for example, in areas like R&D, clinical trials, manufacturing and distribution.  \n",
       "831                                                                                                                                                                                                                                                                                                                                                                    Corporate Integrity Q I work in a clinical research unit and have access to identifiable health information which I would like to share with a colleague. A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence. As a Roche employee you have a strict obligation to treat such information as confidential and to share it only with colleagues who need to know in order to do their work, in accordance with the purpose the data was obtained for and only if and as allowed under applicable law.  \n",
       "832                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Roche is committed to respecting data privacy and has developed principles that must be consistently applied when processing personal data within the Roche Group and by its business partners. Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed. Roche takes due care to prevent any misuse of or unauthorised access to such identifiable health information within its control.  \n",
       "833                                                                                                                                                                                                                                                                                                                                                                                                                                      Every employee is personally responsible for safety, security, health and environmental protection at the workplace to the full extent required by his/her duties to the best of his/her knowledge, ability and experience. We are all encouraged to identify areas for improvements and continuously work towards a better environment. As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment.  \n",
       "834                                                                                                                                                                                                                                                                                                                                                                                                                       We do this by assessing the risks of potential violations, promoting awareness, fostering due diligence, strengthening the legal framework and collaborating on collective actions, and transparent communication. We identified human rights which are potentially susceptible to violations, as well as their associated risks. To enhance awareness, we created a video that explained human rights and Roche’s endeavours with a simple message to our employees: ‘Within your sphere of influence, ensure human rights are respected.’.  \n",
       "835                                                                                                                                                                                                                                                 The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.  \n",
       "836                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.  \n",
       "837                                                                                                                                                                                                                                                                                                                                                                                                                                                                             As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment. Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices. We take all reasonable and practical steps to ensure that we provide a safe, secure, healthy and clean working environment.  \n",
       "838                                                                                                                                                                                                                                                                                    If a meeting in person is needed, reduce the number of participants – send a competent representative instead of a whole team. We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience. In addition, the book “Lifesavers for millions” has been published by Editiones Roche, Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding intellectual property rights, speak up by using the available speak up channels.  \n",
       "839                                                                                                                                                                                                                                                                                                                                                                                               These include excessive overtime, improper pay for overtime, insufficient number of rest days, and inadequate payment of social benefits. For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment. The RocheAbility network, for instance, fosters the inclusion of Basel and Kaiseraugst employees with disabilities and focuses on the strengths and abilities of each individual.  \n",
       "\n",
       "[840 rows x 9 columns]"
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results_PfizerRocheJohnson"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Q_id</th>\n",
       "      <th>Company</th>\n",
       "      <th>Model</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Score</th>\n",
       "      <th>Doc_index</th>\n",
       "      <th>Context_Answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.46158153</td>\n",
       "      <td>2329</td>\n",
       "      <td>During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences. During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. Legal Proceedings Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.39178875</td>\n",
       "      <td>993</td>\n",
       "      <td>We also reviewed and updated our governance structure for managing human rights across our value chain. The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work. Quarterly EGC meetings provide a forum for updates on human rights topics, with an established process for elevating issues to the Johnson &amp; Johnson Executive Committee, our Board of Directors and Board Committees if warranted.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.38455927</td>\n",
       "      <td>954</td>\n",
       "      <td>• Clinical Data Transparency: We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries; publication of results in peer-reviewed journals; and sharing of clinical study reports and participant-level data from clinical trials. Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe. • Political Engagement: As a global healthcare company, we work with many stakeholders in the markets where we operate, and we take a stance on and support certain public policies in the United States and in different parts of the world as they relate to our core business of advancing health.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.38348675</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.37289336</td>\n",
       "      <td>1536</td>\n",
       "      <td>These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.40787455</td>\n",
       "      <td>1040</td>\n",
       "      <td>The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.39962035</td>\n",
       "      <td>1536</td>\n",
       "      <td>These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.39595923</td>\n",
       "      <td>1051</td>\n",
       "      <td>The Commonsense Principles XXX aspire to promote a constructive dialogue on good corporate governance to benefit the millions of . Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets. They are an updated version of the Commonsense Principles successfully launched in XXX to build momentum around the corporate governance conversation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA).</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3935492</td>\n",
       "      <td>903</td>\n",
       "      <td>Our compliance guidelines and policies meet or exceed legal and regulatory requirements in every jurisdiction where we operate. This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, Johnson &amp; Johnson actively participates in the work of industry associations, and helps develop industry codes for ethical and compliant marketing and selling of products.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.38491276</td>\n",
       "      <td>1377</td>\n",
       "      <td>Throughout Johnson &amp; Johnson’s history, we have maintained a strong, consistent andwe have maintained a strong, consistent andwe have maintained a strong, consistent and sustainable business. The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base. We are structured to meet the current and future needs of patients meet the current and future needs of patients meet the current and future needs of patients and consumers globally, and to address the and consumers globally, and to address the and consumers globally, and to address the challenges and opportunities that the worldchallenges and opportunities that the worldchallenges and opportunities that the world of healthcare presents.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4036158531671312</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.3691630723837139</td>\n",
       "      <td>1040</td>\n",
       "      <td>The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.3506139660462462</td>\n",
       "      <td>935</td>\n",
       "      <td>It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.33417458782649534</td>\n",
       "      <td>1932</td>\n",
       "      <td>Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>• Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2932092398258069</td>\n",
       "      <td>1041</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations. • Resources: The GPT assists operating companies with designating privacy resources, considering their local requirements and the risk environments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.38348675</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.34441066</td>\n",
       "      <td>1560</td>\n",
       "      <td>The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.33205885</td>\n",
       "      <td>935</td>\n",
       "      <td>It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28211266</td>\n",
       "      <td>1524</td>\n",
       "      <td>This Committee oversees and coordinates the activities of the Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Johnson &amp; Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.27888668</td>\n",
       "      <td>1521</td>\n",
       "      <td>The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. Johnson &amp; Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world. The Executive Committee of Johnson &amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "      <td>1</td>\n",
       "      <td>0.47936144</td>\n",
       "      <td>1525</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "      <td>2</td>\n",
       "      <td>0.47936144</td>\n",
       "      <td>1514</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.47532654</td>\n",
       "      <td>1521</td>\n",
       "      <td>Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3949507</td>\n",
       "      <td>1618</td>\n",
       "      <td>He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain. He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX Biosimilars have the potential to expand patient access to treatment and to create a more sustainable health care system.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.38917118</td>\n",
       "      <td>1586</td>\n",
       "      <td>She has held roles of increasing global responsibility throughout her career including site leadership, global strategic planning, contractor management, supply chain management and product portfolio leadership. Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States. She has been a member of the PGS Leadership Team since XXX and has represented PGS on several of Pfizer’s Business Leadership Teams.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Member of the American Society for Clinical Investigation and the Association of American Physicians.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.47606385</td>\n",
       "      <td>1495</td>\n",
       "      <td>Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.4706573</td>\n",
       "      <td>1521</td>\n",
       "      <td>Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.36455357</td>\n",
       "      <td>1553</td>\n",
       "      <td>Prior to joining Pfizer in 2009, Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.34432322</td>\n",
       "      <td>1513</td>\n",
       "      <td>He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.34432322</td>\n",
       "      <td>1524</td>\n",
       "      <td>He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>810</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4069019011783869</td>\n",
       "      <td>1684</td>\n",
       "      <td>We take a scientific approach to providing the educational, emotional and psychosocial resources that can help make a real difference in outcomes for cancer patients by leveraging insights and data to inform our content. We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers. To help patients better manage their lives with cancer, this year we launched Pfizer Oncology Together™, a first-of-its-kind program for patient access solutions and personalized support for those using Pfizer Oncology medicines in the U.S. As part of the program, patients will have access to a team of representatives with social work experience ‘Care Champions’ who provide support beyond traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>811</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.3302193053380653</td>\n",
       "      <td>1415</td>\n",
       "      <td>In addition, we implemented disaster relief protocols for our patient assistance programs, allowing existing patients who get their medicines through a Pfizer patient assistance program to request early refills or new shipping addresses, and temporarily waiving financial documentation requirements for eligible new patients who may have lost their paperwork in these crises or their aftermath. When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations. We provided colleagues who work at our Puerto Rico manufacturing and commercial sites with personal care kits, generators and other items to help them through the devastating situation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>812</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.24796468911997185</td>\n",
       "      <td>1820</td>\n",
       "      <td>Access our policy paper on our antibiotic stewardship, and read more about Pfizer’s leadership in the fight against AMR. Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers. While we experienced an increase in our injury rates in 2017, mainly as a result of increased slips, trips and falls and ergonomic injuries, overall our rates are low and comparable to industry benchmarks.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>813</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.19808354546703097</td>\n",
       "      <td>1034</td>\n",
       "      <td>It is only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all XXX states and the District of Columbia and administers all product donation programs for Pfizer. By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis. Available at: http://www.worldbank.org/en/news/pressrelease/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>814</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.17020474685648126</td>\n",
       "      <td>115</td>\n",
       "      <td>Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee. Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals. Pfizer supports the development and adoption of novel, non animal test methods for assessing the safety of new products that can reduce, replace or refine the use of animal testing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>815</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.75440013</td>\n",
       "      <td>146</td>\n",
       "      <td>http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential. That’s why we all share responsibility for reporting safety, quality or performance issues concerning Pfizer products.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>816</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.7390721</td>\n",
       "      <td>145</td>\n",
       "      <td>Competitively sensitive information may not be discussed with friends or former colleagues employed by competitor companies whether in a business or a social setting. http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>817</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6721467</td>\n",
       "      <td>345</td>\n",
       "      <td>Our Commitment…12 \\tHealthcare Laws and Regulatory Requirements…12 \\tAnti-Bribery and Anti-Corruption…13 \\tResearch and Development…15 \\tManufacturing and Supply Quality…17 \\tInteractions with Patients and Patient Organizations…18. The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20. Our Commitment…22 \\tPatents, Trademarks and Copyrights…22 \\tBooks and Record Keeping…22 \\tConfidential and Proprietary Information…23 \\tPrivacy of Personal Data…25 \\tRecords and Information Management…26 \\tAcceptable Use of Information Systems…27 \\tConflicts of Interest…28 \\tSocial Media…30 \\tInside Information…31 \\tCompetitive Intelligence…32 \\tGlobal Trade Control Laws…33.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>818</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.5399316</td>\n",
       "      <td>1226</td>\n",
       "      <td>With XXX manufacturing sites around the world under Pfizer Global Supply (PGS), we harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines. Leveraging Science to Create Supply Chain Solutions Pfizer’s goal is for patients to receive uninterrupted access to our medicines and vaccines.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>819</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.5385889</td>\n",
       "      <td>113</td>\n",
       "      <td>We are committed to the development of publications that report the results of Company-sponsored clinical research studies accurately and objectively and to the disclosure of funding and editorial support. Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted. Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>820</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6585443</td>\n",
       "      <td>1114</td>\n",
       "      <td>What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments. I interact regularly at work calls me and mentions that a patient of hers on Roche drug X was recently hospitalised with pneumonia and died.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>821</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.6315596</td>\n",
       "      <td>1001</td>\n",
       "      <td>The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>822</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6132648</td>\n",
       "      <td>1113</td>\n",
       "      <td>– Immediately report customer complaints relating to Roche medical devices to the local regulatory and quality function. What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>823</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Help &amp; advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.60540605</td>\n",
       "      <td>1118</td>\n",
       "      <td>A In case of an adverse event you should report at least the following four elements: Patient, Reporter, Event and Product (PREP). Help &amp; advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g. Speak up: If you believe in good faith that in connection with business where Roche is involved someone has done, is doing, or may be about to do something that violates quality standards and good practices, speak up by using the available speak up channels.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>824</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.6024178</td>\n",
       "      <td>588</td>\n",
       "      <td>Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>825</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.37645185</td>\n",
       "      <td>994</td>\n",
       "      <td>A cross-divisional working group has established a checklist on Due Diligence for External Business Partners, mainly focusing on agents and distributors. It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework. We maintain and improve operational-level grievance mechanisms, which we understand to encompass also a preventive function.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>826</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>– Contact the related expert department in a timely manner in case of questions or to address an error.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.31262755</td>\n",
       "      <td>1319</td>\n",
       "      <td>– Check for compliance with national and international customs, trade and export control regulations when developing and adapting processes. – Contact the related expert department in a timely manner in case of questions or to address an error. A Every employee asking for the shipment of goods is accountable for providing complete and truthful information for export or import processing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>827</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.29044554</td>\n",
       "      <td>1553</td>\n",
       "      <td>If the remuneration is not commensurate with the services provided, you should not accept the consultant’s request. Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution. Roche protects human rights and does not tolerate behaviour by its business partners which is not in line with applicable laws and generally accepted sustainability standards.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>828</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>It contains the annual financial statements, consolidated financial statements and non­financial performance indicators.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28880537</td>\n",
       "      <td>22</td>\n",
       "      <td>Our financial and non­financial reporting consists of the Annual Report, the Finance Report and the online report. It contains the annual financial statements, consolidated financial statements and non­financial performance indicators. The financial reporting scope is defined and outlined in our Finance Report, and there have been no significant changes in scope in XXX compared to XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>829</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.286755</td>\n",
       "      <td>1324</td>\n",
       "      <td>You should seek guidance from your local logistics department and your local Export Control Officer before processing any shipment. A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation. A Roche does not tolerate any violation of the regulations and will take appropriate corrective measures and sanctions.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>830</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.20979829278490708</td>\n",
       "      <td>1008</td>\n",
       "      <td>Our challenge is to focus our efforts where we see the biggest risks and the biggest levers for remediation and improvement. On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses. We maintain a system of consistent global standards, which we also apply to our business partners, for example, in areas like R&amp;D, clinical trials, manufacturing and distribution.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>831</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.17727548268874965</td>\n",
       "      <td>1337</td>\n",
       "      <td>Corporate Integrity Q I work in a clinical research unit and have access to identifiable health information which I would like to share with a colleague. A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence. As a Roche employee you have a strict obligation to treat such information as confidential and to share it only with colleagues who need to know in order to do their work, in accordance with the purpose the data was obtained for and only if and as allowed under applicable law.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>832</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.1638004762981347</td>\n",
       "      <td>1331</td>\n",
       "      <td>Roche is committed to respecting data privacy and has developed principles that must be consistently applied when processing personal data within the Roche Group and by its business partners. Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed. Roche takes due care to prevent any misuse of or unauthorised access to such identifiable health information within its control.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>833</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We are all encouraged to identify areas for improvements and continuously work towards a better environment.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.16292468426596937</td>\n",
       "      <td>1390</td>\n",
       "      <td>Every employee is personally responsible for safety, security, health and environmental protection at the workplace to the full extent required by his/her duties to the best of his/her knowledge, ability and experience. We are all encouraged to identify areas for improvements and continuously work towards a better environment. As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>834</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We identified human rights which are potentially susceptible to violations, as well as their associated risks.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.1151118637289961</td>\n",
       "      <td>710</td>\n",
       "      <td>We do this by assessing the risks of potential violations, promoting awareness, fostering due diligence, strengthening the legal framework and collaborating on collective actions, and transparent communication. We identified human rights which are potentially susceptible to violations, as well as their associated risks. To enhance awareness, we created a video that explained human rights and Roche’s endeavours with a simple message to our employees: ‘Within your sphere of influence, ensure human rights are respected.’.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>835</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6315596</td>\n",
       "      <td>1001</td>\n",
       "      <td>The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>836</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.6024178</td>\n",
       "      <td>588</td>\n",
       "      <td>Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>837</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.5972139</td>\n",
       "      <td>1385</td>\n",
       "      <td>As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment. Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices. We take all reasonable and practical steps to ensure that we provide a safe, secure, healthy and clean working environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>838</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.58856523</td>\n",
       "      <td>1394</td>\n",
       "      <td>If a meeting in person is needed, reduce the number of participants – send a competent representative instead of a whole team. We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience. In addition, the book “Lifesavers for millions” has been published by Editiones Roche, Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding intellectual property rights, speak up by using the available speak up channels.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>839</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.5406029</td>\n",
       "      <td>717</td>\n",
       "      <td>These include excessive overtime, improper pay for overtime, insufficient number of rest days, and inadequate payment of social benefits. For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment. The RocheAbility network, for instance, fosters the inclusion of Basel and Kaiseraugst employees with disabilities and focuses on the strengths and abilities of each individual.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>840 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                    Question  \\\n",
       "0                           Does the company operate in countries out of the European Union?   \n",
       "1                           Does the company operate in countries out of the European Union?   \n",
       "2                           Does the company operate in countries out of the European Union?   \n",
       "3                           Does the company operate in countries out of the European Union?   \n",
       "4                           Does the company operate in countries out of the European Union?   \n",
       "5                           Does the company operate in countries out of the European Union?   \n",
       "6                           Does the company operate in countries out of the European Union?   \n",
       "7                           Does the company operate in countries out of the European Union?   \n",
       "8                           Does the company operate in countries out of the European Union?   \n",
       "9                           Does the company operate in countries out of the European Union?   \n",
       "10                          Does the company operate in countries out of the European Union?   \n",
       "11                          Does the company operate in countries out of the European Union?   \n",
       "12                          Does the company operate in countries out of the European Union?   \n",
       "13                          Does the company operate in countries out of the European Union?   \n",
       "14                          Does the company operate in countries out of the European Union?   \n",
       "15                          Does the company operate in countries out of the European Union?   \n",
       "16                          Does the company operate in countries out of the European Union?   \n",
       "17                          Does the company operate in countries out of the European Union?   \n",
       "18                          Does the company operate in countries out of the European Union?   \n",
       "19                          Does the company operate in countries out of the European Union?   \n",
       "20                          Does the company operate in countries out of the European Union?   \n",
       "21                          Does the company operate in countries out of the European Union?   \n",
       "22                          Does the company operate in countries out of the European Union?   \n",
       "23                          Does the company operate in countries out of the European Union?   \n",
       "24                          Does the company operate in countries out of the European Union?   \n",
       "25                          Does the company operate in countries out of the European Union?   \n",
       "26                          Does the company operate in countries out of the European Union?   \n",
       "27                          Does the company operate in countries out of the European Union?   \n",
       "28                          Does the company operate in countries out of the European Union?   \n",
       "29                          Does the company operate in countries out of the European Union?   \n",
       "..                                                                                       ...   \n",
       "810  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "811  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "812  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "813  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "814  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "815  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "816  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "817  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "818  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "819  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "820  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "821  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "822  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "823  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "824  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "825  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "826  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "827  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "828  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "829  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "830  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "831  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "832  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "833  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "834  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "835  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "836  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "837  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "838  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "839  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "\n",
       "     Q_id  Company                          Model  \\\n",
       "0       1  Johnson             Bert - transformer   \n",
       "1       1  Johnson             Bert - transformer   \n",
       "2       1  Johnson             Bert - transformer   \n",
       "3       1  Johnson             Bert - transformer   \n",
       "4       1  Johnson             Bert - transformer   \n",
       "5       1  Johnson              Infersent Bi-Lstm   \n",
       "6       1  Johnson              Infersent Bi-Lstm   \n",
       "7       1  Johnson              Infersent Bi-Lstm   \n",
       "8       1  Johnson              Infersent Bi-Lstm   \n",
       "9       1  Johnson              Infersent Bi-Lstm   \n",
       "10      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "11      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "12      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "13      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "14      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "15      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "16      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "17      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "18      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "19      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "20      1   Pfizer             Bert - transformer   \n",
       "21      1   Pfizer             Bert - transformer   \n",
       "22      1   Pfizer             Bert - transformer   \n",
       "23      1   Pfizer             Bert - transformer   \n",
       "24      1   Pfizer             Bert - transformer   \n",
       "25      1   Pfizer              Infersent Bi-Lstm   \n",
       "26      1   Pfizer              Infersent Bi-Lstm   \n",
       "27      1   Pfizer              Infersent Bi-Lstm   \n",
       "28      1   Pfizer              Infersent Bi-Lstm   \n",
       "29      1   Pfizer              Infersent Bi-Lstm   \n",
       "..    ...      ...                            ...   \n",
       "810    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "811    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "812    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "813    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "814    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "815    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "816    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "817    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "818    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "819    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "820    14    Roche             Bert - transformer   \n",
       "821    14    Roche             Bert - transformer   \n",
       "822    14    Roche             Bert - transformer   \n",
       "823    14    Roche             Bert - transformer   \n",
       "824    14    Roche             Bert - transformer   \n",
       "825    14    Roche              Infersent Bi-Lstm   \n",
       "826    14    Roche              Infersent Bi-Lstm   \n",
       "827    14    Roche              Infersent Bi-Lstm   \n",
       "828    14    Roche              Infersent Bi-Lstm   \n",
       "829    14    Roche              Infersent Bi-Lstm   \n",
       "830    14    Roche            Tf-Idf + Lemmatizer   \n",
       "831    14    Roche            Tf-Idf + Lemmatizer   \n",
       "832    14    Roche            Tf-Idf + Lemmatizer   \n",
       "833    14    Roche            Tf-Idf + Lemmatizer   \n",
       "834    14    Roche            Tf-Idf + Lemmatizer   \n",
       "835    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "836    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "837    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "838    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "839    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                        Answer  \\\n",
       "0                                                                                                 During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands.   \n",
       "1                                                                                                                                                         The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work.   \n",
       "2                Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe.   \n",
       "3                                                                                                                                                                                                          The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "4                                                                                                                                                                                                                  The products sold in international business include those developed in the U.S. and by subsidiaries abroad.   \n",
       "5                                                                                                                                                                                                                     Policies in accordance with new requirements or changes in the law of the countries in which we operate.   \n",
       "6                                                                                                                                                                                                                  The products sold in international business include those developed in the U.S. and by subsidiaries abroad.   \n",
       "7                                                                                                                                                                       Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets.   \n",
       "8    This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA).   \n",
       "9                                                                                                                                                                                                   The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base.   \n",
       "10                                                                                                                                                                                                         The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "11                                                                                                                                                                                                                    Policies in accordance with new requirements or changes in the law of the countries in which we operate.   \n",
       "12                                                                                                                                                                                               They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.   \n",
       "13                                                                                                                                     However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.   \n",
       "14                                                                                                                   • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.   \n",
       "15                                                                                                                                                                                                         The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "16                                                                                                                   The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.   \n",
       "17                                                                                                                                                                                               They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.   \n",
       "18                                                                                      Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.   \n",
       "19                                                                                                                                                                            Johnson & Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world.   \n",
       "20                                                                                                                                                     He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX   \n",
       "21                                                                                                                                                     He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX   \n",
       "22                                                                                                                                                          Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.   \n",
       "23                                                                                                                                                  He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX   \n",
       "24                                                                                                                                                Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States.   \n",
       "25                                                                                                                                                                                                                       Member of the American Society for Clinical Investigation and the Association of American Physicians.   \n",
       "26                                                                                                                                                          Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.   \n",
       "27                                                                                                                                           Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors.   \n",
       "28                                                                                                                                                                                      In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.   \n",
       "29                                                                                                                                                                                      In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.   \n",
       "..                                                                                                                                                                                                                                                                                                                         ...   \n",
       "810                                                                                                                                                We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers.   \n",
       "811                                     When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations.   \n",
       "812                                                                                                                                                                               Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers.   \n",
       "813                                                                                                                                                                                                                    By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis.   \n",
       "814                                                                                                                                         Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals.   \n",
       "815                                                                                                                                                                                                            Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.   \n",
       "816                                                                                                                                                                                                            http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products.   \n",
       "817                                                                                                                                    The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20.   \n",
       "818                                                                                                                                                                          In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines.   \n",
       "819                                                                                                        Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted.   \n",
       "820                                                                                                     If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.   \n",
       "821                                                                                                                                                                          As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "822                                                                                                                                                                                                         What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?.   \n",
       "823                                                                                                   Help & advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g.   \n",
       "824                                                                                                                                                                                                           At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.   \n",
       "825                                                                                                                                                                                                        It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework.   \n",
       "826                                                                                                                                                                                                                    – Contact the related expert department in a timely manner in case of questions or to address an error.   \n",
       "827                                                                                                                                                                                                                  Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution.   \n",
       "828                                                                                                                                                                                                   It contains the annual financial statements, consolidated financial statements and non­financial performance indicators.   \n",
       "829                                                                                                                                                       A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation.   \n",
       "830                                                                                                                                                                    On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.   \n",
       "831                                                                                                                                                                            A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence.   \n",
       "832                                                                                                                                                                                              Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.   \n",
       "833                                                                                                                                                                                                               We are all encouraged to identify areas for improvements and continuously work towards a better environment.   \n",
       "834                                                                                                                                                                                                             We identified human rights which are potentially susceptible to violations, as well as their associated risks.   \n",
       "835                                                                                                                                                                          As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "836                                                                                                                                                                                                           At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.   \n",
       "837                                                                                                                                                      Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices.   \n",
       "838                                                                                                                                                        We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience.   \n",
       "839                                                                                   For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment.   \n",
       "\n",
       "    Rank                Score Doc_index  \\\n",
       "0      1           0.46158153      2329   \n",
       "1      2           0.39178875       993   \n",
       "2      3           0.38455927       954   \n",
       "3      4           0.38348675      1925   \n",
       "4      5           0.37289336      1536   \n",
       "5      1           0.40787455      1040   \n",
       "6      2           0.39962035      1536   \n",
       "7      3           0.39595923      1051   \n",
       "8      4            0.3935492       903   \n",
       "9      5           0.38491276      1377   \n",
       "10     1   0.4036158531671312      1925   \n",
       "11     2   0.3691630723837139      1040   \n",
       "12     3   0.3506139660462462       935   \n",
       "13     4  0.33417458782649534      1932   \n",
       "14     5   0.2932092398258069      1041   \n",
       "15     1           0.38348675      1925   \n",
       "16     2           0.34441066      1560   \n",
       "17     3           0.33205885       935   \n",
       "18     4           0.28211266      1524   \n",
       "19     5           0.27888668      1521   \n",
       "20     1           0.47936144      1525   \n",
       "21     2           0.47936144      1514   \n",
       "22     3           0.47532654      1521   \n",
       "23     4            0.3949507      1618   \n",
       "24     5           0.38917118      1586   \n",
       "25     1           0.47606385      1495   \n",
       "26     2            0.4706573      1521   \n",
       "27     3           0.36455357      1553   \n",
       "28     4           0.34432322      1513   \n",
       "29     5           0.34432322      1524   \n",
       "..   ...                  ...       ...   \n",
       "810    1   0.4069019011783869      1684   \n",
       "811    2   0.3302193053380653      1415   \n",
       "812    3  0.24796468911997185      1820   \n",
       "813    4  0.19808354546703097      1034   \n",
       "814    5  0.17020474685648126       115   \n",
       "815    1           0.75440013       146   \n",
       "816    2            0.7390721       145   \n",
       "817    3            0.6721467       345   \n",
       "818    4            0.5399316      1226   \n",
       "819    5            0.5385889       113   \n",
       "820    1            0.6585443      1114   \n",
       "821    2            0.6315596      1001   \n",
       "822    3            0.6132648      1113   \n",
       "823    4           0.60540605      1118   \n",
       "824    5            0.6024178       588   \n",
       "825    1           0.37645185       994   \n",
       "826    2           0.31262755      1319   \n",
       "827    3           0.29044554      1553   \n",
       "828    4           0.28880537        22   \n",
       "829    5             0.286755      1324   \n",
       "830    1  0.20979829278490708      1008   \n",
       "831    2  0.17727548268874965      1337   \n",
       "832    3   0.1638004762981347      1331   \n",
       "833    4  0.16292468426596937      1390   \n",
       "834    5   0.1151118637289961       710   \n",
       "835    1            0.6315596      1001   \n",
       "836    2            0.6024178       588   \n",
       "837    3            0.5972139      1385   \n",
       "838    4           0.58856523      1394   \n",
       "839    5            0.5406029       717   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Context_Answer  \n",
       "0                                                                                                                                                                                                                                                        During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences. During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.  \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                     We also reviewed and updated our governance structure for managing human rights across our value chain. The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work. Quarterly EGC meetings provide a forum for updates on human rights topics, with an established process for elevating issues to the Johnson & Johnson Executive Committee, our Board of Directors and Board Committees if warranted.  \n",
       "2    • Clinical Data Transparency: We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries; publication of results in peer-reviewed journals; and sharing of clinical study reports and participant-level data from clinical trials. Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe. • Political Engagement: As a global healthcare company, we work with many stakeholders in the markets where we operate, and we take a stance on and support certain public policies in the United States and in different parts of the world as they relate to our core business of advancing health.  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "4                                                                                                                                                                                                                                                                                                                                 These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.  \n",
       "5                                                                                                                                                                                                                                                                                                                                                                       The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.  \n",
       "6                                                                                                                                                                                                                                                                                                                                 These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     The Commonsense Principles XXX aspire to promote a constructive dialogue on good corporate governance to benefit the millions of . Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets. They are an updated version of the Commonsense Principles successfully launched in XXX to build momentum around the corporate governance conversation.  \n",
       "8                                                                                                                                                                                                                                                                                                                   Our compliance guidelines and policies meet or exceed legal and regulatory requirements in every jurisdiction where we operate. This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, Johnson & Johnson actively participates in the work of industry associations, and helps develop industry codes for ethical and compliant marketing and selling of products.  \n",
       "9                                                                                                                                                                                 Throughout Johnson & Johnson’s history, we have maintained a strong, consistent andwe have maintained a strong, consistent andwe have maintained a strong, consistent and sustainable business. The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base. We are structured to meet the current and future needs of patients meet the current and future needs of patients meet the current and future needs of patients and consumers globally, and to address the and consumers globally, and to address the and consumers globally, and to address the challenges and opportunities that the worldchallenges and opportunities that the worldchallenges and opportunities that the world of healthcare presents.  \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "11                                                                                                                                                                                                                                                                                                                                                                      The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.  \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.  \n",
       "13                                                                                                                                                                                                                                                                                                                                                                           Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.  \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations. • Resources: The GPT assists operating companies with designating privacy resources, considering their local requirements and the risk environments.  \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "16                                                                                                                                                                                                                                          The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.  \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                  This Committee oversees and coordinates the activities of the Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.  \n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                                                               The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. Johnson & Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world. The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.  \n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.  \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.  \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                               Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.  \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                               He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain. He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX Biosimilars have the potential to expand patient access to treatment and to create a more sustainable health care system.  \n",
       "24                                                                                                                                                                                                                                                                                                                                                                                                                               She has held roles of increasing global responsibility throughout her career including site leadership, global strategic planning, contractor management, supply chain management and product portfolio leadership. Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States. She has been a member of the PGS Leadership Team since XXX and has represented PGS on several of Pfizer’s Business Leadership Teams.  \n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association.  \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                               Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.  \n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Prior to joining Pfizer in 2009, Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council.  \n",
       "28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX  \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX  \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ...  \n",
       "810        We take a scientific approach to providing the educational, emotional and psychosocial resources that can help make a real difference in outcomes for cancer patients by leveraging insights and data to inform our content. We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers. To help patients better manage their lives with cancer, this year we launched Pfizer Oncology Together™, a first-of-its-kind program for patient access solutions and personalized support for those using Pfizer Oncology medicines in the U.S. As part of the program, patients will have access to a team of representatives with social work experience ‘Care Champions’ who provide support beyond traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs.  \n",
       "811                                                                        In addition, we implemented disaster relief protocols for our patient assistance programs, allowing existing patients who get their medicines through a Pfizer patient assistance program to request early refills or new shipping addresses, and temporarily waiving financial documentation requirements for eligible new patients who may have lost their paperwork in these crises or their aftermath. When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations. We provided colleagues who work at our Puerto Rico manufacturing and commercial sites with personal care kits, generators and other items to help them through the devastating situation.  \n",
       "812                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Access our policy paper on our antibiotic stewardship, and read more about Pfizer’s leadership in the fight against AMR. Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers. While we experienced an increase in our injury rates in 2017, mainly as a result of increased slips, trips and falls and ergonomic injuries, overall our rates are low and comparable to industry benchmarks.  \n",
       "813                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   It is only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all XXX states and the District of Columbia and administers all product donation programs for Pfizer. By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis. Available at: http://www.worldbank.org/en/news/pressrelease/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis XXX  \n",
       "814                                                                                                                                                                                                                                                                                                                                                                                      Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee. Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals. Pfizer supports the development and adoption of novel, non animal test methods for assessing the safety of new products that can reduce, replace or refine the use of animal testing.  \n",
       "815                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential. That’s why we all share responsibility for reporting safety, quality or performance issues concerning Pfizer products.  \n",
       "816                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Competitively sensitive information may not be discussed with friends or former colleagues employed by competitor companies whether in a business or a social setting. http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.  \n",
       "817                                                                                                                                          Our Commitment…12 \\tHealthcare Laws and Regulatory Requirements…12 \\tAnti-Bribery and Anti-Corruption…13 \\tResearch and Development…15 \\tManufacturing and Supply Quality…17 \\tInteractions with Patients and Patient Organizations…18. The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20. Our Commitment…22 \\tPatents, Trademarks and Copyrights…22 \\tBooks and Record Keeping…22 \\tConfidential and Proprietary Information…23 \\tPrivacy of Personal Data…25 \\tRecords and Information Management…26 \\tAcceptable Use of Information Systems…27 \\tConflicts of Interest…28 \\tSocial Media…30 \\tInside Information…31 \\tCompetitive Intelligence…32 \\tGlobal Trade Control Laws…33.  \n",
       "818                                                                                                                                                                                                                                                                                                                                                                                    With XXX manufacturing sites around the world under Pfizer Global Supply (PGS), we harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines. Leveraging Science to Create Supply Chain Solutions Pfizer’s goal is for patients to receive uninterrupted access to our medicines and vaccines.  \n",
       "819                                                                                                                                                                                                                                                                                                                             We are committed to the development of publications that report the results of Company-sponsored clinical research studies accurately and objectively and to the disclosure of funding and editorial support. Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted. Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee.  \n",
       "820                                                                                                                                                                                                                                                                                                                                                                                                                                                                             What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments. I interact regularly at work calls me and mentions that a patient of hers on Roche drug X was recently hospitalised with pneumonia and died.  \n",
       "821                                                                                                                                                                                                                                                 The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.  \n",
       "822                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 – Immediately report customer complaints relating to Roche medical devices to the local regulatory and quality function. What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.  \n",
       "823                                                                                                                                                                                                                                                                                                                                     A In case of an adverse event you should report at least the following four elements: Patient, Reporter, Event and Product (PREP). Help & advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g. Speak up: If you believe in good faith that in connection with business where Roche is involved someone has done, is doing, or may be about to do something that violates quality standards and good practices, speak up by using the available speak up channels.  \n",
       "824                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.  \n",
       "825                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         A cross-divisional working group has established a checklist on Due Diligence for External Business Partners, mainly focusing on agents and distributors. It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework. We maintain and improve operational-level grievance mechanisms, which we understand to encompass also a preventive function.  \n",
       "826                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             – Check for compliance with national and international customs, trade and export control regulations when developing and adapting processes. – Contact the related expert department in a timely manner in case of questions or to address an error. A Every employee asking for the shipment of goods is accountable for providing complete and truthful information for export or import processing.  \n",
       "827                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      If the remuneration is not commensurate with the services provided, you should not accept the consultant’s request. Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution. Roche protects human rights and does not tolerate behaviour by its business partners which is not in line with applicable laws and generally accepted sustainability standards.  \n",
       "828                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Our financial and non­financial reporting consists of the Annual Report, the Finance Report and the online report. It contains the annual financial statements, consolidated financial statements and non­financial performance indicators. The financial reporting scope is defined and outlined in our Finance Report, and there have been no significant changes in scope in XXX compared to XXX  \n",
       "829                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   You should seek guidance from your local logistics department and your local Export Control Officer before processing any shipment. A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation. A Roche does not tolerate any violation of the regulations and will take appropriate corrective measures and sanctions.  \n",
       "830                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Our challenge is to focus our efforts where we see the biggest risks and the biggest levers for remediation and improvement. On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses. We maintain a system of consistent global standards, which we also apply to our business partners, for example, in areas like R&D, clinical trials, manufacturing and distribution.  \n",
       "831                                                                                                                                                                                                                                                                                                                                                                    Corporate Integrity Q I work in a clinical research unit and have access to identifiable health information which I would like to share with a colleague. A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence. As a Roche employee you have a strict obligation to treat such information as confidential and to share it only with colleagues who need to know in order to do their work, in accordance with the purpose the data was obtained for and only if and as allowed under applicable law.  \n",
       "832                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Roche is committed to respecting data privacy and has developed principles that must be consistently applied when processing personal data within the Roche Group and by its business partners. Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed. Roche takes due care to prevent any misuse of or unauthorised access to such identifiable health information within its control.  \n",
       "833                                                                                                                                                                                                                                                                                                                                                                                                                                      Every employee is personally responsible for safety, security, health and environmental protection at the workplace to the full extent required by his/her duties to the best of his/her knowledge, ability and experience. We are all encouraged to identify areas for improvements and continuously work towards a better environment. As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment.  \n",
       "834                                                                                                                                                                                                                                                                                                                                                                                                                       We do this by assessing the risks of potential violations, promoting awareness, fostering due diligence, strengthening the legal framework and collaborating on collective actions, and transparent communication. We identified human rights which are potentially susceptible to violations, as well as their associated risks. To enhance awareness, we created a video that explained human rights and Roche’s endeavours with a simple message to our employees: ‘Within your sphere of influence, ensure human rights are respected.’.  \n",
       "835                                                                                                                                                                                                                                                 The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.  \n",
       "836                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.  \n",
       "837                                                                                                                                                                                                                                                                                                                                                                                                                                                                             As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment. Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices. We take all reasonable and practical steps to ensure that we provide a safe, secure, healthy and clean working environment.  \n",
       "838                                                                                                                                                                                                                                                                                    If a meeting in person is needed, reduce the number of participants – send a competent representative instead of a whole team. We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience. In addition, the book “Lifesavers for millions” has been published by Editiones Roche, Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding intellectual property rights, speak up by using the available speak up channels.  \n",
       "839                                                                                                                                                                                                                                                                                                                                                                                               These include excessive overtime, improper pay for overtime, insufficient number of rest days, and inadequate payment of social benefits. For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment. The RocheAbility network, for instance, fosters the inclusion of Basel and Kaiseraugst employees with disabilities and focuses on the strengths and abilities of each individual.  \n",
       "\n",
       "[840 rows x 9 columns]"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results_PfizerRocheJohnson.to_csv('Results_PfizerRocheJohnson.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Q_id</th>\n",
       "      <th>Company</th>\n",
       "      <th>Model</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Score</th>\n",
       "      <th>Doc_index</th>\n",
       "      <th>Context_Answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.57026166</td>\n",
       "      <td>2499</td>\n",
       "      <td>• The FDA may also request that a sponsor conduct pediatric studies, and in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended. Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.5109576</td>\n",
       "      <td>2459</td>\n",
       "      <td>Increasingly strict analyses are applied when evaluating the entry of new products, and as a result, access to innovative medicines is limited based on strict cost-benefit assessments. In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing. As an additional control for healthcare budgets, some EU countries have passed legislation to impose further mandatory rebates for pharmaceutical products and/or financial claw-backs on the pharmaceutical industry.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.48538196</td>\n",
       "      <td>2637</td>\n",
       "      <td>However, generic applicants must launch their products within certain timeframes or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant. In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure. Companies may submit Abridged Applications for approval of a generic medicinal product based upon its “essential similarity” to a medicinal product authorized and marketed in the EU following the expiration of the product’s data exclusivity period.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.48038045</td>\n",
       "      <td>226</td>\n",
       "      <td>Threats to the business include rising costs due to carbon pricing frameworks designed to achieve climate mitigation, risks to reputation if we don't behave as a responsible corporate citizen, loss of biodiversity that will disrupt our supply chain and the physical impacts from climate change that will introduce risk into our sites, the communities we serve and our patients. These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets. Increased costs could impact the bottom line and reduce funding for research and development of new drugs.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.480069</td>\n",
       "      <td>1928</td>\n",
       "      <td>The EU also adopted a new Directive on Administrative Cooperation (DAC6) in 2018, which seeks additional reporting. In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies. These OECD and EU tax reform initiatives also need local country implementation, including in our home country of Switzerland, which may result in significant changes to established tax principles.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4667485</td>\n",
       "      <td>2227</td>\n",
       "      <td>In the EU, Galvus received approval for expanded use as a second-line monotherapy for type  XXX diabetes patients who cannot take metformin. Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America. Diovan is the only agent in its class approved to treat all of the following: patients with high blood pressure (including children XXX to 18 years old), high-risk heart attack survivors, and patients with heart failure.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.4663378</td>\n",
       "      <td>2130</td>\n",
       "      <td>In addition, we are now able to reduce the time lag between availability of medicines in higher- and lower-income countries. For example, the first Entresto local brand was launched within XXX months of the launch in the European Union. Through our Novartis Social Business (NSB) group, we continue to pursue unique social business models, such as the Novartis Access and Healthy Family programs, to help expand access to healthcare in lower-income countries.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.4505594</td>\n",
       "      <td>2683</td>\n",
       "      <td>In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs, diagnostic ophthalmics, and other disposable products for cataract and vitreoretinal surgery. The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe. Sales of the vast majority of our Alcon Division products are not subject to material changes in seasonal demand.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.42783558</td>\n",
       "      <td>1920</td>\n",
       "      <td>Post-employment benefits for associates.” See also “—Political and economic instability may have a material adverse effect on our results,” above. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.42783558</td>\n",
       "      <td>3103</td>\n",
       "      <td>Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6198342429415247</td>\n",
       "      <td>2416</td>\n",
       "      <td>The procedure used for first authorization must continue to be followed for subsequent changes, e.g., to add an indication for a licensed product. Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states). It is optional for other new chemical entities, innovative medicinal products, and medicines for which authorization would be in the interest of public health.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.5869482063619555</td>\n",
       "      <td>2130</td>\n",
       "      <td>In addition, we are now able to reduce the time lag between availability of medicines in higher- and lower-income countries. For example, the first Entresto local brand was launched within XXX months of the launch in the European Union. Through our Novartis Social Business (NSB) group, we continue to pursue unique social business models, such as the Novartis Access and Healthy Family programs, to help expand access to healthcare in lower-income countries.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>In addition, it does not sell short assets it does not have, or does not know it will have, in the future.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.39312472620836497</td>\n",
       "      <td>4628</td>\n",
       "      <td>It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3019442945156682</td>\n",
       "      <td>882</td>\n",
       "      <td>However, we believe that the system needs to help ensure a fair balance between promoting creative and innovative activity and returning value to society. For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries. In late 2018, we reviewed our approach to patent filing in low- and middle income countries (LMICs) in an effort to better align it with the local socioeconomic circumstances that exist in many of these countries.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2949217573271527</td>\n",
       "      <td>4655</td>\n",
       "      <td>In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk. Liquidity risk Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations on time or at a reasonable price.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.30886894</td>\n",
       "      <td>2485</td>\n",
       "      <td>The protection offered by such patents extends for varying periods, depending on the grant and duration of patents in the various jurisdictions. In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries. In addition to patent protection, various countries offer data or marketing exclusivities for a prescribed period of time.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.29680955</td>\n",
       "      <td>1920</td>\n",
       "      <td>Post-employment benefits for associates.” See also “—Political and economic instability may have a material adverse effect on our results,” above. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.29680955</td>\n",
       "      <td>3103</td>\n",
       "      <td>Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28595233</td>\n",
       "      <td>3104</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions. The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX</td>\n",
       "      <td>5</td>\n",
       "      <td>0.28595233</td>\n",
       "      <td>1921</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>At the same time, other companies with specialized expertise or business models are entering the Item XXX</td>\n",
       "      <td>1</td>\n",
       "      <td>0.54087555</td>\n",
       "      <td>1835</td>\n",
       "      <td>In order to succeed, we will be required to encourage a cultural change among our employees, attract and retain employees with appropriate skills and mindset, and successfully innovate across a variety of technology fields. At the same time, other companies with specialized expertise or business models are entering the Item XXX Key Information 18healthcare field, from research and development to pharmaceutical distribution, potentially disrupting our relationships with patients, healthcare professionals, customers, distributors and suppliers, with unknown potential consequences for us.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.51713026</td>\n",
       "      <td>2747</td>\n",
       "      <td>The scope of copyright protection for computer software varies throughout the world, although it is generally for a fixed term that begins on the date of copyright registration. Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world. Some of our principal facilities are subject to mortgages and other security interests granted to secure indebtedness to certain financial institutions.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.51357496</td>\n",
       "      <td>4514</td>\n",
       "      <td>Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans. In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.49095944</td>\n",
       "      <td>2393</td>\n",
       "      <td>These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development. Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.48801655</td>\n",
       "      <td>2499</td>\n",
       "      <td>• The FDA may also request that a sponsor conduct pediatric studies, and in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended. Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.32053015</td>\n",
       "      <td>2227</td>\n",
       "      <td>In the EU, Galvus received approval for expanded use as a second-line monotherapy for type  XXX diabetes patients who cannot take metformin. Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America. Diovan is the only agent in its class approved to treat all of the following: patients with high blood pressure (including children XXX to 18 years old), high-risk heart attack survivors, and patients with heart failure.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.31352153</td>\n",
       "      <td>843</td>\n",
       "      <td>The program was evaluated, and the results were published in a research paper in BMC Medical Education. There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector. It improves our understanding of global healthcare challenges while providing young scientists with skills, knowledge, tools and inspiration to improve healthcare in their communities.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.30220336</td>\n",
       "      <td>2785</td>\n",
       "      <td>Our strategy is to focus Novartis as a leading medicines company powered by advanced therapy platforms and data science. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In June 2018, we announced that we plan to spin off Alcon into a separately-traded standalone company.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.30220336</td>\n",
       "      <td>2094</td>\n",
       "      <td>In compliance with IFRS, beginning with our first-quarter XXX results, Novartis updated its segment financial information to reflect this transfer, both for the current and prior years, to aid comparability of year on year results. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2962501</td>\n",
       "      <td>1981</td>\n",
       "      <td>As a result, we could experience increased production or other costs, business interruptions, destruction of facilities, and loss of life, all of which could have a material adverse effect on our business, financial condition, or results of operations. In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland. Other major facilities are located near major earthquake fault lines in various locations around the world.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>250</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.30741232834573573</td>\n",
       "      <td>873</td>\n",
       "      <td>For the past year, we piloted this digital platform with Aquarelle, a supplier to apparel company Levi’s, near Bangalore. Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease. Pilot results showed that 16% of factory workers were diagnosed as anemic and subsequently treated, and a subgroup analysis showed that absenteeism was reduced by 4% on average in little less than a year.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>251</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.2629575541037144</td>\n",
       "      <td>2573</td>\n",
       "      <td>According to IQVIA (formerly IMS Health), as of November 2018, Sandoz holds a leading global position in sales of biosimilars and of generic anti-infectives and oncology medicines. Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose. The unit comprises several legacy programs (Novartis Access, the Novartis Malaria Initiative, and Novartis Healthy Family) supported by digital enabling platforms, and has full responsibility for the entire Novartis product range for seven countries in Asia and Africa.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>252</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>In addition, it does not sell short assets it does not have, or does not know it will have, in the future.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.2512910648903934</td>\n",
       "      <td>4628</td>\n",
       "      <td>It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>253</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.2087611172195355</td>\n",
       "      <td>3832</td>\n",
       "      <td>Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information. Investor Relations program Investor Relations manages the Group’s interactions with the international financial community.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>254</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.19363820084091854</td>\n",
       "      <td>4669</td>\n",
       "      <td>The VAR computation is a risk analysis tool designed to statistically estimate the potential 10-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates, and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group’s future results of operations or financial position.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>255</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6607314</td>\n",
       "      <td>2429</td>\n",
       "      <td>Once an agreement has been reached, each member state grants national marketing authorizations for the product. After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP). For some medications, post-approval studies (Phase IV) may be imposed to complement available data with additional data to evaluate long-term effects (called a Post-Approval Safety Study, or PASS) or to gather additional efficacy data (called a Post-Approval Efficacy Study, or PAES).</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>256</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.45916152</td>\n",
       "      <td>873</td>\n",
       "      <td>For the past year, we piloted this digital platform with Aquarelle, a supplier to apparel company Levi’s, near Bangalore. Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease. Pilot results showed that 16% of factory workers were diagnosed as anemic and subsequently treated, and a subgroup analysis showed that absenteeism was reduced by 4% on average in little less than a year.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>257</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.45632774</td>\n",
       "      <td>2393</td>\n",
       "      <td>These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development. Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>258</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Defining the Global Health &amp; Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.44425339</td>\n",
       "      <td>652</td>\n",
       "      <td>And we established a new companywide environmental sustainability strategy, with the aspiration to become carbon neutral by 2025, and plastic and water neutral by XXX Defining the Global Health &amp; Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company. In recent years, many aspects of our business model have been debated and questioned in public settings, including how we price our medicines, engage with physicians, and leverage intellectual property to protect our innovations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.4298969</td>\n",
       "      <td>425</td>\n",
       "      <td>If practical and in line with existing globally accepted approaches legislative systems on mandatory corporate reporting could be additionally beneficial to further increase the best practice corporate reporting to additional companies. Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company. We are partnered with MIT Joint Program in designing, piloting and expanding a rigorous scientific approach to assessment and monetization of risk.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>260</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.7060776</td>\n",
       "      <td>1163</td>\n",
       "      <td>Ensuring healthcare products (patented pharmaceuticals and generics) are manufactured at the highest quality level and that the efficacy and safety features of a medicine outweigh its risks (e.g., side effects), as well as collecting and recording adverse event reports. This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.62601626</td>\n",
       "      <td>1064</td>\n",
       "      <td>The RP risk indicator tool uses the category risk, country risk and contract value in combination to indicate a potential risk around the five areas of elevated ethical risk in the supply chain: labor rights, HSE general, HSE specific, animal welfare and anti-bribery. Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review. https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/responsible-procuremen.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>262</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6205468</td>\n",
       "      <td>170</td>\n",
       "      <td>Risks are assessed in the annual risk evaluation process, where natural disasters are a regular part of and are prepared site by site. To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary. Initial global risks are being assessed in collaboration with the Massachusetts Institute of Technology, and have been shared with applicable production, research and facilities staff.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>263</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.61974794</td>\n",
       "      <td>65</td>\n",
       "      <td>Risks can be catalogued at the site level and elevated to senior leadership, they can be identified during site assessments and audits, and they can be identified by more senior leadership in the organization. Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors. Each one of those variables has a different level of change that triggers assessment as a medium or high risk, and the variables are considered in combination.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>264</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.61974794</td>\n",
       "      <td>1392</td>\n",
       "      <td>All the relevant risk information is passed to Business Continuity (BC) staff, risk staff and strategy staff in various positions of the company as applicable. Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors. Each one of those variables has a different level of change that triggers assessment as a medium or high risk, and the variables are considered in combination.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>265</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.33742234</td>\n",
       "      <td>1604</td>\n",
       "      <td>Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.2a \\t(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.3 \\t(W4.3) Have you identified any water-related opportunities with the potential to have a substantive financial or strategic impact on your business?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>266</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.33742234</td>\n",
       "      <td>1602</td>\n",
       "      <td>W4.1c \\t(W4.1c) By river basin, what is the number and proportion of facilities exposed to water risks that could have a substantive impact on your business, and what is the potential business impact associated with those facilities. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.2a \\t(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>267</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Remediation plans to address information security, data privacy and business continuity risks are on track.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.31877115</td>\n",
       "      <td>3637</td>\n",
       "      <td>Internal Audit has performed XXX audits from its annual plan, and has conducted XXX advisory engagements and site visits. Remediation plans to address information security, data privacy and business continuity risks are on track. Recurring observations identified across various functions and business units relate to improving third-party management, cross-functional collaboration, legacy systems and complex processes.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>268</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3186491</td>\n",
       "      <td>185</td>\n",
       "      <td>A current site risk assessment will serve as the model for subsequent detailed risk assessments globally that involve global, regional and local staff, to make informed decisions on acceptable level of risk and the physical investments needed. This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management. Comment C2.4 (C2.4) Have you identified any climate-related opportunities with the potential to have a substantive financial or strategic impact on your business?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>269</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).</td>\n",
       "      <td>5</td>\n",
       "      <td>0.31634763</td>\n",
       "      <td>1163</td>\n",
       "      <td>Ensuring healthcare products (patented pharmaceuticals and generics) are manufactured at the highest quality level and that the efficacy and safety features of a medicine outweigh its risks (e.g., side effects), as well as collecting and recording adverse event reports. This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>270</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.362225367191791</td>\n",
       "      <td>477</td>\n",
       "      <td>That bold action will demand leadership and will require new partners, new networks and new ways of engaging to solve problems. That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change. Job title Corresponding job category Row XXX Head of Novartis Business Services Other C-Suite Officer SC.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>271</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.340272807114573</td>\n",
       "      <td>123</td>\n",
       "      <td>Consolidated tracking of trends in non-energy costs as well as possible exposure to pricing schemes based on energy intensity and physical location are used by procurement to adjust procurement and hedging strategies to reduce volatility and exposure. While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts. Efforts to align with suppliers will also take time and resources that have not been determined yet.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>272</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.33558396034435095</td>\n",
       "      <td>1880</td>\n",
       "      <td>To the extent that economic and financial conditions directly affect consumers, then our Innovative Medicines and Sandoz Divisions may be impacted. Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs. In addition, the elective surgical and contact lens businesses of our Alcon Division may be particularly sensitive to declines in consumer spending.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>273</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.2577721065766643</td>\n",
       "      <td>659</td>\n",
       "      <td>We are committed to taking real, measurable and reportable action in these key areas, and making sure that we communicate about them clearly and transparently. The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices. These topics are at the core of the four GH&amp;CR focus areas outlined above, and are covered in the following sections of this report.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.23025861380513102</td>\n",
       "      <td>117</td>\n",
       "      <td>Potential future increases in both energy prices and the implementation of carbon costs may have a stronger impact of estimated 20-30% of energy cost in the long-term, i.e. Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes. While these are highly variable in projections, the rapid price increase in the EU ETS is an obvious example of the increasing financial risk posed by our carbon footprint.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>275</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.55075574</td>\n",
       "      <td>1512</td>\n",
       "      <td>Other committee, please specify (HSE Governance Board) Responsibility Both assessing and managing water-related risks and opportunities Frequency of reporting to the board on water-related issues. A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action. These roles were selected because the Heads of NTO and NBS have operational responsibility; the Group Head of HR has a key role in ensuring that environmental sustainability are considered as part of routine business decisions because this is part of our culture.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>276</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.511887</td>\n",
       "      <td>1592</td>\n",
       "      <td>W2.2 \\t(W2.2) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations? Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience. Coverage \\tRisk assessment procedure \\tFrequency of assessment \\tHow far into the future are risks considered?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>277</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.5090189</td>\n",
       "      <td>34</td>\n",
       "      <td>The ECN is responsible for overseeing the daily implementation of board policies which includes climate related issues and making sure that the board is establishing and maintaining good governance practices. Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business. The HSE Governance Board also includes the Global Head of Corporate Responsibility for Novartis, the Head of Real Estate and Facilities Services, the Global Head of HSE, and the Global Environment Head.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>278</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization).</td>\n",
       "      <td>4</td>\n",
       "      <td>0.5047898</td>\n",
       "      <td>1033</td>\n",
       "      <td>To inform our human rights strategy and future due diligence program, we piloted three human rights assessments in Turkey, China and Malaysia (in addition to Egypt in November 2017). We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization). We have also identified these common risk areas that require follow-up action in 2019: • Stakeholder engagement: More regular and broader consultation with external stakeholders is needed at the local level (from patient groups, local communities and health authorities to supply chain partners).</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>279</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.48939437</td>\n",
       "      <td>1501</td>\n",
       "      <td>The Global Head of Corporate Responsibility updates the GNCRC regularly on CR strategy and performance. This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed. If they had concerns about of water strategy these would be brought to the attention of the Board and the Executive Committee of the Novartis (ECN).</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>280 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                         Question  \\\n",
       "0                                                                                Does the company operate in countries out of the European Union?   \n",
       "1                                                                                Does the company operate in countries out of the European Union?   \n",
       "2                                                                                Does the company operate in countries out of the European Union?   \n",
       "3                                                                                Does the company operate in countries out of the European Union?   \n",
       "4                                                                                Does the company operate in countries out of the European Union?   \n",
       "5                                                                                Does the company operate in countries out of the European Union?   \n",
       "6                                                                                Does the company operate in countries out of the European Union?   \n",
       "7                                                                                Does the company operate in countries out of the European Union?   \n",
       "8                                                                                Does the company operate in countries out of the European Union?   \n",
       "9                                                                                Does the company operate in countries out of the European Union?   \n",
       "10                                                                               Does the company operate in countries out of the European Union?   \n",
       "11                                                                               Does the company operate in countries out of the European Union?   \n",
       "12                                                                               Does the company operate in countries out of the European Union?   \n",
       "13                                                                               Does the company operate in countries out of the European Union?   \n",
       "14                                                                               Does the company operate in countries out of the European Union?   \n",
       "15                                                                               Does the company operate in countries out of the European Union?   \n",
       "16                                                                               Does the company operate in countries out of the European Union?   \n",
       "17                                                                               Does the company operate in countries out of the European Union?   \n",
       "18                                                                               Does the company operate in countries out of the European Union?   \n",
       "19                                                                               Does the company operate in countries out of the European Union?   \n",
       "20     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "21     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "22     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "23     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "24     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "25     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "26     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "27     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "28     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "29     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "..                                                                                                                                            ...   \n",
       "250  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "251  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "252  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "253  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "254  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "255  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "256  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "257  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "258  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "259  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "260                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "261                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "262                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "263                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "264                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "265                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "266                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "267                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "268                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "269                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "270                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "271                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "272                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "273                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "274                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "275                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "276                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "277                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "278                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "279                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "\n",
       "     Q_id   Company                          Model  \\\n",
       "0       1  Novartis             Bert - transformer   \n",
       "1       1  Novartis             Bert - transformer   \n",
       "2       1  Novartis             Bert - transformer   \n",
       "3       1  Novartis             Bert - transformer   \n",
       "4       1  Novartis             Bert - transformer   \n",
       "5       1  Novartis              Infersent Bi-Lstm   \n",
       "6       1  Novartis              Infersent Bi-Lstm   \n",
       "7       1  Novartis              Infersent Bi-Lstm   \n",
       "8       1  Novartis              Infersent Bi-Lstm   \n",
       "9       1  Novartis              Infersent Bi-Lstm   \n",
       "10      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "11      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "12      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "13      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "14      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "15      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "16      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "17      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "18      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "19      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "20      2  Novartis             Bert - transformer   \n",
       "21      2  Novartis             Bert - transformer   \n",
       "22      2  Novartis             Bert - transformer   \n",
       "23      2  Novartis             Bert - transformer   \n",
       "24      2  Novartis             Bert - transformer   \n",
       "25      2  Novartis              Infersent Bi-Lstm   \n",
       "26      2  Novartis              Infersent Bi-Lstm   \n",
       "27      2  Novartis              Infersent Bi-Lstm   \n",
       "28      2  Novartis              Infersent Bi-Lstm   \n",
       "29      2  Novartis              Infersent Bi-Lstm   \n",
       "..    ...       ...                            ...   \n",
       "250    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "251    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "252    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "253    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "254    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "255    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "256    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "257    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "258    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "259    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "260    14  Novartis             Bert - transformer   \n",
       "261    14  Novartis             Bert - transformer   \n",
       "262    14  Novartis             Bert - transformer   \n",
       "263    14  Novartis             Bert - transformer   \n",
       "264    14  Novartis             Bert - transformer   \n",
       "265    14  Novartis              Infersent Bi-Lstm   \n",
       "266    14  Novartis              Infersent Bi-Lstm   \n",
       "267    14  Novartis              Infersent Bi-Lstm   \n",
       "268    14  Novartis              Infersent Bi-Lstm   \n",
       "269    14  Novartis              Infersent Bi-Lstm   \n",
       "270    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "271    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "272    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "273    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "274    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "275    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "276    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "277    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "278    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "279    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Answer  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                        Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.   \n",
       "1                                                                                                                                                                                                                                                                                                                In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing.   \n",
       "2                                                                                                                                                                                                              In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                    These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets.   \n",
       "4                                                                                                                                                                     In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies.   \n",
       "5                                                                                                                                                                                                                                                                                                                                                            Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.   \n",
       "6                                                                                                                                                                                                                                                                                                                                                                     For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                          The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe.   \n",
       "8                                                                                                                                                                                                                                                                                                                                                                 Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                 Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "10                                                                                                                                                                                                                                                                                                                                   Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states).   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                    For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.   \n",
       "12                                                                                                                                                                                                                                                                                                                                                                         In addition, it does not sell short assets it does not have, or does not know it will have, in the future.   \n",
       "13                                                                                                                                                                                                                                                                                                                                              For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.   \n",
       "14                                                                                                                                                                                                                                                                                                     The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.   \n",
       "15                                                                                                                                                                                                                                                                                    In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries.   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "17                                                                                                                                                                                                                                                                                                                                              For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.   \n",
       "18                                                                                                                                                                                                                                                                                                                                                            We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions.   \n",
       "19                                                                                                                                                                                     The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX   \n",
       "20                                                                                                                                                                                                                                                                                                                                                                          At the same time, other companies with specialized expertise or business models are entering the Item XXX   \n",
       "21                                                                                                                                                                                                                                                                                                                            Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.   \n",
       "22                                                                                                                                                                                                                                                                                                                                             Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans.   \n",
       "23                                                                                                                                                                                                                                                                                                                                       Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.   \n",
       "24                                                                                                                                                                                                                                                                                                                                                       Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.   \n",
       "25                                                                                                                                                                                                                                                                                                                                                           Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.   \n",
       "26                                                                                                                                                                                                                                                                                                                                 There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector.   \n",
       "27                                                                                                                                                                                                                                                                                                                    The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.   \n",
       "28                                                                                                                                                                                                                                                                                                                    The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.   \n",
       "29                                                                                                                                                                                                                           In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland.   \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
       "250                                                                                                                                                                                                                                                                                                                                                  Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.   \n",
       "251                                                                                                                                                                                                                                                                                                                           Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose.   \n",
       "252                                                                                                                                                                                                                                                                                                                                                                        In addition, it does not sell short assets it does not have, or does not know it will have, in the future.   \n",
       "253                                                                                                                                                                                                                                                                                                                                                 Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information.   \n",
       "254                                                                                                                                                                                                                                                                                          The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates.   \n",
       "255                                                                                                                                                                                                                                                           After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP).   \n",
       "256                                                                                                                                                                                                                                                                                                                                                  Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.   \n",
       "257                                                                                                                                                                                                                                                                                                                                      Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.   \n",
       "258                                                                                                                                                                                                                                                                                                                           Defining the Global Health & Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company.   \n",
       "259                                                                                                                                                                                                                                                                                                          Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company.   \n",
       "260                                                                                                                                                                                                                                                                                                                                                This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).   \n",
       "261                                                                                                                                   Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review.   \n",
       "262                                                                                                                                                                                                                                                                                                                                                             To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary.   \n",
       "263                                                                                                                                                                                                                                                                                              Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.   \n",
       "264                                                                                                                                                                                                                                                                                              Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.   \n",
       "265                                                                                                                                                                                                                                                                                                                                        Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.   \n",
       "266                                                                                                                                                                                                                                                                                                                                        Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.   \n",
       "267                                                                                                                                                                                                                                                                                                                                                                       Remediation plans to address information security, data privacy and business continuity risks are on track.   \n",
       "268                                                                                                                                                                                                                                                                                                                                                    This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management.   \n",
       "269                                                                                                                                                                                                                                                                                                                                                This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).   \n",
       "270                                                                                                                                                                                                                                                                                                                                        That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change.   \n",
       "271                                                                                                                                                                                                                                                                                            While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts.   \n",
       "272                                                                                                                                                                                                                                    Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs.   \n",
       "273                                                                                                                                                                                                                                                                                                                              The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices.   \n",
       "274                                                                                                                                                                                                                                                                                                                                                                        Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes.   \n",
       "275                                                                                                                                                                                                           A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action.   \n",
       "276                                                                                                                                                                                                                                                                                                              Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience.   \n",
       "277                                                                                                                                                                                                                                                                                                                    Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business.   \n",
       "278  We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization).   \n",
       "279                                                                                                                                                                                                                                                                                                              This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed.   \n",
       "\n",
       "    Rank                Score Doc_index  \\\n",
       "0      1           0.57026166      2499   \n",
       "1      2            0.5109576      2459   \n",
       "2      3           0.48538196      2637   \n",
       "3      4           0.48038045       226   \n",
       "4      5             0.480069      1928   \n",
       "5      1            0.4667485      2227   \n",
       "6      2            0.4663378      2130   \n",
       "7      3            0.4505594      2683   \n",
       "8      4           0.42783558      1920   \n",
       "9      5           0.42783558      3103   \n",
       "10     1   0.6198342429415247      2416   \n",
       "11     2   0.5869482063619555      2130   \n",
       "12     3  0.39312472620836497      4628   \n",
       "13     4   0.3019442945156682       882   \n",
       "14     5   0.2949217573271527      4655   \n",
       "15     1           0.30886894      2485   \n",
       "16     2           0.29680955      1920   \n",
       "17     3           0.29680955      3103   \n",
       "18     4           0.28595233      3104   \n",
       "19     5           0.28595233      1921   \n",
       "20     1           0.54087555      1835   \n",
       "21     2           0.51713026      2747   \n",
       "22     3           0.51357496      4514   \n",
       "23     4           0.49095944      2393   \n",
       "24     5           0.48801655      2499   \n",
       "25     1           0.32053015      2227   \n",
       "26     2           0.31352153       843   \n",
       "27     3           0.30220336      2785   \n",
       "28     4           0.30220336      2094   \n",
       "29     5            0.2962501      1981   \n",
       "..   ...                  ...       ...   \n",
       "250    1  0.30741232834573573       873   \n",
       "251    2   0.2629575541037144      2573   \n",
       "252    3   0.2512910648903934      4628   \n",
       "253    4   0.2087611172195355      3832   \n",
       "254    5  0.19363820084091854      4669   \n",
       "255    1            0.6607314      2429   \n",
       "256    2           0.45916152       873   \n",
       "257    3           0.45632774      2393   \n",
       "258    4           0.44425339       652   \n",
       "259    5            0.4298969       425   \n",
       "260    1            0.7060776      1163   \n",
       "261    2           0.62601626      1064   \n",
       "262    3            0.6205468       170   \n",
       "263    4           0.61974794        65   \n",
       "264    5           0.61974794      1392   \n",
       "265    1           0.33742234      1604   \n",
       "266    2           0.33742234      1602   \n",
       "267    3           0.31877115      3637   \n",
       "268    4            0.3186491       185   \n",
       "269    5           0.31634763      1163   \n",
       "270    1    0.362225367191791       477   \n",
       "271    2    0.340272807114573       123   \n",
       "272    3  0.33558396034435095      1880   \n",
       "273    4   0.2577721065766643       659   \n",
       "274    5  0.23025861380513102       117   \n",
       "275    1           0.55075574      1512   \n",
       "276    2             0.511887      1592   \n",
       "277    3            0.5090189        34   \n",
       "278    4            0.5047898      1033   \n",
       "279    5           0.48939437      1501   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Context_Answer  \n",
       "0                                                                                                                                                                                                                                                                                                                   • The FDA may also request that a sponsor conduct pediatric studies, and in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended. Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey.  \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                Increasingly strict analyses are applied when evaluating the entry of new products, and as a result, access to innovative medicines is limited based on strict cost-benefit assessments. In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing. As an additional control for healthcare budgets, some EU countries have passed legislation to impose further mandatory rebates for pharmaceutical products and/or financial claw-backs on the pharmaceutical industry.  \n",
       "2                                                                                                                                                                                                                                                                  However, generic applicants must launch their products within certain timeframes or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant. In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure. Companies may submit Abridged Applications for approval of a generic medicinal product based upon its “essential similarity” to a medicinal product authorized and marketed in the EU following the expiration of the product’s data exclusivity period.  \n",
       "3                                                                                                                                                                                                                                                                                                                                               Threats to the business include rising costs due to carbon pricing frameworks designed to achieve climate mitigation, risks to reputation if we don't behave as a responsible corporate citizen, loss of biodiversity that will disrupt our supply chain and the physical impacts from climate change that will introduce risk into our sites, the communities we serve and our patients. These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets. Increased costs could impact the bottom line and reduce funding for research and development of new drugs.  \n",
       "4                                                                                                                                                                                                                                                                                                                                           The EU also adopted a new Directive on Administrative Cooperation (DAC6) in 2018, which seeks additional reporting. In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies. These OECD and EU tax reform initiatives also need local country implementation, including in our home country of Switzerland, which may result in significant changes to established tax principles.  \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  In the EU, Galvus received approval for expanded use as a second-line monotherapy for type  XXX diabetes patients who cannot take metformin. Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America. Diovan is the only agent in its class approved to treat all of the following: patients with high blood pressure (including children XXX to 18 years old), high-risk heart attack survivors, and patients with heart failure.  \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         In addition, we are now able to reduce the time lag between availability of medicines in higher- and lower-income countries. For example, the first Entresto local brand was launched within XXX months of the launch in the European Union. Through our Novartis Social Business (NSB) group, we continue to pursue unique social business models, such as the Novartis Access and Healthy Family programs, to help expand access to healthcare in lower-income countries.  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs, diagnostic ophthalmics, and other disposable products for cataract and vitreoretinal surgery. The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe. Sales of the vast majority of our Alcon Division products are not subject to material changes in seasonal demand.  \n",
       "8                                                                                                                                                                                                                                                                                                                                                       Post-employment benefits for associates.” See also “—Political and economic instability may have a material adverse effect on our results,” above. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.  \n",
       "9                                                                                                                                                                                                                                                                                                                                                                            Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.  \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The procedure used for first authorization must continue to be followed for subsequent changes, e.g., to add an indication for a licensed product. Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states). It is optional for other new chemical entities, innovative medicinal products, and medicines for which authorization would be in the interest of public health.  \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In addition, we are now able to reduce the time lag between availability of medicines in higher- and lower-income countries. For example, the first Entresto local brand was launched within XXX months of the launch in the European Union. Through our Novartis Social Business (NSB) group, we continue to pursue unique social business models, such as the Novartis Access and Healthy Family programs, to help expand access to healthcare in lower-income countries.  \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience.  \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                             However, we believe that the system needs to help ensure a fair balance between promoting creative and innovative activity and returning value to society. For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries. In late 2018, we reviewed our approach to patent filing in low- and middle income countries (LMICs) in an effort to better align it with the local socioeconomic circumstances that exist in many of these countries.  \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                      In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk. Liquidity risk Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations on time or at a reasonable price.  \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The protection offered by such patents extends for varying periods, depending on the grant and duration of patents in the various jurisdictions. In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries. In addition to patent protection, various countries offer data or marketing exclusivities for a prescribed period of time.  \n",
       "16                                                                                                                                                                                                                                                                                                                                                      Post-employment benefits for associates.” See also “—Political and economic instability may have a material adverse effect on our results,” above. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.  \n",
       "17                                                                                                                                                                                                                                                                                                                                                         Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions. The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains.  \n",
       "19                                                                                                                                                                                                                                                                                                                                      Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains.  \n",
       "20                                                                                                                                                                                                                                                                                                                                                                   In order to succeed, we will be required to encourage a cultural change among our employees, attract and retain employees with appropriate skills and mindset, and successfully innovate across a variety of technology fields. At the same time, other companies with specialized expertise or business models are entering the Item XXX Key Information 18healthcare field, from research and development to pharmaceutical distribution, potentially disrupting our relationships with patients, healthcare professionals, customers, distributors and suppliers, with unknown potential consequences for us.  \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The scope of copyright protection for computer software varies throughout the world, although it is generally for a fixed term that begins on the date of copyright registration. Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world. Some of our principal facilities are subject to mortgages and other security interests granted to secure indebtedness to certain financial institutions.  \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans. In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since XXX  \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                              These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development. Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained.  \n",
       "24                                                                                                                                                                                                                                                                                                                  • The FDA may also request that a sponsor conduct pediatric studies, and in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended. Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey.  \n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 In the EU, Galvus received approval for expanded use as a second-line monotherapy for type  XXX diabetes patients who cannot take metformin. Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America. Diovan is the only agent in its class approved to treat all of the following: patients with high blood pressure (including children XXX to 18 years old), high-risk heart attack survivors, and patients with heart failure.  \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The program was evaluated, and the results were published in a research paper in BMC Medical Education. There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector. It improves our understanding of global healthcare challenges while providing young scientists with skills, knowledge, tools and inspiration to improve healthcare in their communities.  \n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Our strategy is to focus Novartis as a leading medicines company powered by advanced therapy platforms and data science. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In June 2018, we announced that we plan to spin off Alcon into a separately-traded standalone company.  \n",
       "28                                                                                                                                                                                                                                           In compliance with IFRS, beginning with our first-quarter XXX results, Novartis updated its segment financial information to reflect this transfer, both for the current and prior years, to aid comparability of year on year results. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.  \n",
       "29                                                                                                                                                                                                                                                                                                                                                  As a result, we could experience increased production or other costs, business interruptions, destruction of facilities, and loss of life, all of which could have a material adverse effect on our business, financial condition, or results of operations. In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland. Other major facilities are located near major earthquake fault lines in various locations around the world.  \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...  \n",
       "250                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           For the past year, we piloted this digital platform with Aquarelle, a supplier to apparel company Levi’s, near Bangalore. Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease. Pilot results showed that 16% of factory workers were diagnosed as anemic and subsequently treated, and a subgroup analysis showed that absenteeism was reduced by 4% on average in little less than a year.  \n",
       "251                                                                                                                                                                                                                                                                                                                                                        According to IQVIA (formerly IMS Health), as of November 2018, Sandoz holds a leading global position in sales of biosimilars and of generic anti-infectives and oncology medicines. Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose. The unit comprises several legacy programs (Novartis Access, the Novartis Malaria Initiative, and Novartis Healthy Family) supported by digital enabling platforms, and has full responsibility for the entire Novartis product range for seven countries in Asia and Africa.  \n",
       "252                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience.  \n",
       "253                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information. Investor Relations program Investor Relations manages the Group’s interactions with the international financial community.  \n",
       "254                                                                                                                                                                                                              The VAR computation is a risk analysis tool designed to statistically estimate the potential 10-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates, and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group’s future results of operations or financial position.  \n",
       "255                                                                                                                                                                                                                                                                                                                                              Once an agreement has been reached, each member state grants national marketing authorizations for the product. After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP). For some medications, post-approval studies (Phase IV) may be imposed to complement available data with additional data to evaluate long-term effects (called a Post-Approval Safety Study, or PASS) or to gather additional efficacy data (called a Post-Approval Efficacy Study, or PAES).  \n",
       "256                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           For the past year, we piloted this digital platform with Aquarelle, a supplier to apparel company Levi’s, near Bangalore. Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease. Pilot results showed that 16% of factory workers were diagnosed as anemic and subsequently treated, and a subgroup analysis showed that absenteeism was reduced by 4% on average in little less than a year.  \n",
       "257                                                                                                                                                                                                                                                                                                                                                                                                             These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development. Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained.  \n",
       "258                                                                                                                                                                                                                                                                                                                                                                                                              And we established a new companywide environmental sustainability strategy, with the aspiration to become carbon neutral by 2025, and plastic and water neutral by XXX Defining the Global Health & Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company. In recent years, many aspects of our business model have been debated and questioned in public settings, including how we price our medicines, engage with physicians, and leverage intellectual property to protect our innovations.  \n",
       "259                                                                                                                                                                                                                                                                                                                                                                                                         If practical and in line with existing globally accepted approaches legislative systems on mandatory corporate reporting could be additionally beneficial to further increase the best practice corporate reporting to additional companies. Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company. We are partnered with MIT Joint Program in designing, piloting and expanding a rigorous scientific approach to assessment and monetization of risk.  \n",
       "260                                                                                                                                                                                                                                                                                                                                                                                                                                     Ensuring healthcare products (patented pharmaceuticals and generics) are manufactured at the highest quality level and that the efficacy and safety features of a medicine outweigh its risks (e.g., side effects), as well as collecting and recording adverse event reports. This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice.  \n",
       "261                                                                                                                                                                                                                                         The RP risk indicator tool uses the category risk, country risk and contract value in combination to indicate a potential risk around the five areas of elevated ethical risk in the supply chain: labor rights, HSE general, HSE specific, animal welfare and anti-bribery. Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review. https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/responsible-procuremen.  \n",
       "262                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Risks are assessed in the annual risk evaluation process, where natural disasters are a regular part of and are prepared site by site. To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary. Initial global risks are being assessed in collaboration with the Massachusetts Institute of Technology, and have been shared with applicable production, research and facilities staff.  \n",
       "263                                                                                                                                                                                                                                                                                                                                                                                                            Risks can be catalogued at the site level and elevated to senior leadership, they can be identified during site assessments and audits, and they can be identified by more senior leadership in the organization. Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors. Each one of those variables has a different level of change that triggers assessment as a medium or high risk, and the variables are considered in combination.  \n",
       "264                                                                                                                                                                                                                                                                                                                                                                                                                                                              All the relevant risk information is passed to Business Continuity (BC) staff, risk staff and strategy staff in various positions of the company as applicable. Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors. Each one of those variables has a different level of change that triggers assessment as a medium or high risk, and the variables are considered in combination.  \n",
       "265                                                                                                                                                   Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.2a \\t(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.3 \\t(W4.3) Have you identified any water-related opportunities with the potential to have a substantive financial or strategic impact on your business?  \n",
       "266                                                                                                                                                                                                                W4.1c \\t(W4.1c) By river basin, what is the number and proportion of facilities exposed to water risks that could have a substantive impact on your business, and what is the potential business impact associated with those facilities. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.2a \\t(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks.  \n",
       "267                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Internal Audit has performed XXX audits from its annual plan, and has conducted XXX advisory engagements and site visits. Remediation plans to address information security, data privacy and business continuity risks are on track. Recurring observations identified across various functions and business units relate to improving third-party management, cross-functional collaboration, legacy systems and complex processes.  \n",
       "268                                                                                                                                                                                                                                                                                                                                                                                                                             A current site risk assessment will serve as the model for subsequent detailed risk assessments globally that involve global, regional and local staff, to make informed decisions on acceptable level of risk and the physical investments needed. This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management. Comment C2.4 (C2.4) Have you identified any climate-related opportunities with the potential to have a substantive financial or strategic impact on your business?  \n",
       "269                                                                                                                                                                                                                                                                                                                                                                                                                                     Ensuring healthcare products (patented pharmaceuticals and generics) are manufactured at the highest quality level and that the efficacy and safety features of a medicine outweigh its risks (e.g., side effects), as well as collecting and recording adverse event reports. This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice.  \n",
       "270                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              That bold action will demand leadership and will require new partners, new networks and new ways of engaging to solve problems. That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change. Job title Corresponding job category Row XXX Head of Novartis Business Services Other C-Suite Officer SC.  \n",
       "271                                                                                                                                                                                                                                                                                                                                                                                                                           Consolidated tracking of trends in non-energy costs as well as possible exposure to pricing schemes based on energy intensity and physical location are used by procurement to adjust procurement and hedging strategies to reduce volatility and exposure. While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts. Efforts to align with suppliers will also take time and resources that have not been determined yet.  \n",
       "272                                                                                                                                                                                                                                                                                                                                                                                                                           To the extent that economic and financial conditions directly affect consumers, then our Innovative Medicines and Sandoz Divisions may be impacted. Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs. In addition, the elective surgical and contact lens businesses of our Alcon Division may be particularly sensitive to declines in consumer spending.  \n",
       "273                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         We are committed to taking real, measurable and reportable action in these key areas, and making sure that we communicate about them clearly and transparently. The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices. These topics are at the core of the four GH&CR focus areas outlined above, and are covered in the following sections of this report.  \n",
       "274                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Potential future increases in both energy prices and the implementation of carbon costs may have a stronger impact of estimated 20-30% of energy cost in the long-term, i.e. Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes. While these are highly variable in projections, the rapid price increase in the EU ETS is an obvious example of the increasing financial risk posed by our carbon footprint.  \n",
       "275                                                                                                                                                                                                                              Other committee, please specify (HSE Governance Board) Responsibility Both assessing and managing water-related risks and opportunities Frequency of reporting to the board on water-related issues. A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action. These roles were selected because the Heads of NTO and NBS have operational responsibility; the Group Head of HR has a key role in ensuring that environmental sustainability are considered as part of routine business decisions because this is part of our culture.  \n",
       "276                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          W2.2 \\t(W2.2) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations? Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience. Coverage \\tRisk assessment procedure \\tFrequency of assessment \\tHow far into the future are risks considered?  \n",
       "277                                                                                                                                                                                                                                                                                                                                                                                        The ECN is responsible for overseeing the daily implementation of board policies which includes climate related issues and making sure that the board is establishing and maintaining good governance practices. Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business. The HSE Governance Board also includes the Global Head of Corporate Responsibility for Novartis, the Head of Real Estate and Facilities Services, the Global Head of HSE, and the Global Environment Head.  \n",
       "278  To inform our human rights strategy and future due diligence program, we piloted three human rights assessments in Turkey, China and Malaysia (in addition to Egypt in November 2017). We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization). We have also identified these common risk areas that require follow-up action in 2019: • Stakeholder engagement: More regular and broader consultation with external stakeholders is needed at the local level (from patient groups, local communities and health authorities to supply chain partners).  \n",
       "279                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The Global Head of Corporate Responsibility updates the GNCRC regularly on CR strategy and performance. This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed. If they had concerns about of water strategy these would be brought to the attention of the Board and the Executive Committee of the Novartis (ECN).  \n",
       "\n",
       "[280 rows x 9 columns]"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results_Novartis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [],
   "source": [
    "results_Novartis.to_csv('Results_Novartis.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Q_id</th>\n",
       "      <th>Company</th>\n",
       "      <th>Model</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Score</th>\n",
       "      <th>Doc_index</th>\n",
       "      <th>Context_Answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.46158153</td>\n",
       "      <td>2329</td>\n",
       "      <td>During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences. During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. Legal Proceedings Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.39178875</td>\n",
       "      <td>993</td>\n",
       "      <td>We also reviewed and updated our governance structure for managing human rights across our value chain. The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work. Quarterly EGC meetings provide a forum for updates on human rights topics, with an established process for elevating issues to the Johnson &amp; Johnson Executive Committee, our Board of Directors and Board Committees if warranted.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.38455927</td>\n",
       "      <td>954</td>\n",
       "      <td>• Clinical Data Transparency: We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries; publication of results in peer-reviewed journals; and sharing of clinical study reports and participant-level data from clinical trials. Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe. • Political Engagement: As a global healthcare company, we work with many stakeholders in the markets where we operate, and we take a stance on and support certain public policies in the United States and in different parts of the world as they relate to our core business of advancing health.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.38348675</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.37289336</td>\n",
       "      <td>1536</td>\n",
       "      <td>These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.40787455</td>\n",
       "      <td>1040</td>\n",
       "      <td>The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.39962035</td>\n",
       "      <td>1536</td>\n",
       "      <td>These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.39595923</td>\n",
       "      <td>1051</td>\n",
       "      <td>The Commonsense Principles XXX aspire to promote a constructive dialogue on good corporate governance to benefit the millions of . Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets. They are an updated version of the Commonsense Principles successfully launched in XXX to build momentum around the corporate governance conversation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA).</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3935492</td>\n",
       "      <td>903</td>\n",
       "      <td>Our compliance guidelines and policies meet or exceed legal and regulatory requirements in every jurisdiction where we operate. This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, Johnson &amp; Johnson actively participates in the work of industry associations, and helps develop industry codes for ethical and compliant marketing and selling of products.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.38491276</td>\n",
       "      <td>1377</td>\n",
       "      <td>Throughout Johnson &amp; Johnson’s history, we have maintained a strong, consistent andwe have maintained a strong, consistent andwe have maintained a strong, consistent and sustainable business. The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base. We are structured to meet the current and future needs of patients meet the current and future needs of patients meet the current and future needs of patients and consumers globally, and to address the and consumers globally, and to address the and consumers globally, and to address the challenges and opportunities that the worldchallenges and opportunities that the worldchallenges and opportunities that the world of healthcare presents.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4036158531671312</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.3691630723837139</td>\n",
       "      <td>1040</td>\n",
       "      <td>The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.3506139660462462</td>\n",
       "      <td>935</td>\n",
       "      <td>It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.33417458782649534</td>\n",
       "      <td>1932</td>\n",
       "      <td>Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>• Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2932092398258069</td>\n",
       "      <td>1041</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations. • Resources: The GPT assists operating companies with designating privacy resources, considering their local requirements and the risk environments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.38348675</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.34441066</td>\n",
       "      <td>1560</td>\n",
       "      <td>The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.33205885</td>\n",
       "      <td>935</td>\n",
       "      <td>It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28211266</td>\n",
       "      <td>1524</td>\n",
       "      <td>This Committee oversees and coordinates the activities of the Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Johnson &amp; Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.27888668</td>\n",
       "      <td>1521</td>\n",
       "      <td>The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. Johnson &amp; Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world. The Executive Committee of Johnson &amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "      <td>1</td>\n",
       "      <td>0.47936144</td>\n",
       "      <td>1525</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "      <td>2</td>\n",
       "      <td>0.47936144</td>\n",
       "      <td>1514</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.47532654</td>\n",
       "      <td>1521</td>\n",
       "      <td>Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3949507</td>\n",
       "      <td>1618</td>\n",
       "      <td>He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain. He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX Biosimilars have the potential to expand patient access to treatment and to create a more sustainable health care system.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.38917118</td>\n",
       "      <td>1586</td>\n",
       "      <td>She has held roles of increasing global responsibility throughout her career including site leadership, global strategic planning, contractor management, supply chain management and product portfolio leadership. Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States. She has been a member of the PGS Leadership Team since XXX and has represented PGS on several of Pfizer’s Business Leadership Teams.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Member of the American Society for Clinical Investigation and the Association of American Physicians.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.47606385</td>\n",
       "      <td>1495</td>\n",
       "      <td>Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.4706573</td>\n",
       "      <td>1521</td>\n",
       "      <td>Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.36455357</td>\n",
       "      <td>1553</td>\n",
       "      <td>Prior to joining Pfizer in 2009, Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.34432322</td>\n",
       "      <td>1513</td>\n",
       "      <td>He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.34432322</td>\n",
       "      <td>1524</td>\n",
       "      <td>He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>810</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4069019011783869</td>\n",
       "      <td>1684</td>\n",
       "      <td>We take a scientific approach to providing the educational, emotional and psychosocial resources that can help make a real difference in outcomes for cancer patients by leveraging insights and data to inform our content. We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers. To help patients better manage their lives with cancer, this year we launched Pfizer Oncology Together™, a first-of-its-kind program for patient access solutions and personalized support for those using Pfizer Oncology medicines in the U.S. As part of the program, patients will have access to a team of representatives with social work experience ‘Care Champions’ who provide support beyond traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>811</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.3302193053380653</td>\n",
       "      <td>1415</td>\n",
       "      <td>In addition, we implemented disaster relief protocols for our patient assistance programs, allowing existing patients who get their medicines through a Pfizer patient assistance program to request early refills or new shipping addresses, and temporarily waiving financial documentation requirements for eligible new patients who may have lost their paperwork in these crises or their aftermath. When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations. We provided colleagues who work at our Puerto Rico manufacturing and commercial sites with personal care kits, generators and other items to help them through the devastating situation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>812</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.24796468911997185</td>\n",
       "      <td>1820</td>\n",
       "      <td>Access our policy paper on our antibiotic stewardship, and read more about Pfizer’s leadership in the fight against AMR. Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers. While we experienced an increase in our injury rates in 2017, mainly as a result of increased slips, trips and falls and ergonomic injuries, overall our rates are low and comparable to industry benchmarks.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>813</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.19808354546703097</td>\n",
       "      <td>1034</td>\n",
       "      <td>It is only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all XXX states and the District of Columbia and administers all product donation programs for Pfizer. By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis. Available at: http://www.worldbank.org/en/news/pressrelease/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>814</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.17020474685648126</td>\n",
       "      <td>115</td>\n",
       "      <td>Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee. Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals. Pfizer supports the development and adoption of novel, non animal test methods for assessing the safety of new products that can reduce, replace or refine the use of animal testing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>815</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.75440013</td>\n",
       "      <td>146</td>\n",
       "      <td>http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential. That’s why we all share responsibility for reporting safety, quality or performance issues concerning Pfizer products.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>816</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.7390721</td>\n",
       "      <td>145</td>\n",
       "      <td>Competitively sensitive information may not be discussed with friends or former colleagues employed by competitor companies whether in a business or a social setting. http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>817</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6721467</td>\n",
       "      <td>345</td>\n",
       "      <td>Our Commitment…12 \\tHealthcare Laws and Regulatory Requirements…12 \\tAnti-Bribery and Anti-Corruption…13 \\tResearch and Development…15 \\tManufacturing and Supply Quality…17 \\tInteractions with Patients and Patient Organizations…18. The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20. Our Commitment…22 \\tPatents, Trademarks and Copyrights…22 \\tBooks and Record Keeping…22 \\tConfidential and Proprietary Information…23 \\tPrivacy of Personal Data…25 \\tRecords and Information Management…26 \\tAcceptable Use of Information Systems…27 \\tConflicts of Interest…28 \\tSocial Media…30 \\tInside Information…31 \\tCompetitive Intelligence…32 \\tGlobal Trade Control Laws…33.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>818</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.5399316</td>\n",
       "      <td>1226</td>\n",
       "      <td>With XXX manufacturing sites around the world under Pfizer Global Supply (PGS), we harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines. Leveraging Science to Create Supply Chain Solutions Pfizer’s goal is for patients to receive uninterrupted access to our medicines and vaccines.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>819</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.5385889</td>\n",
       "      <td>113</td>\n",
       "      <td>We are committed to the development of publications that report the results of Company-sponsored clinical research studies accurately and objectively and to the disclosure of funding and editorial support. Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted. Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>820</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6585443</td>\n",
       "      <td>1114</td>\n",
       "      <td>What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments. I interact regularly at work calls me and mentions that a patient of hers on Roche drug X was recently hospitalised with pneumonia and died.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>821</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.6315596</td>\n",
       "      <td>1001</td>\n",
       "      <td>The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>822</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6132648</td>\n",
       "      <td>1113</td>\n",
       "      <td>– Immediately report customer complaints relating to Roche medical devices to the local regulatory and quality function. What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>823</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Help &amp; advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.60540605</td>\n",
       "      <td>1118</td>\n",
       "      <td>A In case of an adverse event you should report at least the following four elements: Patient, Reporter, Event and Product (PREP). Help &amp; advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g. Speak up: If you believe in good faith that in connection with business where Roche is involved someone has done, is doing, or may be about to do something that violates quality standards and good practices, speak up by using the available speak up channels.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>824</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.6024178</td>\n",
       "      <td>588</td>\n",
       "      <td>Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>825</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.37645185</td>\n",
       "      <td>994</td>\n",
       "      <td>A cross-divisional working group has established a checklist on Due Diligence for External Business Partners, mainly focusing on agents and distributors. It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework. We maintain and improve operational-level grievance mechanisms, which we understand to encompass also a preventive function.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>826</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>– Contact the related expert department in a timely manner in case of questions or to address an error.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.31262755</td>\n",
       "      <td>1319</td>\n",
       "      <td>– Check for compliance with national and international customs, trade and export control regulations when developing and adapting processes. – Contact the related expert department in a timely manner in case of questions or to address an error. A Every employee asking for the shipment of goods is accountable for providing complete and truthful information for export or import processing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>827</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.29044554</td>\n",
       "      <td>1553</td>\n",
       "      <td>If the remuneration is not commensurate with the services provided, you should not accept the consultant’s request. Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution. Roche protects human rights and does not tolerate behaviour by its business partners which is not in line with applicable laws and generally accepted sustainability standards.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>828</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>It contains the annual financial statements, consolidated financial statements and non­financial performance indicators.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28880537</td>\n",
       "      <td>22</td>\n",
       "      <td>Our financial and non­financial reporting consists of the Annual Report, the Finance Report and the online report. It contains the annual financial statements, consolidated financial statements and non­financial performance indicators. The financial reporting scope is defined and outlined in our Finance Report, and there have been no significant changes in scope in XXX compared to XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>829</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.286755</td>\n",
       "      <td>1324</td>\n",
       "      <td>You should seek guidance from your local logistics department and your local Export Control Officer before processing any shipment. A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation. A Roche does not tolerate any violation of the regulations and will take appropriate corrective measures and sanctions.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>830</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.20979829278490708</td>\n",
       "      <td>1008</td>\n",
       "      <td>Our challenge is to focus our efforts where we see the biggest risks and the biggest levers for remediation and improvement. On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses. We maintain a system of consistent global standards, which we also apply to our business partners, for example, in areas like R&amp;D, clinical trials, manufacturing and distribution.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>831</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.17727548268874965</td>\n",
       "      <td>1337</td>\n",
       "      <td>Corporate Integrity Q I work in a clinical research unit and have access to identifiable health information which I would like to share with a colleague. A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence. As a Roche employee you have a strict obligation to treat such information as confidential and to share it only with colleagues who need to know in order to do their work, in accordance with the purpose the data was obtained for and only if and as allowed under applicable law.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>832</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.1638004762981347</td>\n",
       "      <td>1331</td>\n",
       "      <td>Roche is committed to respecting data privacy and has developed principles that must be consistently applied when processing personal data within the Roche Group and by its business partners. Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed. Roche takes due care to prevent any misuse of or unauthorised access to such identifiable health information within its control.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>833</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We are all encouraged to identify areas for improvements and continuously work towards a better environment.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.16292468426596937</td>\n",
       "      <td>1390</td>\n",
       "      <td>Every employee is personally responsible for safety, security, health and environmental protection at the workplace to the full extent required by his/her duties to the best of his/her knowledge, ability and experience. We are all encouraged to identify areas for improvements and continuously work towards a better environment. As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>834</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We identified human rights which are potentially susceptible to violations, as well as their associated risks.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.1151118637289961</td>\n",
       "      <td>710</td>\n",
       "      <td>We do this by assessing the risks of potential violations, promoting awareness, fostering due diligence, strengthening the legal framework and collaborating on collective actions, and transparent communication. We identified human rights which are potentially susceptible to violations, as well as their associated risks. To enhance awareness, we created a video that explained human rights and Roche’s endeavours with a simple message to our employees: ‘Within your sphere of influence, ensure human rights are respected.’.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>835</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6315596</td>\n",
       "      <td>1001</td>\n",
       "      <td>The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>836</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.6024178</td>\n",
       "      <td>588</td>\n",
       "      <td>Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>837</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.5972139</td>\n",
       "      <td>1385</td>\n",
       "      <td>As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment. Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices. We take all reasonable and practical steps to ensure that we provide a safe, secure, healthy and clean working environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>838</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.58856523</td>\n",
       "      <td>1394</td>\n",
       "      <td>If a meeting in person is needed, reduce the number of participants – send a competent representative instead of a whole team. We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience. In addition, the book “Lifesavers for millions” has been published by Editiones Roche, Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding intellectual property rights, speak up by using the available speak up channels.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>839</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.5406029</td>\n",
       "      <td>717</td>\n",
       "      <td>These include excessive overtime, improper pay for overtime, insufficient number of rest days, and inadequate payment of social benefits. For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment. The RocheAbility network, for instance, fosters the inclusion of Basel and Kaiseraugst employees with disabilities and focuses on the strengths and abilities of each individual.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>840 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                    Question  \\\n",
       "0                           Does the company operate in countries out of the European Union?   \n",
       "1                           Does the company operate in countries out of the European Union?   \n",
       "2                           Does the company operate in countries out of the European Union?   \n",
       "3                           Does the company operate in countries out of the European Union?   \n",
       "4                           Does the company operate in countries out of the European Union?   \n",
       "5                           Does the company operate in countries out of the European Union?   \n",
       "6                           Does the company operate in countries out of the European Union?   \n",
       "7                           Does the company operate in countries out of the European Union?   \n",
       "8                           Does the company operate in countries out of the European Union?   \n",
       "9                           Does the company operate in countries out of the European Union?   \n",
       "10                          Does the company operate in countries out of the European Union?   \n",
       "11                          Does the company operate in countries out of the European Union?   \n",
       "12                          Does the company operate in countries out of the European Union?   \n",
       "13                          Does the company operate in countries out of the European Union?   \n",
       "14                          Does the company operate in countries out of the European Union?   \n",
       "15                          Does the company operate in countries out of the European Union?   \n",
       "16                          Does the company operate in countries out of the European Union?   \n",
       "17                          Does the company operate in countries out of the European Union?   \n",
       "18                          Does the company operate in countries out of the European Union?   \n",
       "19                          Does the company operate in countries out of the European Union?   \n",
       "20                          Does the company operate in countries out of the European Union?   \n",
       "21                          Does the company operate in countries out of the European Union?   \n",
       "22                          Does the company operate in countries out of the European Union?   \n",
       "23                          Does the company operate in countries out of the European Union?   \n",
       "24                          Does the company operate in countries out of the European Union?   \n",
       "25                          Does the company operate in countries out of the European Union?   \n",
       "26                          Does the company operate in countries out of the European Union?   \n",
       "27                          Does the company operate in countries out of the European Union?   \n",
       "28                          Does the company operate in countries out of the European Union?   \n",
       "29                          Does the company operate in countries out of the European Union?   \n",
       "..                                                                                       ...   \n",
       "810  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "811  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "812  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "813  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "814  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "815  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "816  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "817  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "818  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "819  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "820  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "821  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "822  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "823  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "824  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "825  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "826  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "827  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "828  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "829  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "830  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "831  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "832  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "833  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "834  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "835  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "836  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "837  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "838  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "839  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "\n",
       "     Q_id  Company                          Model  \\\n",
       "0       1  Johnson             Bert - transformer   \n",
       "1       1  Johnson             Bert - transformer   \n",
       "2       1  Johnson             Bert - transformer   \n",
       "3       1  Johnson             Bert - transformer   \n",
       "4       1  Johnson             Bert - transformer   \n",
       "5       1  Johnson              Infersent Bi-Lstm   \n",
       "6       1  Johnson              Infersent Bi-Lstm   \n",
       "7       1  Johnson              Infersent Bi-Lstm   \n",
       "8       1  Johnson              Infersent Bi-Lstm   \n",
       "9       1  Johnson              Infersent Bi-Lstm   \n",
       "10      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "11      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "12      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "13      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "14      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "15      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "16      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "17      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "18      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "19      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "20      1   Pfizer             Bert - transformer   \n",
       "21      1   Pfizer             Bert - transformer   \n",
       "22      1   Pfizer             Bert - transformer   \n",
       "23      1   Pfizer             Bert - transformer   \n",
       "24      1   Pfizer             Bert - transformer   \n",
       "25      1   Pfizer              Infersent Bi-Lstm   \n",
       "26      1   Pfizer              Infersent Bi-Lstm   \n",
       "27      1   Pfizer              Infersent Bi-Lstm   \n",
       "28      1   Pfizer              Infersent Bi-Lstm   \n",
       "29      1   Pfizer              Infersent Bi-Lstm   \n",
       "..    ...      ...                            ...   \n",
       "810    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "811    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "812    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "813    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "814    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "815    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "816    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "817    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "818    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "819    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "820    14    Roche             Bert - transformer   \n",
       "821    14    Roche             Bert - transformer   \n",
       "822    14    Roche             Bert - transformer   \n",
       "823    14    Roche             Bert - transformer   \n",
       "824    14    Roche             Bert - transformer   \n",
       "825    14    Roche              Infersent Bi-Lstm   \n",
       "826    14    Roche              Infersent Bi-Lstm   \n",
       "827    14    Roche              Infersent Bi-Lstm   \n",
       "828    14    Roche              Infersent Bi-Lstm   \n",
       "829    14    Roche              Infersent Bi-Lstm   \n",
       "830    14    Roche            Tf-Idf + Lemmatizer   \n",
       "831    14    Roche            Tf-Idf + Lemmatizer   \n",
       "832    14    Roche            Tf-Idf + Lemmatizer   \n",
       "833    14    Roche            Tf-Idf + Lemmatizer   \n",
       "834    14    Roche            Tf-Idf + Lemmatizer   \n",
       "835    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "836    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "837    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "838    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "839    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                        Answer  \\\n",
       "0                                                                                                 During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands.   \n",
       "1                                                                                                                                                         The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work.   \n",
       "2                Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe.   \n",
       "3                                                                                                                                                                                                          The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "4                                                                                                                                                                                                                  The products sold in international business include those developed in the U.S. and by subsidiaries abroad.   \n",
       "5                                                                                                                                                                                                                     Policies in accordance with new requirements or changes in the law of the countries in which we operate.   \n",
       "6                                                                                                                                                                                                                  The products sold in international business include those developed in the U.S. and by subsidiaries abroad.   \n",
       "7                                                                                                                                                                       Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets.   \n",
       "8    This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA).   \n",
       "9                                                                                                                                                                                                   The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base.   \n",
       "10                                                                                                                                                                                                         The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "11                                                                                                                                                                                                                    Policies in accordance with new requirements or changes in the law of the countries in which we operate.   \n",
       "12                                                                                                                                                                                               They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.   \n",
       "13                                                                                                                                     However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.   \n",
       "14                                                                                                                   • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.   \n",
       "15                                                                                                                                                                                                         The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "16                                                                                                                   The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.   \n",
       "17                                                                                                                                                                                               They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.   \n",
       "18                                                                                      Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.   \n",
       "19                                                                                                                                                                            Johnson & Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world.   \n",
       "20                                                                                                                                                     He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX   \n",
       "21                                                                                                                                                     He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX   \n",
       "22                                                                                                                                                          Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.   \n",
       "23                                                                                                                                                  He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX   \n",
       "24                                                                                                                                                Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States.   \n",
       "25                                                                                                                                                                                                                       Member of the American Society for Clinical Investigation and the Association of American Physicians.   \n",
       "26                                                                                                                                                          Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.   \n",
       "27                                                                                                                                           Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors.   \n",
       "28                                                                                                                                                                                      In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.   \n",
       "29                                                                                                                                                                                      In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.   \n",
       "..                                                                                                                                                                                                                                                                                                                         ...   \n",
       "810                                                                                                                                                We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers.   \n",
       "811                                     When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations.   \n",
       "812                                                                                                                                                                               Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers.   \n",
       "813                                                                                                                                                                                                                    By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis.   \n",
       "814                                                                                                                                         Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals.   \n",
       "815                                                                                                                                                                                                            Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.   \n",
       "816                                                                                                                                                                                                            http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products.   \n",
       "817                                                                                                                                    The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20.   \n",
       "818                                                                                                                                                                          In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines.   \n",
       "819                                                                                                        Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted.   \n",
       "820                                                                                                     If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.   \n",
       "821                                                                                                                                                                          As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "822                                                                                                                                                                                                         What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?.   \n",
       "823                                                                                                   Help & advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g.   \n",
       "824                                                                                                                                                                                                           At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.   \n",
       "825                                                                                                                                                                                                        It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework.   \n",
       "826                                                                                                                                                                                                                    – Contact the related expert department in a timely manner in case of questions or to address an error.   \n",
       "827                                                                                                                                                                                                                  Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution.   \n",
       "828                                                                                                                                                                                                   It contains the annual financial statements, consolidated financial statements and non­financial performance indicators.   \n",
       "829                                                                                                                                                       A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation.   \n",
       "830                                                                                                                                                                    On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.   \n",
       "831                                                                                                                                                                            A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence.   \n",
       "832                                                                                                                                                                                              Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.   \n",
       "833                                                                                                                                                                                                               We are all encouraged to identify areas for improvements and continuously work towards a better environment.   \n",
       "834                                                                                                                                                                                                             We identified human rights which are potentially susceptible to violations, as well as their associated risks.   \n",
       "835                                                                                                                                                                          As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "836                                                                                                                                                                                                           At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.   \n",
       "837                                                                                                                                                      Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices.   \n",
       "838                                                                                                                                                        We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience.   \n",
       "839                                                                                   For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment.   \n",
       "\n",
       "    Rank                Score Doc_index  \\\n",
       "0      1           0.46158153      2329   \n",
       "1      2           0.39178875       993   \n",
       "2      3           0.38455927       954   \n",
       "3      4           0.38348675      1925   \n",
       "4      5           0.37289336      1536   \n",
       "5      1           0.40787455      1040   \n",
       "6      2           0.39962035      1536   \n",
       "7      3           0.39595923      1051   \n",
       "8      4            0.3935492       903   \n",
       "9      5           0.38491276      1377   \n",
       "10     1   0.4036158531671312      1925   \n",
       "11     2   0.3691630723837139      1040   \n",
       "12     3   0.3506139660462462       935   \n",
       "13     4  0.33417458782649534      1932   \n",
       "14     5   0.2932092398258069      1041   \n",
       "15     1           0.38348675      1925   \n",
       "16     2           0.34441066      1560   \n",
       "17     3           0.33205885       935   \n",
       "18     4           0.28211266      1524   \n",
       "19     5           0.27888668      1521   \n",
       "20     1           0.47936144      1525   \n",
       "21     2           0.47936144      1514   \n",
       "22     3           0.47532654      1521   \n",
       "23     4            0.3949507      1618   \n",
       "24     5           0.38917118      1586   \n",
       "25     1           0.47606385      1495   \n",
       "26     2            0.4706573      1521   \n",
       "27     3           0.36455357      1553   \n",
       "28     4           0.34432322      1513   \n",
       "29     5           0.34432322      1524   \n",
       "..   ...                  ...       ...   \n",
       "810    1   0.4069019011783869      1684   \n",
       "811    2   0.3302193053380653      1415   \n",
       "812    3  0.24796468911997185      1820   \n",
       "813    4  0.19808354546703097      1034   \n",
       "814    5  0.17020474685648126       115   \n",
       "815    1           0.75440013       146   \n",
       "816    2            0.7390721       145   \n",
       "817    3            0.6721467       345   \n",
       "818    4            0.5399316      1226   \n",
       "819    5            0.5385889       113   \n",
       "820    1            0.6585443      1114   \n",
       "821    2            0.6315596      1001   \n",
       "822    3            0.6132648      1113   \n",
       "823    4           0.60540605      1118   \n",
       "824    5            0.6024178       588   \n",
       "825    1           0.37645185       994   \n",
       "826    2           0.31262755      1319   \n",
       "827    3           0.29044554      1553   \n",
       "828    4           0.28880537        22   \n",
       "829    5             0.286755      1324   \n",
       "830    1  0.20979829278490708      1008   \n",
       "831    2  0.17727548268874965      1337   \n",
       "832    3   0.1638004762981347      1331   \n",
       "833    4  0.16292468426596937      1390   \n",
       "834    5   0.1151118637289961       710   \n",
       "835    1            0.6315596      1001   \n",
       "836    2            0.6024178       588   \n",
       "837    3            0.5972139      1385   \n",
       "838    4           0.58856523      1394   \n",
       "839    5            0.5406029       717   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Context_Answer  \n",
       "0                                                                                                                                                                                                                                                        During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences. During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.  \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                     We also reviewed and updated our governance structure for managing human rights across our value chain. The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work. Quarterly EGC meetings provide a forum for updates on human rights topics, with an established process for elevating issues to the Johnson & Johnson Executive Committee, our Board of Directors and Board Committees if warranted.  \n",
       "2    • Clinical Data Transparency: We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries; publication of results in peer-reviewed journals; and sharing of clinical study reports and participant-level data from clinical trials. Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe. • Political Engagement: As a global healthcare company, we work with many stakeholders in the markets where we operate, and we take a stance on and support certain public policies in the United States and in different parts of the world as they relate to our core business of advancing health.  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "4                                                                                                                                                                                                                                                                                                                                 These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.  \n",
       "5                                                                                                                                                                                                                                                                                                                                                                       The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.  \n",
       "6                                                                                                                                                                                                                                                                                                                                 These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     The Commonsense Principles XXX aspire to promote a constructive dialogue on good corporate governance to benefit the millions of . Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets. They are an updated version of the Commonsense Principles successfully launched in XXX to build momentum around the corporate governance conversation.  \n",
       "8                                                                                                                                                                                                                                                                                                                   Our compliance guidelines and policies meet or exceed legal and regulatory requirements in every jurisdiction where we operate. This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, Johnson & Johnson actively participates in the work of industry associations, and helps develop industry codes for ethical and compliant marketing and selling of products.  \n",
       "9                                                                                                                                                                                 Throughout Johnson & Johnson’s history, we have maintained a strong, consistent andwe have maintained a strong, consistent andwe have maintained a strong, consistent and sustainable business. The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base. We are structured to meet the current and future needs of patients meet the current and future needs of patients meet the current and future needs of patients and consumers globally, and to address the and consumers globally, and to address the and consumers globally, and to address the challenges and opportunities that the worldchallenges and opportunities that the worldchallenges and opportunities that the world of healthcare presents.  \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "11                                                                                                                                                                                                                                                                                                                                                                      The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.  \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.  \n",
       "13                                                                                                                                                                                                                                                                                                                                                                           Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.  \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations. • Resources: The GPT assists operating companies with designating privacy resources, considering their local requirements and the risk environments.  \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "16                                                                                                                                                                                                                                          The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.  \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                  This Committee oversees and coordinates the activities of the Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.  \n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                                                               The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. Johnson & Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world. The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.  \n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.  \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.  \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                               Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.  \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                               He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain. He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX Biosimilars have the potential to expand patient access to treatment and to create a more sustainable health care system.  \n",
       "24                                                                                                                                                                                                                                                                                                                                                                                                                               She has held roles of increasing global responsibility throughout her career including site leadership, global strategic planning, contractor management, supply chain management and product portfolio leadership. Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States. She has been a member of the PGS Leadership Team since XXX and has represented PGS on several of Pfizer’s Business Leadership Teams.  \n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association.  \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                               Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.  \n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Prior to joining Pfizer in 2009, Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council.  \n",
       "28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX  \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX  \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ...  \n",
       "810        We take a scientific approach to providing the educational, emotional and psychosocial resources that can help make a real difference in outcomes for cancer patients by leveraging insights and data to inform our content. We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers. To help patients better manage their lives with cancer, this year we launched Pfizer Oncology Together™, a first-of-its-kind program for patient access solutions and personalized support for those using Pfizer Oncology medicines in the U.S. As part of the program, patients will have access to a team of representatives with social work experience ‘Care Champions’ who provide support beyond traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs.  \n",
       "811                                                                        In addition, we implemented disaster relief protocols for our patient assistance programs, allowing existing patients who get their medicines through a Pfizer patient assistance program to request early refills or new shipping addresses, and temporarily waiving financial documentation requirements for eligible new patients who may have lost their paperwork in these crises or their aftermath. When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations. We provided colleagues who work at our Puerto Rico manufacturing and commercial sites with personal care kits, generators and other items to help them through the devastating situation.  \n",
       "812                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Access our policy paper on our antibiotic stewardship, and read more about Pfizer’s leadership in the fight against AMR. Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers. While we experienced an increase in our injury rates in 2017, mainly as a result of increased slips, trips and falls and ergonomic injuries, overall our rates are low and comparable to industry benchmarks.  \n",
       "813                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   It is only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all XXX states and the District of Columbia and administers all product donation programs for Pfizer. By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis. Available at: http://www.worldbank.org/en/news/pressrelease/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis XXX  \n",
       "814                                                                                                                                                                                                                                                                                                                                                                                      Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee. Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals. Pfizer supports the development and adoption of novel, non animal test methods for assessing the safety of new products that can reduce, replace or refine the use of animal testing.  \n",
       "815                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential. That’s why we all share responsibility for reporting safety, quality or performance issues concerning Pfizer products.  \n",
       "816                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Competitively sensitive information may not be discussed with friends or former colleagues employed by competitor companies whether in a business or a social setting. http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.  \n",
       "817                                                                                                                                          Our Commitment…12 \\tHealthcare Laws and Regulatory Requirements…12 \\tAnti-Bribery and Anti-Corruption…13 \\tResearch and Development…15 \\tManufacturing and Supply Quality…17 \\tInteractions with Patients and Patient Organizations…18. The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20. Our Commitment…22 \\tPatents, Trademarks and Copyrights…22 \\tBooks and Record Keeping…22 \\tConfidential and Proprietary Information…23 \\tPrivacy of Personal Data…25 \\tRecords and Information Management…26 \\tAcceptable Use of Information Systems…27 \\tConflicts of Interest…28 \\tSocial Media…30 \\tInside Information…31 \\tCompetitive Intelligence…32 \\tGlobal Trade Control Laws…33.  \n",
       "818                                                                                                                                                                                                                                                                                                                                                                                    With XXX manufacturing sites around the world under Pfizer Global Supply (PGS), we harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines. Leveraging Science to Create Supply Chain Solutions Pfizer’s goal is for patients to receive uninterrupted access to our medicines and vaccines.  \n",
       "819                                                                                                                                                                                                                                                                                                                             We are committed to the development of publications that report the results of Company-sponsored clinical research studies accurately and objectively and to the disclosure of funding and editorial support. Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted. Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee.  \n",
       "820                                                                                                                                                                                                                                                                                                                                                                                                                                                                             What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments. I interact regularly at work calls me and mentions that a patient of hers on Roche drug X was recently hospitalised with pneumonia and died.  \n",
       "821                                                                                                                                                                                                                                                 The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.  \n",
       "822                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 – Immediately report customer complaints relating to Roche medical devices to the local regulatory and quality function. What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.  \n",
       "823                                                                                                                                                                                                                                                                                                                                     A In case of an adverse event you should report at least the following four elements: Patient, Reporter, Event and Product (PREP). Help & advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g. Speak up: If you believe in good faith that in connection with business where Roche is involved someone has done, is doing, or may be about to do something that violates quality standards and good practices, speak up by using the available speak up channels.  \n",
       "824                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.  \n",
       "825                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         A cross-divisional working group has established a checklist on Due Diligence for External Business Partners, mainly focusing on agents and distributors. It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework. We maintain and improve operational-level grievance mechanisms, which we understand to encompass also a preventive function.  \n",
       "826                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             – Check for compliance with national and international customs, trade and export control regulations when developing and adapting processes. – Contact the related expert department in a timely manner in case of questions or to address an error. A Every employee asking for the shipment of goods is accountable for providing complete and truthful information for export or import processing.  \n",
       "827                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      If the remuneration is not commensurate with the services provided, you should not accept the consultant’s request. Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution. Roche protects human rights and does not tolerate behaviour by its business partners which is not in line with applicable laws and generally accepted sustainability standards.  \n",
       "828                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Our financial and non­financial reporting consists of the Annual Report, the Finance Report and the online report. It contains the annual financial statements, consolidated financial statements and non­financial performance indicators. The financial reporting scope is defined and outlined in our Finance Report, and there have been no significant changes in scope in XXX compared to XXX  \n",
       "829                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   You should seek guidance from your local logistics department and your local Export Control Officer before processing any shipment. A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation. A Roche does not tolerate any violation of the regulations and will take appropriate corrective measures and sanctions.  \n",
       "830                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Our challenge is to focus our efforts where we see the biggest risks and the biggest levers for remediation and improvement. On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses. We maintain a system of consistent global standards, which we also apply to our business partners, for example, in areas like R&D, clinical trials, manufacturing and distribution.  \n",
       "831                                                                                                                                                                                                                                                                                                                                                                    Corporate Integrity Q I work in a clinical research unit and have access to identifiable health information which I would like to share with a colleague. A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence. As a Roche employee you have a strict obligation to treat such information as confidential and to share it only with colleagues who need to know in order to do their work, in accordance with the purpose the data was obtained for and only if and as allowed under applicable law.  \n",
       "832                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Roche is committed to respecting data privacy and has developed principles that must be consistently applied when processing personal data within the Roche Group and by its business partners. Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed. Roche takes due care to prevent any misuse of or unauthorised access to such identifiable health information within its control.  \n",
       "833                                                                                                                                                                                                                                                                                                                                                                                                                                      Every employee is personally responsible for safety, security, health and environmental protection at the workplace to the full extent required by his/her duties to the best of his/her knowledge, ability and experience. We are all encouraged to identify areas for improvements and continuously work towards a better environment. As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment.  \n",
       "834                                                                                                                                                                                                                                                                                                                                                                                                                       We do this by assessing the risks of potential violations, promoting awareness, fostering due diligence, strengthening the legal framework and collaborating on collective actions, and transparent communication. We identified human rights which are potentially susceptible to violations, as well as their associated risks. To enhance awareness, we created a video that explained human rights and Roche’s endeavours with a simple message to our employees: ‘Within your sphere of influence, ensure human rights are respected.’.  \n",
       "835                                                                                                                                                                                                                                                 The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.  \n",
       "836                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.  \n",
       "837                                                                                                                                                                                                                                                                                                                                                                                                                                                                             As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment. Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices. We take all reasonable and practical steps to ensure that we provide a safe, secure, healthy and clean working environment.  \n",
       "838                                                                                                                                                                                                                                                                                    If a meeting in person is needed, reduce the number of participants – send a competent representative instead of a whole team. We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience. In addition, the book “Lifesavers for millions” has been published by Editiones Roche, Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding intellectual property rights, speak up by using the available speak up channels.  \n",
       "839                                                                                                                                                                                                                                                                                                                                                                                               These include excessive overtime, improper pay for overtime, insufficient number of rest days, and inadequate payment of social benefits. For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment. The RocheAbility network, for instance, fosters the inclusion of Basel and Kaiseraugst employees with disabilities and focuses on the strengths and abilities of each individual.  \n",
       "\n",
       "[840 rows x 9 columns]"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results_PfizerRocheJohnson"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [],
   "source": [
    "def func_add_context(row):\n",
    "    if row.Company=='Pfizer':\n",
    "        row['Context_Answer']=' '.join([QAmodel.contents_doc[2][1][int(row.Doc_index)-1],row.Answer,QAmodel.contents_doc[2][1][int(row.Doc_index)+1]])\n",
    "    elif row.Company=='Johnson':\n",
    "        row['Context_Answer']=' '.join([QAmodel.contents_doc[1][1][int(row.Doc_index)-1],row.Answer,QAmodel.contents_doc[1][1][int(row.Doc_index)+1]])\n",
    "    else:\n",
    "        row['Context_Answer']=' '.join([QAmodel.contents_doc[0][1][int(row.Doc_index)-1],row.Answer,QAmodel.contents_doc[0][1][int(row.Doc_index)+1]])\n",
    "    return row\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [],
   "source": [
    "results_Novartis=results_Novartis.apply(func_add_context,axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Q_id</th>\n",
       "      <th>Company</th>\n",
       "      <th>Model</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Score</th>\n",
       "      <th>Doc_index</th>\n",
       "      <th>Context_Answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.57026166</td>\n",
       "      <td>2499</td>\n",
       "      <td>• The FDA may also request that a sponsor conduct pediatric studies, and in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended. Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.5109576</td>\n",
       "      <td>2459</td>\n",
       "      <td>Increasingly strict analyses are applied when evaluating the entry of new products, and as a result, access to innovative medicines is limited based on strict cost-benefit assessments. In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing. As an additional control for healthcare budgets, some EU countries have passed legislation to impose further mandatory rebates for pharmaceutical products and/or financial claw-backs on the pharmaceutical industry.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.48538196</td>\n",
       "      <td>2637</td>\n",
       "      <td>However, generic applicants must launch their products within certain timeframes or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant. In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure. Companies may submit Abridged Applications for approval of a generic medicinal product based upon its “essential similarity” to a medicinal product authorized and marketed in the EU following the expiration of the product’s data exclusivity period.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.48038045</td>\n",
       "      <td>226</td>\n",
       "      <td>Threats to the business include rising costs due to carbon pricing frameworks designed to achieve climate mitigation, risks to reputation if we don't behave as a responsible corporate citizen, loss of biodiversity that will disrupt our supply chain and the physical impacts from climate change that will introduce risk into our sites, the communities we serve and our patients. These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets. Increased costs could impact the bottom line and reduce funding for research and development of new drugs.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.480069</td>\n",
       "      <td>1928</td>\n",
       "      <td>The EU also adopted a new Directive on Administrative Cooperation (DAC6) in 2018, which seeks additional reporting. In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies. These OECD and EU tax reform initiatives also need local country implementation, including in our home country of Switzerland, which may result in significant changes to established tax principles.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4667485</td>\n",
       "      <td>2227</td>\n",
       "      <td>In the EU, Galvus received approval for expanded use as a second-line monotherapy for type  XXX diabetes patients who cannot take metformin. Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America. Diovan is the only agent in its class approved to treat all of the following: patients with high blood pressure (including children XXX to 18 years old), high-risk heart attack survivors, and patients with heart failure.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.4663378</td>\n",
       "      <td>2130</td>\n",
       "      <td>In addition, we are now able to reduce the time lag between availability of medicines in higher- and lower-income countries. For example, the first Entresto local brand was launched within XXX months of the launch in the European Union. Through our Novartis Social Business (NSB) group, we continue to pursue unique social business models, such as the Novartis Access and Healthy Family programs, to help expand access to healthcare in lower-income countries.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.4505594</td>\n",
       "      <td>2683</td>\n",
       "      <td>In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs, diagnostic ophthalmics, and other disposable products for cataract and vitreoretinal surgery. The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe. Sales of the vast majority of our Alcon Division products are not subject to material changes in seasonal demand.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.42783558</td>\n",
       "      <td>1920</td>\n",
       "      <td>Post-employment benefits for associates.” See also “—Political and economic instability may have a material adverse effect on our results,” above. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.42783558</td>\n",
       "      <td>3103</td>\n",
       "      <td>Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6198342429415247</td>\n",
       "      <td>2416</td>\n",
       "      <td>The procedure used for first authorization must continue to be followed for subsequent changes, e.g., to add an indication for a licensed product. Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states). It is optional for other new chemical entities, innovative medicinal products, and medicines for which authorization would be in the interest of public health.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.5869482063619555</td>\n",
       "      <td>2130</td>\n",
       "      <td>In addition, we are now able to reduce the time lag between availability of medicines in higher- and lower-income countries. For example, the first Entresto local brand was launched within XXX months of the launch in the European Union. Through our Novartis Social Business (NSB) group, we continue to pursue unique social business models, such as the Novartis Access and Healthy Family programs, to help expand access to healthcare in lower-income countries.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>In addition, it does not sell short assets it does not have, or does not know it will have, in the future.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.39312472620836497</td>\n",
       "      <td>4628</td>\n",
       "      <td>It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3019442945156682</td>\n",
       "      <td>882</td>\n",
       "      <td>However, we believe that the system needs to help ensure a fair balance between promoting creative and innovative activity and returning value to society. For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries. In late 2018, we reviewed our approach to patent filing in low- and middle income countries (LMICs) in an effort to better align it with the local socioeconomic circumstances that exist in many of these countries.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2949217573271527</td>\n",
       "      <td>4655</td>\n",
       "      <td>In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk. Liquidity risk Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations on time or at a reasonable price.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.30886894</td>\n",
       "      <td>2485</td>\n",
       "      <td>The protection offered by such patents extends for varying periods, depending on the grant and duration of patents in the various jurisdictions. In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries. In addition to patent protection, various countries offer data or marketing exclusivities for a prescribed period of time.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.29680955</td>\n",
       "      <td>1920</td>\n",
       "      <td>Post-employment benefits for associates.” See also “—Political and economic instability may have a material adverse effect on our results,” above. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.29680955</td>\n",
       "      <td>3103</td>\n",
       "      <td>Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28595233</td>\n",
       "      <td>3104</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions. The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX</td>\n",
       "      <td>5</td>\n",
       "      <td>0.28595233</td>\n",
       "      <td>1921</td>\n",
       "      <td>Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>At the same time, other companies with specialized expertise or business models are entering the Item XXX</td>\n",
       "      <td>1</td>\n",
       "      <td>0.54087555</td>\n",
       "      <td>1835</td>\n",
       "      <td>In order to succeed, we will be required to encourage a cultural change among our employees, attract and retain employees with appropriate skills and mindset, and successfully innovate across a variety of technology fields. At the same time, other companies with specialized expertise or business models are entering the Item XXX Key Information 18healthcare field, from research and development to pharmaceutical distribution, potentially disrupting our relationships with patients, healthcare professionals, customers, distributors and suppliers, with unknown potential consequences for us.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.51713026</td>\n",
       "      <td>2747</td>\n",
       "      <td>The scope of copyright protection for computer software varies throughout the world, although it is generally for a fixed term that begins on the date of copyright registration. Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world. Some of our principal facilities are subject to mortgages and other security interests granted to secure indebtedness to certain financial institutions.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.51357496</td>\n",
       "      <td>4514</td>\n",
       "      <td>Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans. In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.49095944</td>\n",
       "      <td>2393</td>\n",
       "      <td>These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development. Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.48801655</td>\n",
       "      <td>2499</td>\n",
       "      <td>• The FDA may also request that a sponsor conduct pediatric studies, and in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended. Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.32053015</td>\n",
       "      <td>2227</td>\n",
       "      <td>In the EU, Galvus received approval for expanded use as a second-line monotherapy for type  XXX diabetes patients who cannot take metformin. Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America. Diovan is the only agent in its class approved to treat all of the following: patients with high blood pressure (including children XXX to 18 years old), high-risk heart attack survivors, and patients with heart failure.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.31352153</td>\n",
       "      <td>843</td>\n",
       "      <td>The program was evaluated, and the results were published in a research paper in BMC Medical Education. There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector. It improves our understanding of global healthcare challenges while providing young scientists with skills, knowledge, tools and inspiration to improve healthcare in their communities.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.30220336</td>\n",
       "      <td>2785</td>\n",
       "      <td>Our strategy is to focus Novartis as a leading medicines company powered by advanced therapy platforms and data science. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In June 2018, we announced that we plan to spin off Alcon into a separately-traded standalone company.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.30220336</td>\n",
       "      <td>2094</td>\n",
       "      <td>In compliance with IFRS, beginning with our first-quarter XXX results, Novartis updated its segment financial information to reflect this transfer, both for the current and prior years, to aid comparability of year on year results. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>2</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2962501</td>\n",
       "      <td>1981</td>\n",
       "      <td>As a result, we could experience increased production or other costs, business interruptions, destruction of facilities, and loss of life, all of which could have a material adverse effect on our business, financial condition, or results of operations. In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland. Other major facilities are located near major earthquake fault lines in various locations around the world.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>250</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.30741232834573573</td>\n",
       "      <td>873</td>\n",
       "      <td>For the past year, we piloted this digital platform with Aquarelle, a supplier to apparel company Levi’s, near Bangalore. Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease. Pilot results showed that 16% of factory workers were diagnosed as anemic and subsequently treated, and a subgroup analysis showed that absenteeism was reduced by 4% on average in little less than a year.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>251</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.2629575541037144</td>\n",
       "      <td>2573</td>\n",
       "      <td>According to IQVIA (formerly IMS Health), as of November 2018, Sandoz holds a leading global position in sales of biosimilars and of generic anti-infectives and oncology medicines. Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose. The unit comprises several legacy programs (Novartis Access, the Novartis Malaria Initiative, and Novartis Healthy Family) supported by digital enabling platforms, and has full responsibility for the entire Novartis product range for seven countries in Asia and Africa.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>252</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>In addition, it does not sell short assets it does not have, or does not know it will have, in the future.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.2512910648903934</td>\n",
       "      <td>4628</td>\n",
       "      <td>It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>253</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.2087611172195355</td>\n",
       "      <td>3832</td>\n",
       "      <td>Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information. Investor Relations program Investor Relations manages the Group’s interactions with the international financial community.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>254</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.19363820084091854</td>\n",
       "      <td>4669</td>\n",
       "      <td>The VAR computation is a risk analysis tool designed to statistically estimate the potential 10-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates, and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group’s future results of operations or financial position.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>255</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6607314</td>\n",
       "      <td>2429</td>\n",
       "      <td>Once an agreement has been reached, each member state grants national marketing authorizations for the product. After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP). For some medications, post-approval studies (Phase IV) may be imposed to complement available data with additional data to evaluate long-term effects (called a Post-Approval Safety Study, or PASS) or to gather additional efficacy data (called a Post-Approval Efficacy Study, or PAES).</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>256</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.45916152</td>\n",
       "      <td>873</td>\n",
       "      <td>For the past year, we piloted this digital platform with Aquarelle, a supplier to apparel company Levi’s, near Bangalore. Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease. Pilot results showed that 16% of factory workers were diagnosed as anemic and subsequently treated, and a subgroup analysis showed that absenteeism was reduced by 4% on average in little less than a year.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>257</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.45632774</td>\n",
       "      <td>2393</td>\n",
       "      <td>These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development. Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>258</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Defining the Global Health &amp; Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.44425339</td>\n",
       "      <td>652</td>\n",
       "      <td>And we established a new companywide environmental sustainability strategy, with the aspiration to become carbon neutral by 2025, and plastic and water neutral by XXX Defining the Global Health &amp; Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company. In recent years, many aspects of our business model have been debated and questioned in public settings, including how we price our medicines, engage with physicians, and leverage intellectual property to protect our innovations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?</td>\n",
       "      <td>13</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.4298969</td>\n",
       "      <td>425</td>\n",
       "      <td>If practical and in line with existing globally accepted approaches legislative systems on mandatory corporate reporting could be additionally beneficial to further increase the best practice corporate reporting to additional companies. Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company. We are partnered with MIT Joint Program in designing, piloting and expanding a rigorous scientific approach to assessment and monetization of risk.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>260</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).</td>\n",
       "      <td>1</td>\n",
       "      <td>0.7060776</td>\n",
       "      <td>1163</td>\n",
       "      <td>Ensuring healthcare products (patented pharmaceuticals and generics) are manufactured at the highest quality level and that the efficacy and safety features of a medicine outweigh its risks (e.g., side effects), as well as collecting and recording adverse event reports. This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.62601626</td>\n",
       "      <td>1064</td>\n",
       "      <td>The RP risk indicator tool uses the category risk, country risk and contract value in combination to indicate a potential risk around the five areas of elevated ethical risk in the supply chain: labor rights, HSE general, HSE specific, animal welfare and anti-bribery. Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review. https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/responsible-procuremen.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>262</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6205468</td>\n",
       "      <td>170</td>\n",
       "      <td>Risks are assessed in the annual risk evaluation process, where natural disasters are a regular part of and are prepared site by site. To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary. Initial global risks are being assessed in collaboration with the Massachusetts Institute of Technology, and have been shared with applicable production, research and facilities staff.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>263</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.61974794</td>\n",
       "      <td>65</td>\n",
       "      <td>Risks can be catalogued at the site level and elevated to senior leadership, they can be identified during site assessments and audits, and they can be identified by more senior leadership in the organization. Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors. Each one of those variables has a different level of change that triggers assessment as a medium or high risk, and the variables are considered in combination.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>264</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.61974794</td>\n",
       "      <td>1392</td>\n",
       "      <td>All the relevant risk information is passed to Business Continuity (BC) staff, risk staff and strategy staff in various positions of the company as applicable. Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors. Each one of those variables has a different level of change that triggers assessment as a medium or high risk, and the variables are considered in combination.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>265</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.33742234</td>\n",
       "      <td>1604</td>\n",
       "      <td>Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.2a \\t(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.3 \\t(W4.3) Have you identified any water-related opportunities with the potential to have a substantive financial or strategic impact on your business?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>266</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.33742234</td>\n",
       "      <td>1602</td>\n",
       "      <td>W4.1c \\t(W4.1c) By river basin, what is the number and proportion of facilities exposed to water risks that could have a substantive impact on your business, and what is the potential business impact associated with those facilities. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.2a \\t(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>267</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Remediation plans to address information security, data privacy and business continuity risks are on track.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.31877115</td>\n",
       "      <td>3637</td>\n",
       "      <td>Internal Audit has performed XXX audits from its annual plan, and has conducted XXX advisory engagements and site visits. Remediation plans to address information security, data privacy and business continuity risks are on track. Recurring observations identified across various functions and business units relate to improving third-party management, cross-functional collaboration, legacy systems and complex processes.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>268</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3186491</td>\n",
       "      <td>185</td>\n",
       "      <td>A current site risk assessment will serve as the model for subsequent detailed risk assessments globally that involve global, regional and local staff, to make informed decisions on acceptable level of risk and the physical investments needed. This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management. Comment C2.4 (C2.4) Have you identified any climate-related opportunities with the potential to have a substantive financial or strategic impact on your business?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>269</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).</td>\n",
       "      <td>5</td>\n",
       "      <td>0.31634763</td>\n",
       "      <td>1163</td>\n",
       "      <td>Ensuring healthcare products (patented pharmaceuticals and generics) are manufactured at the highest quality level and that the efficacy and safety features of a medicine outweigh its risks (e.g., side effects), as well as collecting and recording adverse event reports. This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>270</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.362225367191791</td>\n",
       "      <td>477</td>\n",
       "      <td>That bold action will demand leadership and will require new partners, new networks and new ways of engaging to solve problems. That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change. Job title Corresponding job category Row XXX Head of Novartis Business Services Other C-Suite Officer SC.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>271</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.340272807114573</td>\n",
       "      <td>123</td>\n",
       "      <td>Consolidated tracking of trends in non-energy costs as well as possible exposure to pricing schemes based on energy intensity and physical location are used by procurement to adjust procurement and hedging strategies to reduce volatility and exposure. While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts. Efforts to align with suppliers will also take time and resources that have not been determined yet.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>272</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.33558396034435095</td>\n",
       "      <td>1880</td>\n",
       "      <td>To the extent that economic and financial conditions directly affect consumers, then our Innovative Medicines and Sandoz Divisions may be impacted. Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs. In addition, the elective surgical and contact lens businesses of our Alcon Division may be particularly sensitive to declines in consumer spending.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>273</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.2577721065766643</td>\n",
       "      <td>659</td>\n",
       "      <td>We are committed to taking real, measurable and reportable action in these key areas, and making sure that we communicate about them clearly and transparently. The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices. These topics are at the core of the four GH&amp;CR focus areas outlined above, and are covered in the following sections of this report.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.23025861380513102</td>\n",
       "      <td>117</td>\n",
       "      <td>Potential future increases in both energy prices and the implementation of carbon costs may have a stronger impact of estimated 20-30% of energy cost in the long-term, i.e. Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes. While these are highly variable in projections, the rapid price increase in the EU ETS is an obvious example of the increasing financial risk posed by our carbon footprint.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>275</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.55075574</td>\n",
       "      <td>1512</td>\n",
       "      <td>Other committee, please specify (HSE Governance Board) Responsibility Both assessing and managing water-related risks and opportunities Frequency of reporting to the board on water-related issues. A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action. These roles were selected because the Heads of NTO and NBS have operational responsibility; the Group Head of HR has a key role in ensuring that environmental sustainability are considered as part of routine business decisions because this is part of our culture.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>276</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.511887</td>\n",
       "      <td>1592</td>\n",
       "      <td>W2.2 \\t(W2.2) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations? Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience. Coverage \\tRisk assessment procedure \\tFrequency of assessment \\tHow far into the future are risks considered?</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>277</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.5090189</td>\n",
       "      <td>34</td>\n",
       "      <td>The ECN is responsible for overseeing the daily implementation of board policies which includes climate related issues and making sure that the board is establishing and maintaining good governance practices. Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business. The HSE Governance Board also includes the Global Head of Corporate Responsibility for Novartis, the Head of Real Estate and Facilities Services, the Global Head of HSE, and the Global Environment Head.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>278</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization).</td>\n",
       "      <td>4</td>\n",
       "      <td>0.5047898</td>\n",
       "      <td>1033</td>\n",
       "      <td>To inform our human rights strategy and future due diligence program, we piloted three human rights assessments in Turkey, China and Malaysia (in addition to Egypt in November 2017). We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization). We have also identified these common risk areas that require follow-up action in 2019: • Stakeholder engagement: More regular and broader consultation with external stakeholders is needed at the local level (from patient groups, local communities and health authorities to supply chain partners).</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>279</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.48939437</td>\n",
       "      <td>1501</td>\n",
       "      <td>The Global Head of Corporate Responsibility updates the GNCRC regularly on CR strategy and performance. This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed. If they had concerns about of water strategy these would be brought to the attention of the Board and the Executive Committee of the Novartis (ECN).</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>280 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                         Question  \\\n",
       "0                                                                                Does the company operate in countries out of the European Union?   \n",
       "1                                                                                Does the company operate in countries out of the European Union?   \n",
       "2                                                                                Does the company operate in countries out of the European Union?   \n",
       "3                                                                                Does the company operate in countries out of the European Union?   \n",
       "4                                                                                Does the company operate in countries out of the European Union?   \n",
       "5                                                                                Does the company operate in countries out of the European Union?   \n",
       "6                                                                                Does the company operate in countries out of the European Union?   \n",
       "7                                                                                Does the company operate in countries out of the European Union?   \n",
       "8                                                                                Does the company operate in countries out of the European Union?   \n",
       "9                                                                                Does the company operate in countries out of the European Union?   \n",
       "10                                                                               Does the company operate in countries out of the European Union?   \n",
       "11                                                                               Does the company operate in countries out of the European Union?   \n",
       "12                                                                               Does the company operate in countries out of the European Union?   \n",
       "13                                                                               Does the company operate in countries out of the European Union?   \n",
       "14                                                                               Does the company operate in countries out of the European Union?   \n",
       "15                                                                               Does the company operate in countries out of the European Union?   \n",
       "16                                                                               Does the company operate in countries out of the European Union?   \n",
       "17                                                                               Does the company operate in countries out of the European Union?   \n",
       "18                                                                               Does the company operate in countries out of the European Union?   \n",
       "19                                                                               Does the company operate in countries out of the European Union?   \n",
       "20     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "21     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "22     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "23     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "24     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "25     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "26     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "27     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "28     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "29     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "..                                                                                                                                            ...   \n",
       "250  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "251  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "252  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "253  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "254  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "255  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "256  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "257  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "258  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "259  Does the company monitor performance indicators with regard to health safety for aspects for workers relying on frequency or severity rates?   \n",
       "260                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "261                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "262                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "263                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "264                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "265                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "266                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "267                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "268                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "269                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "270                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "271                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "272                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "273                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "274                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "275                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "276                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "277                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "278                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "279                                                       Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "\n",
       "     Q_id   Company                          Model  \\\n",
       "0       1  Novartis             Bert - transformer   \n",
       "1       1  Novartis             Bert - transformer   \n",
       "2       1  Novartis             Bert - transformer   \n",
       "3       1  Novartis             Bert - transformer   \n",
       "4       1  Novartis             Bert - transformer   \n",
       "5       1  Novartis              Infersent Bi-Lstm   \n",
       "6       1  Novartis              Infersent Bi-Lstm   \n",
       "7       1  Novartis              Infersent Bi-Lstm   \n",
       "8       1  Novartis              Infersent Bi-Lstm   \n",
       "9       1  Novartis              Infersent Bi-Lstm   \n",
       "10      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "11      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "12      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "13      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "14      1  Novartis            Tf-Idf + Lemmatizer   \n",
       "15      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "16      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "17      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "18      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "19      1  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "20      2  Novartis             Bert - transformer   \n",
       "21      2  Novartis             Bert - transformer   \n",
       "22      2  Novartis             Bert - transformer   \n",
       "23      2  Novartis             Bert - transformer   \n",
       "24      2  Novartis             Bert - transformer   \n",
       "25      2  Novartis              Infersent Bi-Lstm   \n",
       "26      2  Novartis              Infersent Bi-Lstm   \n",
       "27      2  Novartis              Infersent Bi-Lstm   \n",
       "28      2  Novartis              Infersent Bi-Lstm   \n",
       "29      2  Novartis              Infersent Bi-Lstm   \n",
       "..    ...       ...                            ...   \n",
       "250    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "251    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "252    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "253    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "254    13  Novartis            Tf-Idf + Lemmatizer   \n",
       "255    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "256    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "257    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "258    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "259    13  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "260    14  Novartis             Bert - transformer   \n",
       "261    14  Novartis             Bert - transformer   \n",
       "262    14  Novartis             Bert - transformer   \n",
       "263    14  Novartis             Bert - transformer   \n",
       "264    14  Novartis             Bert - transformer   \n",
       "265    14  Novartis              Infersent Bi-Lstm   \n",
       "266    14  Novartis              Infersent Bi-Lstm   \n",
       "267    14  Novartis              Infersent Bi-Lstm   \n",
       "268    14  Novartis              Infersent Bi-Lstm   \n",
       "269    14  Novartis              Infersent Bi-Lstm   \n",
       "270    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "271    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "272    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "273    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "274    14  Novartis            Tf-Idf + Lemmatizer   \n",
       "275    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "276    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "277    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "278    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "279    14  Novartis  Tf-Idf- Semantic Kernel- Bert   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Answer  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                        Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.   \n",
       "1                                                                                                                                                                                                                                                                                                                In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing.   \n",
       "2                                                                                                                                                                                                              In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                    These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets.   \n",
       "4                                                                                                                                                                     In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies.   \n",
       "5                                                                                                                                                                                                                                                                                                                                                            Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.   \n",
       "6                                                                                                                                                                                                                                                                                                                                                                     For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                          The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe.   \n",
       "8                                                                                                                                                                                                                                                                                                                                                                 Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                 Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "10                                                                                                                                                                                                                                                                                                                                   Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states).   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                    For example, the first Entresto local brand was launched within XXX months of the launch in the European Union.   \n",
       "12                                                                                                                                                                                                                                                                                                                                                                         In addition, it does not sell short assets it does not have, or does not know it will have, in the future.   \n",
       "13                                                                                                                                                                                                                                                                                                                                              For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.   \n",
       "14                                                                                                                                                                                                                                                                                                     The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.   \n",
       "15                                                                                                                                                                                                                                                                                    In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries.   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate.   \n",
       "17                                                                                                                                                                                                                                                                                                                                              For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries.   \n",
       "18                                                                                                                                                                                                                                                                                                                                                            We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions.   \n",
       "19                                                                                                                                                                                     The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX   \n",
       "20                                                                                                                                                                                                                                                                                                                                                                          At the same time, other companies with specialized expertise or business models are entering the Item XXX   \n",
       "21                                                                                                                                                                                                                                                                                                                            Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.   \n",
       "22                                                                                                                                                                                                                                                                                                                                             Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans.   \n",
       "23                                                                                                                                                                                                                                                                                                                                       Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.   \n",
       "24                                                                                                                                                                                                                                                                                                                                                       Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe.   \n",
       "25                                                                                                                                                                                                                                                                                                                                                           Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America.   \n",
       "26                                                                                                                                                                                                                                                                                                                                 There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector.   \n",
       "27                                                                                                                                                                                                                                                                                                                    The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.   \n",
       "28                                                                                                                                                                                                                                                                                                                    The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries.   \n",
       "29                                                                                                                                                                                                                           In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland.   \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
       "250                                                                                                                                                                                                                                                                                                                                                  Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.   \n",
       "251                                                                                                                                                                                                                                                                                                                           Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose.   \n",
       "252                                                                                                                                                                                                                                                                                                                                                                        In addition, it does not sell short assets it does not have, or does not know it will have, in the future.   \n",
       "253                                                                                                                                                                                                                                                                                                                                                 Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information.   \n",
       "254                                                                                                                                                                                                                                                                                          The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates.   \n",
       "255                                                                                                                                                                                                                                                           After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP).   \n",
       "256                                                                                                                                                                                                                                                                                                                                                  Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease.   \n",
       "257                                                                                                                                                                                                                                                                                                                                      Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation.   \n",
       "258                                                                                                                                                                                                                                                                                                                           Defining the Global Health & Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company.   \n",
       "259                                                                                                                                                                                                                                                                                                          Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company.   \n",
       "260                                                                                                                                                                                                                                                                                                                                                This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).   \n",
       "261                                                                                                                                   Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review.   \n",
       "262                                                                                                                                                                                                                                                                                                                                                             To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary.   \n",
       "263                                                                                                                                                                                                                                                                                              Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.   \n",
       "264                                                                                                                                                                                                                                                                                              Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors.   \n",
       "265                                                                                                                                                                                                                                                                                                                                        Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.   \n",
       "266                                                                                                                                                                                                                                                                                                                                        Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response.   \n",
       "267                                                                                                                                                                                                                                                                                                                                                                       Remediation plans to address information security, data privacy and business continuity risks are on track.   \n",
       "268                                                                                                                                                                                                                                                                                                                                                    This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management.   \n",
       "269                                                                                                                                                                                                                                                                                                                                                This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls).   \n",
       "270                                                                                                                                                                                                                                                                                                                                        That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change.   \n",
       "271                                                                                                                                                                                                                                                                                            While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts.   \n",
       "272                                                                                                                                                                                                                                    Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs.   \n",
       "273                                                                                                                                                                                                                                                                                                                              The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices.   \n",
       "274                                                                                                                                                                                                                                                                                                                                                                        Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes.   \n",
       "275                                                                                                                                                                                                           A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action.   \n",
       "276                                                                                                                                                                                                                                                                                                              Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience.   \n",
       "277                                                                                                                                                                                                                                                                                                                    Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business.   \n",
       "278  We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization).   \n",
       "279                                                                                                                                                                                                                                                                                                              This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed.   \n",
       "\n",
       "    Rank                Score Doc_index  \\\n",
       "0      1           0.57026166      2499   \n",
       "1      2            0.5109576      2459   \n",
       "2      3           0.48538196      2637   \n",
       "3      4           0.48038045       226   \n",
       "4      5             0.480069      1928   \n",
       "5      1            0.4667485      2227   \n",
       "6      2            0.4663378      2130   \n",
       "7      3            0.4505594      2683   \n",
       "8      4           0.42783558      1920   \n",
       "9      5           0.42783558      3103   \n",
       "10     1   0.6198342429415247      2416   \n",
       "11     2   0.5869482063619555      2130   \n",
       "12     3  0.39312472620836497      4628   \n",
       "13     4   0.3019442945156682       882   \n",
       "14     5   0.2949217573271527      4655   \n",
       "15     1           0.30886894      2485   \n",
       "16     2           0.29680955      1920   \n",
       "17     3           0.29680955      3103   \n",
       "18     4           0.28595233      3104   \n",
       "19     5           0.28595233      1921   \n",
       "20     1           0.54087555      1835   \n",
       "21     2           0.51713026      2747   \n",
       "22     3           0.51357496      4514   \n",
       "23     4           0.49095944      2393   \n",
       "24     5           0.48801655      2499   \n",
       "25     1           0.32053015      2227   \n",
       "26     2           0.31352153       843   \n",
       "27     3           0.30220336      2785   \n",
       "28     4           0.30220336      2094   \n",
       "29     5            0.2962501      1981   \n",
       "..   ...                  ...       ...   \n",
       "250    1  0.30741232834573573       873   \n",
       "251    2   0.2629575541037144      2573   \n",
       "252    3   0.2512910648903934      4628   \n",
       "253    4   0.2087611172195355      3832   \n",
       "254    5  0.19363820084091854      4669   \n",
       "255    1            0.6607314      2429   \n",
       "256    2           0.45916152       873   \n",
       "257    3           0.45632774      2393   \n",
       "258    4           0.44425339       652   \n",
       "259    5            0.4298969       425   \n",
       "260    1            0.7060776      1163   \n",
       "261    2           0.62601626      1064   \n",
       "262    3            0.6205468       170   \n",
       "263    4           0.61974794        65   \n",
       "264    5           0.61974794      1392   \n",
       "265    1           0.33742234      1604   \n",
       "266    2           0.33742234      1602   \n",
       "267    3           0.31877115      3637   \n",
       "268    4            0.3186491       185   \n",
       "269    5           0.31634763      1163   \n",
       "270    1    0.362225367191791       477   \n",
       "271    2    0.340272807114573       123   \n",
       "272    3  0.33558396034435095      1880   \n",
       "273    4   0.2577721065766643       659   \n",
       "274    5  0.23025861380513102       117   \n",
       "275    1           0.55075574      1512   \n",
       "276    2             0.511887      1592   \n",
       "277    3            0.5090189        34   \n",
       "278    4            0.5047898      1033   \n",
       "279    5           0.48939437      1501   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Context_Answer  \n",
       "0                                                                                                                                                                                                                                                                                                                   • The FDA may also request that a sponsor conduct pediatric studies, and in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended. Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey.  \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                Increasingly strict analyses are applied when evaluating the entry of new products, and as a result, access to innovative medicines is limited based on strict cost-benefit assessments. In addition, prices for marketed products are referenced within member states and across member state borders, further impacting individual EU member state pricing. As an additional control for healthcare budgets, some EU countries have passed legislation to impose further mandatory rebates for pharmaceutical products and/or financial claw-backs on the pharmaceutical industry.  \n",
       "2                                                                                                                                                                                                                                                                  However, generic applicants must launch their products within certain timeframes or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant. In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure. Companies may submit Abridged Applications for approval of a generic medicinal product based upon its “essential similarity” to a medicinal product authorized and marketed in the EU following the expiration of the product’s data exclusivity period.  \n",
       "3                                                                                                                                                                                                                                                                                                                                               Threats to the business include rising costs due to carbon pricing frameworks designed to achieve climate mitigation, risks to reputation if we don't behave as a responsible corporate citizen, loss of biodiversity that will disrupt our supply chain and the physical impacts from climate change that will introduce risk into our sites, the communities we serve and our patients. These impacts are being felt through EU ETS in Europe for a pricing scheme, and the other impacts may occur in multiple markets. Increased costs could impact the bottom line and reduce funding for research and development of new drugs.  \n",
       "4                                                                                                                                                                                                                                                                                                                                           The EU also adopted a new Directive on Administrative Cooperation (DAC6) in 2018, which seeks additional reporting. In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, and the related investigation of the member states’ practices regarding the issuance of rulings on tax matters relating to individual companies. These OECD and EU tax reform initiatives also need local country implementation, including in our home country of Switzerland, which may result in significant changes to established tax principles.  \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  In the EU, Galvus received approval for expanded use as a second-line monotherapy for type  XXX diabetes patients who cannot take metformin. Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America. Diovan is the only agent in its class approved to treat all of the following: patients with high blood pressure (including children XXX to 18 years old), high-risk heart attack survivors, and patients with heart failure.  \n",
       "6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         In addition, we are now able to reduce the time lag between availability of medicines in higher- and lower-income countries. For example, the first Entresto local brand was launched within XXX months of the launch in the European Union. Through our Novartis Social Business (NSB) group, we continue to pursue unique social business models, such as the Novartis Access and Healthy Family programs, to help expand access to healthcare in lower-income countries.  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs, diagnostic ophthalmics, and other disposable products for cataract and vitreoretinal surgery. The principal markets for our Alcon Division include North America, Latin America, Japan, Asia and Europe. Sales of the vast majority of our Alcon Division products are not subject to material changes in seasonal demand.  \n",
       "8                                                                                                                                                                                                                                                                                                                                                       Post-employment benefits for associates.” See also “—Political and economic instability may have a material adverse effect on our results,” above. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.  \n",
       "9                                                                                                                                                                                                                                                                                                                                                                            Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.  \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The procedure used for first authorization must continue to be followed for subsequent changes, e.g., to add an indication for a licensed product. Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states). It is optional for other new chemical entities, innovative medicinal products, and medicines for which authorization would be in the interest of public health.  \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In addition, we are now able to reduce the time lag between availability of medicines in higher- and lower-income countries. For example, the first Entresto local brand was launched within XXX months of the launch in the European Union. Through our Novartis Social Business (NSB) group, we continue to pursue unique social business models, such as the Novartis Access and Healthy Family programs, to help expand access to healthcare in lower-income countries.  \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience.  \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                             However, we believe that the system needs to help ensure a fair balance between promoting creative and innovative activity and returning value to society. For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries. In late 2018, we reviewed our approach to patent filing in low- and middle income countries (LMICs) in an effort to better align it with the local socioeconomic circumstances that exist in many of these countries.  \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                      In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk. Liquidity risk Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations on time or at a reasonable price.  \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        The protection offered by such patents extends for varying periods, depending on the grant and duration of patents in the various jurisdictions. In recent years, there has been a trend of increasing government investigations and litigation against companies operating in our industry, including in the United States and other countries. In addition to patent protection, various countries offer data or marketing exclusivities for a prescribed period of time.  \n",
       "16                                                                                                                                                                                                                                                                                                                                                      Post-employment benefits for associates.” See also “—Political and economic instability may have a material adverse effect on our results,” above. Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.  \n",
       "17                                                                                                                                                                                                                                                                                                                                                         Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. For that reason, among other factors, Novartis does not file or enforce patents in least developed countries or low-income countries. However, the integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing.  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. We have already seen disruptions to supply chain operations in multiple countries due to flooding and carbon emissions. The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains.  \n",
       "19                                                                                                                                                                                                                                                                                                                                      Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. The Board of Directors agreed to a six-month reduction of the notice period, without compensation, of the President of Novartis Operations and Country President of Switzerland, to allow him to take on a new position with a company that does not compete with Novartis from October 1, XXX The majority of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains.  \n",
       "20                                                                                                                                                                                                                                                                                                                                                                   In order to succeed, we will be required to encourage a cultural change among our employees, attract and retain employees with appropriate skills and mindset, and successfully innovate across a variety of technology fields. At the same time, other companies with specialized expertise or business models are entering the Item XXX Key Information 18healthcare field, from research and development to pharmaceutical distribution, potentially disrupting our relationships with patients, healthcare professionals, customers, distributors and suppliers, with unknown potential consequences for us.  \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The scope of copyright protection for computer software varies throughout the world, although it is generally for a fixed term that begins on the date of copyright registration. Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world. Some of our principal facilities are subject to mortgages and other security interests granted to secure indebtedness to certain financial institutions.  \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. Furthermore, in certain countries, associates are covered under other post-employment benefit plans and post-retirement medical plans. In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since XXX  \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                              These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development. Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained.  \n",
       "24                                                                                                                                                                                                                                                                                                                  • The FDA may also request that a sponsor conduct pediatric studies, and in exchange, it will grant an additional six-month period of pediatric market exclusivity if the FDA accepts the data, the sponsor makes a timely application for approval for pediatric treatment, and the sponsor has either a patent-based or regulatory-based exclusivity period for the product that can be extended. Patents Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country in Europe. The EPO system permits a single application to be granted for the EU plus other non-EU countries such as Switzerland and Turkey.  \n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 In the EU, Galvus received approval for expanded use as a second-line monotherapy for type  XXX diabetes patients who cannot take metformin. Galvus and Eucreas are co-marketed by Merck KGaA as Jalra and Jalra M, respectively, in some countries in Latin America. Diovan is the only agent in its class approved to treat all of the following: patients with high blood pressure (including children XXX to 18 years old), high-risk heart attack survivors, and patients with heart failure.  \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The program was evaluated, and the results were published in a research paper in BMC Medical Education. There was a high retention rate of fellows in their home countries (more than 75%), with over 60% being employed in the public or academic sector. It improves our understanding of global healthcare challenges while providing young scientists with skills, knowledge, tools and inspiration to improve healthcare in their communities.  \n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Our strategy is to focus Novartis as a leading medicines company powered by advanced therapy platforms and data science. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In June 2018, we announced that we plan to spin off Alcon into a separately-traded standalone company.  \n",
       "28                                                                                                                                                                                                                                           In compliance with IFRS, beginning with our first-quarter XXX results, Novartis updated its segment financial information to reflect this transfer, both for the current and prior years, to aid comparability of year on year results. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.  \n",
       "29                                                                                                                                                                                                                                                                                                                                                  As a result, we could experience increased production or other costs, business interruptions, destruction of facilities, and loss of life, all of which could have a material adverse effect on our business, financial condition, or results of operations. In addition, our corporate headquarters, the headquarters of our Innovative Medicines Division, and certain of our major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland. Other major facilities are located near major earthquake fault lines in various locations around the world.  \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...  \n",
       "250                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           For the past year, we piloted this digital platform with Aquarelle, a supplier to apparel company Levi’s, near Bangalore. Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease. Pilot results showed that 16% of factory workers were diagnosed as anemic and subsequently treated, and a subgroup analysis showed that absenteeism was reduced by 4% on average in little less than a year.  \n",
       "251                                                                                                                                                                                                                                                                                                                                                        According to IQVIA (formerly IMS Health), as of November 2018, Sandoz holds a leading global position in sales of biosimilars and of generic anti-infectives and oncology medicines. Everything Novartis Social Business does is rooted in the local communities it serves and relies on its network of partners who share the same purpose. The unit comprises several legacy programs (Novartis Access, the Novartis Malaria Initiative, and Novartis Healthy Family) supported by digital enabling platforms, and has full responsibility for the entire Novartis product range for seven countries in Asia and Africa.  \n",
       "252                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience.  \n",
       "253                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information. Investor Relations program Investor Relations manages the Group’s interactions with the international financial community.  \n",
       "254                                                                                                                                                                                                              The VAR computation is a risk analysis tool designed to statistically estimate the potential 10-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates, and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group’s future results of operations or financial position.  \n",
       "255                                                                                                                                                                                                                                                                                                                                              Once an agreement has been reached, each member state grants national marketing authorizations for the product. After the marketing authorizations have been granted, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP). For some medications, post-approval studies (Phase IV) may be imposed to complement available data with additional data to evaluate long-term effects (called a Post-Approval Safety Study, or PASS) or to gather additional efficacy data (called a Post-Approval Efficacy Study, or PAES).  \n",
       "256                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           For the past year, we piloted this digital platform with Aquarelle, a supplier to apparel company Levi’s, near Bangalore. Health camps were held with workers from one plant, on topics including anemia, menstrual health, hygiene and diarrheal disease. Pilot results showed that 16% of factory workers were diagnosed as anemic and subsequently treated, and a subgroup analysis showed that absenteeism was reduced by 4% on average in little less than a year.  \n",
       "257                                                                                                                                                                                                                                                                                                                                                                                                             These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development. Information on the Company XXX Health authorities, including those in the US, the EU and Japan, have high standards of technical evaluation. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained.  \n",
       "258                                                                                                                                                                                                                                                                                                                                                                                                              And we established a new companywide environmental sustainability strategy, with the aspiration to become carbon neutral by 2025, and plastic and water neutral by XXX Defining the Global Health & Corporate Responsibility priorities Novartis recognizes society’s increasing expectations of our industry and our company. In recent years, many aspects of our business model have been debated and questioned in public settings, including how we price our medicines, engage with physicians, and leverage intellectual property to protect our innovations.  \n",
       "259                                                                                                                                                                                                                                                                                                                                                                                                         If practical and in line with existing globally accepted approaches legislative systems on mandatory corporate reporting could be additionally beneficial to further increase the best practice corporate reporting to additional companies. Support We support Task Force on Climate-related Financial Disclosures as a prudent planning tool for companies to understand the risk and benefit posed to the company. We are partnered with MIT Joint Program in designing, piloting and expanding a rigorous scientific approach to assessment and monetization of risk.  \n",
       "260                                                                                                                                                                                                                                                                                                                                                                                                                                     Ensuring healthcare products (patented pharmaceuticals and generics) are manufactured at the highest quality level and that the efficacy and safety features of a medicine outweigh its risks (e.g., side effects), as well as collecting and recording adverse event reports. This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice.  \n",
       "261                                                                                                                                                                                                                                         The RP risk indicator tool uses the category risk, country risk and contract value in combination to indicate a potential risk around the five areas of elevated ethical risk in the supply chain: labor rights, HSE general, HSE specific, animal welfare and anti-bribery. Collaboration/ Focuses on implementing improvement plans (developed after audits or other assessments) and other targeted engagement initiatives to help suppliers improve their standards and ethical business practices Case review If noncompliance is found through assessment and due diligence, the matter is escalated to a case review. https://www.novartis.com/our-company/corporate-responsibility/ethics-risk-compliance/responsible-procuremen.  \n",
       "262                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Risks are assessed in the annual risk evaluation process, where natural disasters are a regular part of and are prepared site by site. To avoid such events, specific risk assessment and consequently necessary protection measures might become necessary. Initial global risks are being assessed in collaboration with the Massachusetts Institute of Technology, and have been shared with applicable production, research and facilities staff.  \n",
       "263                                                                                                                                                                                                                                                                                                                                                                                                            Risks can be catalogued at the site level and elevated to senior leadership, they can be identified during site assessments and audits, and they can be identified by more senior leadership in the organization. Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors. Each one of those variables has a different level of change that triggers assessment as a medium or high risk, and the variables are considered in combination.  \n",
       "264                                                                                                                                                                                                                                                                                                                                                                                                                                                              All the relevant risk information is passed to Business Continuity (BC) staff, risk staff and strategy staff in various positions of the company as applicable. Substantive impact level could be triggered by significant change in health/safety, environment, regulatory/compliance, operations/business, reputation/image and financial factors. Each one of those variables has a different level of change that triggers assessment as a medium or high risk, and the variables are considered in combination.  \n",
       "265                                                                                                                                                   Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.2a \\t(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.3 \\t(W4.3) Have you identified any water-related opportunities with the potential to have a substantive financial or strategic impact on your business?  \n",
       "266                                                                                                                                                                                                                W4.1c \\t(W4.1c) By river basin, what is the number and proportion of facilities exposed to water risks that could have a substantive impact on your business, and what is the potential business impact associated with those facilities. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response. Explanation of financial impact \\tPrimary response to risk \\tDescription of response \\tCost of response \\tExplanation of cost of response \\tW4.2a \\t(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks.  \n",
       "267                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Internal Audit has performed XXX audits from its annual plan, and has conducted XXX advisory engagements and site visits. Remediation plans to address information security, data privacy and business continuity risks are on track. Recurring observations identified across various functions and business units relate to improving third-party management, cross-functional collaboration, legacy systems and complex processes.  \n",
       "268                                                                                                                                                                                                                                                                                                                                                                                                                             A current site risk assessment will serve as the model for subsequent detailed risk assessments globally that involve global, regional and local staff, to make informed decisions on acceptable level of risk and the physical investments needed. This could be shared with applicable group level business continuity, risk and strategy staff for coordinated risk management. Comment C2.4 (C2.4) Have you identified any climate-related opportunities with the potential to have a substantive financial or strategic impact on your business?  \n",
       "269                                                                                                                                                                                                                                                                                                                                                                                                                                     Ensuring healthcare products (patented pharmaceuticals and generics) are manufactured at the highest quality level and that the efficacy and safety features of a medicine outweigh its risks (e.g., side effects), as well as collecting and recording adverse event reports. This includes transparent and timely communication in the case of product safety or quality issues (e.g., prompt product recalls). We work closely with trade associations, which create opportunities to raise industry standards and exchange best practice.  \n",
       "270                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              That bold action will demand leadership and will require new partners, new networks and new ways of engaging to solve problems. That is the approach that Novartis is taking to address our responsibility in addressing the global health crisis posed by climate change. Job title Corresponding job category Row XXX Head of Novartis Business Services Other C-Suite Officer SC.  \n",
       "271                                                                                                                                                                                                                                                                                                                                                                                                                           Consolidated tracking of trends in non-energy costs as well as possible exposure to pricing schemes based on energy intensity and physical location are used by procurement to adjust procurement and hedging strategies to reduce volatility and exposure. While the costs to manage the existing EU ETS scheme within the company are limited, the expansion of schemes into other markets will require additional management focus and efforts. Efforts to align with suppliers will also take time and resources that have not been determined yet.  \n",
       "272                                                                                                                                                                                                                                                                                                                                                                                                                           To the extent that economic and financial conditions directly affect consumers, then our Innovative Medicines and Sandoz Divisions may be impacted. Given the requirements in certain countries that patients directly pay an increasingly large contribution toward their own healthcare costs, there is a risk that consumers may cut back on prescription drugs to help cope with rising costs. In addition, the elective surgical and contact lens businesses of our Alcon Division may be particularly sensitive to declines in consumer spending.  \n",
       "273                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         We are committed to taking real, measurable and reportable action in these key areas, and making sure that we communicate about them clearly and transparently. The results identified four material CR issue clusters: access to healthcare, innovation, patient health and safety, and ethical business practices. These topics are at the core of the four GH&CR focus areas outlined above, and are covered in the following sections of this report.  \n",
       "274                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Potential future increases in both energy prices and the implementation of carbon costs may have a stronger impact of estimated 20-30% of energy cost in the long-term, i.e. Estimates are based on the range of expected price increases in trading schemes and proposed carbon taxes. While these are highly variable in projections, the rapid price increase in the EU ETS is an obvious example of the increasing financial risk posed by our carbon footprint.  \n",
       "275                                                                                                                                                                                                                              Other committee, please specify (HSE Governance Board) Responsibility Both assessing and managing water-related risks and opportunities Frequency of reporting to the board on water-related issues. A cross-divisional program for harmonization of HSE processes and implementation includes environmental topics and allows tracking of events, identifying relevant impacts, performing a root cause analysis, and triggering/managing corrective and preventive action. These roles were selected because the Heads of NTO and NBS have operational responsibility; the Group Head of HR has a key role in ensuring that environmental sustainability are considered as part of routine business decisions because this is part of our culture.  \n",
       "276                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          W2.2 \\t(W2.2) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations? Physicians, patients and payers may choose competitor products instead of ours if they perceive them to be better in terms of efficacy, safety, cost or convenience. Coverage \\tRisk assessment procedure \\tFrequency of assessment \\tHow far into the future are risks considered?  \n",
       "277                                                                                                                                                                                                                                                                                                                                                                                        The ECN is responsible for overseeing the daily implementation of board policies which includes climate related issues and making sure that the board is establishing and maintaining good governance practices. Yes C2.3a (C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your CDP Page of 6911business. The HSE Governance Board also includes the Global Head of Corporate Responsibility for Novartis, the Head of Real Estate and Facilities Services, the Global Head of HSE, and the Global Environment Head.  \n",
       "278  To inform our human rights strategy and future due diligence program, we piloted three human rights assessments in Turkey, China and Malaysia (in addition to Egypt in November 2017). We have established that we have strong policies and solid processes to identify and manage potential human rights risks in our operations (e.g., comprehensive processes to try to ensure patient health and safety at all stages of the value chain; efficient workplace health and safety management systems; a living wage program; a functioning whistle blower system with a high level of awareness among associates; and a solid, responsible procurement organization). We have also identified these common risk areas that require follow-up action in 2019: • Stakeholder engagement: More regular and broader consultation with external stakeholders is needed at the local level (from patient groups, local communities and health authorities to supply chain partners).  \n",
       "279                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The Global Head of Corporate Responsibility updates the GNCRC regularly on CR strategy and performance. This group is responsible for identifying and investigating issues which are of strategic importance to the business and checking if they are appropriately managed. If they had concerns about of water strategy these would be brought to the attention of the Board and the Executive Committee of the Novartis (ECN).  \n",
       "\n",
       "[280 rows x 9 columns]"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results_Novartis.to_csv('')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "results_PfizerRocheJohnson.to_csv('Results_PfizerRocheJohnson.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Q_id</th>\n",
       "      <th>Company</th>\n",
       "      <th>Model</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Score</th>\n",
       "      <th>Doc_index</th>\n",
       "      <th>Context_Answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.46158153</td>\n",
       "      <td>2329</td>\n",
       "      <td>During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences. During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. Legal Proceedings Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.39178875</td>\n",
       "      <td>993</td>\n",
       "      <td>We also reviewed and updated our governance structure for managing human rights across our value chain. The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work. Quarterly EGC meetings provide a forum for updates on human rights topics, with an established process for elevating issues to the Johnson &amp; Johnson Executive Committee, our Board of Directors and Board Committees if warranted.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.38455927</td>\n",
       "      <td>954</td>\n",
       "      <td>• Clinical Data Transparency: We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries; publication of results in peer-reviewed journals; and sharing of clinical study reports and participant-level data from clinical trials. Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe. • Political Engagement: As a global healthcare company, we work with many stakeholders in the markets where we operate, and we take a stance on and support certain public policies in the United States and in different parts of the world as they relate to our core business of advancing health.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.38348675</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.37289336</td>\n",
       "      <td>1536</td>\n",
       "      <td>These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.40787455</td>\n",
       "      <td>1040</td>\n",
       "      <td>The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.39962035</td>\n",
       "      <td>1536</td>\n",
       "      <td>These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.39595923</td>\n",
       "      <td>1051</td>\n",
       "      <td>The Commonsense Principles XXX aspire to promote a constructive dialogue on good corporate governance to benefit the millions of . Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets. They are an updated version of the Commonsense Principles successfully launched in XXX to build momentum around the corporate governance conversation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA).</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3935492</td>\n",
       "      <td>903</td>\n",
       "      <td>Our compliance guidelines and policies meet or exceed legal and regulatory requirements in every jurisdiction where we operate. This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, Johnson &amp; Johnson actively participates in the work of industry associations, and helps develop industry codes for ethical and compliant marketing and selling of products.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.38491276</td>\n",
       "      <td>1377</td>\n",
       "      <td>Throughout Johnson &amp; Johnson’s history, we have maintained a strong, consistent andwe have maintained a strong, consistent andwe have maintained a strong, consistent and sustainable business. The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base. We are structured to meet the current and future needs of patients meet the current and future needs of patients meet the current and future needs of patients and consumers globally, and to address the and consumers globally, and to address the and consumers globally, and to address the challenges and opportunities that the worldchallenges and opportunities that the worldchallenges and opportunities that the world of healthcare presents.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4036158531671312</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.3691630723837139</td>\n",
       "      <td>1040</td>\n",
       "      <td>The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.3506139660462462</td>\n",
       "      <td>935</td>\n",
       "      <td>It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.33417458782649534</td>\n",
       "      <td>1932</td>\n",
       "      <td>Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>• Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.2932092398258069</td>\n",
       "      <td>1041</td>\n",
       "      <td>Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson &amp; Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations. • Resources: The GPT assists operating companies with designating privacy resources, considering their local requirements and the risk environments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Company operates in certain countries where the economic conditions continue to present significant challenges.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.38348675</td>\n",
       "      <td>1925</td>\n",
       "      <td>In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.34441066</td>\n",
       "      <td>1560</td>\n",
       "      <td>The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.33205885</td>\n",
       "      <td>935</td>\n",
       "      <td>It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28211266</td>\n",
       "      <td>1524</td>\n",
       "      <td>This Committee oversees and coordinates the activities of the Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Johnson</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Johnson &amp; Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.27888668</td>\n",
       "      <td>1521</td>\n",
       "      <td>The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. Johnson &amp; Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world. The Executive Committee of Johnson &amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "      <td>1</td>\n",
       "      <td>0.47936144</td>\n",
       "      <td>1525</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "      <td>2</td>\n",
       "      <td>0.47936144</td>\n",
       "      <td>1514</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.47532654</td>\n",
       "      <td>1521</td>\n",
       "      <td>Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX</td>\n",
       "      <td>4</td>\n",
       "      <td>0.3949507</td>\n",
       "      <td>1618</td>\n",
       "      <td>He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain. He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX Biosimilars have the potential to expand patient access to treatment and to create a more sustainable health care system.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.38917118</td>\n",
       "      <td>1586</td>\n",
       "      <td>She has held roles of increasing global responsibility throughout her career including site leadership, global strategic planning, contractor management, supply chain management and product portfolio leadership. Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States. She has been a member of the PGS Leadership Team since XXX and has represented PGS on several of Pfizer’s Business Leadership Teams.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Member of the American Society for Clinical Investigation and the Association of American Physicians.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.47606385</td>\n",
       "      <td>1495</td>\n",
       "      <td>Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.4706573</td>\n",
       "      <td>1521</td>\n",
       "      <td>Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.36455357</td>\n",
       "      <td>1553</td>\n",
       "      <td>Prior to joining Pfizer in 2009, Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.34432322</td>\n",
       "      <td>1513</td>\n",
       "      <td>He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>1</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.34432322</td>\n",
       "      <td>1524</td>\n",
       "      <td>He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>810</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.4069019011783869</td>\n",
       "      <td>1684</td>\n",
       "      <td>We take a scientific approach to providing the educational, emotional and psychosocial resources that can help make a real difference in outcomes for cancer patients by leveraging insights and data to inform our content. We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers. To help patients better manage their lives with cancer, this year we launched Pfizer Oncology Together™, a first-of-its-kind program for patient access solutions and personalized support for those using Pfizer Oncology medicines in the U.S. As part of the program, patients will have access to a team of representatives with social work experience ‘Care Champions’ who provide support beyond traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>811</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.3302193053380653</td>\n",
       "      <td>1415</td>\n",
       "      <td>In addition, we implemented disaster relief protocols for our patient assistance programs, allowing existing patients who get their medicines through a Pfizer patient assistance program to request early refills or new shipping addresses, and temporarily waiving financial documentation requirements for eligible new patients who may have lost their paperwork in these crises or their aftermath. When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations. We provided colleagues who work at our Puerto Rico manufacturing and commercial sites with personal care kits, generators and other items to help them through the devastating situation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>812</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.24796468911997185</td>\n",
       "      <td>1820</td>\n",
       "      <td>Access our policy paper on our antibiotic stewardship, and read more about Pfizer’s leadership in the fight against AMR. Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers. While we experienced an increase in our injury rates in 2017, mainly as a result of increased slips, trips and falls and ergonomic injuries, overall our rates are low and comparable to industry benchmarks.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>813</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.19808354546703097</td>\n",
       "      <td>1034</td>\n",
       "      <td>It is only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all XXX states and the District of Columbia and administers all product donation programs for Pfizer. By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis. Available at: http://www.worldbank.org/en/news/pressrelease/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>814</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.17020474685648126</td>\n",
       "      <td>115</td>\n",
       "      <td>Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee. Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals. Pfizer supports the development and adoption of novel, non animal test methods for assessing the safety of new products that can reduce, replace or refine the use of animal testing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>815</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.75440013</td>\n",
       "      <td>146</td>\n",
       "      <td>http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential. That’s why we all share responsibility for reporting safety, quality or performance issues concerning Pfizer products.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>816</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.7390721</td>\n",
       "      <td>145</td>\n",
       "      <td>Competitively sensitive information may not be discussed with friends or former colleagues employed by competitor companies whether in a business or a social setting. http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>817</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6721467</td>\n",
       "      <td>345</td>\n",
       "      <td>Our Commitment…12 \\tHealthcare Laws and Regulatory Requirements…12 \\tAnti-Bribery and Anti-Corruption…13 \\tResearch and Development…15 \\tManufacturing and Supply Quality…17 \\tInteractions with Patients and Patient Organizations…18. The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20. Our Commitment…22 \\tPatents, Trademarks and Copyrights…22 \\tBooks and Record Keeping…22 \\tConfidential and Proprietary Information…23 \\tPrivacy of Personal Data…25 \\tRecords and Information Management…26 \\tAcceptable Use of Information Systems…27 \\tConflicts of Interest…28 \\tSocial Media…30 \\tInside Information…31 \\tCompetitive Intelligence…32 \\tGlobal Trade Control Laws…33.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>818</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.5399316</td>\n",
       "      <td>1226</td>\n",
       "      <td>With XXX manufacturing sites around the world under Pfizer Global Supply (PGS), we harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines. Leveraging Science to Create Supply Chain Solutions Pfizer’s goal is for patients to receive uninterrupted access to our medicines and vaccines.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>819</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.5385889</td>\n",
       "      <td>113</td>\n",
       "      <td>We are committed to the development of publications that report the results of Company-sponsored clinical research studies accurately and objectively and to the disclosure of funding and editorial support. Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted. Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>820</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6585443</td>\n",
       "      <td>1114</td>\n",
       "      <td>What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments. I interact regularly at work calls me and mentions that a patient of hers on Roche drug X was recently hospitalised with pneumonia and died.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>821</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.6315596</td>\n",
       "      <td>1001</td>\n",
       "      <td>The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>822</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.6132648</td>\n",
       "      <td>1113</td>\n",
       "      <td>– Immediately report customer complaints relating to Roche medical devices to the local regulatory and quality function. What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>823</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>Help &amp; advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.60540605</td>\n",
       "      <td>1118</td>\n",
       "      <td>A In case of an adverse event you should report at least the following four elements: Patient, Reporter, Event and Product (PREP). Help &amp; advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g. Speak up: If you believe in good faith that in connection with business where Roche is involved someone has done, is doing, or may be about to do something that violates quality standards and good practices, speak up by using the available speak up channels.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>824</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Bert - transformer</td>\n",
       "      <td>At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.6024178</td>\n",
       "      <td>588</td>\n",
       "      <td>Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>825</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.37645185</td>\n",
       "      <td>994</td>\n",
       "      <td>A cross-divisional working group has established a checklist on Due Diligence for External Business Partners, mainly focusing on agents and distributors. It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework. We maintain and improve operational-level grievance mechanisms, which we understand to encompass also a preventive function.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>826</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>– Contact the related expert department in a timely manner in case of questions or to address an error.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.31262755</td>\n",
       "      <td>1319</td>\n",
       "      <td>– Check for compliance with national and international customs, trade and export control regulations when developing and adapting processes. – Contact the related expert department in a timely manner in case of questions or to address an error. A Every employee asking for the shipment of goods is accountable for providing complete and truthful information for export or import processing.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>827</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.29044554</td>\n",
       "      <td>1553</td>\n",
       "      <td>If the remuneration is not commensurate with the services provided, you should not accept the consultant’s request. Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution. Roche protects human rights and does not tolerate behaviour by its business partners which is not in line with applicable laws and generally accepted sustainability standards.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>828</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>It contains the annual financial statements, consolidated financial statements and non­financial performance indicators.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.28880537</td>\n",
       "      <td>22</td>\n",
       "      <td>Our financial and non­financial reporting consists of the Annual Report, the Finance Report and the online report. It contains the annual financial statements, consolidated financial statements and non­financial performance indicators. The financial reporting scope is defined and outlined in our Finance Report, and there have been no significant changes in scope in XXX compared to XXX</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>829</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Infersent Bi-Lstm</td>\n",
       "      <td>A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.286755</td>\n",
       "      <td>1324</td>\n",
       "      <td>You should seek guidance from your local logistics department and your local Export Control Officer before processing any shipment. A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation. A Roche does not tolerate any violation of the regulations and will take appropriate corrective measures and sanctions.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>830</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.20979829278490708</td>\n",
       "      <td>1008</td>\n",
       "      <td>Our challenge is to focus our efforts where we see the biggest risks and the biggest levers for remediation and improvement. On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses. We maintain a system of consistent global standards, which we also apply to our business partners, for example, in areas like R&amp;D, clinical trials, manufacturing and distribution.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>831</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.17727548268874965</td>\n",
       "      <td>1337</td>\n",
       "      <td>Corporate Integrity Q I work in a clinical research unit and have access to identifiable health information which I would like to share with a colleague. A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence. As a Roche employee you have a strict obligation to treat such information as confidential and to share it only with colleagues who need to know in order to do their work, in accordance with the purpose the data was obtained for and only if and as allowed under applicable law.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>832</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.1638004762981347</td>\n",
       "      <td>1331</td>\n",
       "      <td>Roche is committed to respecting data privacy and has developed principles that must be consistently applied when processing personal data within the Roche Group and by its business partners. Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed. Roche takes due care to prevent any misuse of or unauthorised access to such identifiable health information within its control.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>833</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We are all encouraged to identify areas for improvements and continuously work towards a better environment.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.16292468426596937</td>\n",
       "      <td>1390</td>\n",
       "      <td>Every employee is personally responsible for safety, security, health and environmental protection at the workplace to the full extent required by his/her duties to the best of his/her knowledge, ability and experience. We are all encouraged to identify areas for improvements and continuously work towards a better environment. As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>834</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>We identified human rights which are potentially susceptible to violations, as well as their associated risks.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.1151118637289961</td>\n",
       "      <td>710</td>\n",
       "      <td>We do this by assessing the risks of potential violations, promoting awareness, fostering due diligence, strengthening the legal framework and collaborating on collective actions, and transparent communication. We identified human rights which are potentially susceptible to violations, as well as their associated risks. To enhance awareness, we created a video that explained human rights and Roche’s endeavours with a simple message to our employees: ‘Within your sphere of influence, ensure human rights are respected.’.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>835</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.</td>\n",
       "      <td>1</td>\n",
       "      <td>0.6315596</td>\n",
       "      <td>1001</td>\n",
       "      <td>The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>836</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.</td>\n",
       "      <td>2</td>\n",
       "      <td>0.6024178</td>\n",
       "      <td>588</td>\n",
       "      <td>Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>837</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices.</td>\n",
       "      <td>3</td>\n",
       "      <td>0.5972139</td>\n",
       "      <td>1385</td>\n",
       "      <td>As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment. Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices. We take all reasonable and practical steps to ensure that we provide a safe, secure, healthy and clean working environment.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>838</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience.</td>\n",
       "      <td>4</td>\n",
       "      <td>0.58856523</td>\n",
       "      <td>1394</td>\n",
       "      <td>If a meeting in person is needed, reduce the number of participants – send a competent representative instead of a whole team. We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience. In addition, the book “Lifesavers for millions” has been published by Editiones Roche, Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding intellectual property rights, speak up by using the available speak up channels.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>839</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>14</td>\n",
       "      <td>Roche</td>\n",
       "      <td>Tf-Idf- Semantic Kernel- Bert</td>\n",
       "      <td>For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment.</td>\n",
       "      <td>5</td>\n",
       "      <td>0.5406029</td>\n",
       "      <td>717</td>\n",
       "      <td>These include excessive overtime, improper pay for overtime, insufficient number of rest days, and inadequate payment of social benefits. For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment. The RocheAbility network, for instance, fosters the inclusion of Basel and Kaiseraugst employees with disabilities and focuses on the strengths and abilities of each individual.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>840 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                    Question  \\\n",
       "0                           Does the company operate in countries out of the European Union?   \n",
       "1                           Does the company operate in countries out of the European Union?   \n",
       "2                           Does the company operate in countries out of the European Union?   \n",
       "3                           Does the company operate in countries out of the European Union?   \n",
       "4                           Does the company operate in countries out of the European Union?   \n",
       "5                           Does the company operate in countries out of the European Union?   \n",
       "6                           Does the company operate in countries out of the European Union?   \n",
       "7                           Does the company operate in countries out of the European Union?   \n",
       "8                           Does the company operate in countries out of the European Union?   \n",
       "9                           Does the company operate in countries out of the European Union?   \n",
       "10                          Does the company operate in countries out of the European Union?   \n",
       "11                          Does the company operate in countries out of the European Union?   \n",
       "12                          Does the company operate in countries out of the European Union?   \n",
       "13                          Does the company operate in countries out of the European Union?   \n",
       "14                          Does the company operate in countries out of the European Union?   \n",
       "15                          Does the company operate in countries out of the European Union?   \n",
       "16                          Does the company operate in countries out of the European Union?   \n",
       "17                          Does the company operate in countries out of the European Union?   \n",
       "18                          Does the company operate in countries out of the European Union?   \n",
       "19                          Does the company operate in countries out of the European Union?   \n",
       "20                          Does the company operate in countries out of the European Union?   \n",
       "21                          Does the company operate in countries out of the European Union?   \n",
       "22                          Does the company operate in countries out of the European Union?   \n",
       "23                          Does the company operate in countries out of the European Union?   \n",
       "24                          Does the company operate in countries out of the European Union?   \n",
       "25                          Does the company operate in countries out of the European Union?   \n",
       "26                          Does the company operate in countries out of the European Union?   \n",
       "27                          Does the company operate in countries out of the European Union?   \n",
       "28                          Does the company operate in countries out of the European Union?   \n",
       "29                          Does the company operate in countries out of the European Union?   \n",
       "..                                                                                       ...   \n",
       "810  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "811  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "812  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "813  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "814  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "815  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "816  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "817  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "818  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "819  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "820  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "821  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "822  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "823  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "824  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "825  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "826  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "827  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "828  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "829  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "830  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "831  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "832  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "833  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "834  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "835  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "836  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "837  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "838  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "839  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "\n",
       "     Q_id  Company                          Model  \\\n",
       "0       1  Johnson             Bert - transformer   \n",
       "1       1  Johnson             Bert - transformer   \n",
       "2       1  Johnson             Bert - transformer   \n",
       "3       1  Johnson             Bert - transformer   \n",
       "4       1  Johnson             Bert - transformer   \n",
       "5       1  Johnson              Infersent Bi-Lstm   \n",
       "6       1  Johnson              Infersent Bi-Lstm   \n",
       "7       1  Johnson              Infersent Bi-Lstm   \n",
       "8       1  Johnson              Infersent Bi-Lstm   \n",
       "9       1  Johnson              Infersent Bi-Lstm   \n",
       "10      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "11      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "12      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "13      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "14      1  Johnson            Tf-Idf + Lemmatizer   \n",
       "15      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "16      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "17      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "18      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "19      1  Johnson  Tf-Idf- Semantic Kernel- Bert   \n",
       "20      1   Pfizer             Bert - transformer   \n",
       "21      1   Pfizer             Bert - transformer   \n",
       "22      1   Pfizer             Bert - transformer   \n",
       "23      1   Pfizer             Bert - transformer   \n",
       "24      1   Pfizer             Bert - transformer   \n",
       "25      1   Pfizer              Infersent Bi-Lstm   \n",
       "26      1   Pfizer              Infersent Bi-Lstm   \n",
       "27      1   Pfizer              Infersent Bi-Lstm   \n",
       "28      1   Pfizer              Infersent Bi-Lstm   \n",
       "29      1   Pfizer              Infersent Bi-Lstm   \n",
       "..    ...      ...                            ...   \n",
       "810    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "811    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "812    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "813    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "814    14   Pfizer            Tf-Idf + Lemmatizer   \n",
       "815    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "816    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "817    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "818    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "819    14   Pfizer  Tf-Idf- Semantic Kernel- Bert   \n",
       "820    14    Roche             Bert - transformer   \n",
       "821    14    Roche             Bert - transformer   \n",
       "822    14    Roche             Bert - transformer   \n",
       "823    14    Roche             Bert - transformer   \n",
       "824    14    Roche             Bert - transformer   \n",
       "825    14    Roche              Infersent Bi-Lstm   \n",
       "826    14    Roche              Infersent Bi-Lstm   \n",
       "827    14    Roche              Infersent Bi-Lstm   \n",
       "828    14    Roche              Infersent Bi-Lstm   \n",
       "829    14    Roche              Infersent Bi-Lstm   \n",
       "830    14    Roche            Tf-Idf + Lemmatizer   \n",
       "831    14    Roche            Tf-Idf + Lemmatizer   \n",
       "832    14    Roche            Tf-Idf + Lemmatizer   \n",
       "833    14    Roche            Tf-Idf + Lemmatizer   \n",
       "834    14    Roche            Tf-Idf + Lemmatizer   \n",
       "835    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "836    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "837    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "838    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "839    14    Roche  Tf-Idf- Semantic Kernel- Bert   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                        Answer  \\\n",
       "0                                                                                                 During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands.   \n",
       "1                                                                                                                                                         The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work.   \n",
       "2                Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe.   \n",
       "3                                                                                                                                                                                                          The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "4                                                                                                                                                                                                                  The products sold in international business include those developed in the U.S. and by subsidiaries abroad.   \n",
       "5                                                                                                                                                                                                                     Policies in accordance with new requirements or changes in the law of the countries in which we operate.   \n",
       "6                                                                                                                                                                                                                  The products sold in international business include those developed in the U.S. and by subsidiaries abroad.   \n",
       "7                                                                                                                                                                       Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets.   \n",
       "8    This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA).   \n",
       "9                                                                                                                                                                                                   The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base.   \n",
       "10                                                                                                                                                                                                         The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "11                                                                                                                                                                                                                    Policies in accordance with new requirements or changes in the law of the countries in which we operate.   \n",
       "12                                                                                                                                                                                               They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.   \n",
       "13                                                                                                                                     However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results.   \n",
       "14                                                                                                                   • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.   \n",
       "15                                                                                                                                                                                                         The Company operates in certain countries where the economic conditions continue to present significant challenges.   \n",
       "16                                                                                                                   The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation.   \n",
       "17                                                                                                                                                                                               They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations.   \n",
       "18                                                                                      Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.   \n",
       "19                                                                                                                                                                            Johnson & Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world.   \n",
       "20                                                                                                                                                     He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX   \n",
       "21                                                                                                                                                     He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX   \n",
       "22                                                                                                                                                          Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.   \n",
       "23                                                                                                                                                  He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX   \n",
       "24                                                                                                                                                Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States.   \n",
       "25                                                                                                                                                                                                                       Member of the American Society for Clinical Investigation and the Association of American Physicians.   \n",
       "26                                                                                                                                                          Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council.   \n",
       "27                                                                                                                                           Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors.   \n",
       "28                                                                                                                                                                                      In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.   \n",
       "29                                                                                                                                                                                      In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada.   \n",
       "..                                                                                                                                                                                                                                                                                                                         ...   \n",
       "810                                                                                                                                                We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers.   \n",
       "811                                     When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations.   \n",
       "812                                                                                                                                                                               Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers.   \n",
       "813                                                                                                                                                                                                                    By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis.   \n",
       "814                                                                                                                                         Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals.   \n",
       "815                                                                                                                                                                                                            Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.   \n",
       "816                                                                                                                                                                                                            http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products.   \n",
       "817                                                                                                                                    The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20.   \n",
       "818                                                                                                                                                                          In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines.   \n",
       "819                                                                                                        Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted.   \n",
       "820                                                                                                     If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.   \n",
       "821                                                                                                                                                                          As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "822                                                                                                                                                                                                         What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?.   \n",
       "823                                                                                                   Help & advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g.   \n",
       "824                                                                                                                                                                                                           At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.   \n",
       "825                                                                                                                                                                                                        It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework.   \n",
       "826                                                                                                                                                                                                                    – Contact the related expert department in a timely manner in case of questions or to address an error.   \n",
       "827                                                                                                                                                                                                                  Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution.   \n",
       "828                                                                                                                                                                                                   It contains the annual financial statements, consolidated financial statements and non­financial performance indicators.   \n",
       "829                                                                                                                                                       A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation.   \n",
       "830                                                                                                                                                                    On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses.   \n",
       "831                                                                                                                                                                            A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence.   \n",
       "832                                                                                                                                                                                              Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed.   \n",
       "833                                                                                                                                                                                                               We are all encouraged to identify areas for improvements and continuously work towards a better environment.   \n",
       "834                                                                                                                                                                                                             We identified human rights which are potentially susceptible to violations, as well as their associated risks.   \n",
       "835                                                                                                                                                                          As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees.   \n",
       "836                                                                                                                                                                                                           At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices.   \n",
       "837                                                                                                                                                      Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices.   \n",
       "838                                                                                                                                                        We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience.   \n",
       "839                                                                                   For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment.   \n",
       "\n",
       "    Rank                Score Doc_index  \\\n",
       "0      1           0.46158153      2329   \n",
       "1      2           0.39178875       993   \n",
       "2      3           0.38455927       954   \n",
       "3      4           0.38348675      1925   \n",
       "4      5           0.37289336      1536   \n",
       "5      1           0.40787455      1040   \n",
       "6      2           0.39962035      1536   \n",
       "7      3           0.39595923      1051   \n",
       "8      4            0.3935492       903   \n",
       "9      5           0.38491276      1377   \n",
       "10     1   0.4036158531671312      1925   \n",
       "11     2   0.3691630723837139      1040   \n",
       "12     3   0.3506139660462462       935   \n",
       "13     4  0.33417458782649534      1932   \n",
       "14     5   0.2932092398258069      1041   \n",
       "15     1           0.38348675      1925   \n",
       "16     2           0.34441066      1560   \n",
       "17     3           0.33205885       935   \n",
       "18     4           0.28211266      1524   \n",
       "19     5           0.27888668      1521   \n",
       "20     1           0.47936144      1525   \n",
       "21     2           0.47936144      1514   \n",
       "22     3           0.47532654      1521   \n",
       "23     4            0.3949507      1618   \n",
       "24     5           0.38917118      1586   \n",
       "25     1           0.47606385      1495   \n",
       "26     2            0.4706573      1521   \n",
       "27     3           0.36455357      1553   \n",
       "28     4           0.34432322      1513   \n",
       "29     5           0.34432322      1524   \n",
       "..   ...                  ...       ...   \n",
       "810    1   0.4069019011783869      1684   \n",
       "811    2   0.3302193053380653      1415   \n",
       "812    3  0.24796468911997185      1820   \n",
       "813    4  0.19808354546703097      1034   \n",
       "814    5  0.17020474685648126       115   \n",
       "815    1           0.75440013       146   \n",
       "816    2            0.7390721       145   \n",
       "817    3            0.6721467       345   \n",
       "818    4            0.5399316      1226   \n",
       "819    5            0.5385889       113   \n",
       "820    1            0.6585443      1114   \n",
       "821    2            0.6315596      1001   \n",
       "822    3            0.6132648      1113   \n",
       "823    4           0.60540605      1118   \n",
       "824    5            0.6024178       588   \n",
       "825    1           0.37645185       994   \n",
       "826    2           0.31262755      1319   \n",
       "827    3           0.29044554      1553   \n",
       "828    4           0.28880537        22   \n",
       "829    5             0.286755      1324   \n",
       "830    1  0.20979829278490708      1008   \n",
       "831    2  0.17727548268874965      1337   \n",
       "832    3   0.1638004762981347      1331   \n",
       "833    4  0.16292468426596937      1390   \n",
       "834    5   0.1151118637289961       710   \n",
       "835    1            0.6315596      1001   \n",
       "836    2            0.6024178       588   \n",
       "837    3            0.5972139      1385   \n",
       "838    4           0.58856523      1394   \n",
       "839    5            0.5406029       717   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Context_Answer  \n",
       "0                                                                                                                                                                                                                                                        During 2017, the Company divestitures primarily included: the Codman Neurosurgery business, to Integra LifeSciences. During 2016, the Company divestitures included: the controlled substance raw material and active pharmaceutical ingredient (API) business; certain anesthetic products in Europe; and certain non-strategic Consumer brands. Legal Proceedings Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.  \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                     We also reviewed and updated our governance structure for managing human rights across our value chain. The Enterprise Governance Council (EGC), a global, cross functional team of senior leaders representing functional groups and business segments, oversees this work. Quarterly EGC meetings provide a forum for updates on human rights topics, with an established process for elevating issues to the Johnson & Johnson Executive Committee, our Board of Directors and Board Committees if warranted.  \n",
       "2    • Clinical Data Transparency: We support the overall principles of greater clinical trial data transparency, including registration and disclosure of clinical trial results in external registries; publication of results in peer-reviewed journals; and sharing of clinical study reports and participant-level data from clinical trials. Clinical trials conducted around the world by our pharmaceutical, medical devices and consumer product companies are listed on the U.S. National Institutes of Health’s website, www.clinicaltrials.gov, the European Clinical Trial Register, and country-specific and regional registries across the globe. • Political Engagement: As a global healthcare company, we work with many stakeholders in the markets where we operate, and we take a stance on and support certain public policies in the United States and in different parts of the world as they relate to our core business of advancing health.  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "4                                                                                                                                                                                                                                                                                                                                 These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.  \n",
       "5                                                                                                                                                                                                                                                                                                                                                                       The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.  \n",
       "6                                                                                                                                                                                                                                                                                                                                 These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. The products sold in international business include those developed in the U.S. and by subsidiaries abroad. Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     The Commonsense Principles XXX aspire to promote a constructive dialogue on good corporate governance to benefit the millions of . Americans who work for and invest in America’s public companies, create economic growth, and sustain the health of America’s corporations and markets. They are an updated version of the Commonsense Principles successfully launched in XXX to build momentum around the corporate governance conversation.  \n",
       "8                                                                                                                                                                                                                                                                                                                   Our compliance guidelines and policies meet or exceed legal and regulatory requirements in every jurisdiction where we operate. This includes industry standards and local codes of conduct, such as Advancing Medical Technology Association (AdvaMed), Asia Pacific Medical Technology Association (APACMED), Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industry Associations (EFPIA). In addition, Johnson & Johnson actively participates in the work of industry associations, and helps develop industry codes for ethical and compliant marketing and selling of products.  \n",
       "9                                                                                                                                                                                 Throughout Johnson & Johnson’s history, we have maintained a strong, consistent andwe have maintained a strong, consistent andwe have maintained a strong, consistent and sustainable business. The StrategicThe StrategicThe Strategic AAAdvantage of Our Broad Basedvantage of Our Broad Basedvantage of Our Broad Base. We are structured to meet the current and future needs of patients meet the current and future needs of patients meet the current and future needs of patients and consumers globally, and to address the and consumers globally, and to address the and consumers globally, and to address the challenges and opportunities that the worldchallenges and opportunities that the worldchallenges and opportunities that the world of healthcare presents.  \n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "11                                                                                                                                                                                                                                                                                                                                                                      The Global Privacy Team (GPT) and the ISRM teams strengthen the embedding of privacy reviews and privacy risk assessments in our organizations, reinforcing a formal breach notification and escalation process, and strengthen the audit, monitoring and testing strategy. Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations.  \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.  \n",
       "13                                                                                                                                                                                                                                                                                                                                                                           Brexit creates global political and economic uncertainty, which may cause, among other consequences, volatility in exchange rates and interest rates, additional cost containment by third-party payors and changes in regulations. However, the Company currently does not believe that these and other related effects will have a material impact on the Company’s consolidated financial position or operating results. Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates.  \n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Policies in accordance with new requirements or changes in the law of the countries in which we operate. • Operational Management: Operational management at each Johnson & Johnson operating company is accountable for establishing and implementing privacy compliance for that operating company’s operations. • Resources: The GPT assists operating companies with designating privacy resources, considering their local requirements and the risk environments.  \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In response to these concerns, the Company has a long-standing policy of pricing products responsibly. The Company operates in certain countries where the economic conditions continue to present significant challenges. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.  \n",
       "16                                                                                                                                                                                                                                          The Company’s compliance with these requirements did not change during the past year, and is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position. The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the FDA) continues to result in increases in the amounts of testing and documentation required for FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction.  \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  It is an anonymous whistle-blowing mechanism that provides a channel for all employees, contingent workers, customers, third-party agencies and other partners to report potential violations. They may relate to the CBC, other Company policies or the applicable laws and regulations in the countries of our operations. Our Escalation Procedure Policy requires all employees to escalate any violations of our policies or applicable laws.  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                  This Committee oversees and coordinates the activities of the Company’s three business segments: Consumer, Pharmaceutical and Medical Devices. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.  \n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                                                               The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments. Johnson & Johnson is a holding company, which has more than XXX operating companies conducting business in virtually all countries of the world. The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.  \n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.  \n",
       "21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX Mr. Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.  \n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                               Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.  \n",
       "23                                                                                                                                                                                                                                                                                                                                                                                                               He was later appointed President and General Manager of the Primary Care Business, where he led both the commercial organization and clinical development of medicines in key disease areas including cardiovascular disease, diabetes and pain. He is also a member of the Boards of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the Ministerial Industry Strategy Group (MISG), since XXX Biosimilars have the potential to expand patient access to treatment and to create a more sustainable health care system.  \n",
       "24                                                                                                                                                                                                                                                                                                                                                                                                                               She has held roles of increasing global responsibility throughout her career including site leadership, global strategic planning, contractor management, supply chain management and product portfolio leadership. Lund-Jurgensen joined the company in XXX from SmithKline Beecham where she held various global operational and leadership roles in Australia, Germany and the United States. She has been a member of the PGS Leadership Team since XXX and has represented PGS on several of Pfizer’s Business Leadership Teams.  \n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Professor of Internal Medicine and Molecular Genetics, and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association.  \n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                               Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. In that role, he oversaw five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.  \n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Prior to joining Pfizer in 2009, Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council.  \n",
       "28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX  \n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     He worked in Latin America through 1995, holding positions including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in XXX  \n",
       "..                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ...  \n",
       "810        We take a scientific approach to providing the educational, emotional and psychosocial resources that can help make a real difference in outcomes for cancer patients by leveraging insights and data to inform our content. We also provide millions of dollars in grants each year to fund organizations that provide essential programs and services to patients coping with a wide range of cancers. To help patients better manage their lives with cancer, this year we launched Pfizer Oncology Together™, a first-of-its-kind program for patient access solutions and personalized support for those using Pfizer Oncology medicines in the U.S. As part of the program, patients will have access to a team of representatives with social work experience ‘Care Champions’ who provide support beyond traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs.  \n",
       "811                                                                        In addition, we implemented disaster relief protocols for our patient assistance programs, allowing existing patients who get their medicines through a Pfizer patient assistance program to request early refills or new shipping addresses, and temporarily waiving financial documentation requirements for eligible new patients who may have lost their paperwork in these crises or their aftermath. When our operations in Puerto Rico were impacted by Hurricane Maria, to ensure colleague safety and minimize business interruption, well-trained crisis management teams were immediately activated to first support colleagues and then work to support safely restarting operations. We provided colleagues who work at our Puerto Rico manufacturing and commercial sites with personal care kits, generators and other items to help them through the devastating situation.  \n",
       "812                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Access our policy paper on our antibiotic stewardship, and read more about Pfizer’s leadership in the fight against AMR. Culture, colleagues can focus on the choices they make every day to care for their safety and the safety and health of their fellow workers. While we experienced an increase in our injury rates in 2017, mainly as a result of increased slips, trips and falls and ergonomic injuries, overall our rates are low and comparable to industry benchmarks.  \n",
       "813                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   It is only nonprofit 501(c)(3) in U.S. licensed to distribute pharmaceuticals in all XXX states and the District of Columbia and administers all product donation programs for Pfizer. By 2050, drug-resistant infections could cause global economic damage on par with XXX financial crisis. Available at: http://www.worldbank.org/en/news/pressrelease/2016/09/18/by-2050-drug-resistant-infections-could-cause-global-economic-damage-on-par-with-2008-financial-crisis XXX  \n",
       "814                                                                                                                                                                                                                                                                                                                                                                                      Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee. Many of our trials use independent data-monitoring committees to help ensure patient safety, in addition to internal reviews conducted by our physicians and safety professionals. Pfizer supports the development and adoption of novel, non animal test methods for assessing the safety of new products that can reduce, replace or refine the use of animal testing.  \n",
       "815                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential. That’s why we all share responsibility for reporting safety, quality or performance issues concerning Pfizer products.  \n",
       "816                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Competitively sensitive information may not be discussed with friends or former colleagues employed by competitor companies whether in a business or a social setting. http://policysource.pfizer.com XXX Ensuring and Monitoring the Safety, Quality and Performance of Our Products. Understanding a product’s safety profile, as well as its quality and performance characteristics, is essential.  \n",
       "817                                                                                                                                          Our Commitment…12 \\tHealthcare Laws and Regulatory Requirements…12 \\tAnti-Bribery and Anti-Corruption…13 \\tResearch and Development…15 \\tManufacturing and Supply Quality…17 \\tInteractions with Patients and Patient Organizations…18. The Marketplace and Interactions with Healthcare Professionals…18 \\tAntitrust and Competition Laws…19 \\tEnsuring and Monitoring the Safety, Quality and Performance of Our Products…20. Our Commitment…22 \\tPatents, Trademarks and Copyrights…22 \\tBooks and Record Keeping…22 \\tConfidential and Proprietary Information…23 \\tPrivacy of Personal Data…25 \\tRecords and Information Management…26 \\tAcceptable Use of Information Systems…27 \\tConflicts of Interest…28 \\tSocial Media…30 \\tInside Information…31 \\tCompetitive Intelligence…32 \\tGlobal Trade Control Laws…33.  \n",
       "818                                                                                                                                                                                                                                                                                                                                                                                    With XXX manufacturing sites around the world under Pfizer Global Supply (PGS), we harness data to inform our decisions and processes, creating a highly efficient manufacturing and supply network that continually optimizes the way we deliver medicines to our patients. In 2017, we continued to strive to set the industry standard for quality, safety and value in the development and manufacturing of our medicines. Leveraging Science to Create Supply Chain Solutions Pfizer’s goal is for patients to receive uninterrupted access to our medicines and vaccines.  \n",
       "819                                                                                                                                                                                                                                                                                                                             We are committed to the development of publications that report the results of Company-sponsored clinical research studies accurately and objectively and to the disclosure of funding and editorial support. Our policies and procedures aim to ensure respect for the health, well-being and safety of research participants, as well as for the culture, laws and regulations of the countries in which studies are conducted. Our interventional trials adhere to globally recognized principles of international ethics and are prospectively reviewed by a qualified Institutional Review Board or Independent Ethics Committee.  \n",
       "820                                                                                                                                                                                                                                                                                                                                                                                                                                                                             What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments. I interact regularly at work calls me and mentions that a patient of hers on Roche drug X was recently hospitalised with pneumonia and died.  \n",
       "821                                                                                                                                                                                                                                                 The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.  \n",
       "822                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 – Immediately report customer complaints relating to Roche medical devices to the local regulatory and quality function. What should I do if I notice that some finished products coming off the line do not meet Roche quality standards?. If you notice products that do not meet Roche standards, follow the processes as defined in the applicable documentation and if necessary inform your Line Manager and experts from the quality assurance departments.  \n",
       "823                                                                                                                                                                                                                                                                                                                                     A In case of an adverse event you should report at least the following four elements: Patient, Reporter, Event and Product (PREP). Help & advice: In case of questions regarding regulatory compliance, including your obligation to report adverse events and customer complaints relating to Roche products, please contact the responsible experts, e.g. Speak up: If you believe in good faith that in connection with business where Roche is involved someone has done, is doing, or may be about to do something that violates quality standards and good practices, speak up by using the available speak up channels.  \n",
       "824                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.  \n",
       "825                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         A cross-divisional working group has established a checklist on Due Diligence for External Business Partners, mainly focusing on agents and distributors. It includes guidance regarding a risk assessment, including a Human Rights Assessment and Implementation Framework. We maintain and improve operational-level grievance mechanisms, which we understand to encompass also a preventive function.  \n",
       "826                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             – Check for compliance with national and international customs, trade and export control regulations when developing and adapting processes. – Contact the related expert department in a timely manner in case of questions or to address an error. A Every employee asking for the shipment of goods is accountable for providing complete and truthful information for export or import processing.  \n",
       "827                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      If the remuneration is not commensurate with the services provided, you should not accept the consultant’s request. Immediately inform your Line Manager and the local Compliance Officer to discuss an appropriate solution. Roche protects human rights and does not tolerate behaviour by its business partners which is not in line with applicable laws and generally accepted sustainability standards.  \n",
       "828                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Our financial and non­financial reporting consists of the Annual Report, the Finance Report and the online report. It contains the annual financial statements, consolidated financial statements and non­financial performance indicators. The financial reporting scope is defined and outlined in our Finance Report, and there have been no significant changes in scope in XXX compared to XXX  \n",
       "829                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   You should seek guidance from your local logistics department and your local Export Control Officer before processing any shipment. A If you notice an error, you are obliged to timely contact the related expert department to address the issue and contribute to problem solving and implementation. A Roche does not tolerate any violation of the regulations and will take appropriate corrective measures and sanctions.  \n",
       "830                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Our challenge is to focus our efforts where we see the biggest risks and the biggest levers for remediation and improvement. On a global level, we are systematically identifying human rights and identify vulnerable groups, which could be negatively impacted by our businesses. We maintain a system of consistent global standards, which we also apply to our business partners, for example, in areas like R&D, clinical trials, manufacturing and distribution.  \n",
       "831                                                                                                                                                                                                                                                                                                                                                                    Corporate Integrity Q I work in a clinical research unit and have access to identifiable health information which I would like to share with a colleague. A Being active in clinical and genetic research, Roche has to ensure that identifiable health information is processed with care and diligence. As a Roche employee you have a strict obligation to treat such information as confidential and to share it only with colleagues who need to know in order to do their work, in accordance with the purpose the data was obtained for and only if and as allowed under applicable law.  \n",
       "832                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Roche is committed to respecting data privacy and has developed principles that must be consistently applied when processing personal data within the Roche Group and by its business partners. Being active in clinical and genetic research, Roche must ensure that identifiable health information is carefully processed. Roche takes due care to prevent any misuse of or unauthorised access to such identifiable health information within its control.  \n",
       "833                                                                                                                                                                                                                                                                                                                                                                                                                                      Every employee is personally responsible for safety, security, health and environmental protection at the workplace to the full extent required by his/her duties to the best of his/her knowledge, ability and experience. We are all encouraged to identify areas for improvements and continuously work towards a better environment. As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment.  \n",
       "834                                                                                                                                                                                                                                                                                                                                                                                                                       We do this by assessing the risks of potential violations, promoting awareness, fostering due diligence, strengthening the legal framework and collaborating on collective actions, and transparent communication. We identified human rights which are potentially susceptible to violations, as well as their associated risks. To enhance awareness, we created a video that explained human rights and Roche’s endeavours with a simple message to our employees: ‘Within your sphere of influence, ensure human rights are respected.’.  \n",
       "835                                                                                                                                                                                                                                                 The collaboration with society organisations, government bodies and international organisations is essential to identify areas of concerns, and enables Roche have a positive impact on human rights in general. As part of our comprehensive Compliance Management System, we have adopted a policy on safety, security, health and environment of our employees. Similarly, Roche is committed to uphold the freedom of association and the effective recognition of the right of collective bargaining, the elimination of all forms of forced and compulsory labour (including all forms of slavery), the effective abolition of child labour, and the elimination of discrimination in respect of employment.  \n",
       "836                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Our ecological mindset helps customers to address some of their key challenges in lab testing sustainability. At Roche, we aim to minimise the safety, security, health and environmental impacts of our products and devices. Our efforts also help address customer demands for greener products and supply chains, and public concerns about chemicals and pharmaceuticals in the environment.  \n",
       "837                                                                                                                                                                                                                                                                                                                                                                                                                                                                             As part of our commitments towards sustainable development we proactively seek to employ new, more sustainable technologies and processes to minimise our impact on the environment. Roche’s operations are conducted in compliance with applicable health, security, safety and environmental laws and regulations, company standards and best practices. We take all reasonable and practical steps to ensure that we provide a safe, secure, healthy and clean working environment.  \n",
       "838                                                                                                                                                                                                                                                                                    If a meeting in person is needed, reduce the number of participants – send a competent representative instead of a whole team. We are all expected to: – Ensure safety and security, and protect health and the environment at our workplace to the best of our knowledge, ability and experience. In addition, the book “Lifesavers for millions” has been published by Editiones Roche, Speak up: If you believe in good faith that in connection with a business where Roche is involved someone has done, is doing, or may be about to do something that violates the provisions regarding intellectual property rights, speak up by using the available speak up channels.  \n",
       "839                                                                                                                                                                                                                                                                                                                                                                                               These include excessive overtime, improper pay for overtime, insufficient number of rest days, and inadequate payment of social benefits. For example, a sustainability assurance visit at a Chinese supplier of pharmaceutical manufacturing equipment revealed unsatisfactory standards in working conditions, especially with regards to health and safety and the environment. The RocheAbility network, for instance, fosters the inclusion of Basel and Kaiseraugst employees with disabilities and focuses on the strengths and abilities of each individual.  \n",
       "\n",
       "[840 rows x 9 columns]"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results_PfizerRocheJohnson"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## PARTIE TESTS --------------------------------------------------------------"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<div style=\"color:blue;\"> With one or two unordered keywords Tf-Idf is much more powerful to retrieve the proper textchunk, whereas Infersent is a mess !</div>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 511,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>chunk</th>\n",
       "      <th>context</th>\n",
       "      <th>doc index</th>\n",
       "      <th>scores</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>even if an action might have a very</td>\n",
       "      <td>Even if an action might have a very positive en- vironmental and business impact, if you do not  have the resources to implement it, you may  need to start with other actions while working  towards getting the resources required for it.</td>\n",
       "      <td>362</td>\n",
       "      <td>0.44531984194401203</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>and customers will evaluate hotels performance during their</td>\n",
       "      <td>Customers then experience the hotel’s performance when they stay at the hotel and  customers will evaluate hotel’s performance during their stay.</td>\n",
       "      <td>66</td>\n",
       "      <td>0.3382647816612852</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>to evaluate report and improve their environmental performance</td>\n",
       "      <td>EMAS is a management instrument  developed by the European Commission for organisations to evaluate, report, and improve  their environmental performance.</td>\n",
       "      <td>31</td>\n",
       "      <td>0.33504579011448593</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>but action can and also needs to be</td>\n",
       "      <td>But, action can and also needs to be taken  at the level of private individuals, whether as  consumers or businesses.</td>\n",
       "      <td>151</td>\n",
       "      <td>0.32290915359965466</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>actions to start with you can use the</td>\n",
       "      <td>In order to  help you decide on priority actions to start  with, you can use the prioritisation matrix.</td>\n",
       "      <td>359</td>\n",
       "      <td>0.2407440758560424</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                            chunk  \\\n",
       "1                             even if an action might have a very   \n",
       "3     and customers will evaluate hotels performance during their   \n",
       "0  to evaluate report and improve their environmental performance   \n",
       "2                             but action can and also needs to be   \n",
       "4                           actions to start with you can use the   \n",
       "\n",
       "                                                                                                                                                                                                                                        context  \\\n",
       "1  Even if an action might have a very positive en- vironmental and business impact, if you do not  have the resources to implement it, you may  need to start with other actions while working  towards getting the resources required for it.   \n",
       "3                                                                                             Customers then experience the hotel’s performance when they stay at the hotel and  customers will evaluate hotel’s performance during their stay.   \n",
       "0                                                                                    EMAS is a management instrument  developed by the European Commission for organisations to evaluate, report, and improve  their environmental performance.   \n",
       "2                                                                                                                         But, action can and also needs to be taken  at the level of private individuals, whether as  consumers or businesses.   \n",
       "4                                                                                                                                       In order to  help you decide on priority actions to start  with, you can use the prioritisation matrix.   \n",
       "\n",
       "  doc index               scores  \n",
       "1       362  0.44531984194401203  \n",
       "3        66   0.3382647816612852  \n",
       "0        31  0.33504579011448593  \n",
       "2       151  0.32290915359965466  \n",
       "4       359   0.2407440758560424  "
      ]
     },
     "execution_count": 511,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "q='A safety program to evaluate risk and action '\n",
    "data1,data2,data3=QAmodel.predict(q, VE_type='DP',range_chunks=(8,35))\n",
    "data1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['The Final Rule requires registration and results submission for applicable clinical trials (ACTs); clarifies and expands registration data elements; expands scope of results reporting requirements to include trials of unapproved products; clarifies and expands results data elements; and revises Quality Control (QC) and posting process.. Additionally, in January 2018, the FDA launched a new pilot program to evaluate whether disclosing certain information included within clinical study reports (“CSRs”) of approved drugs is beneficial to the public.',\n",
       " 'Sanofi has rigorous policies to identify and evaluate safety risks and to develop preventive safety measures, and methods for checking their efficacy.',\n",
       " 'Should these factors continue, it may require us to re-evaluate the collectability of these receivables in future periods.']"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data1.context.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Sanofi has rigorous policies to identify and evaluate safety risks and to develop preventive safety measures, and methods for checking their efficacy.',\n",
       " 'Oncology SAR408701 SAR439459 SAR439859 SAR439459+cemiplimab SAR439859+palbociclib isatuximab+cemiplimab (RRMM(b)) isatuximab+CyBord (NDMM(c)).',\n",
       " 'The following discussion contains forward-looking statements that involve inherent risks and uncertainties.']"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data2.context.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[]"
      ]
     },
     "execution_count": 150,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data3"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<div style=\"color:blue;\"> With synonym sentences Tf-Idf is unable to retrieve the proper text chunk whereas Infersent achieves it !</div>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "q='Sanofi has plan to determine risks '\n",
    "data1,data2=QAmodel.predict(q, VE_type='DP',range_chunks=(8,35))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['The two most significant arrangements are the Sanofi plan and the Genzyme Limited plan; both are defined-benefit plans, and both have been closed since October 1, 2015.',\n",
       " 'The benchmarks used to determine discount rates were the same in 2017, 2016 and 2015.. (b) The rate depends on the duration of the plan (7 to 10 years and more than 10 years, respectively).',\n",
       " 'agencies worldwide are also considering measures to reduce these risks, such as through Supply Risk Management Plans for some products with high medical need, e.g.']"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data1.context.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Sanofi has rigorous policies to identify and evaluate safety risks and to develop preventive safety measures, and methods for checking their efficacy.',\n",
       " 'Oncology SAR408701 SAR439459 SAR439859 SAR439459+cemiplimab SAR439859+palbociclib isatuximab+cemiplimab (RRMM(b)) isatuximab+CyBord (NDMM(c)).',\n",
       " 'E. Share Ownership\\r \\tSeniorManagement \\tExistingOptionPlansasofDecember31,2017 \\tSharePurchaseOptionPlans \\tShareSubscriptionOptionPlans \\tExistingRestrictedSharePlansasofDecember31,2017 \\tRestrictedSharePlans \\tSharesOwnedbyMembersoftheBoardofDirectors \\tTransactionsinSharesbyMembersoftheBoardofDirectorsandequivalentpersonsin2017.']"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data2.context.tolist()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Improvements and Exploration of models "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 1- PCA rule of thumbs for sentence embedings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[-0.11870896, -0.17141134, -0.25657487, ..., -0.00675341,\n",
       "        -0.00658866,  0.001618  ],\n",
       "       [-0.20133254, -0.11525958, -0.1446851 , ..., -0.00469425,\n",
       "        -0.00567443,  0.01826299],\n",
       "       [-0.21105017, -0.16787814, -0.08773766, ..., -0.01501247,\n",
       "         0.01551257,  0.00610685],\n",
       "       ...,\n",
       "       [ 0.31333008,  0.239265  ,  0.11931197, ..., -0.00172511,\n",
       "         0.00253627, -0.02521423],\n",
       "       [-0.10448226,  0.14699961,  0.1112683 , ...,  0.00347155,\n",
       "        -0.00092772,  0.00507497],\n",
       "       [-0.257527  ,  0.09303123,  0.03653834, ..., -0.00190206,\n",
       "        -0.00399859, -0.00538475]], dtype=float32)"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "pca = decomposition.PCA(n_components=800)\n",
    "pca.fit(QAmodel.inferst.embeddings)\n",
    "plt.plot(np.cumsum(pca.explained_variance_ratio_))\n",
    "plt.xlabel('number of components')\n",
    "plt.ylabel('cumulative explained variance');\n",
    "emb = pca.transform(QAmodel.inferst.embeddings)\n",
    "emb"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2) Tests of sentence embeddings models with cloud visualisation https://github.com/facebookresearch/InferSent "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 303,
   "metadata": {},
   "outputs": [],
   "source": [
    "def normalize(array):\n",
    "    return array/np.linalg.norm(array)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 309,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "IncompatibleKeys(missing_keys=[], unexpected_keys=[])"
      ]
     },
     "execution_count": 309,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "MODEL_PATH = 'dataset/encoder/infersent2.pkl' \n",
    "params_model = {'bsize': 64, 'word_emb_dim': 300, 'enc_lstm_dim': 2048,\n",
    "                'pool_type': 'max', 'dpout_model': 0.0, 'version': 2}\n",
    "infersent = InferSent_(params_model)\n",
    "infersent.load_state_dict(torch.load(MODEL_PATH))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 310,
   "metadata": {},
   "outputs": [],
   "source": [
    "W2V_PATH = 'dataset/fastText/crawl-300d-2M.vec'\n",
    "dic=infersent.set_w2v_path(W2V_PATH)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_w2v(self, word_dict):\n",
    "        assert hasattr(self, 'w2v_path'), 'w2v path not set'\n",
    "        # create word_vec with w2v vectors\n",
    "        word_vec = {}\n",
    "        with open(self.w2v_path) as f:\n",
    "            for line in f:\n",
    "                word, vec = line.split(' ', 1)\n",
    "                if word in word_dict:\n",
    "                    word_vec[word] = np.fromstring(vec, sep=' ')\n",
    "        print('Found %s(/%s) words with w2v vectors' % (len(word_vec), len(word_dict)))\n",
    "        return word_vec"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vocab size : 200000\n"
     ]
    }
   ],
   "source": [
    "infersent.build_vocab_k_words(K=200000)\n",
    "#infersent.update_vocab(list(QAmodel.voc))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings = infersent.encode(['chocolate', 'dance','chemicals',\n",
    "                               'clothes', 'safety'\n",
    "                               ,'animals', 'environment', 'risk',\n",
    "                              ],\n",
    "                              tokenize=True)\n",
    "q_str=\"'hazard products.'\"\n",
    "question=infersent.encode([q_str])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'hazard products'"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "q_str=pdfconverter().remove_non_alpha(q_str)\n",
    "q_str=q_str.replace('.','')\n",
    "q_str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings_normalized=np.apply_along_axis(lambda v: normalize(v), 1,embeddings)\n",
    "question_normalized=normalize(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 504x360 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "from sklearn import decomposition\n",
    "from sklearn import datasets\n",
    "import matplotlib.pyplot as plt\n",
    "from mpl_toolkits.mplot3d import Axes3D\n",
    "import numpy as np\n",
    "\n",
    "from sklearn import decomposition\n",
    "from sklearn import datasets\n",
    "\n",
    "np.random.seed(5)\n",
    "\n",
    "centers = [[1, 1], [-1, -1], [1, -1]]\n",
    "iris = datasets.load_iris()\n",
    "X =embeddings_normalized\n",
    "Q=question_normalized\n",
    "y=np.array(range(8))\n",
    "\n",
    "fig = plt.figure(1, figsize=(7, 5))\n",
    "plt.clf()\n",
    "ax = Axes3D(fig, rect=[0, 0, .95, 1], elev=48, azim=134)\n",
    "\n",
    "plt.cla()\n",
    "pca = decomposition.PCA(n_components=3)\n",
    "pca.fit(X)\n",
    "X = pca.transform(X)\n",
    "Q=pca.transform(Q)\n",
    "dic={'Chocolate':0, 'Dance':1, 'Chemicals':2,'Clothes':3,'Safety':4,'Animals':5, 'Environment':6,'Risk':7}\n",
    "\n",
    "for name, label in dic.items():\n",
    "    ax.text3D(X[y == label, 0].mean()+0.1,\n",
    "              X[y == label, 1].mean(),\n",
    "              X[y == label, 2].mean(),name,\n",
    "              horizontalalignment='center',\n",
    "              bbox=dict(alpha=.1, edgecolor='w', facecolor='w'))\n",
    "    \n",
    "ax.text3D(Q[0, 0].mean()+0.1,Q[0, 1].mean(),Q[0, 2].mean(),'Question: '+q_str,horizontalalignment='center',\n",
    "          bbox=dict(alpha=.1, edgecolor='w', facecolor='w'))\n",
    "\n",
    "# Reorder the labels to have colors matching the cluster results\n",
    "y = np.choose(y, range(8)).astype(np.float)\n",
    "ax.scatter(X[:, 0], X[:, 1], X[:, 2], c=y, edgecolor='k')\n",
    "ax.scatter(Q[:,0],Q[:,1],Q[:,2],c='red',edgecolor='k')\n",
    "\n",
    "ax.w_xaxis.set_ticklabels([])\n",
    "ax.w_yaxis.set_ticklabels([])\n",
    "ax.w_zaxis.set_ticklabels([])\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[0.6139592 ],\n",
       "       [0.5630848 ],\n",
       "       [0.7196866 ],\n",
       "       [0.6994362 ],\n",
       "       [0.70133   ],\n",
       "       [0.6499989 ],\n",
       "       [0.74974275],\n",
       "       [0.6651032 ]], dtype=float32)"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "embeddings_normalized.dot(question_normalized.T)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 360,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>scores</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0.749743</td>\n",
       "      <td>Environment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.719687</td>\n",
       "      <td>Chemicals</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.701330</td>\n",
       "      <td>Safety</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.699436</td>\n",
       "      <td>Clothes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>0.665103</td>\n",
       "      <td>Risk</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>0.649999</td>\n",
       "      <td>Animals</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.613959</td>\n",
       "      <td>Chocolate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.563085</td>\n",
       "      <td>Dance</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     scores        label\n",
       "6  0.749743  Environment\n",
       "2  0.719687    Chemicals\n",
       "4  0.701330       Safety\n",
       "3  0.699436      Clothes\n",
       "7  0.665103         Risk\n",
       "5  0.649999      Animals\n",
       "0  0.613959    Chocolate\n",
       "1  0.563085        Dance"
      ]
     },
     "execution_count": 360,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "scores=embeddings_normalized.dot(question_normalized.T)\n",
    "df=pd.DataFrame(np.c_[scores,y],columns=['scores','label']).sort_values(by=['scores'],ascending=False)\n",
    "df['label']=df['label'].apply(lambda k: list(dic.keys())[list(dic.values()).index(k)])\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "[7.6171875,\n",
       " 15.380859375,\n",
       " 2.8564453125,\n",
       " 6.4208984375,\n",
       " 9.4970703125,\n",
       " 4.2724609375,\n",
       " 8.6669921875,\n",
       " 7.421875,\n",
       " 3.9306640625,\n",
       " 3.662109375,\n",
       " 9.0087890625,\n",
       " 13.818359375,\n",
       " 7.4462890625]"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "obs=QAmodel.inferst.infersent.visualize('Does the company operate in countries out of the European Union')\n",
    "obs[2]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3) Elastic Search for faster indexing"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 4) Automatic Querry Generator (using Infersent word importance)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_querry(querries):\n",
    "    querries=[pdfconverter().remove_non_alpha(q) for q in querries]    \n",
    "    sentences=[s[0].lower()+s[1:].replace('?','')  for s in querries]\n",
    "    i=0\n",
    "    important_words=[]\n",
    "    unsorted_words=[]\n",
    "    \n",
    "    for qu in sentences:\n",
    "        \n",
    "        #Get scores from infersent visualization function (max-pooling et each layer)\n",
    "        tensor,vector,scores,words=QAmodel.inferst.infersent.visualize(qu)\n",
    "        scores=np.array(scores[1:len(scores)-1])\n",
    "        words=np.array(words[1:len(words)-1])\n",
    "        \n",
    "        #Remove stopwords from querries and attributed scores\n",
    "        pos=[i for i,c in enumerate(list(words)) if c not in QAmodel.retriever.stop_words_list]\n",
    "        words=words[pos]\n",
    "        scores=np.array(scores)[pos]\n",
    "        scores=scores/np.sum(scores)\n",
    "        \n",
    "        #Sort query words by word importance keeping idx in memory to unsort it back\n",
    "        data=pd.DataFrame(np.c_[words,scores],columns=['word','score'])\n",
    "        idx=np.argsort(-np.array(data.score.values,dtype='float64'))\n",
    "        idx_unsort=np.argsort(idx)\n",
    "        data=data.sort_values(by=['score'],ascending=False)\n",
    "        new_words=data.word.values\n",
    "        new_scores=np.array(data.score.values,dtype=float)\n",
    "        \n",
    "        #Keeping a set of words that satisfy 70% of cumulative importance\n",
    "        score_cum=np.cumsum(new_scores)\n",
    "        pos=score_cum<0.75\n",
    "        lw=new_words[pos]\n",
    "        ls=new_scores[pos]\n",
    "        lw_unsort=words[pos[idx]]\n",
    "        \n",
    "        important_words.append(lw)\n",
    "        unsorted_words.append(lw_unsort)\n",
    "        i+=1\n",
    "    \n",
    "    return pd.DataFrame(np.c_[querries, important_words,unsorted_words],columns=['query','words_sort','words_unsort'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Test on annual reports of top chemicals companies "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "questions=['Does the company operate in countries out of the European Union?',\n",
    "'Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries',\n",
    "'Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?',\n",
    "'Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?',\n",
    "'Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?',\n",
    "           'Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?',\n",
    "'Has the company formalized  a strategy to reduce its greenhouse gas  emissions?',\n",
    "'Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?',\n",
    "'Does the company monitor performance indicators to assess its progress compared to its climate related commitments?',\n",
    "'Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?',\n",
    "'Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?',\n",
    "'Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)',\n",
    "'Does the company monitor performance indicators with regard to health & safety for aspects for workers relying on frequency or severity rates ?',\n",
    "'Is there a crisis management scheme to cope with an identified issue on product safety?']\n",
    "\n",
    "#data=generate_querry(questions)\n",
    "#data     "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>query</th>\n",
       "      <th>words_sort</th>\n",
       "      <th>words_unsort</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union</td>\n",
       "      <td>[Union, does, operate, countries]</td>\n",
       "      <td>[company, operate, countries, Union]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Is at least one of the companys production facilities classified as Seveso High European Detective or equivalent in other countries</td>\n",
       "      <td>[Seveso, countries, Detective, facilities, classified, production]</td>\n",
       "      <td>[companys, classified, Seveso, High, Detective, countries]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                 query  \\\n",
       "0                                                                      Does the company operate in countries out of the European Union   \n",
       "1  Is at least one of the companys production facilities classified as Seveso High European Detective or equivalent in other countries   \n",
       "\n",
       "                                                           words_sort  \\\n",
       "0                                   [Union, does, operate, countries]   \n",
       "1  [Seveso, countries, Detective, facilities, classified, production]   \n",
       "\n",
       "                                                 words_unsort  \n",
       "0                        [company, operate, countries, Union]  \n",
       "1  [companys, classified, Seveso, High, Detective, countries]  "
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "questions=['Does the company operate in countries out of the European Union?',\n",
    "'Is at least one of the company’s production facilities classified as Seveso « High » (European Detective) or equivalent in other countries',\n",
    "          ]\n",
    "data=generate_querry(questions)\n",
    "data     "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Get Answers and display it nicely"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'questions' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-1-bb199a0dcf99>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      5\u001b[0m \u001b[0manswers_be\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      6\u001b[0m \u001b[0mqux\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 7\u001b[0;31m \u001b[0;32mfor\u001b[0m \u001b[0mq\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mquestions\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      8\u001b[0m     \u001b[0;32mfor\u001b[0m \u001b[0mj\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mrange\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;36m2\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      9\u001b[0m         \u001b[0mqux\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mq\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'questions' is not defined"
     ]
    }
   ],
   "source": [
    "from IPython.display import display\n",
    "cq=1\n",
    "answers_tf=[]\n",
    "answers_if=[]\n",
    "answers_be=[]\n",
    "qux=[]\n",
    "for q in questions:\n",
    "    for j in range(2):\n",
    "        qux.append(q)\n",
    "sequence=['Sanofi','BasF']*len(data.words_unsort)\n",
    "for i in range(0,len(data.words_unsort)):\n",
    "    L=data.loc[i,'words_unsort']\n",
    "    for x in range(2):\n",
    "        d1,d2,d3=QAmodel.predict(' '.join(L), VE_type='DP',range_chunks=(8,35))\n",
    "        d3,d4,d5=QAmodel.predict(questions[i], VE_type='DP',range_chunks=(8,35))\n",
    "        contextd1=str([ c+\" ( \"+str(np.round(float(d1.scores.tolist()[i]),2))+\" ) \" for i,c in  enumerate(d1.context.tolist())])\n",
    "        contextd4=str([ c+\" ( \"+str(np.round(float(d4.score.tolist()[i]),2))+\" ) \" for i,c in  enumerate(d4.context.tolist())])\n",
    "        contextd5=str([ c+\" ( \"+str(np.round(float(d5.score.tolist()[i]),2))+\" ) \" for i,c in  enumerate(d5.context.tolist())])\n",
    "        answers_tf.append(contextd1)\n",
    "        answers_if.append(contextd4)\n",
    "        answers_be.append(contextd5)\n",
    "data_show=pd.DataFrame(np.c_[qux,sequence,answers_tf,answers_if,answers_be],columns=['Question','Company','Tf-Idf','Infersent','Bert'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'sequence' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-111-d6446e2641d7>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mdata_show\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mpd\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mDataFrame\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mc_\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mqux\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0msequence\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0manswers_tf\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0manswers_if\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0manswers_be\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mcolumns\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'Question'\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m'Company'\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m'Tf-Idf'\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m'Infersent'\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m'Bert'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'sequence' is not defined"
     ]
    }
   ],
   "source": [
    "data_show=pd.DataFrame(np.c_[qux,sequence,answers_tf,answers_if,answers_be],columns=['Question','Company','Tf-Idf','Infersent','Bert'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(7845, 1178)"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "QAmodel.tf_idf_farahat.TF_FARAHAT_emb.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 158,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Company</th>\n",
       "      <th>Tf-Idf</th>\n",
       "      <th>Infersent</th>\n",
       "      <th>Bert</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['It encompasses how Sanofi promotes and respects human rights in our business operations in all countries where we operate. ( 0.59 ) ', 'In all countries where we operate, we seek to strike a bal...</td>\n",
       "      <td>['European countries including the United Kingdom, Belgium, France, Germany, the Netherlands, Italy and Norway. ( 0.51 ) ', 'European Patent Convention accession of some current European Patent Co...</td>\n",
       "      <td>['European countries including the United Kingdom, Belgium, France, Germany, the Netherlands, Italy and Norway. ( 0.58 ) ', 'Specific situations may vary by country, most notably with respect to o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['The working conditions of our employees are, at minimum, in compliance with internationally recognized labor standards and the laws of the countries we operate in. ( 0.61 ) ', 'BASF will hold a ...</td>\n",
       "      <td>['The “IAS Regulation” made the application of IFRSs mandatory for listed companies headquartered in the European Union starting in 2005. ( 0.48 ) ', 'This is why the BASF Europa Betriebsrat (Euro...</td>\n",
       "      <td>['This is why the BASF Europa Betriebsrat (European Works Council) addresses cross-border matters in Europe. ( 0.6 ) ', 'For certain companies outside the eurozone or U.S. dollar zone, the euro or...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as Seveso « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['The French chemical manufacturing sites in Aramon, Sisteron and Vertolaye, as well as the plants located in the Hoechst Industry Park in Frankfurt, Germany, and the chemical production site in B...</td>\n",
       "      <td>['Our headquarters are located in France and the intellectual property of many of\\xa0our\\xa0leading products originates from Western Europe. ( 0.37 ) ', 'European Patent Convention accession of so...</td>\n",
       "      <td>['Global markets are supplied from our facilities at Compiègne (France), Origgio (Italy), Cologne (Germany) and Veresegyház (Hungary). ( 0.54 ) ', 'INFORMATION ON THE COMPANYcomposed of a central ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as Seveso « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['BASF will lose control over the oil and gas activities as a result of the agreements signed by the shareholders on the management of the newly created company, and therefore classified these act...</td>\n",
       "      <td>['These include the Verbund site in Geismar, Louisiana, as well as another 19 sites in Brazil, India, Malaysia, Thailand, France and the Netherlands, among other countries. ( 0.33 ) ', 'At the Lud...</td>\n",
       "      <td>['Specifically, this refers to Solvay’s production plants and innovation competencies in the engineering plastics field in Europe. ( 0.47 ) ', 'For certain companies outside the eurozone or U.S. d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['Muzammil Mansuri Executive Vice President, Strategy and Business Development Date of birth: January 20, 1954 Muzammil Mansuri holds a Bachelor of Science degree in Chemistry and a Ph.D. in Organ...</td>\n",
       "      <td>['The term “Regenerative Medicinal Products” used in the law includes cellular and tissue-based products and gene therapies. ( 0.48 ) ', 'Nutritionals ■ Pharmaton® is a range of products which con...</td>\n",
       "      <td>['Nutritionals ■ Pharmaton® is a range of products which contain vitamins, minerals and standardized Ginseng Extract G115. ( 0.56 ) ', 'Waste generated in operations: 371,036 tCO2 e Definition: Th...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['Research here concentrates on supramolecular chemistry as well as nanotechnology and polymer chemistry. ( 0.35 ) ', 'In addition, we are also involved in initiatives such as workshops and traini...</td>\n",
       "      <td>['The Performance Products segment consists of the Dispersions &amp; Pigments, Care Chemicals, Nutrition &amp; Health and Performance Chemicals divisions. ( 0.52 ) ', 'Use in the BASF Verbund Plastics, co...</td>\n",
       "      <td>['Cosmetics industry, detergent and cleaner industry, agrochemical industry, technical applications for various industries, hygiene industry Nutrition &amp; Health Additives for the food and feed indu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['It requires the full commitment of the entire Company, from top executives to each individual in our operations around the globe. ( 0.31 ) ', 'On January 2019, the Ministry for Environment launc...</td>\n",
       "      <td>['Responsible use of water: specific operating procedures govern the use of water during manufacturing and heat exchanges and promote reduced consumption. ( 0.4 ) ', 'Deforestation, water pollutio...</td>\n",
       "      <td>['The SBTi provides a framework for companies to define how much and how quickly we must reduce our GHG emissions. ( 0.74 ) ', 'Sanofi is committed to reducing our carbon footprint by adopting res...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['This plastic is used for applications ranging from the soles of high tech running shoes and shock absorbers for vehicle engines to insulation for refrigerators and buildings. ( 0.41 ) ', 'Emissi...</td>\n",
       "      <td>['CDP’s evaluation of sustainable water management includes how transparently companies report on their water manage ment activities and what they do to reduce risks, such as water scarcity. ( 0.4...</td>\n",
       "      <td>['The reporting standards and recommendations for implementing projects to reduce emissions are jointly developed by companies, nongovernmental organizations and governments under the guidance of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['To safeguard continuity of operations and secure timely execution of its core tasks, the EMA has launched a Business Continuity Plan (BCP). ( 0.44 ) ', 'See also below “– Global economic conditi...</td>\n",
       "      <td>['Provisions for environmental risks and remediation mainly relate to contingencies arising from business divestitures. ( 0.35 ) ', 'Sanofi’s activities Supply chain Access to healthcare for the u...</td>\n",
       "      <td>['and result in better knowledge of risk in the workplace to promote the implementation of preventive measures. ( 0.66 ) ', 'The complexity of these processes, as well as strict internal and healt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['In the event of a crisis, our global, regional or local emergency response plans and crisis management structures are engaged, depending on the impact scope. ( 0.29 ) ', 'In the event of a produ...</td>\n",
       "      <td>['We regularly check our emergency systems, crisis management structures and drill procedures with employees, contractors, local authorities and emergency rescue workers. ( 0.36 ) ', 'To address t...</td>\n",
       "      <td>['In order to maintain the highest level of safety at our plants across their entire life cycle, we review the implementation of our protection plans in all facilities at regular intervals and dep...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['Specialist site visits are conducted every year to address specific needs, such as testing of sprinkler systems or emergency plans to deal with flooding risks. ( 0.34 ) ', 'Provisions for enviro...</td>\n",
       "      <td>['Provisions for environmental risks and remediation mainly relate to contingencies arising from business divestitures. ( 0.36 ) ', 'We take a preventive approach by seeking to avoid accidents and...</td>\n",
       "      <td>['Factors – Environmental Risks of Our Industrial Activities – Risks from the handling of hazardous materials could adversely affect our results of operations”. ( 0.68 ) ', 'Environmental Risks of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['In the event of a production outage – caused by an accident, for example – our global, regional or local emergency response plans and crisis management structures are engaged, depending on the i...</td>\n",
       "      <td>['We regularly check our emergency systems, crisis management structures and drill procedures with employees, contractors, local authorities and emergency rescue workers. ( 0.39 ) ', 'The wastewat...</td>\n",
       "      <td>['In the event of a production outage – caused by an accident, for example – our global, regional or local emergency response plans and crisis management structures are engaged, depending on the i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Has the company formalized  a strategy to reduce its greenhouse gas  emissions?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['Sanofi is committed to reducing our carbon footprint by adopting responsible practices to reduce our greenhouse gas emissions throughout the world. ( 0.64 ) ', 'Through our Stakeholder Committee...</td>\n",
       "      <td>['Mitigation: reducing Sanofi’s greenhouse gas (GHG) emissions, which are the first driver of climate change. ( 0.58 ) ', 'Our mitigation strategy for climate change involves limiting our greenhou...</td>\n",
       "      <td>['This study was designed to identify activities that could be modified to reduce energy consumption and CO2 emissions. ( 0.75 ) ', 'The SBTi provides a framework for companies to define how much ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Has the company formalized  a strategy to reduce its greenhouse gas  emissions?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['Analysis shows that in addition to ecological and economic advantages, these can reduce greenhouse gas emissions by an average of 85% per metric ton of feed. ( 0.64 ) ', 'The program targets new...</td>\n",
       "      <td>['When deciding on investments and acquisitions, we systematically consider the effects on greenhouse gas emissions. ( 0.59 ) ', 'The program targets new technologies to significantly reduce green...</td>\n",
       "      <td>['The reporting standards and recommendations for implementing projects to reduce emissions are jointly developed by companies, nongovernmental organizations and governments under the guidance of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['Sanofi is committed to reducing our carbon footprint by adopting responsible practices to reduce our greenhouse gas emissions throughout the world. ( 0.64 ) ', 'We have identified five major env...</td>\n",
       "      <td>['Mitigation: reducing Sanofi’s greenhouse gas (GHG) emissions, which are the first driver of climate change. ( 0.57 ) ', 'Sanofi is committed to reducing our carbon footprint by adopting responsi...</td>\n",
       "      <td>['This study was designed to identify activities that could be modified to reduce energy consumption and CO2 emissions. ( 0.81 ) ', 'Our mitigation strategy for climate change involves limiting ou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['We offer our customers solutions that help prevent greenhouse gas emissions and improve energy and resource efficiency. ( 0.69 ) ', 'This reports on all greenhouse gas emissions along the value ...</td>\n",
       "      <td>['We offer our customers solutions that help prevent greenhouse gas emissions and improve energy and resource efficiency. ( 0.61 ) ', 'The program targets new technologies to significantly reduce ...</td>\n",
       "      <td>['We offer our customers solutions that help prevent greenhouse gas emissions and improve energy and resource efficiency. ( 0.79 ) ', '• You use resources efficiently, apply energy-efficient and e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress compared to its climate related commitments?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['Any material deterioration in Regeneron’s share price or financial performance would be an indicator that the value of our investment might have become impaired. ( 0.52 ) ', 'Sanofi was an offic...</td>\n",
       "      <td>['This feedback helps identify and prioritize opportunities to improve employee engagement and organizational performance. ( 0.51 ) ', 'This process involves identifying and prioritizing topics ac...</td>\n",
       "      <td>['It\\xa0demonstrates our contribution to the major challenges and key issues that Sanofi must address today, linking sustainability performance to business results. ( 0.59 ) ', 'Every year, steps ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress compared to its climate related commitments?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['The ROCE of the particular financial year serves as the key performance indicator for the success of the company when determining the performance bonus. ( 0.52 ) ', '– Until the end of 2017, the...</td>\n",
       "      <td>['For example, the material topic “energy and climate” is analyzed to enable us to identify, assess and manage climate-related risks and opportunities. ( 0.56 ) ', 'It can be used to evaluate and ...</td>\n",
       "      <td>['We continuously analyze potential risks to our business operations arising in connection with the topics of energy and climate protection and derive appropriate measures. ( 0.64 ) ', 'We plan ou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['At the site, a specific energy policy supports this approach by strongly encouraging the control of energy consumption, energy-efficient purchasing and the replacement of equipment by identical ...</td>\n",
       "      <td>['The performance of those segments is monitored individually using internal reports and common indicators. ( 0.36 ) ', 'The performance of those segments is monitored individually using internal ...</td>\n",
       "      <td>['Fuel and energy-related activities Use of data related to energy consumption from industrial and R&amp;D sites and assumptions to calculate emissions from the tertiary sites . ( 0.66 ) ', 'Levers of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['We are constantly working to optimize our energy consumption and the amount of water we use, and to adapt to the needs of our business and the environment. ( 0.43 ) ', 'To address specific risks...</td>\n",
       "      <td>['It can be used to evaluate and compare the environmental impact, costs and social aspects of products and manufacturing processes. ( 0.34 ) ', 'They focus on tailor-made solutions enabling custo...</td>\n",
       "      <td>['In long-term estimates, assumptions were made regarding factors such as inflation, production quantities and costs as well as energy efficiency and the substitution of energy sources. ( 0.65 ) '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['Sanofi is committed to reducing our carbon footprint by adopting responsible practices to reduce our greenhouse gas emissions throughout the world. ( 0.42 ) ', 'We have identified five major env...</td>\n",
       "      <td>['Mitigation: reducing Sanofi’s greenhouse gas (GHG) emissions, which are the first driver of climate change. ( 0.46 ) ', 'Our mitigation strategy for climate change involves limiting our greenhou...</td>\n",
       "      <td>['The SBTi provides a framework for companies to define how much and how quickly we must reduce our GHG emissions. ( 0.57 ) ', 'Fuel and energy-related activities Use of data related to energy con...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['We report on greenhouse gas emissions in accordance with the Greenhouse Gas Protocol Standard as well as the sector-specific standard for the chemical industry. ( 0.49 ) ', 'From 2019 onward, we...</td>\n",
       "      <td>['When deciding on investments and acquisitions, we systematically consider the effects on greenhouse gas emissions. ( 0.65 ) ', 'Engagements on Greenhouse Gas Statements), the relevant internatio...</td>\n",
       "      <td>['We report on greenhouse gas emissions in accordance with the Greenhouse Gas Protocol Standard as well as the sector-specific standard for the chemical industry. ( 0.66 ) ', 'When deciding on inv...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of s...</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['The following discussion does not address the French tax consequences applicable to Securities held in trusts. ( 0.27 ) ', 'It also incorporates a prevention program, including a comprehensive s...</td>\n",
       "      <td>['In order to implement this master policy, Sanofi key requirements have been drawn up in the key fields of HSE management, HSE leadership, safety in the workplace, process safety, occupational hy...</td>\n",
       "      <td>['In order to implement this master policy, Sanofi key requirements have been drawn up in the key fields of HSE management, HSE leadership, safety in the workplace, process safety, occupational hy...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of s...</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['Other digital solutions will enable us to perform predictive maintenance or efficiently simulate maintenance and production processes in digital plant models. ( 0.27 ) ', 'In the previous year, ...</td>\n",
       "      <td>['Our experts have developed a protection plan with the appropriate safety inspections for every plant that considers the key aspects of safety, health and environmental protection – from concepti...</td>\n",
       "      <td>['• You ensure by using appropriate management systems that product quality and safety meet the applicable requirements. ( 0.7 ) ', 'During our audits, we create a safety and environmental profile...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health &amp; safety for aspects for workers relying on frequency or severity rates ?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['Severity rate for Sanofi employees Sanofi has chosen to disclose the total reportable injury frequency rate as a severity indicator, as this takes into account all injuries with a significant se...</td>\n",
       "      <td>['Employees receive information and training about the types of risks and prevention, personal protective equipment, and personal hygiene. ( 0.38 ) ', 'This feedback helps identify and prioritize ...</td>\n",
       "      <td>['Recognizing professionalism in occupational hygiene training \\tEmployee wellness and disease prevention ( 0.71 ) ', 'The broad range of initiatives to ensure our employees’ health and well-being...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Does the company monitor performance indicators with regard to health &amp; safety for aspects for workers relying on frequency or severity rates ?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['It can be used to evaluate and compare the environmental impact, costs and social aspects of products and manufacturing processes. ( 0.21 ) ', 'With the initiative, the project members aim to im...</td>\n",
       "      <td>['• You enable your employees and other stakeholders to report concerns or potentially unlawful practices at the workplace. ( 0.39 ) ', 'We assess the potential risks and weak points of all our ac...</td>\n",
       "      <td>['• You ensure by using appropriate management systems that product quality and safety meet the applicable requirements. ( 0.71 ) ', 'For more information on occupational medicine, health campaign...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>['In the event of a liquidity crisis, we could be exposed to difficulties in calling up our available cash, a scarcity of sources of funding including the above-mentioned programs, and/or a deteri...</td>\n",
       "      <td>['This feedback helps identify and prioritize opportunities to improve employee engagement and organizational performance. ( 0.33 ) ', 'Decisions concerning the studies to be carried out can have ...</td>\n",
       "      <td>['Health authorities are increasingly focusing on product safety and on the risk/benefit profile of pharmaceutical products. ( 0.71 ) ', 'It is possible for the regulatory authorities to withdraw ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Is there a crisis management scheme to cope with an identified issue on product safety?</td>\n",
       "      <td>BasF</td>\n",
       "      <td>['In the event of a crisis, our global, regional or local emergency response plans and crisis management structures are engaged, depending on the impact scope. ( 0.57 ) ', 'In the event of a produ...</td>\n",
       "      <td>['• You ensure by using appropriate management systems that product quality and safety meet the applicable requirements. ( 0.36 ) ', 'We analyze the potential safety and security risks associated ...</td>\n",
       "      <td>['• You ensure by using appropriate management systems that product quality and safety meet the applicable requirements. ( 0.78 ) ', 'We stipulate globally mandatory standards for safety, security...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                   Question  \\\n",
       "0                                                                                                                                          Does the company operate in countries out of the European Union?   \n",
       "1                                                                                                                                          Does the company operate in countries out of the European Union?   \n",
       "2                                                                Is at least one of the company’s production facilities classified as Seveso « High » (European Detective) or equivalent in other countries   \n",
       "3                                                                Is at least one of the company’s production facilities classified as Seveso « High » (European Detective) or equivalent in other countries   \n",
       "4                                                             Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?   \n",
       "5                                                             Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers?   \n",
       "6                                                                                          Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "7                                                                                          Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "8                                                   Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "9                                                   Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "10                                                                                    Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?   \n",
       "11                                                                                    Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?   \n",
       "12                                                                                                                          Has the company formalized  a strategy to reduce its greenhouse gas  emissions?   \n",
       "13                                                                                                                          Has the company formalized  a strategy to reduce its greenhouse gas  emissions?   \n",
       "14                                                 Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?   \n",
       "15                                                 Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?   \n",
       "16                                                                                      Does the company monitor performance indicators to assess its progress compared to its climate related commitments?   \n",
       "17                                                                                      Does the company monitor performance indicators to assess its progress compared to its climate related commitments?   \n",
       "18                                                                             Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?   \n",
       "19                                                                             Does the company monitor performance indicators to assess its progress with regard to energy consumption  per tons produced?   \n",
       "20                                                                                          Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?   \n",
       "21                                                                                          Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?   \n",
       "22  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of s...   \n",
       "23  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of s...   \n",
       "24                                                          Does the company monitor performance indicators with regard to health & safety for aspects for workers relying on frequency or severity rates ?   \n",
       "25                                                          Does the company monitor performance indicators with regard to health & safety for aspects for workers relying on frequency or severity rates ?   \n",
       "26                                                                                                                  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "27                                                                                                                  Is there a crisis management scheme to cope with an identified issue on product safety?   \n",
       "\n",
       "   Company  \\\n",
       "0   Sanofi   \n",
       "1     BasF   \n",
       "2   Sanofi   \n",
       "3     BasF   \n",
       "4   Sanofi   \n",
       "5     BasF   \n",
       "6   Sanofi   \n",
       "7     BasF   \n",
       "8   Sanofi   \n",
       "9     BasF   \n",
       "10  Sanofi   \n",
       "11    BasF   \n",
       "12  Sanofi   \n",
       "13    BasF   \n",
       "14  Sanofi   \n",
       "15    BasF   \n",
       "16  Sanofi   \n",
       "17    BasF   \n",
       "18  Sanofi   \n",
       "19    BasF   \n",
       "20  Sanofi   \n",
       "21    BasF   \n",
       "22  Sanofi   \n",
       "23    BasF   \n",
       "24  Sanofi   \n",
       "25    BasF   \n",
       "26  Sanofi   \n",
       "27    BasF   \n",
       "\n",
       "                                                                                                                                                                                                     Tf-Idf  \\\n",
       "0   ['It encompasses how Sanofi promotes and respects human rights in our business operations in all countries where we operate. ( 0.59 ) ', 'In all countries where we operate, we seek to strike a bal...   \n",
       "1   ['The working conditions of our employees are, at minimum, in compliance with internationally recognized labor standards and the laws of the countries we operate in. ( 0.61 ) ', 'BASF will hold a ...   \n",
       "2   ['The French chemical manufacturing sites in Aramon, Sisteron and Vertolaye, as well as the plants located in the Hoechst Industry Park in Frankfurt, Germany, and the chemical production site in B...   \n",
       "3   ['BASF will lose control over the oil and gas activities as a result of the agreements signed by the shareholders on the management of the newly created company, and therefore classified these act...   \n",
       "4   ['Muzammil Mansuri Executive Vice President, Strategy and Business Development Date of birth: January 20, 1954 Muzammil Mansuri holds a Bachelor of Science degree in Chemistry and a Ph.D. in Organ...   \n",
       "5   ['Research here concentrates on supramolecular chemistry as well as nanotechnology and polymer chemistry. ( 0.35 ) ', 'In addition, we are also involved in initiatives such as workshops and traini...   \n",
       "6   ['It requires the full commitment of the entire Company, from top executives to each individual in our operations around the globe. ( 0.31 ) ', 'On January 2019, the Ministry for Environment launc...   \n",
       "7   ['This plastic is used for applications ranging from the soles of high tech running shoes and shock absorbers for vehicle engines to insulation for refrigerators and buildings. ( 0.41 ) ', 'Emissi...   \n",
       "8   ['To safeguard continuity of operations and secure timely execution of its core tasks, the EMA has launched a Business Continuity Plan (BCP). ( 0.44 ) ', 'See also below “– Global economic conditi...   \n",
       "9   ['In the event of a crisis, our global, regional or local emergency response plans and crisis management structures are engaged, depending on the impact scope. ( 0.29 ) ', 'In the event of a produ...   \n",
       "10  ['Specialist site visits are conducted every year to address specific needs, such as testing of sprinkler systems or emergency plans to deal with flooding risks. ( 0.34 ) ', 'Provisions for enviro...   \n",
       "11  ['In the event of a production outage – caused by an accident, for example – our global, regional or local emergency response plans and crisis management structures are engaged, depending on the i...   \n",
       "12  ['Sanofi is committed to reducing our carbon footprint by adopting responsible practices to reduce our greenhouse gas emissions throughout the world. ( 0.64 ) ', 'Through our Stakeholder Committee...   \n",
       "13  ['Analysis shows that in addition to ecological and economic advantages, these can reduce greenhouse gas emissions by an average of 85% per metric ton of feed. ( 0.64 ) ', 'The program targets new...   \n",
       "14  ['Sanofi is committed to reducing our carbon footprint by adopting responsible practices to reduce our greenhouse gas emissions throughout the world. ( 0.64 ) ', 'We have identified five major env...   \n",
       "15  ['We offer our customers solutions that help prevent greenhouse gas emissions and improve energy and resource efficiency. ( 0.69 ) ', 'This reports on all greenhouse gas emissions along the value ...   \n",
       "16  ['Any material deterioration in Regeneron’s share price or financial performance would be an indicator that the value of our investment might have become impaired. ( 0.52 ) ', 'Sanofi was an offic...   \n",
       "17  ['The ROCE of the particular financial year serves as the key performance indicator for the success of the company when determining the performance bonus. ( 0.52 ) ', '– Until the end of 2017, the...   \n",
       "18  ['At the site, a specific energy policy supports this approach by strongly encouraging the control of energy consumption, energy-efficient purchasing and the replacement of equipment by identical ...   \n",
       "19  ['We are constantly working to optimize our energy consumption and the amount of water we use, and to adapt to the needs of our business and the environment. ( 0.43 ) ', 'To address specific risks...   \n",
       "20  ['Sanofi is committed to reducing our carbon footprint by adopting responsible practices to reduce our greenhouse gas emissions throughout the world. ( 0.42 ) ', 'We have identified five major env...   \n",
       "21  ['We report on greenhouse gas emissions in accordance with the Greenhouse Gas Protocol Standard as well as the sector-specific standard for the chemical industry. ( 0.49 ) ', 'From 2019 onward, we...   \n",
       "22  ['The following discussion does not address the French tax consequences applicable to Securities held in trusts. ( 0.27 ) ', 'It also incorporates a prevention program, including a comprehensive s...   \n",
       "23  ['Other digital solutions will enable us to perform predictive maintenance or efficiently simulate maintenance and production processes in digital plant models. ( 0.27 ) ', 'In the previous year, ...   \n",
       "24  ['Severity rate for Sanofi employees Sanofi has chosen to disclose the total reportable injury frequency rate as a severity indicator, as this takes into account all injuries with a significant se...   \n",
       "25  ['It can be used to evaluate and compare the environmental impact, costs and social aspects of products and manufacturing processes. ( 0.21 ) ', 'With the initiative, the project members aim to im...   \n",
       "26  ['In the event of a liquidity crisis, we could be exposed to difficulties in calling up our available cash, a scarcity of sources of funding including the above-mentioned programs, and/or a deteri...   \n",
       "27  ['In the event of a crisis, our global, regional or local emergency response plans and crisis management structures are engaged, depending on the impact scope. ( 0.57 ) ', 'In the event of a produ...   \n",
       "\n",
       "                                                                                                                                                                                                  Infersent  \\\n",
       "0   ['European countries including the United Kingdom, Belgium, France, Germany, the Netherlands, Italy and Norway. ( 0.51 ) ', 'European Patent Convention accession of some current European Patent Co...   \n",
       "1   ['The “IAS Regulation” made the application of IFRSs mandatory for listed companies headquartered in the European Union starting in 2005. ( 0.48 ) ', 'This is why the BASF Europa Betriebsrat (Euro...   \n",
       "2   ['Our headquarters are located in France and the intellectual property of many of\\xa0our\\xa0leading products originates from Western Europe. ( 0.37 ) ', 'European Patent Convention accession of so...   \n",
       "3   ['These include the Verbund site in Geismar, Louisiana, as well as another 19 sites in Brazil, India, Malaysia, Thailand, France and the Netherlands, among other countries. ( 0.33 ) ', 'At the Lud...   \n",
       "4   ['The term “Regenerative Medicinal Products” used in the law includes cellular and tissue-based products and gene therapies. ( 0.48 ) ', 'Nutritionals ■ Pharmaton® is a range of products which con...   \n",
       "5   ['The Performance Products segment consists of the Dispersions & Pigments, Care Chemicals, Nutrition & Health and Performance Chemicals divisions. ( 0.52 ) ', 'Use in the BASF Verbund Plastics, co...   \n",
       "6   ['Responsible use of water: specific operating procedures govern the use of water during manufacturing and heat exchanges and promote reduced consumption. ( 0.4 ) ', 'Deforestation, water pollutio...   \n",
       "7   ['CDP’s evaluation of sustainable water management includes how transparently companies report on their water manage ment activities and what they do to reduce risks, such as water scarcity. ( 0.4...   \n",
       "8   ['Provisions for environmental risks and remediation mainly relate to contingencies arising from business divestitures. ( 0.35 ) ', 'Sanofi’s activities Supply chain Access to healthcare for the u...   \n",
       "9   ['We regularly check our emergency systems, crisis management structures and drill procedures with employees, contractors, local authorities and emergency rescue workers. ( 0.36 ) ', 'To address t...   \n",
       "10  ['Provisions for environmental risks and remediation mainly relate to contingencies arising from business divestitures. ( 0.36 ) ', 'We take a preventive approach by seeking to avoid accidents and...   \n",
       "11  ['We regularly check our emergency systems, crisis management structures and drill procedures with employees, contractors, local authorities and emergency rescue workers. ( 0.39 ) ', 'The wastewat...   \n",
       "12  ['Mitigation: reducing Sanofi’s greenhouse gas (GHG) emissions, which are the first driver of climate change. ( 0.58 ) ', 'Our mitigation strategy for climate change involves limiting our greenhou...   \n",
       "13  ['When deciding on investments and acquisitions, we systematically consider the effects on greenhouse gas emissions. ( 0.59 ) ', 'The program targets new technologies to significantly reduce green...   \n",
       "14  ['Mitigation: reducing Sanofi’s greenhouse gas (GHG) emissions, which are the first driver of climate change. ( 0.57 ) ', 'Sanofi is committed to reducing our carbon footprint by adopting responsi...   \n",
       "15  ['We offer our customers solutions that help prevent greenhouse gas emissions and improve energy and resource efficiency. ( 0.61 ) ', 'The program targets new technologies to significantly reduce ...   \n",
       "16  ['This feedback helps identify and prioritize opportunities to improve employee engagement and organizational performance. ( 0.51 ) ', 'This process involves identifying and prioritizing topics ac...   \n",
       "17  ['For example, the material topic “energy and climate” is analyzed to enable us to identify, assess and manage climate-related risks and opportunities. ( 0.56 ) ', 'It can be used to evaluate and ...   \n",
       "18  ['The performance of those segments is monitored individually using internal reports and common indicators. ( 0.36 ) ', 'The performance of those segments is monitored individually using internal ...   \n",
       "19  ['It can be used to evaluate and compare the environmental impact, costs and social aspects of products and manufacturing processes. ( 0.34 ) ', 'They focus on tailor-made solutions enabling custo...   \n",
       "20  ['Mitigation: reducing Sanofi’s greenhouse gas (GHG) emissions, which are the first driver of climate change. ( 0.46 ) ', 'Our mitigation strategy for climate change involves limiting our greenhou...   \n",
       "21  ['When deciding on investments and acquisitions, we systematically consider the effects on greenhouse gas emissions. ( 0.65 ) ', 'Engagements on Greenhouse Gas Statements), the relevant internatio...   \n",
       "22  ['In order to implement this master policy, Sanofi key requirements have been drawn up in the key fields of HSE management, HSE leadership, safety in the workplace, process safety, occupational hy...   \n",
       "23  ['Our experts have developed a protection plan with the appropriate safety inspections for every plant that considers the key aspects of safety, health and environmental protection – from concepti...   \n",
       "24  ['Employees receive information and training about the types of risks and prevention, personal protective equipment, and personal hygiene. ( 0.38 ) ', 'This feedback helps identify and prioritize ...   \n",
       "25  ['• You enable your employees and other stakeholders to report concerns or potentially unlawful practices at the workplace. ( 0.39 ) ', 'We assess the potential risks and weak points of all our ac...   \n",
       "26  ['This feedback helps identify and prioritize opportunities to improve employee engagement and organizational performance. ( 0.33 ) ', 'Decisions concerning the studies to be carried out can have ...   \n",
       "27  ['• You ensure by using appropriate management systems that product quality and safety meet the applicable requirements. ( 0.36 ) ', 'We analyze the potential safety and security risks associated ...   \n",
       "\n",
       "                                                                                                                                                                                                       Bert  \n",
       "0   ['European countries including the United Kingdom, Belgium, France, Germany, the Netherlands, Italy and Norway. ( 0.58 ) ', 'Specific situations may vary by country, most notably with respect to o...  \n",
       "1   ['This is why the BASF Europa Betriebsrat (European Works Council) addresses cross-border matters in Europe. ( 0.6 ) ', 'For certain companies outside the eurozone or U.S. dollar zone, the euro or...  \n",
       "2   ['Global markets are supplied from our facilities at Compiègne (France), Origgio (Italy), Cologne (Germany) and Veresegyház (Hungary). ( 0.54 ) ', 'INFORMATION ON THE COMPANYcomposed of a central ...  \n",
       "3   ['Specifically, this refers to Solvay’s production plants and innovation competencies in the engineering plastics field in Europe. ( 0.47 ) ', 'For certain companies outside the eurozone or U.S. d...  \n",
       "4   ['Nutritionals ■ Pharmaton® is a range of products which contain vitamins, minerals and standardized Ginseng Extract G115. ( 0.56 ) ', 'Waste generated in operations: 371,036 tCO2 e Definition: Th...  \n",
       "5   ['Cosmetics industry, detergent and cleaner industry, agrochemical industry, technical applications for various industries, hygiene industry Nutrition & Health Additives for the food and feed indu...  \n",
       "6   ['The SBTi provides a framework for companies to define how much and how quickly we must reduce our GHG emissions. ( 0.74 ) ', 'Sanofi is committed to reducing our carbon footprint by adopting res...  \n",
       "7   ['The reporting standards and recommendations for implementing projects to reduce emissions are jointly developed by companies, nongovernmental organizations and governments under the guidance of ...  \n",
       "8   ['and result in better knowledge of risk in the workplace to promote the implementation of preventive measures. ( 0.66 ) ', 'The complexity of these processes, as well as strict internal and healt...  \n",
       "9   ['In order to maintain the highest level of safety at our plants across their entire life cycle, we review the implementation of our protection plans in all facilities at regular intervals and dep...  \n",
       "10  ['Factors – Environmental Risks of Our Industrial Activities – Risks from the handling of hazardous materials could adversely affect our results of operations”. ( 0.68 ) ', 'Environmental Risks of...  \n",
       "11  ['In the event of a production outage – caused by an accident, for example – our global, regional or local emergency response plans and crisis management structures are engaged, depending on the i...  \n",
       "12  ['This study was designed to identify activities that could be modified to reduce energy consumption and CO2 emissions. ( 0.75 ) ', 'The SBTi provides a framework for companies to define how much ...  \n",
       "13  ['The reporting standards and recommendations for implementing projects to reduce emissions are jointly developed by companies, nongovernmental organizations and governments under the guidance of ...  \n",
       "14  ['This study was designed to identify activities that could be modified to reduce energy consumption and CO2 emissions. ( 0.81 ) ', 'Our mitigation strategy for climate change involves limiting ou...  \n",
       "15  ['We offer our customers solutions that help prevent greenhouse gas emissions and improve energy and resource efficiency. ( 0.79 ) ', '• You use resources efficiently, apply energy-efficient and e...  \n",
       "16  ['It\\xa0demonstrates our contribution to the major challenges and key issues that Sanofi must address today, linking sustainability performance to business results. ( 0.59 ) ', 'Every year, steps ...  \n",
       "17  ['We continuously analyze potential risks to our business operations arising in connection with the topics of energy and climate protection and derive appropriate measures. ( 0.64 ) ', 'We plan ou...  \n",
       "18  ['Fuel and energy-related activities Use of data related to energy consumption from industrial and R&D sites and assumptions to calculate emissions from the tertiary sites . ( 0.66 ) ', 'Levers of...  \n",
       "19  ['In long-term estimates, assumptions were made regarding factors such as inflation, production quantities and costs as well as energy efficiency and the substitution of energy sources. ( 0.65 ) '...  \n",
       "20  ['The SBTi provides a framework for companies to define how much and how quickly we must reduce our GHG emissions. ( 0.57 ) ', 'Fuel and energy-related activities Use of data related to energy con...  \n",
       "21  ['We report on greenhouse gas emissions in accordance with the Greenhouse Gas Protocol Standard as well as the sector-specific standard for the chemical industry. ( 0.66 ) ', 'When deciding on inv...  \n",
       "22  ['In order to implement this master policy, Sanofi key requirements have been drawn up in the key fields of HSE management, HSE leadership, safety in the workplace, process safety, occupational hy...  \n",
       "23  ['• You ensure by using appropriate management systems that product quality and safety meet the applicable requirements. ( 0.7 ) ', 'During our audits, we create a safety and environmental profile...  \n",
       "24  ['Recognizing professionalism in occupational hygiene training \\tEmployee wellness and disease prevention ( 0.71 ) ', 'The broad range of initiatives to ensure our employees’ health and well-being...  \n",
       "25  ['• You ensure by using appropriate management systems that product quality and safety meet the applicable requirements. ( 0.71 ) ', 'For more information on occupational medicine, health campaign...  \n",
       "26  ['Health authorities are increasingly focusing on product safety and on the risk/benefit profile of pharmaceutical products. ( 0.71 ) ', 'It is possible for the regulatory authorities to withdraw ...  \n",
       "27  ['• You ensure by using appropriate management systems that product quality and safety meet the applicable requirements. ( 0.78 ) ', 'We stipulate globally mandatory standards for safety, security...  "
      ]
     },
     "execution_count": 158,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_show"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[34mInferSent-master\u001b[m\u001b[m   \u001b[34mcdQA-master\u001b[m\u001b[m        \u001b[34menvblackjack\u001b[m\u001b[m       ques.pdf\r\n",
      "\u001b[34mPrésentationCDQA\u001b[m\u001b[m   cdQA-master.zip    \u001b[34minclude\u001b[m\u001b[m            requirements.txt\r\n",
      "Q&A_t.ipynb        \u001b[34mdata\u001b[m\u001b[m               \u001b[34mlib\u001b[m\u001b[m                restats\r\n",
      "Untitled.ipynb     \u001b[34mdataset\u001b[m\u001b[m            \u001b[34mmodels\u001b[m\u001b[m             \u001b[34mresults\u001b[m\u001b[m\r\n",
      "\u001b[34m__pycache__\u001b[m\u001b[m        dev-v1.1.json      \u001b[31mmodels.py\u001b[m\u001b[m          \u001b[31mrun_squad.py\u001b[m\u001b[m\r\n",
      "\u001b[34mbin\u001b[m\u001b[m                \u001b[34menv\u001b[m\u001b[m                \u001b[34mpdf_files\u001b[m\u001b[m          train-v1.1.json\r\n"
     ]
    }
   ],
   "source": [
    "!ls"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {},
   "outputs": [],
   "source": [
    "data_show.to_csv('Chemicals.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Choose answers program"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "Question 1:  Does the company operate in countries out of the European Union\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>scores</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>It encompasses how Sanofi promotes and respects human rights in our business operations in all countries where we operate.</td>\n",
       "      <td>0.5658546096670526</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>In all countries where we operate, we seek to strike a balance between our economic interests and those of our employees, which we regard as inseparable.</td>\n",
       "      <td>0.546178560807816</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>This category is mostly applicable to companies  that operate leased assets (i.e., lessees), but can also be applicable to all companies leasing assets.</td>\n",
       "      <td>0.47139165377872655</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>We also operate other insurance programs, but these are of much lesser importance than those described above.</td>\n",
       "      <td>0.3759826144492756</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>We operate our business through office premises and research, production and logistics facilities in approximately 100 countries around the world.</td>\n",
       "      <td>0.3157031957615065</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                     context  \\\n",
       "0                                 It encompasses how Sanofi promotes and respects human rights in our business operations in all countries where we operate.   \n",
       "1  In all countries where we operate, we seek to strike a balance between our economic interests and those of our employees, which we regard as inseparable.   \n",
       "3   This category is mostly applicable to companies  that operate leased assets (i.e., lessees), but can also be applicable to all companies leasing assets.   \n",
       "4                                              We also operate other insurance programs, but these are of much lesser importance than those described above.   \n",
       "2         We operate our business through office premises and research, production and logistics facilities in approximately 100 countries around the world.   \n",
       "\n",
       "                scores  \n",
       "0   0.5658546096670526  \n",
       "1    0.546178560807816  \n",
       "3  0.47139165377872655  \n",
       "4   0.3759826144492756  \n",
       "2   0.3157031957615065  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Tf-Idf (press enter if nothing is pertinent) \n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>European countries including the United Kingdom, Belgium, France, Germany, the Netherlands, Italy and Norway.</td>\n",
       "      <td>0.5180734</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>European Patent Convention accession of some current European Patent Convention Member States, resulting in different treatment in those countries.</td>\n",
       "      <td>0.48480105</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Our headquarters are located in France and the intellectual property of many of our leading products originates from Western Europe.</td>\n",
       "      <td>0.4561284</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The granted “European Patent” establishes corresponding national patents with uniform patent claims among the Member States.</td>\n",
       "      <td>0.45545483</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>The principal markets for Lemtrada® in terms of sales are the US, the UK, Germany, Spain, Canada and Italy.</td>\n",
       "      <td>0.44236198</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                               context  \\\n",
       "0                                        European countries including the United Kingdom, Belgium, France, Germany, the Netherlands, Italy and Norway.   \n",
       "1  European Patent Convention accession of some current European Patent Convention Member States, resulting in different treatment in those countries.   \n",
       "2                 Our headquarters are located in France and the intellectual property of many of our leading products originates from Western Europe.   \n",
       "3                         The granted “European Patent” establishes corresponding national patents with uniform patent claims among the Member States.   \n",
       "4                                          The principal markets for Lemtrada® in terms of sales are the US, the UK, Germany, Spain, Canada and Italy.   \n",
       "\n",
       "        score  \n",
       "0   0.5180734  \n",
       "1  0.48480105  \n",
       "2   0.4561284  \n",
       "3  0.45545483  \n",
       "4  0.44236198  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Infersent (press enter if nothing is pertinent) \n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>European countries including the United Kingdom, Belgium, France, Germany, the Netherlands, Italy and Norway.</td>\n",
       "      <td>0.5767701</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Specific situations may vary by country, most notably with respect to older patents and to countries that have only recently joined the EU.</td>\n",
       "      <td>0.56638044</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>European Patent Convention accession of some current European Patent Convention Member States, resulting in different treatment in those countries.</td>\n",
       "      <td>0.5300329</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>While EU regulatory exclusivity is intended to be applied throughout the EU, in some cases Member States have taken positions prejudicial to our exclusivity rights.</td>\n",
       "      <td>0.516057</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Operating Foreign Exchange Risk A substantial portion of our net sales is generated in countries where the euro, which is our reporting currency, is not the functional currency.</td>\n",
       "      <td>0.49603373</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                             context  \\\n",
       "0                                                                      European countries including the United Kingdom, Belgium, France, Germany, the Netherlands, Italy and Norway.   \n",
       "1                                        Specific situations may vary by country, most notably with respect to older patents and to countries that have only recently joined the EU.   \n",
       "2                                European Patent Convention accession of some current European Patent Convention Member States, resulting in different treatment in those countries.   \n",
       "3               While EU regulatory exclusivity is intended to be applied throughout the EU, in some cases Member States have taken positions prejudicial to our exclusivity rights.   \n",
       "4  Operating Foreign Exchange Risk A substantial portion of our net sales is generated in countries where the euro, which is our reporting currency, is not the functional currency.   \n",
       "\n",
       "        score  \n",
       "0   0.5767701  \n",
       "1  0.56638044  \n",
       "2   0.5300329  \n",
       "3    0.516057  \n",
       "4  0.49603373  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Bert (press enter if nothing is pertinent) \n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "Question 2:  Is at least one of the companys production facilities classified as Seveso High European Detective or equivalent in other countries\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>scores</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>The French chemical manufacturing sites in Aramon, Sisteron and Vertolaye, as well as the plants located in the Hoechst Industry Park in Frankfurt, Germany, and the chemical production site in Budapest, Hungary, are listed Seveso III (from the name of the European directive that deals with potentially dangerous sites through a list of activities and substances associated with classification thresholds).</td>\n",
       "      <td>0.5982648233583138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The Board of Directors noted that the Company and its subsidiaries had, in the normal course of business, over the past three years, sold products and provided services to, and/or purchased products and received services from, companies in which certain of the Company’s directors who are classified as independent (or their close family members) were senior executives or employees during 2017.</td>\n",
       "      <td>0.4527138648971805</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Finally, in the event of changes to a plan of sale that require an asset no longer to be classified as held for sale, IFRS 5 specifies the following treatment:\\n■ The assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods.</td>\n",
       "      <td>0.303648663105362</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>These assets are classified in the balance sheet within the line items Other non-current assets, Other current assets and Cash and cash equivalents.</td>\n",
       "      <td>0.27992655249436005</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>European Patent Convention accession of some current European Patent Convention Member States, resulting in different treatment in those countries.</td>\n",
       "      <td>0.2119383891071344</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                                                                  context  \\\n",
       "3  The French chemical manufacturing sites in Aramon, Sisteron and Vertolaye, as well as the plants located in the Hoechst Industry Park in Frankfurt, Germany, and the chemical production site in Budapest, Hungary, are listed Seveso III (from the name of the European directive that deals with potentially dangerous sites through a list of activities and substances associated with classification thresholds).   \n",
       "2             The Board of Directors noted that the Company and its subsidiaries had, in the normal course of business, over the past three years, sold products and provided services to, and/or purchased products and received services from, companies in which certain of the Company’s directors who are classified as independent (or their close family members) were senior executives or employees during 2017.   \n",
       "4                                                                          Finally, in the event of changes to a plan of sale that require an asset no longer to be classified as held for sale, IFRS 5 specifies the following treatment:\\n■ The assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods.   \n",
       "0                                                                                                                                                                                                                                                                    These assets are classified in the balance sheet within the line items Other non-current assets, Other current assets and Cash and cash equivalents.   \n",
       "1                                                                                                                                                                                                                                                                     European Patent Convention accession of some current European Patent Convention Member States, resulting in different treatment in those countries.   \n",
       "\n",
       "                scores  \n",
       "3   0.5982648233583138  \n",
       "2   0.4527138648971805  \n",
       "4    0.303648663105362  \n",
       "0  0.27992655249436005  \n",
       "1   0.2119383891071344  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Tf-Idf (press enter if nothing is pertinent)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Our headquarters are located in France and the intellectual property of many of our leading products originates from Western Europe.</td>\n",
       "      <td>0.3766396</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>European Patent Convention accession of some current European Patent Convention Member States, resulting in different treatment in those countries.</td>\n",
       "      <td>0.34062135</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>More than \\n30 production plants, including the majority of our plants and over half our Research and Development sites are also located in Western  Europe.</td>\n",
       "      <td>0.32603288</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>We operate our business through office premises and research, production and logistics facilities in approximately 100 countries around the world.</td>\n",
       "      <td>0.3235063</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Sanofi Global  Quality unites all 9,000 employees operating in the Company’s global quality functions, operational quality units and Medical, Clinical and Country organizations.</td>\n",
       "      <td>0.3128326</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                             context  \\\n",
       "0                                               Our headquarters are located in France and the intellectual property of many of our leading products originates from Western Europe.   \n",
       "1                                European Patent Convention accession of some current European Patent Convention Member States, resulting in different treatment in those countries.   \n",
       "2                       More than \\n30 production plants, including the majority of our plants and over half our Research and Development sites are also located in Western  Europe.   \n",
       "3                                 We operate our business through office premises and research, production and logistics facilities in approximately 100 countries around the world.   \n",
       "4  Sanofi Global  Quality unites all 9,000 employees operating in the Company’s global quality functions, operational quality units and Medical, Clinical and Country organizations.   \n",
       "\n",
       "        score  \n",
       "0   0.3766396  \n",
       "1  0.34062135  \n",
       "2  0.32603288  \n",
       "3   0.3235063  \n",
       "4   0.3128326  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Infersent (press enter if nothing is pertinent)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Global markets are supplied from our facilities at Compiègne (France), Origgio (Italy), Cologne (Germany) and Veresegyház (Hungary).</td>\n",
       "      <td>0.53888655</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>INFORMATION ON THE COMPANYcomposed of a central division (headquartered in Paris) and several local and regional divisions in the contracting Member.</td>\n",
       "      <td>0.528618</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Through patent and other proprietary rights such as data exclusivity or supplementary protection certificates in Europe, we hold exclusivity rights for a number of our research-based products.</td>\n",
       "      <td>0.52614295</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Our headquarters are located in France and the intellectual property of many of our leading products originates from Western Europe.</td>\n",
       "      <td>0.5231866</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Between 1994 and 2004 he held increasingly senior functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, in Europe and the US.</td>\n",
       "      <td>0.5152808</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                            context  \\\n",
       "0                                                              Global markets are supplied from our facilities at Compiègne (France), Origgio (Italy), Cologne (Germany) and Veresegyház (Hungary).   \n",
       "1                                             INFORMATION ON THE COMPANYcomposed of a central division (headquartered in Paris) and several local and regional divisions in the contracting Member.   \n",
       "2  Through patent and other proprietary rights such as data exclusivity or supplementary protection certificates in Europe, we hold exclusivity rights for a number of our research-based products.   \n",
       "3                                                              Our headquarters are located in France and the intellectual property of many of our leading products originates from Western Europe.   \n",
       "4   Between 1994 and 2004 he held increasingly senior functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, in Europe and the US.   \n",
       "\n",
       "        score  \n",
       "0  0.53888655  \n",
       "1    0.528618  \n",
       "2  0.52614295  \n",
       "3   0.5231866  \n",
       "4   0.5152808  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Bert (press enter if nothing is pertinent)\n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "Question 3:  Is the Company involved in agricultural chemistry activities including the production of nitrogenous potash and phosphate based fertilizers\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>scores</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Muzammil Mansuri Executive Vice President, Strategy and Business Development Date of birth: January 20, 1954 Muzammil Mansuri holds a Bachelor of Science degree in Chemistry and a Ph.D. in Organic Chemistry from University College London.</td>\n",
       "      <td>0.38689201047307187</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>These guidelines set out the requirements on preclinical, clinical and Chemistry, Manufacturing and Control (CMC) data to be considered for the development of the new application category of biosimilars.</td>\n",
       "      <td>0.29739084193823334</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Sanofi is involved in several programs to minimize the potential environmental impacts of medicines, including: Evaluating and minimizing the environmental impacts of manufacturing activities.</td>\n",
       "      <td>0.24298416198814726</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Sciences in 2017, a company whose influenza vaccine production technology will allow  Sanofi Pasteur to expand its production expertise and capacity.</td>\n",
       "      <td>0.2091346135215787</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Since 2013 Member of the Scientific Advisory Board of the Shemyakin-Ovchinnikov Institute of Bio-Organic Chemistry (Russia).</td>\n",
       "      <td>0.1950289238428835</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                          context  \\\n",
       "1  Muzammil Mansuri Executive Vice President, Strategy and Business Development Date of birth: January 20, 1954 Muzammil Mansuri holds a Bachelor of Science degree in Chemistry and a Ph.D. in Organic Chemistry from University College London.   \n",
       "2                                     These guidelines set out the requirements on preclinical, clinical and Chemistry, Manufacturing and Control (CMC) data to be considered for the development of the new application category of biosimilars.   \n",
       "0                                                Sanofi is involved in several programs to minimize the potential environmental impacts of medicines, including: Evaluating and minimizing the environmental impacts of manufacturing activities.   \n",
       "4                                                                                           Sciences in 2017, a company whose influenza vaccine production technology will allow  Sanofi Pasteur to expand its production expertise and capacity.   \n",
       "3                                                                                                                    Since 2013 Member of the Scientific Advisory Board of the Shemyakin-Ovchinnikov Institute of Bio-Organic Chemistry (Russia).   \n",
       "\n",
       "                scores  \n",
       "1  0.38689201047307187  \n",
       "2  0.29739084193823334  \n",
       "0  0.24298416198814726  \n",
       "4   0.2091346135215787  \n",
       "3   0.1950289238428835  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Tf-Idf (press enter if nothing is pertinent)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The term “Regenerative Medicinal Products” used in the law includes cellular and tissue-based products and gene therapies.</td>\n",
       "      <td>0.49991506</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Nutritionals\\n■ Pharmaton® is a range of products which contain vitamins, minerals and standardized Ginseng Extract G115.</td>\n",
       "      <td>0.4422735</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>In Emerging Markets:\\n• Full Sanofi pharma portfolio: Solutions for  Diabetes, Cardiovascular diseases, Specialty  Care medicines, Established Products and .</td>\n",
       "      <td>0.42354715</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Production of biological, chemical and pharmaceutical products is the responsibility of our Industrial Affairs department, which is also in charge of most of our logistics facilities (distribution and storage centers).</td>\n",
       "      <td>0.40692127</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Note that Emerging Markets sales of Diabetes &amp; Cardiovascular and Specialty Care products are included in the General Medicines &amp; Emerging Markets GBU.</td>\n",
       "      <td>0.3988991</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                      context  \\\n",
       "0                                                                                                  The term “Regenerative Medicinal Products” used in the law includes cellular and tissue-based products and gene therapies.   \n",
       "1                                                                                                   Nutritionals\\n■ Pharmaton® is a range of products which contain vitamins, minerals and standardized Ginseng Extract G115.   \n",
       "2                                                               In Emerging Markets:\\n• Full Sanofi pharma portfolio: Solutions for  Diabetes, Cardiovascular diseases, Specialty  Care medicines, Established Products and .   \n",
       "3  Production of biological, chemical and pharmaceutical products is the responsibility of our Industrial Affairs department, which is also in charge of most of our logistics facilities (distribution and storage centers).   \n",
       "4                                                                     Note that Emerging Markets sales of Diabetes & Cardiovascular and Specialty Care products are included in the General Medicines & Emerging Markets GBU.   \n",
       "\n",
       "        score  \n",
       "0  0.49991506  \n",
       "1   0.4422735  \n",
       "2  0.42354715  \n",
       "3  0.40692127  \n",
       "4   0.3988991  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Infersent (press enter if nothing is pertinent)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Nutritionals\\n■ Pharmaton® is a range of products which contain vitamins, minerals and standardized Ginseng Extract G115.</td>\n",
       "      <td>0.56347585</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Waste generated in operations: 371,036 tCO2 e  Definition: This category includes emissions from third-party disposal and treatment of waste that is generated  in Sanofi-owned or controlled operations.</td>\n",
       "      <td>0.53754044</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The GHG emissions related to the processing of these APIs into  final medicines at clients’ plants is part of this category.</td>\n",
       "      <td>0.5106852</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Our Rare Diseases business is focused on products for the treatment of rare genetic diseases and other rare chronic debilitating diseases, including lysosomal storage disorders (LSDs), a group of metabolic disorders caused by enzyme deficiencies.</td>\n",
       "      <td>0.4815372</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Since 2013 Member of the Scientific Advisory Board of the Shemyakin-Ovchinnikov Institute of Bio-Organic Chemistry (Russia).</td>\n",
       "      <td>0.4738804</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                  context  \\\n",
       "0                                                                                                                               Nutritionals\\n■ Pharmaton® is a range of products which contain vitamins, minerals and standardized Ginseng Extract G115.   \n",
       "1                                               Waste generated in operations: 371,036 tCO2 e  Definition: This category includes emissions from third-party disposal and treatment of waste that is generated  in Sanofi-owned or controlled operations.   \n",
       "2                                                                                                                            The GHG emissions related to the processing of these APIs into  final medicines at clients’ plants is part of this category.   \n",
       "3  Our Rare Diseases business is focused on products for the treatment of rare genetic diseases and other rare chronic debilitating diseases, including lysosomal storage disorders (LSDs), a group of metabolic disorders caused by enzyme deficiencies.   \n",
       "4                                                                                                                            Since 2013 Member of the Scientific Advisory Board of the Shemyakin-Ovchinnikov Institute of Bio-Organic Chemistry (Russia).   \n",
       "\n",
       "        score  \n",
       "0  0.56347585  \n",
       "1  0.53754044  \n",
       "2   0.5106852  \n",
       "3   0.4815372  \n",
       "4   0.4738804  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Bert (press enter if nothing is pertinent)\n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "Question 4:  Has the company formalized a commitment policy or program to control and reduce pollution water air and sol\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>scores</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>It requires the full commitment of the entire Company, from top executives to each individual in our operations around the globe.</td>\n",
       "      <td>0.3920099391109528</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>On January 2019, the Ministry for Environment launched the national clean air programme (NCAP), a  scheme to provide the states and the union government with a framework to combat air pollution.</td>\n",
       "      <td>0.31624560176505606</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>The Directors &amp; Officers Liability program protects all legal entities under our control, and their directors and officers.</td>\n",
       "      <td>0.29804724777883396</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Report of Management on Internal Control Over Financial Reporting.</td>\n",
       "      <td>0.27406098771514736</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>(c) Irrevocable purchase commitments given as of December 31, 2017 include €1,207 million of commitments to joint ventures.</td>\n",
       "      <td>0.2703509356375344</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                context  \\\n",
       "1                                                                                                                                                                     It requires the full commitment of the entire Company, from top executives to each individual in our operations around the globe.   \n",
       "0                                                                                                    On January 2019, the Ministry for Environment launched the national clean air programme (NCAP), a  scheme to provide the states and the union government with a framework to combat air pollution.   \n",
       "4                                                                                                                                                                           The Directors & Officers Liability program protects all legal entities under our control, and their directors and officers.   \n",
       "2  The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Report of Management on Internal Control Over Financial Reporting.   \n",
       "3                                                                                                                                                                           (c) Irrevocable purchase commitments given as of December 31, 2017 include €1,207 million of commitments to joint ventures.   \n",
       "\n",
       "                scores  \n",
       "1   0.3920099391109528  \n",
       "0  0.31624560176505606  \n",
       "4  0.29804724777883396  \n",
       "2  0.27406098771514736  \n",
       "3   0.2703509356375344  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Tf-Idf (press enter if nothing is pertinent)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Responsible use of water: specific operating procedures govern the use of water during manufacturing and heat exchanges and promote reduced consumption.</td>\n",
       "      <td>0.41528153</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Deforestation, water pollution, clean  water shortages, and waste management are further issues of concern.</td>\n",
       "      <td>0.37438285</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>We have also set ourselves the target of achieving sustainable water resource management, especially at sites which are under hydric stress.</td>\n",
       "      <td>0.37166452</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>This study was designed to identify activities that could be modified to reduce  energy consumption and CO2 emissions.</td>\n",
       "      <td>0.3652539</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Sites at potential risk from water scarcity also must establish and comply with a plan for reducing water consumption tailored to the site’s local context and industrial characteristics.</td>\n",
       "      <td>0.35788453</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                      context  \\\n",
       "0                                    Responsible use of water: specific operating procedures govern the use of water during manufacturing and heat exchanges and promote reduced consumption.   \n",
       "1                                                                                 Deforestation, water pollution, clean  water shortages, and waste management are further issues of concern.   \n",
       "2                                                We have also set ourselves the target of achieving sustainable water resource management, especially at sites which are under hydric stress.   \n",
       "3                                                                      This study was designed to identify activities that could be modified to reduce  energy consumption and CO2 emissions.   \n",
       "4  Sites at potential risk from water scarcity also must establish and comply with a plan for reducing water consumption tailored to the site’s local context and industrial characteristics.   \n",
       "\n",
       "        score  \n",
       "0  0.41528153  \n",
       "1  0.37438285  \n",
       "2  0.37166452  \n",
       "3   0.3652539  \n",
       "4  0.35788453  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Infersent (press enter if nothing is pertinent)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>The SBTi provides a framework for companies to define how much and how quickly we must reduce our GHG emissions.</td>\n",
       "      <td>0.7437533</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Sanofi is committed to reducing our carbon  footprint by adopting responsible practices to reduce our greenhouse gas emissions throughout the world.</td>\n",
       "      <td>0.66050047</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The Company is committed to closely managing and reducing our environmental footprint (e.g., carbon emissions), ensuring that products and waste are appropriately managed by internal teams and third parties, anticipating potential business discontinuity due to less available resources and adapting solutions to respond to the effects of climate change on public health.</td>\n",
       "      <td>0.65487695</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Sites at potential risk from water scarcity also must establish and comply with a plan for reducing water consumption tailored to the site’s local context and industrial characteristics.</td>\n",
       "      <td>0.648137</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Responsible use of water: specific operating procedures govern the use of water during manufacturing and heat exchanges and promote reduced consumption.</td>\n",
       "      <td>0.6293419</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                              context  \\\n",
       "0                                                                                                                                                                                                                                                                    The SBTi provides a framework for companies to define how much and how quickly we must reduce our GHG emissions.   \n",
       "1                                                                                                                                                                                                                                Sanofi is committed to reducing our carbon  footprint by adopting responsible practices to reduce our greenhouse gas emissions throughout the world.   \n",
       "2  The Company is committed to closely managing and reducing our environmental footprint (e.g., carbon emissions), ensuring that products and waste are appropriately managed by internal teams and third parties, anticipating potential business discontinuity due to less available resources and adapting solutions to respond to the effects of climate change on public health.   \n",
       "3                                                                                                                                                                                          Sites at potential risk from water scarcity also must establish and comply with a plan for reducing water consumption tailored to the site’s local context and industrial characteristics.   \n",
       "4                                                                                                                                                                                                                            Responsible use of water: specific operating procedures govern the use of water during manufacturing and heat exchanges and promote reduced consumption.   \n",
       "\n",
       "        score  \n",
       "0   0.7437533  \n",
       "1  0.66050047  \n",
       "2  0.65487695  \n",
       "3    0.648137  \n",
       "4   0.6293419  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Bert (press enter if nothing is pertinent)\n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "\n",
      "\n",
      " Choose a repository \n",
      "\n",
      "  directory\n",
      "0    Others\n",
      "1    Sanofi\n",
      "\n",
      "1\n",
      "Question 5:  Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>scores</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>■ Provisions for environmental risks and remediation amount to\\n€686 million in 2017, the majority of which are related to contingencies that have arisen from business divestitures.</td>\n",
       "      <td>0.33451365704476965</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>To safeguard continuity of operations and secure timely execution of its core tasks, the EMA has launched a Business Continuity Plan\\n(BCP).</td>\n",
       "      <td>0.33251818041499887</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Global economic conditions and an unfavorable financial environment could have negative consequences for our business(2).</td>\n",
       "      <td>0.28071449675747484</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>See also below “– Global economic conditions and an unfavorable financial environment could have negative consequences for our business”.</td>\n",
       "      <td>0.28071449675747484</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Provisions for environmental risks and remediation mainly relate to contingencies arising from business divestitures.</td>\n",
       "      <td>0.25248864839309804</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                 context  \\\n",
       "2  ■ Provisions for environmental risks and remediation amount to\\n€686 million in 2017, the majority of which are related to contingencies that have arisen from business divestitures.   \n",
       "0                                           To safeguard continuity of operations and secure timely execution of its core tasks, the EMA has launched a Business Continuity Plan\\n(BCP).   \n",
       "3                                                              Global economic conditions and an unfavorable financial environment could have negative consequences for our business(2).   \n",
       "4                                              See also below “– Global economic conditions and an unfavorable financial environment could have negative consequences for our business”.   \n",
       "1                                                                  Provisions for environmental risks and remediation mainly relate to contingencies arising from business divestitures.   \n",
       "\n",
       "                scores  \n",
       "2  0.33451365704476965  \n",
       "0  0.33251818041499887  \n",
       "3  0.28071449675747484  \n",
       "4  0.28071449675747484  \n",
       "1  0.25248864839309804  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Tf-Idf (press enter if nothing is pertinent)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Provisions for environmental risks and remediation mainly relate to contingencies arising from business divestitures.</td>\n",
       "      <td>0.36727214</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Our Industrial Affairs Department has an ongoing policy of adapting industrial facilities to market needs.</td>\n",
       "      <td>0.34481108</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Our Industrial Affairs Department has an ongoing policy of adapting industrial facilities to market needs.</td>\n",
       "      <td>0.34481108</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Our Industrial Affairs Department has an ongoing policy of adapting industrial facilities to market needs.</td>\n",
       "      <td>0.34481108</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Sanofi’s activities  Supply chain  Access to healthcare for the underserved  Product quality and patient safety  Business ethics.</td>\n",
       "      <td>0.3328748</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                             context  \\\n",
       "0              Provisions for environmental risks and remediation mainly relate to contingencies arising from business divestitures.   \n",
       "1                         Our Industrial Affairs Department has an ongoing policy of adapting industrial facilities to market needs.   \n",
       "2                         Our Industrial Affairs Department has an ongoing policy of adapting industrial facilities to market needs.   \n",
       "3                         Our Industrial Affairs Department has an ongoing policy of adapting industrial facilities to market needs.   \n",
       "4  Sanofi’s activities  Supply chain  Access to healthcare for the underserved  Product quality and patient safety  Business ethics.   \n",
       "\n",
       "        score  \n",
       "0  0.36727214  \n",
       "1  0.34481108  \n",
       "2  0.34481108  \n",
       "3  0.34481108  \n",
       "4   0.3328748  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Choose for Infersent (press enter if nothing is pertinent)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>context</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>and result in better knowledge of risk in the workplace to promote the implementation of preventive measures.</td>\n",
       "      <td>0.66125154</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The complexity of these processes, as well as strict internal and health authority standards for the manufacture of our products, subject us to risks because the investigation and remediation of any identified or suspected problems can cause production delays, substantial expense, product recalls or lost sales and inventories, and delay the launch of new products; this could adversely affect our operating results and financial condition, and cause reputational damage and the risk of product liability (see “– Product liability claims could adversely affect our business, results of operations and financial condition above”).</td>\n",
       "      <td>0.6364193</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Our target is to focus the company’s efforts on actions to pro-actively prevent potentially serious accidents rather than limiting efforts to post-accidental corrective measures.</td>\n",
       "      <td>0.6277626</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Environmental Risks of Our Industrial Activities Risks from the handling of hazardous materials could adversely affect our results of operations.</td>\n",
       "      <td>0.6238846</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>With a focus on prevention, each year the number of occupational diseases is consolidated at company level with the aim of improving,  year by year, the level of available information according to local regulations, which may differ from one country to another.</td>\n",
       "      <td>0.6234863</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  context  \\\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           and result in better knowledge of risk in the workplace to promote the implementation of preventive measures.   \n",
       "1  The complexity of these processes, as well as strict internal and health authority standards for the manufacture of our products, subject us to risks because the investigation and remediation of any identified or suspected problems can cause production delays, substantial expense, product recalls or lost sales and inventories, and delay the launch of new products; this could adversely affect our operating results and financial condition, and cause reputational damage and the risk of product liability (see “– Product liability claims could adversely affect our business, results of operations and financial condition above”).   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Our target is to focus the company’s efforts on actions to pro-actively prevent potentially serious accidents rather than limiting efforts to post-accidental corrective measures.   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Environmental Risks of Our Industrial Activities Risks from the handling of hazardous materials could adversely affect our results of operations.   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                   With a focus on prevention, each year the number of occupational diseases is consolidated at company level with the aim of improving,  year by year, the level of available information according to local regulations, which may differ from one country to another.   \n",
       "\n",
       "        score  \n",
       "0  0.66125154  \n",
       "1   0.6364193  \n",
       "2   0.6277626  \n",
       "3   0.6238846  \n",
       "4   0.6234863  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/ipykernel/kernelbase.py\u001b[0m in \u001b[0;36m_input_request\u001b[0;34m(self, prompt, ident, parent, password)\u001b[0m\n\u001b[1;32m    884\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 885\u001b[0;31m                 \u001b[0mident\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mreply\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msession\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstdin_socket\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;36m0\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    886\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mException\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/jupyter_client/session.py\u001b[0m in \u001b[0;36mrecv\u001b[0;34m(self, socket, mode, content, copy)\u001b[0m\n\u001b[1;32m    802\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 803\u001b[0;31m             \u001b[0mmsg_list\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msocket\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv_multipart\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmode\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcopy\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    804\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0mzmq\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mZMQError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/zmq/sugar/socket.py\u001b[0m in \u001b[0;36mrecv_multipart\u001b[0;34m(self, flags, copy, track)\u001b[0m\n\u001b[1;32m    469\u001b[0m         \"\"\"\n\u001b[0;32m--> 470\u001b[0;31m         \u001b[0mparts\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mflags\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcopy\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtrack\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtrack\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    471\u001b[0m         \u001b[0;31m# have first part already, only loop while more to receive\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket.Socket.recv\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket.Socket.recv\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket._recv_copy\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/zmq/backend/cython/checkrc.pxd\u001b[0m in \u001b[0;36mzmq.backend.cython.checkrc._check_rc\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: ",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-17-ebbe499b576f>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     25\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     26\u001b[0m     \u001b[0mdisplay\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0md5\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'context'\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m'score'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 27\u001b[0;31m     \u001b[0mix\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Choose for Bert (press enter if nothing is pertinent)'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     28\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mix\u001b[0m\u001b[0;34m!=\u001b[0m\u001b[0;34m''\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     29\u001b[0m         \u001b[0manswers_be\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0md5\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'context'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtolist\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/ipykernel/kernelbase.py\u001b[0m in \u001b[0;36mraw_input\u001b[0;34m(self, prompt)\u001b[0m\n\u001b[1;32m    858\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_parent_ident\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    859\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_parent_header\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 860\u001b[0;31m             \u001b[0mpassword\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mFalse\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    861\u001b[0m         )\n\u001b[1;32m    862\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/ipykernel/kernelbase.py\u001b[0m in \u001b[0;36m_input_request\u001b[0;34m(self, prompt, ident, parent, password)\u001b[0m\n\u001b[1;32m    888\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mKeyboardInterrupt\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    889\u001b[0m                 \u001b[0;31m# re-raise KeyboardInterrupt, to truncate traceback\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 890\u001b[0;31m                 \u001b[0;32mraise\u001b[0m \u001b[0mKeyboardInterrupt\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    891\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    892\u001b[0m                 \u001b[0;32mbreak\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "from IPython.display import display\n",
    "cq=1\n",
    "answers_tf=[]\n",
    "answers_if=[]\n",
    "answers_be=[]\n",
    "for i in range(0,len(data.words_unsort)):\n",
    "    L=data.loc[i,'words_unsort']\n",
    "    #d1,d2=QAmodel.predict(' '.join(L), VE_type='DP',range_chunks=(8,35))\n",
    "    d1,d2,d3=QAmodel.predict(' '.join(L), VE_type='DP',range_chunks=(8,35))\n",
    "    d3,d4,d5=QAmodel.predict(questions[i], VE_type='DP',range_chunks=(8,35))\n",
    "    print('Question {}:  {}'.format(cq,questions[i]))\n",
    "    cq+=1\n",
    "    display(d1[['context','scores']])\n",
    "    ix=str(input('Choose for Tf-Idf (press enter if nothing is pertinent)'))\n",
    "    if ix!='':\n",
    "        answers_tf.append(d1['context'].tolist())\n",
    "    else:\n",
    "        answers_tf.append('')\n",
    "    display(d4[['context','score']])\n",
    "    ix=str(input('Choose for Infersent (press enter if nothing is pertinent)'))\n",
    "    if ix!='':\n",
    "        answers_if.append(d4['context'].tolist())\n",
    "    else:\n",
    "        answers_if.append('')\n",
    "    \n",
    "    display(d5[['context','score']])\n",
    "    ix=str(input('Choose for Bert (press enter if nothing is pertinent)'))\n",
    "    if ix!='':\n",
    "        answers_be.append(d5['context'].tolist())\n",
    "    else:\n",
    "        answers_be.append('')\n",
    "    \n",
    "data_show=pd.DataFrame(np.c_[questions,answers_tf,answers_if,answers_be],columns=['Questions', 'Tf-Idf best answer', 'Infersent best answer','Bert best answer'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from IPython.display import display\n",
    "cq=1\n",
    "answers_tf=[]\n",
    "answers_if=[]\n",
    "answers_be=[]\n",
    "for i in range(0,len(data.words_unsort)):\n",
    "    L=data.loc[i,'words_unsort']\n",
    "    #d1,d2=QAmodel.predict(' '.join(L), VE_type='DP',range_chunks=(8,35))\n",
    "    d1,d2,d3=QAmodel.predict(' '.join(L), VE_type='DP',range_chunks=(8,35))\n",
    "    d3,d4,d5=QAmodel.predict(questions[i], VE_type='DP',range_chunks=(8,35))\n",
    "    print('Question {}:  {}'.format(cq,questions[i]))\n",
    "    cq+=1\n",
    "    display(d1[['context','scores']])\n",
    "    ix=str(input('Choose for Tf-Idf (press enter if nothing is pertinent)'))\n",
    "    if ix!='':\n",
    "        answers_tf.append(d1.loc[int(ix),'context'])\n",
    "    else:\n",
    "        answers_tf.append('')\n",
    "    display(d4[['context','score']])\n",
    "    ix=str(input('Choose for Infersent (press enter if nothing is pertinent)'))\n",
    "    if ix!='':\n",
    "        answers_if.append(d4.loc[int(ix),'context'])\n",
    "    else:\n",
    "        answers_if.append('')\n",
    "    display(d5[['context','score']])\n",
    "    ix=str(input('Choose for Bert (press enter if nothing is pertinent)'))\n",
    "    if ix!='':\n",
    "        answers_be.append(d5.loc[int(ix),'context'])\n",
    "    else:\n",
    "        answers_be.append('')\n",
    "pd.DataFrame(np.c_[questions,answers_tf,answers_if,answers_be],columns=['Questions', 'Tf-Idf best answer', 'Infersent best answer','Bert best answer'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Sources"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "- Useful Github pages\n",
    "-  <https://github.com/UKPLab/sentence-transformers>\n",
    "- < https://github.com/huggingface/pytorch-transformers>\n",
    "- < https://github.com/cdqa-suite>\n",
    "- Google Brain Original Paper:\n",
    "- < https://nlp.stanford.edu/seminar/details/jdevlin.pdf?fbclid=IwAR2TBFCJOeZ9cGhxB-z5cJJ17vHN4W25oWsjI8NqJoTEmlYIYEKG7oh4tlY>\n",
    "<  http://papers.nips.cc/paper/7181-attention-is-all-you-need.pdf>\n",
    "- Tf-Idf semantic expansion\n",
    "- < https://www.sciencedirect.com/science/article/pii/S1877050916311589 >\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Semantic Expansion:  Enhancement of tf-idf model with the information provided by co-occurence of terms within documents <http://www2015.wwwconference.org/documents/proceedings/companion/p805.pdf>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Let's start with few interestings statistics :  "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### Average document length:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "176.320530815363"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.mean([len(x) for x in QAmodel.content])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Tf_iDf matrix dimension and sparsity of the matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 298,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(documents,vocab)= (7843, 6896)\n"
     ]
    }
   ],
   "source": [
    "(c,d)=(len(QAmodel.content),len(QAmodel.retriever.vectorizer.get_feature_names()))\n",
    "print(\"(documents,vocab)=\",(c,d))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 299,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<7843x6896 sparse matrix of type '<class 'numpy.float64'>'\n",
       "\twith 111515 stored elements in Compressed Sparse Row format>"
      ]
     },
     "execution_count": 299,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "T=QAmodel.retriever.tfidf_matrix\n",
    "T"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 300,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tf-Idf Matrix is 99.79 % sparse\n"
     ]
    }
   ],
   "source": [
    "(a,b)=T.shape\n",
    "non_zeros=100*np.sum(np.abs(T)>0)/(a*b) \n",
    "print('Tf-Idf Matrix is',100-np.round(non_zeros,2),'% sparse')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Two observations: \n",
    "- Each document is approximately a tweet: that's short !   \n",
    "- Tf-idf matrix is a (very) sparse matrix\n",
    "\n",
    "Idea : In this project we want to return a text chunk, among those with the highest similarities with the querry.\n",
    "However Tf-Idf is bad for small document (here a document is one or two sentences). Yan et al mentioned that for short texts using tf-idf is not very efficient since term frequency in all documents is not a good\n",
    "measure to capture the discriminative power of the data due to the sparsity.\n",
    "Short-text segments are typically represented by very sparse\n",
    "vectors, where each has non-zero weights for only a very few\n",
    "terms. In this case, traditional techniques for calculating\n",
    "text similarity results in measures which are very close to\n",
    "zeros. This is due to the fact that documents, even the\n",
    "very similar ones, do have a very few or mostly no terms in\n",
    "common. In order to alleviate this limitation, we need to\n",
    "enriched the representation of short-text segments by incorporating information about correlation between terms. Towards achieving this goal, we employ a method for enhancing document clustering using statistical semantics proposed by Farahat and Kamel and enhance it to handle large amounts of short documents. This is done by the following semantic kernel formula : $$K=X^{t}GX \\hspace{4pt} \\text{where} \\hspace{4pt} G \\hspace{4pt} \\text{is the}\\hspace{3pt} mxm \\hspace{3pt} \\text{term correlation matrix} \\hspace{3pt} \\text{and}\\hspace{3pt} X^{t} \\hspace{3pt} \\text{is the tf-idf matrix with stemming and stopword removal} $$\n",
    "$$\\text{Problem : To compute the matrix} \\hspace{2pt} G: \\text{ the time complexity is} \\hspace{2pt} O(n^2)$$\n",
    "$$ \\text{Solution : Factorisation method suggested by Nystrom }$$"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Term selection for correlation matrix : "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### First we select words that have a sufficent frequency throughout documents (set to 1%)\n",
    "\n",
    "#### We perform a random sampling of 20% of the terms using term-importance probabilities. The importance probability of a term is given by the length of his vector sparse representation inside the tf-idf matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "def select_term_Naystrom(T,s=1.0):\n",
    "    \n",
    "    #T is the Tf-Idf Matrix \n",
    "    #s is the fraction of important words that we want to retrieve (s=1.0 generally)\n",
    "    \n",
    "    #Here are all the stems of tf-idf vocabulary\n",
    "    terms=QAmodel.retriever.vectorizer.get_feature_names()\n",
    "    \n",
    "    #First we want to remove digits that are not important terms\n",
    "    n=int(s*len(terms))\n",
    "    idx_words=[]\n",
    "    for i,term in enumerate(terms):\n",
    "        try: float(term)\n",
    "        except: idx_words.append(i)\n",
    "   \n",
    "    #Secondly we set a threshold to select words that appear at least each p documents \n",
    "    threshold=0.002 #Set threshold to select words that appear at least each p documents \n",
    "    freq_term=np.zeros((len(QAmodel.content),len(terms)))\n",
    "    for j,sentence in enumerate(QAmodel.content):\n",
    "        stem=QAmodel.retriever.tokenize(sentence) \n",
    "        for i,c in enumerate(terms):\n",
    "            if c in stem:\n",
    "                freq_term[j,i]+=1\n",
    "    freq_term_by_doc=np.apply_along_axis(lambda x: np.mean(x),0,freq_term)\n",
    "    ids=np.where(freq_term_by_doc>threshold)[0]\n",
    "    idx_words=[ i for i in ids if i in idx_words]\n",
    "    \n",
    "\n",
    "    #Init selection of terms with most correlation \n",
    "    if s!=1.0:\n",
    "        prob=np.sum(np.abs(T)>0,axis=0)\n",
    "        prob=prob/np.sum(prob)\n",
    "        prob=np.squeeze(prob)\n",
    "        idx=[]\n",
    "        m=len(idx_words)\n",
    "\n",
    "        for i in range(n):\n",
    "\n",
    "            p=int(np.random.choice(m,1,prob[0]))\n",
    "            idx.append(int(idx_words[p]))\n",
    "            prob[idx_words[p]]=0\n",
    "            prob=prob/np.sum(prob)\n",
    "\n",
    "        return idx,np.squeeze(T[:,idx])\n",
    "    else:\n",
    "        idx=idx_words\n",
    "        return idx,np.squeeze(T[:,idx])\n",
    "\n",
    "        "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### 1)Proceed First step"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(7843, 1178)"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "M=QAmodel.retriever.tfidf_matrix.toarray()\n",
    "idx,A=select_term_Naystrom(M)\n",
    "A.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Visualize terms selected"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 301,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['area',\n",
       " 'aris',\n",
       " 'arrang',\n",
       " 'articl',\n",
       " 'asia',\n",
       " 'ask',\n",
       " 'aspect',\n",
       " 'assess',\n",
       " 'asset',\n",
       " 'assist']"
      ]
     },
     "execution_count": 301,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[QAmodel.retriever.vectorizer.get_feature_names()[i] for i in idx[80:90]]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Implementation of  Farahat - Nystrom method to compute the semantic Kernel and overcome sparcity "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Nystrom Method Explained: \n",
    "\n",
    "$$\\text{Let} \\hspace{3pt} X^T \\hspace{3pt} \\text{be our tf-idf matrix whose element} \\hspace{3pt}X_{i,j} \\hspace{3pt}\\text{represents the weight of term i inside document j }$$\n",
    "$$ \\text{We want to express a semantic kernel K which includes the correlation between important terms and factorize it to get new sentence embeddings  } $$ $$ \\text{Formally we want to approximate:}\\hspace{3pt} K=X^TGX \\hspace{3pt} \\text{as the product: }\\hspace{3pt} K\\simeq W^{T}W \\hspace{3pt} \\text{where} \\hspace{3pt} W=Z^{T}X \\hspace{3pt}\\ $$ $$\\leftrightarrow  \\hspace{3pt} \\text{Equivalently : } \\hspace{3pt} G=L_{X}^{-1/2}XX^{T}L_{X}^{-1/2}\\hspace{5pt} \\text{is approximated by}\\hspace{3pt} G \\simeq ZZ^{T} \\hspace{4pt}  $$\n",
    "The important idea is that K is a squarred matrix of document size and W is of shape (documents,term). Hence K stands as the similarity matrix between sentences and W is the sentence embedding matrix. Moreover K and W incorporate the correlation between terms provided by G. This is what we was looking for ! \n",
    "$$ \\text{Such approximation for G is suggested by Nystrom in this formula} \\hspace{3pt}\\hat{G}=G_{:S}G_{SS}^{-1}{}G_{:S}^{T} \\hspace{3pt} \\text{where S is the set of selected terms}\\hspace{4pt} \\text{The important terms are selected given a frequency threshold.}  $$\n",
    "$$ \\text{Then our approximation is} \\hspace{3pt} Z=G_{:S}G_{SS}^{-1/2} \\hspace{3pt} \\text{with G (correlation matrix)} \\hspace{3pt} \\text{defined as} \\hspace{3pt} G=L_{X}^{-1/2}XX^{T}L_{X}^{-1/2} $$\n",
    "$$ \\text{It follows that } \\hspace{3pt} W=Z^{T}X=(G_{:S}G_{SS}^{-1/2})^{T}X=(X_{S:}X_{S:}^{T})^{-1/2}X_{S:}X_{S:}^{T} L_{X}^{-1/2}X$$\n",
    "$$ \\text{We can now perform the Spherical K-means on the sentence embedding matrix } \\hspace{3pt} W^T \\hspace{3pt} \\text{! } \\hspace{3pt}  $$ Spherical K-means seeks to minimize cosine dissimilarity instead of euclidian distance.  $$ \\text{Formally : } \\hspace{4pt}𝐽=∑_{𝑖}𝑑(𝑥_𝑖,𝑝𝑐(𝑖)) \\hspace{3pt} \\text{where} \\hspace{3pt} 𝑑(𝑥,𝑝)=1−𝑐𝑜𝑠(𝑥,𝑝)=\\frac{⟨𝑥,𝑝⟩}{‖𝑥‖‖𝑝‖}$$\n",
    "It is greatly used in NLP tasks since. One other major reason opting cosine similarity over euclidean distance will be to avoid ineffectiveness of euclidean distance when handling high dimensionality and sparse dataset. An other reason is that cosine dissimilarity doesn't account for differences of size between documents.\n",
    "\n",
    "Enhancement of the method : We can perform a low rank SVD to compute $G_{SS}^{-1/2}$, that reduces the dimension of the semantic space to k. It makes the clustering algorithm even more efficient and reduces drastically time complexity.  We use the following SVD decomposition: $G_{SS}=UDU^T$ where $U$ is a $(k,l)$, ($k\\leq l$ ) matrix which contains the k-eigen vectors associated with the k highest eigen values in the standard SVD decomposition $$ \\text{Finally} \\hspace{3pt} G_{SS}^{-1/2}=UD^{-1/2}U  \\hspace{3pt} \\text{which gives us}  \\hspace{3pt}W=D^{-1/2}U^{T}X_{S:}X^TX$$"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Ajout des querries dans le corpus pour la méthode de Naystrom, approximation low rank de la matrice W"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_kernel_decomposition(rank=None,subset=[]):\n",
    "    if rank==None:\n",
    "        rank=len(subset)\n",
    "    ids=subset\n",
    "    querries=data['words_sort'].tolist()\n",
    "    for i,q in enumerate(querries):\n",
    "        q=' '.join(list(q))\n",
    "        q=q.lower()\n",
    "        q=pdfconverter().remove_non_alpha(q)\n",
    "        q=q.replace('.','')\n",
    "        querries[i]=q\n",
    "        \n",
    "    qemb=QAmodel.retriever.vectorizer.transform(querries).toarray().transpose()\n",
    "    X=QAmodel.retriever.tfidf_matrix.toarray().transpose()\n",
    "    print(qemb.shape,X.shape)\n",
    "    X=np.c_[X,qemb]\n",
    "    \n",
    "    L=np.eye(X.shape[0])*np.sqrt(X.shape[0])\n",
    "    L_inv=np.linalg.inv(L)\n",
    "    G=L_inv@X@X.transpose()@L_inv\n",
    "    Gs=G[ids,:]\n",
    "    Gs=Gs[:,ids]\n",
    "    S,V,D=np.linalg.svd(Gs, full_matrices=True)\n",
    "    Ssub,Vsub=S[:,:rank], np.diag(V)[:rank,:rank]\n",
    "    #Ssub,Vsub=S,np.diag(V)\n",
    "    #G=Ssub@Vsub$Ssub.transpose() but this operation is not necessary, we just need the decomposition of G\n",
    "    \n",
    "    D_sub_inv=np.diag(np.apply_along_axis(lambda x: 1/np.sqrt(x) , 0, V[:rank]))\n",
    "    #D_sub_inv=np.diag(np.apply_along_axis(lambda x: 1/np.sqrt(x) , 0, V))\n",
    "    W=(((D_sub_inv@Ssub.transpose())@X[ids,:])@(X.transpose()))@X\n",
    "    return W\n",
    "    \n",
    "    \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(6896, 14) (6896, 7843)\n"
     ]
    }
   ],
   "source": [
    "W=generate_kernel_decomposition(rank=500,subset=idx)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 283,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(500, 7857)"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "W.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(14, 4311)"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "W_=np.apply_along_axis(lambda x: x/np.sqrt(np.sum(x**2)), 1,W.transpose())\n",
    "scores=W_@W_.transpose()\n",
    "scores=scores[len(scores)-len(questions):,:len(scores)-len(questions)]\n",
    "scores=scores[:,QAmodel.borders[2]:QAmodel.borders[3]]\n",
    "scores.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 358,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(14, 3132)"
      ]
     },
     "execution_count": 358,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "W_=np.apply_along_axis(lambda x: x/np.sqrt(np.sum(x**2)), 1,W.transpose())\n",
    "scores=W_@W_.transpose()\n",
    "scores=scores[len(scores)-len(questions):,:len(scores)-len(questions)]\n",
    "scores=scores[:,QAmodel.borders[1]:QAmodel.borders[2]]\n",
    "scores.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Finally: Spherical Kmeans cluster  + Bert Transformer to retrieve best candidates within each clusters"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 306,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "New Tf-Idf Matrix is 0.0 % sparse\n",
      "7857 500\n"
     ]
    }
   ],
   "source": [
    "(a,b)=W_.shape\n",
    "non_zeros=100*np.sum(np.abs(W_)>0)/(a*b) \n",
    "print('New Tf-Idf Matrix is',100-np.round(non_zeros,4),'% sparse')\n",
    "print(a,b)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "*****  Question 0 : Does the company operate in countries out of the European Union? ********\n",
      "Is there an Important Word? press enter if no :  \n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 1 : Specific situations may vary by country, most notably with respect to older patents and to countries that have only recently joined the EU.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 2 : We operate our business through office premises and research, production and logistics facilities in approximately 100 countries around the world.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 3 : In certain countries, we carry on some of our business operations through joint ventures with local partners.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 4 : In many European countries, automatic substitution of biologics is officially prohibited or not recommended.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 5 : In all countries where we operate, we seek to strike a balance between our economic interests and those of our employees, which we regard as inseparable.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 6 : One of the main limitations on our operations in emerging market countries is the lack of effective intellectual property protection or enforcement for our products.\n",
      "\n",
      "----------------\n",
      "\n",
      "*****  Question 1 : Is at least one of the company’s production facilities classified as Seveso « High » (European Detective) or equivalent in other countries ********\n",
      "Is there an Important Word? press enter if no :  \n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 1 : The product has also been approved in Europe, and has been launched in a number of countries (Germany, the Netherlands and the United Kingdom).\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 2 : In Europe, where Cerdelga® became available in a number of countries (including Germany, France, Italy and some Nordic countries), net sales of the product were €17 million.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 3 : This has included switching some CHC products from non-CHC facilities to the dedicated CHC network, transferring some liquid and effervescent formulations of CHC products to the Cologne site, and transforming the Origgio site into a facility dedicated to a single product family (Enterogermina®).\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 4 : In 2017, we also invested in our industrial facilities to deliver the production capacity needed for those products, including an extension to our vaccine facility at Val-de-Reuil (France) and a strategic alliance with Lonza to create a large-scale biologics production facility at Visp (Switzerland).\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 5 : However, the protection that we are able to obtain varies in its duration and scope from product to product and country by country.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 6 : It is our policy to protect and register our trademarks with a strategy adapted to each product or service depending on the countries where they are commercialized: on a worldwide basis for worldwide products or services, or on a regional or local basis for regional or local products or services.\n",
      "\n",
      "----------------\n",
      "\n",
      "*****  Question 2 : Is the Company involved in agricultural chemistry activities, including the production of nitrogenous potash and phosphate based fertilizers? ********\n",
      "Is there an Important Word? press enter if no :  \n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 1 : However, the companies in which Sanofi owns shares are also suppliers or customers, which means that these companies’ emissions in connection with Sanofi’s activities are already accounted for in other categories (purchased goods and services, energy, processing of sold products, etc.).\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 2 : This covers all active ingredients handled in production at company sites or in processes sub-contracted for manufacture.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 3 : Planet Mobilization is a global project that involves all the company’s resources in defining objectives and engaging with external partners.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 4 : Information on the Company Introduction Sanofi is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 5 : The Sanofi parent company raises the bulk of the Company’s external financing and uses the funds raised to meet, directly or indirectly, the financing needs of its subsidiaries.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 6 : A consent decree is a court order entered into by agreement between a company and the government (in this case the FDA) that requires the company to take certain actions as set out in the decree.\n",
      "\n",
      "----------------\n",
      "\n",
      "*****  Question 3 : Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)? ********\n",
      "Is there an Important Word? press enter if no :  \n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 1 : We have committed to an ambitious policy aimed at limiting the direct and indirect impacts of our activities on the environment, throughout the life cycle of our products.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 2 : Sanofi must comply with applicable laws and regulations applicable in the jurisdictions in which we operate, with pharmaceutical industry codes and with the Company’s ethical principles, values and policies.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 3 : A Chief Quality Officer (CQO), reporting to the CEO, is responsible for defining the Sanofi Quality policy, coordinating its implementation and ensuring compliance with the related applicable regulatory and Company requirements.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 4 : A consent decree is a court order entered into by agreement between a company and the government (in this case the FDA) that requires the company to take certain actions as set out in the decree.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 5 : Downstream transportation and distribution: : 983,559 tCO2 e Definition: This category includes emissions from transportation and distribution of products sold by the reporting company between the company’s operation and the end consumer, if not paid for by the reporting company, in vehicles and facilities not owned or controlled by the reporting company.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 6 : Sanofi’s Code of Ethics addresses 13 topics relating to ethical matters and is supported by dedicated policies and procedures, such as an anti bribery policy, a policy on interactions with patients, patient advocates and groups, and a policy on donations and other contributions.\n",
      "\n",
      "----------------\n",
      "\n",
      "*****  Question 4 : Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity? ********\n",
      "Is there an Important Word? press enter if no :  \n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 1 : To safeguard continuity of operations and secure timely execution of its core tasks, the EMA has launched a Business Continuity Plan (BCP).\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 2 : Business ethics and employee integrity are crucial to safeguard the Company’s image and reputation and protect Sanofi employees.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 3 : To reinforce our business ethics culture, a formal company-wide Ethics & Business Integrity program has been developed and implemented.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 4 : See “– Critical accounting and reporting policies – Business combinations” below for an explanation of the impact of business combinations on our results of operations.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 5 : As a result, the environment in which pharmaceutical companies must operate in order to make their products available to patients and providers who need them continues to grow more complex each year.\n",
      "\n",
      "----------------\n",
      "\n",
      "Anserws n° 6 : The Board of Directors noted that the Company and its subsidiaries had, in the normal course of business, over the past three years, sold products and provided services to, and/or purchased products and received services from, companies in which certain of the Company’s directors who are classified as independent (or their close family members) were senior executives or employees during 2017.\n",
      "\n",
      "----------------\n",
      "\n",
      "*****  Question 5 : Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents? ********\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/ipykernel/kernelbase.py\u001b[0m in \u001b[0;36m_input_request\u001b[0;34m(self, prompt, ident, parent, password)\u001b[0m\n\u001b[1;32m    884\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 885\u001b[0;31m                 \u001b[0mident\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mreply\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msession\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstdin_socket\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;36m0\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    886\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mException\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/jupyter_client/session.py\u001b[0m in \u001b[0;36mrecv\u001b[0;34m(self, socket, mode, content, copy)\u001b[0m\n\u001b[1;32m    802\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 803\u001b[0;31m             \u001b[0mmsg_list\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msocket\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv_multipart\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmode\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcopy\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    804\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0mzmq\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mZMQError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/zmq/sugar/socket.py\u001b[0m in \u001b[0;36mrecv_multipart\u001b[0;34m(self, flags, copy, track)\u001b[0m\n\u001b[1;32m    469\u001b[0m         \"\"\"\n\u001b[0;32m--> 470\u001b[0;31m         \u001b[0mparts\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mflags\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcopy\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcopy\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtrack\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtrack\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    471\u001b[0m         \u001b[0;31m# have first part already, only loop while more to receive\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket.Socket.recv\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket.Socket.recv\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32mzmq/backend/cython/socket.pyx\u001b[0m in \u001b[0;36mzmq.backend.cython.socket._recv_copy\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/zmq/backend/cython/checkrc.pxd\u001b[0m in \u001b[0;36mzmq.backend.cython.checkrc._check_rc\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: ",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-69-ea56d59a379d>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      9\u001b[0m     \u001b[0mcount_answers\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     10\u001b[0m     \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'*****  Question {} : {} {}'\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mquestion\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mquestions\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mquestion\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m'********'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 11\u001b[0;31m     \u001b[0mw\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Is there an Important Word? press enter if no :  '\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     12\u001b[0m     \u001b[0mrk\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     13\u001b[0m     \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'\\n----------------\\n'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/ipykernel/kernelbase.py\u001b[0m in \u001b[0;36mraw_input\u001b[0;34m(self, prompt)\u001b[0m\n\u001b[1;32m    858\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_parent_ident\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    859\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_parent_header\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 860\u001b[0;31m             \u001b[0mpassword\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mFalse\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    861\u001b[0m         )\n\u001b[1;32m    862\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/lib/python3.7/site-packages/ipykernel/kernelbase.py\u001b[0m in \u001b[0;36m_input_request\u001b[0;34m(self, prompt, ident, parent, password)\u001b[0m\n\u001b[1;32m    888\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mKeyboardInterrupt\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    889\u001b[0m                 \u001b[0;31m# re-raise KeyboardInterrupt, to truncate traceback\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 890\u001b[0;31m                 \u001b[0;32mraise\u001b[0m \u001b[0mKeyboardInterrupt\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    891\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    892\u001b[0m                 \u001b[0;32mbreak\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "rank=np.apply_along_axis(lambda x:np.argsort(-x),1,scores)\n",
    "repo=2 #Sanofi\n",
    "raw_or_treated=1 #raw text\n",
    "all_answers=[]\n",
    "for question in range(14):\n",
    "    answers=[]\n",
    "    answers_raw=[]\n",
    "    special_answers_raw=[]\n",
    "    dic_answers={}\n",
    "    count_answers=1\n",
    "    print('*****  Question {} : {} {}'.format(question,questions[question],'********'))\n",
    "    w_important=[w for w in questions[question].split(\" \") if w=w.upper()]\n",
    "    rk=0\n",
    "    print('\\n----------------\\n')\n",
    "    #Display best candidates according to clustering\n",
    "    if w_important==[]:\n",
    "        for answ in range(30):\n",
    "            while True:\n",
    "                answer_raw=QAmodel.contents_doc[repo][raw_or_treated][rank[question,rk]]\n",
    "                answer=QAmodel.contents_doc[repo][1-raw_or_treated][rank[question,rk]]\n",
    "                rk+=1\n",
    "                dic_answers[answer]=dic_answers.get(answer,0)+1\n",
    "                if dic_answers[answer]==1:\n",
    "                    break\n",
    "            answers.append(answer)\n",
    "            answers_raw.append(answer_raw)\n",
    "            \n",
    "            #print('Anserw n°{} : {}'.format(count_answers,answer))\n",
    "            #print('\\n----------------\\n')\n",
    "            \n",
    "    else:\n",
    "        for w in w_important:\n",
    "            w=QAmodel.retriever.tokenize(w)[0]\n",
    "            print('token=', w)\n",
    "            best_id=[i for i in range(rank.shape[1]) if w in QAmodel.contents_doc[repo][0][rank[question,i]].split(' ')][:2]\n",
    "            for idd in best_id[:2]:\n",
    "                print('Special Anserw n° {} : {}'.format(count_answers,QAmodel.contents_doc[repo][raw_or_treated][rank[question,idd]]))\n",
    "                print('\\n----------------\\n')\n",
    "                special_answers_raw.append(QAmodel.contents_doc[repo][raw_or_treated][rank[question,idd]])\n",
    "                count_answers+=1\n",
    "                rk+=1\n",
    "            \n",
    "        for answ in range(30):\n",
    "            while True:\n",
    "                answer_raw=QAmodel.contents_doc[repo][raw_or_treated][rank[question,rk]]\n",
    "                answer=QAmodel.contents_doc[repo][1-raw_or_treated][rank[question,rk]]\n",
    "                rk+=1\n",
    "                dic_answers[answer_raw]=dic_answers.get(answer,0)+1\n",
    "                if dic_answers[answer_raw]==1:\n",
    "                    break\n",
    "            answers.append(answer)\n",
    "            answers_raw.append(answer_raw)#Cluster Tf-Idf \n",
    "            count_answers+=1\n",
    "            rk+=1\n",
    "            #transform question\n",
    "            \n",
    "    Qst=questions[question].lower()\n",
    "    newQst=pdfconverter().remove_non_alpha(Qst)\n",
    "    newQst=newQst.replace('.','')\n",
    "\n",
    "    #Use Bert inside clusters\n",
    "    bert=BertRetriever(top_n=5)\n",
    "    embeddings = bert.transform(list([s for s in answers ]))\n",
    "    indices,scores_bert=bert.predict(newQst,[0,len(answers)])\n",
    "    scores_bert=scores_bert.loc[indices].values[:,0]\n",
    "    text=[ answers_raw[i] for i in indices]\n",
    "    \n",
    "    for i,c in enumerate(text):\n",
    "        print('Anserws n° {} : {}'.format(i+1,c))\n",
    "        print('\\n----------------\\n')\n",
    "    \n",
    "    all_answers.append(answers)\n",
    "\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "*****  Question 0 : Does the company operate in countries out of the European Union? ********\n",
      "Is there an Important Word? press enter if no :  \n",
      "\n",
      "----------------\n",
      "\n"
     ]
    },
    {
     "ename": "IndexError",
     "evalue": "list index out of range",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-66-3795b1fab87c>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     16\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mansw\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mrange\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;36m20\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     17\u001b[0m             \u001b[0;32mwhile\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 18\u001b[0;31m                 \u001b[0manswer_raw\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mQAmodel\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcontents_doc\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mrepo\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mraw_or_treated\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mrank\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mquestion\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mrk\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     19\u001b[0m                 \u001b[0manswer\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mQAmodel\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcontents_doc\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mrepo\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m-\u001b[0m\u001b[0mraw_or_treated\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mrank\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mquestion\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0mrk\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     20\u001b[0m                 \u001b[0mrk\u001b[0m\u001b[0;34m+=\u001b[0m\u001b[0;36m1\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mIndexError\u001b[0m: list index out of range"
     ]
    }
   ],
   "source": [
    "rank=np.apply_along_axis(lambda x:np.argsort(-x),1,scores)\n",
    "repo=1 #BasF\n",
    "raw_or_treated=1 #raw text\n",
    "all_answers=[]\n",
    "for question in range(14):\n",
    "    answers=[]\n",
    "    answers_raw=[]\n",
    "    dic_answers={}\n",
    "    count_answers=1\n",
    "    print('*****  Question {} : {} {}'.format(question,questions[question],'********'))\n",
    "    w=str(input('Is there an Important Word? press enter if no :  '))\n",
    "    rk=0\n",
    "    print('\\n----------------\\n')\n",
    "    #Display best candidates according to clustering\n",
    "    if w=='':\n",
    "        for answ in range(20):\n",
    "            while True:\n",
    "                answer_raw=QAmodel.contents_doc[repo][raw_or_treated][rank[question,rk]]\n",
    "                answer=QAmodel.contents_doc[repo][1-raw_or_treated][rank[question,rk]]\n",
    "                rk+=1\n",
    "                dic_answers[answer]=dic_answers.get(answer,0)+1\n",
    "                if dic_answers[answer]==1:\n",
    "                    break\n",
    "            answers.append(answer)\n",
    "            answers_raw.append(answer_raw)\n",
    "            \n",
    "            #print('Anserw n°{} : {}'.format(count_answers,answer))\n",
    "            #print('\\n----------------\\n')\n",
    "            count_answers+=1\n",
    "            rk+=1\n",
    "    else:\n",
    "        w=QAmodel.retriever.tokenize(w)[0]\n",
    "        print('token=', w)\n",
    "        best_id=[i for i in range(rank.shape[1]) if w in QAmodel.contents_doc[repo][0][rank[question,i]].split(' ')][:3]\n",
    "        for idd in best_id[:2]:\n",
    "            print('Special Anserw n° {} : {}'.format(count_answers,QAmodel.contents_doc[repo][raw_or_treated][rank[question,idd]]))\n",
    "            print('\\n----------------\\n')\n",
    "            count_answers+=1\n",
    "            rk+=1\n",
    "            \n",
    "        for answ in range(30):\n",
    "            while True:\n",
    "                answer_raw=QAmodel.contents_doc[repo][raw_or_treated][rank[question,rk]]\n",
    "                answer=QAmodel.contents_doc[repo][1-raw_or_treated][rank[question,rk]]\n",
    "                rk+=1\n",
    "                dic_answers[answer_raw]=dic_answers.get(answer,0)+1\n",
    "                if dic_answers[answer_raw]==1:\n",
    "                    break\n",
    "            answers.append(answer)\n",
    "            answers_raw.append(answer_raw)#Cluster Tf-Idf \n",
    "            count_answers+=1\n",
    "            rk+=1\n",
    "            #transform question\n",
    "    Qst=questions[question].lower()\n",
    "    newQst=pdfconverter().remove_non_alpha(Qst)\n",
    "    newQst=newQst.replace('.','')\n",
    "\n",
    "    #Use Bert inside clusters\n",
    "    bert=BertRetriever(top_n=5)\n",
    "    embeddings = bert.transform(list([s for s in answers ]))\n",
    "    indices,scores_bert=bert.predict(newQst,[0,len(answers)])\n",
    "    scores_bert=scores_bert.loc[indices].values[:,0]\n",
    "    text=[ answers_raw[i] for i in indices]\n",
    "    \n",
    "    for i,c in enumerate(text):\n",
    "        print('Anserws n° {} : {}'.format(i+1,c))\n",
    "        print('\\n----------------\\n')\n",
    "    \n",
    "    all_answers.append(answers)\n",
    "\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 174,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question</th>\n",
       "      <th>Model</th>\n",
       "      <th>Rank</th>\n",
       "      <th>Doc_index</th>\n",
       "      <th>Answer</th>\n",
       "      <th>Score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>874</td>\n",
       "      <td>This investment supports the European Commission’s goal of establishing a European value chain for battery production.</td>\n",
       "      <td>0.31171599430448255</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3042</td>\n",
       "      <td>The Greenhouse Gas Protocol, used by many companies in different sectors as well as nongovernmental organizations and governments, is a globally recognized standard to quantify and manage greenhouse gas emissions.</td>\n",
       "      <td>0.11287900009404585</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>17</td>\n",
       "      <td>You may acknowledge the principles stated above or demonstrate your commitment via compliance with your own code of conduct or company policies that embrace these standards.</td>\n",
       "      <td>0.12097840050324711</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>2915</td>\n",
       "      <td>The objectives of the company’s financing policy are to ensure solvency, limit financial risks and optimize the cost of capital.</td>\n",
       "      <td>0.10296618510641711</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Has the company formalized  a strategy to reduce its greenhouse gas  emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3042</td>\n",
       "      <td>The Greenhouse Gas Protocol, used by many companies in different sectors as well as nongovernmental organizations and governments, is a globally recognized standard to quantify and manage greenhouse gas emissions.</td>\n",
       "      <td>0.11287900009404585</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3046</td>\n",
       "      <td>The “IAS Regulation” made the application of IFRSs mandatory for listed companies headquartered in the European Union starting in 2005.</td>\n",
       "      <td>0.5405327704499229</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1107</td>\n",
       "      <td>Animal studies are at times stipulated by REACH and other national legislation outside the European Union in order to obtain more information on the properties and effects of chemical products.</td>\n",
       "      <td>0.5275011498120308</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>191</td>\n",
       "      <td>However, the figures does not take into account the structural decline in sales and EBITDA due to the classification of the oil and gas business as a discontinued operation.</td>\n",
       "      <td>0.28685204760864724</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1192</td>\n",
       "      <td>Our reporting does not take into account air pollutant emissions from oil and gas operations due to their substantial fluctuation during exploration phases.</td>\n",
       "      <td>0.25917926506202765</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Does the company operate in countries out of the European Union?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>5.0</td>\n",
       "      <td>2370</td>\n",
       "      <td>BASF does not exercise the option to subsequently measure equity instruments through other comprehensive income.</td>\n",
       "      <td>0.22998484097492808</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3042</td>\n",
       "      <td>The Greenhouse Gas Protocol, used by many companies in different sectors as well as nongovernmental organizations and governments, is a globally recognized standard to quantify and manage greenhouse gas emissions.</td>\n",
       "      <td>0.11287900009404585</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3089</td>\n",
       "      <td>TUIS TUIS is a German transport accident information and emergency response system jointly operated by around 130 company fire depart ments within the chemical industry and specialists.</td>\n",
       "      <td>0.17756806965421823</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3089</td>\n",
       "      <td>TUIS TUIS is a German transport accident information and emergency response system jointly operated by around 130 company fire depart ments within the chemical industry and specialists.</td>\n",
       "      <td>0.17756806965421823</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>2577</td>\n",
       "      <td>Activities that are not allocated to any of the continued operating divisions continue to be recorded under Other.</td>\n",
       "      <td>0.1448696881843766</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>1.0</td>\n",
       "      <td>17</td>\n",
       "      <td>You may acknowledge the principles stated above or demonstrate your commitment via compliance with your own code of conduct or company policies that embrace these standards.</td>\n",
       "      <td>0.12097840050324711</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>2.0</td>\n",
       "      <td>2295</td>\n",
       "      <td>Costs for maintenance and repair as part of normal business operations are recognized as an expense.</td>\n",
       "      <td>0.11976282718207869</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)</td>\n",
       "      <td>Tf-Idf + Lemmatizer</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2915</td>\n",
       "      <td>The objectives of the company’s financing policy are to ensure solvency, limit financial risks and optimize the cost of capital.</td>\n",
       "      <td>0.10296618510641711</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                        Question  \\\n",
       "5                                                                                                     Is at least one of the company’s production facilities classified as SEVESO « High » (European Detective) or equivalent in other countries   \n",
       "12                                                                                      Has the company implemented measures to reduce its greenhouse gas emissions, use of low-carbon energy sources and energy recovery and efficiency system?   \n",
       "6                                                                                                                               Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "7                                                                                                                               Has the company formalized a commitment (policy or program) to control and reduce pollution (water air and sol)?   \n",
       "11                                                                                                                                                               Has the company formalized  a strategy to reduce its greenhouse gas  emissions?   \n",
       "2                                                                                                                                                                               Does the company operate in countries out of the European Union?   \n",
       "4                                                                                                                                                                               Does the company operate in countries out of the European Union?   \n",
       "0                                                                                                                                                                               Does the company operate in countries out of the European Union?   \n",
       "1                                                                                                                                                                               Does the company operate in countries out of the European Union?   \n",
       "3                                                                                                                                                                               Does the company operate in countries out of the European Union?   \n",
       "13                                                                                                                               Does the company monitor performance indicators to assess its progress with regard to greenhouse gas emissions?   \n",
       "10                                                                                                                         Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents?   \n",
       "8                                                                                        Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "9                                                                                        Does the company have an emergency plan and a remediation plan to cope with the consequences of industrial accidents and to ensure business continuity?   \n",
       "14  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)   \n",
       "16  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)   \n",
       "15  Does the company have a formalized commitment policy (policy or program) that addresses the safety of its plants or facilities (implementation of safety procedures and standards, installation of secondary containment, maintenance etc..)   \n",
       "\n",
       "                  Model Rank Doc_index  \\\n",
       "5   Tf-Idf + Lemmatizer  1.0       874   \n",
       "12  Tf-Idf + Lemmatizer  1.0      3042   \n",
       "6   Tf-Idf + Lemmatizer  1.0        17   \n",
       "7   Tf-Idf + Lemmatizer  2.0      2915   \n",
       "11  Tf-Idf + Lemmatizer  1.0      3042   \n",
       "2   Tf-Idf + Lemmatizer  1.0      3046   \n",
       "4   Tf-Idf + Lemmatizer  2.0      1107   \n",
       "0   Tf-Idf + Lemmatizer  3.0       191   \n",
       "1   Tf-Idf + Lemmatizer  4.0      1192   \n",
       "3   Tf-Idf + Lemmatizer  5.0      2370   \n",
       "13  Tf-Idf + Lemmatizer  1.0      3042   \n",
       "10  Tf-Idf + Lemmatizer  1.0      3089   \n",
       "8   Tf-Idf + Lemmatizer  1.0      3089   \n",
       "9   Tf-Idf + Lemmatizer  2.0      2577   \n",
       "14  Tf-Idf + Lemmatizer  1.0        17   \n",
       "16  Tf-Idf + Lemmatizer  2.0      2295   \n",
       "15  Tf-Idf + Lemmatizer  3.0      2915   \n",
       "\n",
       "                                                                                                                                                                                                                   Answer  \\\n",
       "5                                                                                                  This investment supports the European Commission’s goal of establishing a European value chain for battery production.   \n",
       "12  The Greenhouse Gas Protocol, used by many companies in different sectors as well as nongovernmental organizations and governments, is a globally recognized standard to quantify and manage greenhouse gas emissions.   \n",
       "6                                           You may acknowledge the principles stated above or demonstrate your commitment via compliance with your own code of conduct or company policies that embrace these standards.   \n",
       "7                                                                                        The objectives of the company’s financing policy are to ensure solvency, limit financial risks and optimize the cost of capital.   \n",
       "11  The Greenhouse Gas Protocol, used by many companies in different sectors as well as nongovernmental organizations and governments, is a globally recognized standard to quantify and manage greenhouse gas emissions.   \n",
       "2                                                                                 The “IAS Regulation” made the application of IFRSs mandatory for listed companies headquartered in the European Union starting in 2005.   \n",
       "4                       Animal studies are at times stipulated by REACH and other national legislation outside the European Union in order to obtain more information on the properties and effects of chemical products.   \n",
       "0                                           However, the figures does not take into account the structural decline in sales and EBITDA due to the classification of the oil and gas business as a discontinued operation.   \n",
       "1                                                            Our reporting does not take into account air pollutant emissions from oil and gas operations due to their substantial fluctuation during exploration phases.   \n",
       "3                                                                                                        BASF does not exercise the option to subsequently measure equity instruments through other comprehensive income.   \n",
       "13  The Greenhouse Gas Protocol, used by many companies in different sectors as well as nongovernmental organizations and governments, is a globally recognized standard to quantify and manage greenhouse gas emissions.   \n",
       "10                              TUIS TUIS is a German transport accident information and emergency response system jointly operated by around 130 company fire depart ments within the chemical industry and specialists.   \n",
       "8                               TUIS TUIS is a German transport accident information and emergency response system jointly operated by around 130 company fire depart ments within the chemical industry and specialists.   \n",
       "9                                                                                                      Activities that are not allocated to any of the continued operating divisions continue to be recorded under Other.   \n",
       "14                                          You may acknowledge the principles stated above or demonstrate your commitment via compliance with your own code of conduct or company policies that embrace these standards.   \n",
       "16                                                                                                                   Costs for maintenance and repair as part of normal business operations are recognized as an expense.   \n",
       "15                                                                                       The objectives of the company’s financing policy are to ensure solvency, limit financial risks and optimize the cost of capital.   \n",
       "\n",
       "                  Score  \n",
       "5   0.31171599430448255  \n",
       "12  0.11287900009404585  \n",
       "6   0.12097840050324711  \n",
       "7   0.10296618510641711  \n",
       "11  0.11287900009404585  \n",
       "2    0.5405327704499229  \n",
       "4    0.5275011498120308  \n",
       "0   0.28685204760864724  \n",
       "1   0.25917926506202765  \n",
       "3   0.22998484097492808  \n",
       "13  0.11287900009404585  \n",
       "10  0.17756806965421823  \n",
       "8   0.17756806965421823  \n",
       "9    0.1448696881843766  \n",
       "14  0.12097840050324711  \n",
       "16  0.11976282718207869  \n",
       "15  0.10296618510641711  "
      ]
     },
     "execution_count": 174,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
